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Summary: 
It is well documented that for prostate cancer patients undergoing radiation therapy 
there is a correlation between target volume displacement and changes in bladder 
and rectal volumes. However, these studies have used a methodology that has 
captured only a subset of all treatment positions. This research used daily Computer 
Tomography (CT) imaging to comprehensively assess organ volumes, organ motion 
and their effect on dose, something that has never been performed previously, thus 
adding considerably to the understanding of the topic.  
 
Daily CT images were obtained using a Siemens Primus Linear Accelerator 
equipped with an in-room Somatom CT unit in the accelerator suite, marketed as 
‘Primatom’, to accurately position the patient prior to treatment delivery. The 
internal structures of interest were contoured on the planning workstation by the 
investigator. The daily volume and location of the organs were derived from the 
computer to assess and analyse internal organ motion. The planned dose distribution 
was then imported onto the treatment CT datasets and used to compare the planned 
dose to i) the actual isocentre, where the isocentre was actually placed for that 
fraction, ii) the uncorrected isocentre, by un-doing any on-line corrections performed 
by the treatment staff prior to treatment delivery, and iii) the future isocentre, by 
placing the isocentre relative to internal organ motion on a daily basis. 
  
The results of this study did not confirm a statistically significant decrease in rectum 
volumes over time (hypothesis 1), however large fluctuations in bladder volume 
were confirmed (hypothesis 2). Internal organ motion for the rectum and bladder 
was demonstrated to be related to organ filling. Ideal planning volumes for these 
organs have been reported to minimise systematic and random uncertainty in the 
treatment volumes. An observed decrease in prostate volume over time, a systematic 
uncertainty in the location of the prostate at the time of the planning CT scan and a 
significant relationship between prostate centre of volume and rectum and bladder 
volumes has resulted in a recommendation that patients should be re-scanned during 
treatment to ensure appropriate clinical target volume coverage. A significant 
relationship between rectal and bladder volumes and the dose delivered to these 
organs was found (hypothesis 3). The dose delivered to the planning target volume 
was not related to the rectal or bladder volumes, although it was related to the 
 iii
 
motion of these organs. Despite these results only minimal effects on the dose 
delivered to any of the three isocentres occurred, indicating that the planned dose 
was accurately delivered using the methodology presented here (hypothesis 4). 
However the results do indicate that the patient preparation instructions need to be 
improved if margins are to be reduced in the future. 
 
It is unrealistic to assume that Image Guided Radiation Therapy will ever become 
routine practice due to infrastructure costs and time limitations. This research will 
inform radiation therapy centres of the variables associated with prostate cancer 
treatment on a daily basis, something that has never before been realistically 
achievable. As a result centres will be able to devise protocols to improve treatment 
outcomes. 
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1. Introduction 
Prostate cancer is to men what breast cancer is to women. Both have the highest 
incidence of cancer for their sex and radical radiation therapy is a mainstay of 
curative treatment.  
 
The development of Prostate Specific Antigen (PSA) testing has lead to an increase 
in early detection of low stage localised prostate cancers. However, “there is no 
recognised single best treatment for localised prostate cancer, as each patient is 
unique and different. The current treatment options for localised prostate cancer 
include surgery, radiation therapy, hormone manipulation and observation as well as 
various combinations thereof” (Eng, Thomas & Herman 2002, p. 239).  
 
Radiation therapy can consist of External Beam Radiation Therapy (EBRT) and/or 
Brachytherapy (radioactive implant). The most common form of radiation therapy to 
the prostate is EBRT. Three-Dimensional Conformal Radiation Therapy (3D-CRT) 
is widely used to treat localised prostate cancer during a standard fractionated course 
of around seven to eight weeks. The intention of 3D-CRT is to deliver high target 
doses to the prostate while optimally reducing irradiation of critical non-target 
structures such as the rectum and the bladder. This has been made possible by 
advances in imaging techniques, planning computer systems and treatment 
technology (Martinez et al. 2001; Fiorino et al. 1998). As a result of 3D-CRT the 
incidence of severe bladder and rectal toxicity has decreased compared to previous 
treatment techniques. The continued use of 3D-CRT relates to its suitability for 
“medically non-surgical candidates, relatively low morbidity, cost, preservation of 
normal sexual function in some patients, less time lost from work and patient 
preference.” (Eng, Thomas & Herman 2002, p. 239)  
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1.1 Importance of prostate positioning 
During a seven to eight week course of radical External Beam Radiation Therapy 
(EBRT) there are several variables that affect the accuracy with which the patient’s 
treatment can be delivered. These include daily patient set-up uncertainties, organ 
volume uncertainties and organ motion.  
 
Numerous authors have demonstrated that there is a correlation between target 
volume displacement and variations in rectal and/or bladder volume (Antolak et al. 
1998; Dawson et al. 1998; Miralbell et al, 2003a; Roeske et al. 1995; Zelefsky et al. 
1999; Zellars et al. 2000). These volumes are affected on a daily basis by fluid 
intake, fibre supplements and patient diet. Although conventionally the accuracy of 
treatment set-up in prostate cancer patients has been verified according to bony 
anatomy, the bladder status, rectal distension and pelvic muscle contraction may all 
affect daily prostate motion. Patient treatment position and stabilisation methods 
also affect treatment accuracy. 
 
These uncertainties all contribute to an inability to deliver the planned dose 
distribution which may lead to an under-dosage of part of the target or to the over-
dosage of healthy tissues. 
 
Throughout this thesis anterior-posterior refers to the Z direction on the Cartesian 
axis and will be abbreviated to AP, superior-inferior (SI) refers to the Y direction 
and right-left (RL or Lateral where more appropriate) refers to the X direction. 
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1.2 Hypotheses 
Based on the published literature and clinical observations, the following hypotheses 
were proposed in the context of prostate radiotherapy and tested during this research 
study. 
1.2.1 Hypothesis 1: Rectal volumes decrease 
That rectal volume decreases across a course of radiotherapy. 
 
1.2.2 Hypothesis 2: Bladder volumes fluctuate 
That bladder volume fluctuates/alters during a course of radiotherapy. 
 
1.2.3 Hypothesis 3: Reduced rectal volumes lead to increased dose 
That reducing rectal volume leads to increasing rectal radiation dose; i.e. that more 
of the rectum is inside the high dose region. 
 
1.2.4 Hypothesis 4: Current instructions are inadequate 
That the current patient preparation instructions regarding bladder filling and rectal 
emptying are inadequate to maintain the planned dose distribution. 
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2. Anatomy and Physiology  
The anatomy and physiology of the male pelvis will be briefly described. The focus 
of this section will be on providing the relevant anatomical and physiological 
information that relates to radiation therapy for prostate cancer. 
2.1 The Pelvis 
The pelvic organs are located inferiorly to the abdominal cavity, and are enclosed 
within the bony pelvis. The prostate gland is a centrally located organ at the base of 
the bladder surrounding the urethra. The proximity of the rectum and anal canal to 
the prostate gland makes them vulnerable to radiation-induced injury during 
radiation therapy (Figure 2-1).  
Figure 2 - 1: The Male Pelvis  
 
Reproduced from Marieb (1992), p. 933 
 
 
The large intestine technically consists of four principal regions: the caecum, colon, 
rectum and the anal canal, which extend from the ilium to the anus. The rectum and 
anal canal form the most distal portions of the gastrointestinal tract and when 
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discussing the large intestine, the rectum and anal canal are often discussed 
separately.  
2.2 Prostate Gland 
The prostate gland is a single doughnut shaped solid organ about the size of a walnut 
or chestnut. The prostate gland sits inferiorly to the urinary bladder, anterior to the 
rectum, posterior to the symphysis pubis and surrounds the prostatic urethra between 
the base of the bladder and the urogenital diaphragm. Anteriorly, the prostate is 
attached to the pubis symphysis by the puboprostatic ligaments and posteriorly it is 
separated from the rectum by the Denonvilliers’ fascia. Denonvilliers’ fascia is 
attached above to the peritoneum and below to the urogenital diaphragm, thus 
limiting the extension of carcinoma into the rectum. The seminal vesicles are 
attached to the superior-posterior aspect of the prostate. The prostate consists of an 
outer fibrous covering, a layer of smooth muscle and glandular substance composed 
of columnar epithelial cells. 
 
The prostate gland slowly increases in size from birth to puberty when a rapid 
increase in size occurs. The size of the gland remains fairly constant between the 
ages of 30-45, when further enlargement of between two to four times its normal 
size may occur. One third of all males over 60 have an enlarged prostate, a condition 
called benign prostatic hyperplasia (Tortora & Grabowski 1996). A blood test that 
measures the levels of prostate-specific antigen (PSA) can be used to detect enlarged 
prostate glands. PSA is a protein secreted by the prostate into the ejaculate to help 
nourish sperm. The amount of PSA increases as the size of the gland increases and 
may indicate infection, benign enlargement or malignant prostate cancer. 
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Due to the prostate surrounding a portion of the urethra, as the size of the gland 
increases it can cause the flow of urine to be obstructed. Both benign and malignant 
tumours are common in elderly men and can cause serious infections and painful 
and difficult urination.  
2.3 Seminal Vesicles 
Like the prostate gland, the seminal vesicles provide secretions into the prostatic 
urethra to aid the delivery of sperm. The seminal vesicles are a paired organ. They 
are convoluted, pouch-like structures about 5cm in length, situated posterior to the 
base of the urinary bladder but anterior to the rectum.  
2.4 Large Intestine 
The large intestine joins the distal end of the small intestine at the ileum, and 
consists of the ascending, transverse and descending colon. At the distal end of the 
large intestine are the rectum, anal canal and anus. The major function of the large 
intestine, including the rectum, is to propel the faecal contents towards the anus and 
thus eliminate them from the body. Chyme delivered to the large intestine contains 
few nutrients, as most have been absorbed in the small intestine, and therefore no 
chemical digestion occurs in the large intestine. However a small amount of 
digestion still occurs through the action of bacteria that is present in the rectum. A 
minor function of the large intestine is to absorb the remaining water and 
electrolytes and vitamins produced by the bacteria (Sherwood 1993). Therefore the 
large intestine could be thought of as a drying and storage organ. The mucosa of the 
large intestine contains crypts and mucous producing goblet cells to lubricate the 
wall to protect it from irritating acids and gases. 
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2.5 Rectum 
The rectum is the last 13-20cm of the GI tract, lying anteriorly to the sacrum and 
coccyx. Different authors of anatomy and physiology texts quote varying lengths of 
the rectum (Ross & Wilson 1981; Tortora & Grabowski 2000). Marieb (1992) 
prefers to determine the start of the rectum relative to the surrounding anatomy, 
stating that the sigmoid colon joins the rectum at the level of the third sacral 
vertebra.  
 
The rectum’s structure is similar to that of the more proximal large intestine. The 
mucosa consists of simple columnar epithelium, lamina propria (areolar connective 
tissue) and muscularis mucosae (smooth muscle). The mucosa is structured in long, 
straight, tubular intestinal glands that extend its full thickness. Located within these 
intestinal glands are absorptive and goblet cells. The absorptive cells’ primary 
function is to absorb water; whereas the goblet cells secrete an alkaline mucus that 
lubricates the rectum to make the passage of faecal contents easier and protects the 
large intestine mucosa from mechanical and chemical injury by neutralising acids 
produced by bacterial fermentation. Although mucus is secreted by the glands in the 
rectum, no enzymes are secreted. Within the rectum and large intestine, bacteria 
ferment the remaining carbohydrates and release hydrogen, carbon dioxide and 
methane gas. These bacteria also convert any remaining proteins into amino acids 
and then break down the amino acids. Lymphatic nodules can also be found within 
the mucosa. 
 
The submucosa, the layer just external to the mucosa of the rectum, is similar to that 
of the small intestine. The submucosa is moderately dense connective tissue and 
contains blood and lymphatic vessels, lymph nodes, nerve fibres, as well as elastic 
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fibres. The nerve supply, known as the submucosal plexus, is part of the autonomic 
nervous system and regulates the activity of the glands and the smooth muscles.  
 
The muscularis of the rectum consists of an external layer of longitudinal smooth 
muscle and an internal layer of circular smooth muscle. It is the muscularis that is 
responsible for the propulsion of food through the gastrointestinal tract. The 
myenteric plexus, also part of the autonomic nervous system, lies between the 
circular and longitudinal smooth muscle layers and controls the activities of the 
rectum. The parasympathetic fibres stimulate motility and glandular secretion, 
whereas the sympathetic fibres inhibit motility. 
 
The final layer of the digestive tract wall is the serosa. The serosa is the outer 
connective tissue covering that secretes a watery serous fluid that lubricates and 
prevents friction between the digestive organs and surrounding viscera. 
 
Each day around 500ml of chyme is received by the large intestine. After absorption 
of the remaining water about 150ml is eliminated as faeces via the process of 
defecation (Marieb 1992; Sherwood 1993). The rectum is normally empty until just 
prior to defecation as faecal mass is stored in the sigmoid colon. The 
parasympathetic ‘gastrocolic’ reflex causes the walls of the sigmoid colon and the 
rectum to contract, pushing the faeces into the rectum. When faeces are forced into 
the rectum by mass movements, the stretching of the rectal wall initiates a defecation 
reflex and causes the anal sphincters to relax (Marieb, 1992). As the faeces reach the 
anal canal, we are able to decide whether the external, voluntary, sphincter should be 
opened. During defecation not only do the muscles of the rectum contract, but the 
diaphragm, abdominal wall and levator ani muscles also contract. 
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2.6 Anal Canal 
The terminal 2-4cm of the rectum is known as the anal canal, which in turn opens in 
to the anus. Similar to the rectum, authors differ on the actual length of the canal. 
Tortora and Grabowski (2000) quote a length of 2-3cm, Jacob, Francone and 
Lossow (1978) quote 2.5cm, Marieb (1992) quote 3cm and Ross & Wilson (1981) 
quote 3.8cm. Anatomically the anal canal begins when the rectum penetrates the 
levator ani muscle of the pelvic floor. 
 
The anal canal’s mucous membrane is arranged in longitudinal or vertical folds 
called anal columns and consist of stratified squamous epithelium and contain a 
network of arteries and veins. Goblet cells, which secrete mucus, cease at the 
junction between the rectum and the anus but between the vertical folds are anal 
sinuses that produce mucus when compressed by faeces to aid in defecation. There 
are two sphincter muscles that control the anus formed by thickening of the circular 
muscle layers. The circular smooth muscle of the anal canal is thickened to form the 
internal sphincter, which is involuntary. Bundles of the skeletal muscle surround the 
canal to form the external, voluntary, sphincter. The defecation reflex can be 
voluntarily prevented by contraction of the external anal sphincter to allow 
defecation at an appropriate time. 
2.7 Urinary bladder 
The urinary bladder is a hollow muscular organ located posterior to the pubic 
symphysis. In men it is directly anterior to the rectum, the small intestine lies 
superiorly and the urethra and prostate gland lie inferiorly. The urinary bladder is a 
freely movable organ held in position by folds in the peritoneum. Its shape depends 
on the amount of urine it contains. When empty the bladder is collapsed, becoming 
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spherical when slightly distended and as urine volume increases it become pear-
shaped and rises into the abdominal cavity. The average capacity of the urinary 
bladder is 700-800ml. Once the bladder volume reaches 200-400ml stretch receptors 
in the wall send sensory impulses, which initiate the desire to expel urine through 
micturition. The floor of the bladder is a small triangular area called the trigone. It 
has a smooth appearance as the mucosa is firmly fixed to the muscularis. The 
anterior corner of the trigone opens into the urethra, where as the two posterior 
corners contain the two ureteric openings.  
3. Prostate cancer 
3.1 Epidemiology 
Prostate cancer is the fourth most commonly diagnosed malignancy in men world-
wide (Parkin, Pisani & Ferlay 1993; Shibuya et al. 2002). In Australia 
adenocarcinoma of the prostate is the 4th highest cause of male deaths (ABS 1995), 
although it is the largest leading cause of male deaths in the USA (Tortora & 
Grabowksi 1996). In Victoria, cancer is the single largest cause of death at 29%, 
with prostate cancer the most commonly diagnosed cancer in men (23.4%) and the 
third most common cancer diagnosed (12.7%) in the population of Victoria behind 
bowel and breast (Australian Institute of Health and Welfare (AIHW) & 
Australasian Association of Cancer Registeries (AACR), 2004).   
 
Prostate cancer is predominantly a disease of the elderly, with a mean age of 
diagnosis in the early seventies. Since life expectancy is increasing, the absolute 
number of men diagnosed with prostate cancer is expected to increase accordingly. 
Prostate cancer has been a leading contributor to the rise in cancer deaths in older 
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men. In 1993, 97% of prostate cancer deaths occurred in men aged over 60 (ABS, 
1995).   
3.2 Pathophysiology 
More than 95% of prostate cancers arise in the glandular epithelium of the peripheral 
gland. Of these cancers, 64% occur in the apex, or distal end of the prostate. In 
contrast benign hyperplasia originates in the central or periurethral portions. Cancer 
can develop in the form of one or more nodules which later spread into and through 
the capsule of the gland and invade the periprostatic tissue. Involvement may spread 
to the seminal vesicles, and later into the bladder and rectum. Depending on the 
stage of the tumour, invasion into the perineural spaces, blood vesicles and the 
lymphatics result in the development of metastases. The likelihood of spread appears 
to be related to the stage and grade of the cancer. Poorly differentiated, higher stage 
cancers are more likely to have nodal metastases at the time of presentation than 
well differentiated, lower stage cancers. 
 
The pathological scoring of prostate specimens is based on the cellular architecture 
and is known as the Gleason scoring system. The Gleason score is used to predict 
the prognosis for prostatic adenocarcinoma and combines the histological grading 
and clinical staging to calculate an overall score (Gleason & Mellinger 1974).The 
severity of cellular pattern changes reflects the score given to the majority of the 
cells in the specimen: lower scores (1-3) are considered well-differentiated and 4-5 
are considered poorly-differentiated. This primary number is then added to a 
secondary number, the second most common type of cellular structure, to give the 
total Gleason Grade. This Gleason grade can then be used to predict the presence of 
lymph node metastases and subsequent survival.  
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3.3 Staging 
Once a definitive diagnosis of prostate cancer is known, staging investigations are 
needed as defining the extent of a patient’s cancer is vital when designing and 
planning for successful treatment. The International Union Against Cancer (UICC) 
formulated the TNM classification system to ensure that there is international 
agreement on the staging of many cancers, including prostate cancer, thus allowing 
accurate comparisons between different centres and clinical studies. The TNM 
classification system for describing the anatomical extent of disease includes a 
description of the extent of the primary tumour (T), the absence or presence and 
extent of regional lymph node metastasis (N) and the absence or presence of distant 
metastases (M) (Sobin & Wittekind, 2002). According to the TNM classification 
system prostate cancer that has not yet invaded adjacent structures can be defined 
anywhere between a T1 to T3N0M0 tumour depending on its size, whereas more 
advanced cancers are T4 tumours.  
3.4 Diagnostic Imaging 
3.4.1 CT 
CT imaging plays a relatively minor role in managing early prostate cancer because 
of its poor precision in staging (Lee et al. 2003). However CT plays a vital role in 
the planning of radiation therapy and is now a standard procedure in most radiation 
therapy departments. CT information is useful in two aspects of treatment planning 
(Khan 1994; Lattanzi et al. 1999):  
(a) Precise delineation of target volume (location and size) and the surrounding 
structures in relation to the external contour  
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(b) Providing quantitative data for tissue heterogeneity corrections. Since the CT 
image pixel values relate to the electron density of the tissues imaged, by utilising 
appropriate calibration data the planning computer system can accurately calculate 
the effect different tissue densities have on the dose distribution. 
 
Although CT can provide the spatial resolution and electron density information 
essential for quantitative dose computation during radiation therapy treatment 
planning, the limitations of contrast and spatial resolution need to be considered 
when interpreting structures in a CT.  
 
Contrast resolution is the ability to distinguish between soft tissues other than by 
virtue of their size or shape. On CT images the prostate appears as a homogenous 
soft tissue density which often makes it difficult to distinguish the prostate from 
surrounding soft tissues because the organs in the pelvis have similar apparent 
density. The seminal vesicles are also often hard to distinguish from surrounding fat 
and soft tissue, especially when the rectum is distended.  
 
Spatial resolution determines how well a CT image can represent the object scanned. 
Objects running obliquely and objects not running through the full thickness of a 
slice will ‘blur’ in the final image. This blurring is a result of a complex number of 
machine related factors including pixel size resulting in a partial volume effect, 
detector size, the design of the collimators, slice thickness, the reconstruction 
algorithm and the x-ray beam properties. Further discussion is beyond the scope of 
this thesis, it is considered sufficient to indicate an appreciation of the limitations of 
this modality. 
 
Larger structures such as the rectum, ascending, descending and sigmoid colons can 
easily be identified because of their relatively fixed positions within the pelvis, 
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although the change from one section of the GI tract to another is difficult to 
determine. The presence of air and faeces also allows distinction of the GI tract from 
other surrounding structures. The urinary bladder wall is displayed as a soft tissue 
density, whereas the urine displays a near-water density. Pelvic muscles are typically 
well delineated on CT images. However, small structures such as lymph nodes 
cannot be identified using CT imaging, unless they are larger than 1cm in size. 
 
Contrast and spatial resolution limitations degrade reconstructed images in the 
sagittal and coronal planes, limiting their usefulness for visualisation of structures 
such as the prostate and seminal vesicles. This results in a decrease in the accuracy 
of CT defined prostate volumes, especially in the determination of the apex (Khoo et 
al. 1999) leading to high inter-observer contouring variability (Lee et al. 2003).  
 
There are several patient related artefacts that need to be considered as possible 
factors that affect the quantitative data. Patient movement during a scan causes 
motion artefacts that can manifest as blurring through to ghosting. Although this 
may be seen as a disadvantage during a diagnostic scan, small patient movements, 
such as breathing, cause averaging that more accurately mimics the treatment 
situation.  
 
High-density objects such as hip prostheses cause streak artefacts. Although there 
are filters to minimise the effect these high-density objects have on the quantitative 
data, they are not normally utilised in radiation therapy planning as they affect the 
calibration parameters. Although patient sources of streak artefacts cannot be 
avoided, other sources such as patient stabilisation devices and radiographic contrast 
media should be minimised. Stabilisation devices intended to be used during 
treatment should be used during CT to assess their affect on the dosimetry, and if 
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possible, should be located outside the treatment field area. Contrast media should 
not be used for planning CTs and care should be taken to ensure that the patient has 
no residual contrast from diagnostic studies. 
 
In order to overcome the limitations in CT to accurately visualise the target volume 
and in order to incorporate functional and biological imaging into the planning 
process, other diagnostic modalities have been incorporated. 
3.4.2 MRI 
Magnetic Resonance Imaging (MRI) has been the most popular imaging technique 
used to complement the standard planning CT scan for prostate patients. MRI can 
produce images with superior tissue discrimination, with the ability to visualise the 
prostatic capsule, periprostatic plexus, prostatic apex and seminal vesicles as 
separate and discrete structures in multiple planes, without the use of ionising 
radiation. However MRI does not provide electron density information, essential for 
accurate radiation therapy planning dose calculations and can suffer from significant 
image spatial distortion. Therefore currently MRI data is used in radiation therapy 
treatment planning through the process of image fusion. Image fusion or co-
registration, integrates complementary information from CT and MRI into a single 
imaging study, most commonly using bony landmarks as reference points.  
3.5 Treatments 
The appropriate treatment for localised prostate cancer is controversial.  Much of the 
controversy relates to the debate over the natural progression of the disease and the 
diverse philosophical positions of the treating doctors. The lack of a well-designed 
randomised control trial also makes it difficult to compare different treatments. 
Current treatments for prostate cancer include surgery (radical prostatectomy) and 
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radiation therapy (external or brachytherapy), and less aggressive treatment options 
such as hormone manipulation. The treatment decision is often influenced by the 
TNM stage of the tumour at the time of presentation. Tumours classified up to T3 
are often classed as early stage and treated radically. Since the natural progression of 
prostate cancer is typically slow, a legitimate treatment that may be recommended 
for men with small tumours (T1-2) and aged over 70 is ‘watchful waiting’.  
 
4. Radiation Therapy for Prostate Cancer 
4.1 Introduction 
Radiation Therapy for early stage prostate cancer has become a very popular 
treatment option, especially for men where watchful waiting is not preferred or men 
with pre-existing medical conditions that preclude the use of surgical interventions. 
There are two main options for prostate cancer treatment with radiation; External 
Beam Radiation Therapy and Brachytherapy. 
 
External Beam Radiation Therapy (EBRT) is the most common form of radiation 
therapy and is the focus of this study.  
4.2 External Beam 
External Beam Radiation Therapy (EBRT) aims to deliver the most effective 
treatment dose whilst minimising the risk of treatment related morbidity. Morbidity 
is related to the dose prescribed to the treatment volume and the location of any  
dose limiting structures relative to this volume, which for prostate cancer are the 
rectum and bladder. Most commonly treatment is delivered using a Linear 
Accelerator which produces a mega-voltage (MV) x-ray beam. 
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4.3 Planning process 
Once the diagnosis of prostate cancer is confirmed and the decision is made to 
proceed with EBRT, the patient undergoes the planning process prior to 
commencing treatment. The planning process includes patient data acquisition, 
geographical planning which uses computers to design the treatment and produce 
dose distributions, plan verification and the preparation of treatment instructions.  
 
The following sections review patient data acquisition (4.3.1) and the geographical 
planning process (4.3.2 to 4.3.7), followed by a discussion of the uncertainties in 
radiation therapy (sections 4.4-4.7), and their effect on dose (4.8). An in depth 
analysis of plan verification techniques is presented in section 5.  
4.3.1 Patient data acquisition 
As previously discussed, CT imaging of the region of interest provides a 3D dataset 
demonstrating the spatial relationships of internal anatomy relative to the external 
contour. The electron density information required to accurately calculate dose 
distributions using radiation therapy treatment planning computers can also be 
derived from the CT dataset using the Houndsfield numbers.  
4.3.2 Geographical planning 
Once the patient dataset has been acquired, the geographical planning commences 
with the determination of the target and critical organ volumes that will be used for 
treatment. Once these volumes have been contoured onto the axial CT images using 
the treatment planning computer system, an appropriate treatment technique and 
beam arrangement is chosen and the dose distribution is calculated. This plan is then 
reviewed to ensure that the dose being delivered is appropriate, and that the potential 
morbidity associated with the treatment plan is acceptable. 
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4.3.3 GTV/CTV/PTV definitions 
The Gross Tumour Volume (GTV) is the gross palpable disease or the disease 
visible on diagnostic tests. It marks the location and size of the malignant growth 
that is intended for treatment (ICRU 50, 1993; ICRU 62, 1999). 
 
The Clinical Tumour Volume (CTV) is a tissue volume that contains the GTV with 
a margin for subclinical microscopic malignant disease and the uncertainty 
associated with defining the GTV. The Radiation Oncologists (ROs) use their 
clinical skills to define this CTV, which must be treated adequately in order to reach 
the aim of therapy. There is debate whether the seminal vesicles should be included 
in the CTV. Although electively treating patients at risk of seminal vesicle 
involvement seems logical, increasing the volume may not add to the cure rate and 
may increase morbidity due to an increase in the rectum volume treated by 40-50% 
when the seminal vesicles are included in the treatment field (Katcher et al. 1997). 
Seminal vesicle involvement indicates that the cancer has spread outside the prostate 
gland, which also indicates that there is a significant probability of nodal 
involvement and hence poor prognosis. Several authors have proposed that treating 
the seminal vesicles in early stage disease is not warranted. Katcher et al (1997) 
proposed that patients with PSA levels less than 4ng/mL and patients with PSA 
levels of 4 to 10ng/mL with a Gleason score of 6 or less, only have a risk of 6% of 
seminal vesicle involvement. Using a maximum risk of 13%, Diaz et al (1994) found 
that by omitting the seminal vesicles 47% of their patients could have their treatment 
localised to the prostate only, consequently reducing the rectal and bladder dose by 
up to one-third. Therefore for early stage disease it seems reasonable to omit the 
seminal vesicles and minimise morbidity. 
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The Planning Target Volume (PTV) is a geometric concept and it is defined to select 
appropriate beam sizes and arrangements, taking into consideration the net effect of 
all the possible geometric variations and inaccuracies in order to ensure that the 
prescribed dose is actually absorbed by the CTV (ICRU 50, 1993). An in depth 
analysis of the uncertainties in radiation therapy, as well as their effect on the 
treatment plan, will be presented later in this thesis (section 4.4-4.8). 
 
In summary, the CTV is the volume that must be treated to the dose prescribed by 
the RO. The PTV is the geometric concept that is determined by the RO, physicists 
and radiation therapists (RTs) that allows margins for uncertainties in the position of 
the CTV.  
4.3.4 Treatment techniques 
There are many different techniques used, for a variety of reasons, to deliver a 
treatment plan. Some techniques are quite simple and others very complex, however 
the aim is always the same, to treat the tumour to the maximum dose, whilst 
minimising the risk of morbidity. 
4.3.4a Three-Dimensional Conformal Radiation Therapy  
Three-Dimensional Conformal Radiation Therapy (3D-CRT) has become the 
standard form of radiation therapy made possible by advances in modern 
technology. 3D conformal techniques allow the radiation dose to be delivered more 
precisely than previously, thus enabling a steep drop-off in dose to the surrounding 
organs. 3D-CRT allows an increased radiation dose to be delivered to clinically 
localised prostate cancer thus reducing the risk of biochemical failure. This 
improvement in clinical outcome using 3D-CRT can also be achieved without an 
increase in associated acute or late morbidity (Zietman et al, 2005).  
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3D-CRT techniques usually consist of multiple static fields, customised shielding 
and patient immobilisation devices, and are planned using 3D planning computer 
systems. It is possible to design the size, shape and direction of the beams to 
conform the shape of the isodose curves to the shape of the target volume. There are 
many field arrangements possible to deliver 3D-CRT. The conventional four-field 
box technique is the most commonly used field arrangement in Australia (Knight 
2005) although some favour a three or six-field technique that eliminates the 
posterior field to limit dose to the rectum.  
4.3.4b Intensity Modulated Radiation Therapy (IMRT) 
Intensity Modulated Radiation Therapy (IMRT) techniques have been in use 
clinically for some time and have been demonstrated to be a feasible and safe 
method of delivering high doses to prostate cancer patients but are usually reserved 
for cases that have an increased need for dose conformity. IMRT utilises non-
uniform dynamic beams with varying intensities to deliver a dose that is tightly 
conformed to the target volume (Zelefsky et al. 2000; Zelefsky et al. 2005). IMRT 
techniques are more complex and time consuming during the planning stages, 
utilising inverse planning techniques to achieve the desired dose distribution. 
However this time can be minimised by adopting a standard field arrangement, 
generally 5-7 fields, and then optimising the dose distribution using IMRT 
principles. A recent review of IMRT workflow at the Royal Marsden Hospital in 
London found that IMRT increased the overall planning time as well as the time 
required for physics quality assurance procedures prior to the patient commencing 
treatment, however treatment times were similar to conformal techniques (Miles et 
al. 2005) 
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4.3.5 Dosimetry 
The treatment beam parameters are designed around the PTV to ensure that adequate 
dose is delivered to the CTV. It is generally accepted that the PTV should be 
encompassed by 95% of the prescribed dose, however researchers are unsure 
whether 99% coverage is better or, conversely, if 90% coverage is worse (Tinger et 
al. 1998). Until diagnostic biological imaging techniques, such as Positron Emission 
Tomograph (PET) scanning which is capable of more accurately identifying the 
location of cancer cells, is incorporated into planning researchers will not be able to 
answer the question of whether it is acceptable for a portion of the prostate to 
receive less than the prescribed dose to the CTV and preferentially deliver more 
dose to portions with increased tumour cell activity. 
 
Due to the location of the prostate within the pelvis significant radiation dose is 
often delivered to the rectum and bladder. The total tolerance doses for these organs 
are listed along with the associated morbidities in section 4.3.7. In order to assess the 
adequacy of a treatment plan, it is standard practice to calculate a cumulative Dose 
Volume Histogram (DVH) for each of the organs of interest. These doses are 
calculated based on the organ volumes at the time of the planning CT and dose 
points are compared to previous clinical data. It is routinely assumed that the 
volumes at the planning stage are a reasonable representation of those throughout the 
entire course of treatment. Therefore the DVH produced to assess the adequacy of a 
treatment plan assumes no uncertainties whereas it has been well established that 
many uncertainties in radiation therapy exist.  
 
Mathematical models to assist with plan assessment have also been developed to 
estimate Tumour Control Probability (TCP) and Normal Tissue Complication 
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Probability (NTCP). These models are based on assumptions from the planning 
information, and have similar limitations as DVHs.  
 
Despite their limitations, DVHs have continued to be the most common method of 
predicting morbidities (these morbidities will be discussed in more detail in section 
4.3.7). If the risk of morbidity is deemed too high by the RO, the treatment plan or 
the prescription dose is adjusted. However there is some evidence to suggest that in 
some patients a second planning CT scan can more accurately predict the mean 
target position and organ volumes compared with the initial planning scan (Dawson 
et al. 1998). Antolak et al. (1998) summarised the published data to conclude that 
the initial CT scan is not representative of the mean organ volume or position. 
Therefore for patients having a boost, the prostate position on a second planning CT 
scan taken closer to the time of the boost should better represent the mean position 
and therefore more adequately assess the risk of radiation induced morbidity (Crook 
et al. 1995). 
4.3.6 Prescribed Dose 
The clinical utilisation of 3D-CRT has allowed the prescribed dose to the tumour to 
be escalated without the risk of increased morbidity. Prior to the introduction of 3D-
CRT and IMRT, when the prescribed dose to the prostate exceeded 70Gy, there was 
an increased risk of developing severe morbidity. However since 3D-CRT and 
IMRT are able to more accurately conform dose to the target volume, and therefore 
decrease exposure of the surrounding tissues to high dose regions, morbidity has 
decreased (Perez et al. 2000; Zelefsky et al. 2002). Doses in excess of 70Gy are now 
common, provided the rectal volume receiving more than 70Gy is less than 25%, but 
the optimal dose for local control is still limited by the dose delivered to the 
surrounding tissues. There is a clear dose-response relationship indicating that 
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higher doses may cure more patients (Hanks, Matz & Diamond 1988; Liebel et al. 
1994).  
4.3.7 Morbidity and Side effects 
Although the majority of patients tolerate radiation therapy well, as with all forms of 
treatment there is an associated risk of side effects. The doses necessary to achieve 
tumour control for prostate cancer exceed the normal tissue tolerance of many of the 
normal structures also located in the pelvis. For prostate cancer patients the rectum 
and bladder are the organs of primary concern. Despite improvements in tumour and 
normal tissue localisation, more sophisticated treatment techniques and the increased 
use of stabilisation devices, most patients being treated with radical intent will 
experience side effects relating to the irradiation of the rectum. The resulting 
symptoms are dependant on radiation dose and fractionation, field location and size, 
concurrent treatments and related co-morbidities. However they are also influenced 
by psychosocial issues such as interpersonal relationships, body image and sexuality 
(O’Brien 2001). 
 
Radiobiological modelling has demonstrated a dose relationship between the rectal 
and bladder volume and dose delivered (Lebesque et al. 1995; Jackson et al. 2001; 
Somosy et al. 2002). As a result many institutions utilise a cumulative Dose Volume 
Histogram (DVH) to calculate the dose that will be delivered to these organs at the 
time of planning and by using predetermined dose limits the suitability of a 
treatment plan can be assessed prior to the patient commencing treatment.  
4.3.7a Basics of radiation biology: Radiobiological effects: 
The decision on whether radiation therapy is an appropriate treatment for each 
cancer depends on the ‘tolerance doses’ of the organs within the treatment field. In 
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clinical practice the tolerance dose is defined as the total dose, given under specific 
conditions (dose/fraction etc), which results in an incidence of serious complications 
in 5% of cases within 5 years (TD 5/5). Another tissue tolerance measurement used 
is TD 50/5 which represents a 50% incidence of severe complications within 5 years. 
The 5-year time frame takes into account the latency period before the onset of late 
effects so that the maximum incidence and severity can be assessed. Table 4-1 gives 
the common normal tolerances for tissues relating to prostate radiation therapy based 
on 2Gy per fraction doses and 5 fractions per week.  
Table 4 - 1: Normal tissue tolerance doses 
Tissue Injury TD 5/5 TD 50/5 Volume 
Rectum Ulcer, stricture 55Gy 80Gy 100cc 
Bladder Ulcer, constriction 60Gy 80Gy Whole bladder 
Extracted from Awwad, 1990 p148 
 
However a review of normal tissue tolerance data by Emami et al. (1991) states that 
the TD5/5 for the rectum is actually 60Gy and that there was no difference in effect 
for irradiation of one-third or two-thirds of the organ. Miralbell et al. (2003b) found 
that severe rectal toxicity may be mostly dependent on the highest dose to the 
rectum, whilst mild-to-moderate rectal toxicity may be related to volumetric 
parameters. It appears as if there is a minimal risk of complications if the posterior 
rectal dose remains between 50-60Gy, but the risk does significantly increase when 
the dose reaches 65-70Gy. Similarly, the anterior wall of the rectum treated to a dose 
of greater than 75Gy dramatically increases the incidence of moderate to severe 
proctitis (O’Brien 2001). 
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4.3.7b Rectum morbidity 
The rectum and anal canal play an important role in the gastrointestinal process. 
Despite their lack of function in digestion and their minor role in absorption, 
radiobiological side effects can have a debilitating effect on the quality of life for 
patients undergoing prostate radiotherapy. Gastrointestinal toxicity resulting in 
diarrhoea is frequently observed during radiotherapy of the abdomen and pelvis 
because of its effect on rapidly proliferating epithelial cells. The entire 
gastrointestinal tract is lined with a mucous membrane that contains layers of cells. 
A large proportion of the mucous membrane cells are undifferentiated and highly 
mitotic and as a result are extremely radiosensitive. Glandular tissue embedded in 
the mucous membrane is also affected by radiation. 
 
Whilst there is no doubt that the incidence and severity of side effects has decreased 
since the introduction of 3D-CRT and the virtual elimination of small bowel 
irradiation, many patients still experience low-grade gastrointestinal toxicity 
(O’Brien 2001). Perez, Fair and Idhe (2001) estimate 85% of abdomen and pelvis 
radiotherapy patients experience diarrhoea. The daily and total dose delivered to, 
and the volume of, normal bowel as well as individual patient variables, affect the 
incidence and severity of radiation enteritis.  
 
Diarrhoea results when the total secretion of fluid and electrolytes overwhelms the 
absorptive capacity of the bowel. Radiation-induced diarrhoea is caused by a range 
of patho-physiological mechanisms including malabsorption of bile salt and lactose, 
bacteria imbalances and intestinal motility changes, causing modification of the 
intestinal motility and structural alteration of the intestinal mucosa (Awwad 1990; 
Somosy et al. 2002). However the aetiology and pathogenesis of some mechanisms 
remains unclear (Somosy et al. 2002). Despite this lack of knowledge, 
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pharmaceuticals for the treatment and management of diarrhoea have made radical 
radiotherapy possible. More recently, medical intervention has been complemented 
by prophylactic treatments and nutritional support. Future research will continue to 
improve our understanding of the aetiologies and provide the basis for improved 
management strategies.  
 
Disturbed intestinal motility contributes to radiation-induced diarrhoea through the 
hastened passage of food and inadequate mixing of chyme. Increased motility 
manifests in the first days of treatment, preceding significant histopathological 
changes. When diarrhoea manifests after only 1-2 fractions it can therefore be 
attributed to gastrointestinal motility. Increased intestinal motility is attributed to an 
increase in prostaglandins, strong smooth muscle stimulators, from the irradiated 
intestine (Somosy. et al 2002,; Awwad 1990). Although the exact mechanism is not 
known, this explanation is supported by the observation that prostaglandin inhibitors 
minimise radiation-induced diarrhoea.  
 
The mature cells of the rectal mucosal membrane originate from rapidly reproducing 
differentiated stem cells and therefore have an increased radiosensitivity. In these 
healthy tissues radiation therapy induces an inflammatory response in the mucosal 
membrane of the rectum resulting in histamine and serotonin being released. This 
results in an increase in tissue perfusion allowing the treatment area to be infiltrated 
by increased numbers of leukocytes. These biological responses to radiation alter the 
ability of the mucosa to maintain its integrity resulting in mucositis (Moore-Higgs & 
Amdur 2001). 
 
Slower responding tissues such as connective tissue and vascular elements may 
cause radiation-induced diarrhoea. Fibrosis, an accumulation of dense extracellular 
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matrix (collagen), can occur in the submucosa, muscularis propria and subserosa. 
Increased collagen deposits are observable on day three and result in fibrotic 
strictures forming that effect motility and absorption. Heavy collagen accumulation 
accompanies oedema of the lamina propria manifesting in chronic clinical 
symptoms. The aetiology of fibrosis is poorly understood but it may be due to 
“direct effects of radiation on collagen or other constituents of the extracellular 
matrix, modified production or degradation of extracellular materials, direct or in-
direct effects of radiation to the vascular and/or parenchymal cells constituents, (or 
due to) consequences of non-specific inflammatory or autoimmune processes.” 
(Somosy et al. 2002) 
 
The contributing factors presented thus far are those that contribute to acute (early) 
effects. Nuyttens et al. (2002) were able to demonstrate a dose-volume relationship 
between rectal volume and dose. They found that a mean rectal volume of 11cc 
receiving >75Gy resulted in diarrhoea-requiring medication. The development of 
late radiation induced diarrhoea can also occur in 5-15% of all patients treated with a 
total prescribed dose of greater than 50Gy (Goodman, Hilderley & Purl 1997). The 
severity of early mucosal damage does not necessarily predict the severity of late 
effects (Awwad, 1990) as “a clear relationship between dose, volume and the risk of 
late toxicity is yet to emerge.” (O’Brien 2001, p.3)  
 
The multifactorial nature of diarrhoea and the tendency of patients to under report its 
occurrence produce challenges as to how to accurately measure the impact of 
diarrhoea management interventions. Most of the instruments used to measure 
diarrhoea in patients rely heavily on patient self-report and clinical interpretation. 
“Patients are not always forthcoming in describing symptoms that they find socially 
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embarrassing; clinicians perhaps reticent in pursuing symptoms that may be resistant 
to intervention.” (O’Brien, 2001 p 1) 
 
Some measures assist in minimising the effect of radiotherapy. Instructing the 
patient on the use of a low-residue diet that reduces the amount of fat in the diet can 
be helpful because fats are difficult to digest. If milk products are not tolerated, they 
should also be avoided. Pharmacological approaches may also be considered. 
Several anti-diarrhoeal drugs, including Loperamide (Imodium), Diphenoxylate 
(Lomotil) and Codeine, have the mechanism to bind to opiate receptors on the 
smooth muscle of the bowel. This results in slowed motility, improved bile acid 
absorption and increases fluid absorption.  
 
To increase absorption, drugs such as Pectin and Aluminium Hydroxide (Mylanta) 
can be used, while natural bulking agents such as Psyllium fibres (Metamucil, 
Citracil) provide bulk and are effective in mild diarrhoea. Anti-prostaglandin 
compounds (Salicylate) are used to control diarrhoea by blocking prostaglandin 
secretion. Bismuth products, such as Pepto-Bismol, are also useful in normalising 
fluid movements in the bowel while binding bacterial toxins and minimising 
antibacterial activity.  
 
Unfortunately the management and treatment of chronic radiation-induced diarrhoea 
is not thoroughly researched. Yeoh et al. (1993) claim that even those studies 
published have considerable limitations due to patient mortality and a lack of long-
term follow up. Their results demonstrated that changes in absorption persist after 
histological recovery of the mucosa, indicating “changes in intestinal transit 
contribute to diarrhoea and malabsorption” (Yeoh et al. 1993, p.404). Therefore 
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treatment of chronic diarrhoea is the same as that used to slow bowel movements in 
the acute stages, with surgical intervention if necessary. 
4.3.7c Anal Canal morbidity 
The impact of radiation therapy on the anorectal sphincter function is not as widely 
considered as the effects it has on the rectum proper, however the distressing 
symptom of tenesmus sometimes occurs when the anal sphincter is irradiated. 
Anorectal dysfunction has a major negative impact on patient’s quality of life. The 
processes leading to anorectal dysfunction are not well known. Yeoh et al (1998; 
cited by Gervaz, Wexner & Pemberton 2002) studied anorectal function in prostate 
patients. Resting and squeezing anal canal pressures were measured and found to be 
lower post-treatment than their pre-treatment base lines, indicating that possibly the 
internal and external anal sphincter functions are altered by irradiation. 
4.3.7d Bladder morbidity 
The bladder mucosa consists of 3-5 layers of epithelial cells. In the basal layer there 
is normally very little proliferation, indicating a slow turn over rate. When subjected 
to radiation injury there is therefore a long dose-dependent latency period before late 
occurring radiation injury appears in the bladder. However, clinically some forms of 
cystitis may manifest during a 7 week course of radiation therapy. Most patients 
experiencing early cystitis have a pre-existing bladder irritation due to bacterial 
infection or mechanical irritation such as bladder neck obstruction due to tumour 
growth. 
 
Although not as common as radiation-induced diarrhoea, alteration of urinary 
elimination due to temporary irritation of the bladder (cystitis) and or the urethra 
(urethritis), is a possible side effect from radiation therapy for prostate cancer. 
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Nuyttens et al. (2002) did not find a relationship between bladder dose and 
symptoms. 
 
Cystitis is an inflammation of the bladder wall lining and can present as increased 
frequency, dysuria, urgency, haematuria and may produce urinary incontinence. 
Urinary frequency is the most common symptom and is defined as voiding at 
frequent intervals that produces a sense of bladder fullness even in the absence of a 
full bladder. The onset of cystitis generally occurs during the third to fourth week of 
treatment and usually resolves within a few months of treatment completion.  
 
Radiation induced bladder capacity reduction, also resulting in urinary frequency, is 
influenced by the dose and volume of bladder irradiated (Perez et al. 2000). In men 
treated for prostate cancer reductions in bladder volume can occur from week 2 and 
continue during treatment. Chronic cystitis, which causes significant reductions in 
bladder capacity, can occur within 6 to 18 months post radiation therapy. 
 
Urinary incontinence can occur as a direct result of cystitis or as a late side effect of 
radiation therapy. Incontinence can be experienced as a result of stress or urge. 
Tenesmus, the persistent sensation of the need to empty the bladder or bowel, can 
also occur as a result of irritation of the sphincter. Urge incontinence is the 
involuntary loss of urine after a strong sensation of urgency. It is caused by 
uncontrolled bladder spasms or an unstable detrusor muscle.  
4.3.7d Sexual function  
The treatment of prostate cancer is also associated with post-treatment erectile 
dysfunction. Although radiation therapy is thought to have a lower risk of affecting 
sexual function than surgery, patients that undergo radiation therapy also report this 
side effect (Sethi et al. 2003). The aetiology of erectile dysfunction is not completely 
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understood. It is thought that erectile dysfunction after radiation therapy could be 
attributed to either vascular damage or due to the dose delivered to the penile bulb 
(Incrocci, Slob & Levendag 2002; Incrocci 2005). The penile bulb and 
neurovascular bundle are difficult to accurately defining on a CT scan. As such there 
is limited data on the relationship between dose delivered to the either the 
neurovascular bundles or penile bulb and the onset of symptoms. The introduction of 
MRI into treatment planning will allow the penile structures to be more accurately 
defined (Incrocci 2005) and therefore in the future a DVH may be able to more 
accurately predict the risk of decreased sexual function. IMRT techniques have also 
be shown to minimise doses delivered to the penile structures and may decrease the 
incidence of post-treatment erectile dysfunction (Sethi et al. 2003). 
 
4.4 Sources of uncertainty in Radiation Therapy 
There are many sources of uncertainty or error in radiation therapy that lead to 
incorrect field placement relative to the target volume. Sources of potential 
uncertainty and error for patients having radiation therapy include: 
a) Physical parameters of the treatment machine – SSD, field size, 
collimator rotation, couch height indicators incorrectly calibrated. 
b) Errors in the calibration of the treatment beam due to faults in the 
equipment or dosimetry measurements. 
c) Dose distribution measurement uncertainty and lack of reproducibility 
(eg, beam symmetry) 
d) Uncertainty in the determination of the contour of the patient, internal 
anatomy and/or tumour localisation. 
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e) Stabilisation and Positioning uncertainty: Uncertainty due to treatment 
position, comfort and immobilisation devices. 
f) Organ motion uncertainty: Uncertainty due to organ volume changes, 
organ motion and respiration. 
 
The uncertainties from a) through c) are related to the physical parameters of the 
treatment machine. Although these uncertainties cannot be completely eliminated, 
most centres have rigorous quality assurance programs in place that minimise the 
effect machine related uncertainties have on the dose delivered to the patient.  
 
Uncertainties d) through f) are related to the patient and the planning and treatment 
processes. These uncertainties are much more difficult to quantify, as they vary for 
each individual patient. The aims of this thesis are to investigate these types of 
planning and treatment uncertainties, and will therefore be the focus of the 
discussion in sections 4.4-4.8. 
 
4.4.1 Systematic errors 
Systematic errors are the difference between what is planned and what is treated. 
They are also known as preparation uncertainties, or simulator to treatment errors. 
Systematic errors are consistent errors, with the same magnitude and direction, every 
time that the incorrect parameter is used (van Herk et al. 2000). Systematic error can 
be calculated by taking a series of measurements and comparing them to the original 
measurement. By comparing the mean isocentre position from a series of 
measurements to the planned isocentre position the difference between the two 
isocentre positions is a measure of systematic error. Systematic errors are generally 
expressed as a standard deviation (SD). 
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This systematic variation leads to a displacement, or shift, of the dose distribution 
relative to the CTV and therefore has a large impact on the dose delivered, leading to 
a large under-dosage of the CTV in some patients.  
4.4.2 Random errors 
Random errors are the variations that occur on a daily basis, or from treatment to 
treatment, but do not have a constant magnitude or direction. They are also known as 
treatment execution uncertainties.  
 
Random error estimates can be derived from repeated measurements of a given 
parameter in the same conditions. For example, in the same series of port films taken 
to assess systematic error, the isocentre will generally randomly fluctuate around the 
mean treatment position. Although the isocentre location may not be the same as 
planned, the magnitude and direction of the variation changes on a daily basis. 
 
Random errors can also be expressed in terms of a SD for statistical consideration 
(Dutreix 2000). Random errors lead to a blurred dose distribution as the variations 
cumulate over the course of treatment. The impact of large random errors is much 
smaller than for systematic errors and leads to a moderate under-dosage for a large 
number of patients. 
4.4.3 Total Uncertainty 
Since it is often difficult to separate the types of error in practice, a combined 
uncertainty is often used to consider all sources of uncertainty. Total uncertainty (T) 
is related to patient set-up (S) uncertainties (combining positioning and equipment 
factors) and internal organ motion (I) uncertainties (including random and 
systematic components of each).  
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When the SD is low it corresponds to a narrow variation in dose distribution, 
however a large SD indicates a large degree of uncertainty in the ability to deliver 
the planned dose. The weakest point of the chain is the largest uncertainty, since the 
contribution of small uncertainties is relatively negligible, therefore every effort 
must be made to eliminate the largest uncertainties.  
 
Total uncertainty can be minimised depending on the type of verification used. 
Although these will be discussed in greater detail later, if patients have no on-line 
pre-treatment verification, total uncertainty will include set-up error and organ 
motion. If on-line position verification using bony landmarks is used, set-up error 
can be virtually eliminated from the total uncertainty equation, and as will be 
discussed later, reduce the margins necessary to ensure the CTV is delivered the 
prescribed dose. If on-line organ motion verification is used (CT verification or 
implanted fiducial markers), both set-up error and organ motion can potentially be 
omitted. However, uncertainty will never become ‘zero’ as there will always be 
some uncertainties involved in radiation therapy. For example, how accurately do 
the markers represent the entire prostate gland, what is the potential for seed 
migration and how accurately can the CTV contours be delineated?  
 
It is clear that further investigation is needed on how to reduce these uncertainties, 
along with a better understanding of how they affect the dose delivered. This is the 
focus of this thesis.  
4.5 Contouring uncertainty 
4.5.1 Defining the Prostate (CTV) 
The delineation of the CTV is subject to intra and inter-observer variation, and 
should be one of the uncertainties that are accounted for in the CTVÆ PTV margin. 
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This contouring uncertainty becomes more critical when using CT imaging for 
treatment verification and will be discussed in greater detail in following sections. 
 
Uncertainty in volume delineation and hence the location of the centre of volume 
(COV) is a function of partial volume averaging, poorly defined anatomy, variations 
in contouring and operator misinterpretation. Larger uncertainties may exist in the SI 
measurements due to the slice thickness which magnifies difficulties in determining 
the upper and lower level borders of the prostate. However the increased patient 
dose necessary to reduce the slice thickness cannot usually be justified. According to 
Beard et al. (1996) contouring errors are only a minor contributing factor compared 
to observed COV motion and these uncertainties can be minimised by limiting the 
contouring to only one observer (which may be possible during research studies but 
is unrealistic in clinical practice), using a standard slice thickness, ensuring the 
definitions of the organs are well established and evaluating reproducibility.   
 
Contouring uncertainty has been demonstrated in the literature. Studies assessing 
contouring uncertainty take repeat measurements using the same patient data to 
evaluate reproducibility. If there was no contouring variation, repeat measurements 
would be identical. Despite every effort to outline soft tissue volumes consistently 
and correctly, significant operator judgement is required in the interpretation of the 
CT scans, particularly at the apex of the prostate, junction of the bladder and base of 
prostate and this results in inter and intra-observer variations.  
 
A 6% (1SD) variability of PTV contours has been attributed to contouring variation 
including an estimate of reproducibility of 1.5mm in PTV border position and 1mm 
in the COV position (Melian et al. 1997). These figures are comparable with an 
uncertainty associated with COV co-ordinates of 1.6mm in the AP and RL directions 
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calculated by Roeske et al. (1995) and by Beard et al. (1996) who demonstrated 
differences of 2mm in the AP and 1mm in the RL directions. This estimate was 
based on uncertainty in alignment and inconsistencies in contouring. It was 
acknowledged that larger uncertainties may be present in the SI measurements due 
to the slice thickness and difficulties in determining the superior and inferior levels 
of the prostate on CT. 
 
Valicenti et al. (1999) demonstrated that there was excellent agreement among 
multiple observers when defining the prostate volume and COV, but poor agreement 
when defining the seminal vesicles. They also compared the variability with and 
without contrast to assist target volume delineation. The SDs of the prostate volume 
for 6 patients without contrast ranged from 2.9-9.1cc, mean volume ranging from 
24.9-57.8cc, and for the 4 patients with contrast SD ranged from 5.9-15.6cc, mean 
volume range 42.4-109.5cc. Although there was an improvement in reliability with 
contrast, it was not statistically significant. 
 
To quantify differences between contours from different CT scans it is possible for 
each scan, to calculate the ratio between the absolute volume and the mean volume. 
This ratio will calculate the measure of volume variability of the prostate during 
treatment for each CT scan. 
4.5.2 Rectum solid, rectal wall, anal canal & Bladder 
There are surprisingly few articles that report results on contouring reproducibility 
of critical structures in the pelvis. Lebesque et al. (1995) estimated contouring 
reproducibility to be approximately 3% for the rectum, 7% for the rectal wall and 
2.5% for the bladder.  However these figures were based on the sequential 
contouring of only 1 patient. As with the prostate, an important factor for the 
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variation in rectum and rectal wall volumes could have been as a result of the CT 
partial volume effect, resulting in variation in the determination of the upper and 
lower levels of the rectum. As expected, bladder reproducibility is greatest probably 
due increased contrast compared to the surrounding pelvic organs. 
 
Although there are obvious pathological differences between the large intestine, 
rectum and anal canal, defining the junction between these different structures using 
diagnostic imaging modalities is difficult. Because structural differences cannot be 
seen, other methods of defining these structures need to be used. Many of the 
radiation therapy articles reviewed used ambiguous definitions of the rectum. The 
rectum is generally defined as a solid organ (Beard et al. 1996; Fiorino et al. 2002; 
Foppiano et al. 2003; Zellars et al. 2000), however some authors contour the rectal 
wall or hollow organ (Foppiano et al. 2002; Meijer et al. 1999), some also used the 
rectal diameter (Beard et al. 1995) and some made distinctions between the upper 
and lower halves of the rectum (Zellars et al. 2000). Other authors gave no 
indication as to how the contours were defined or generated (Emami et al. 1991; 
Roeske et al. 1995). Similarly there was no agreement amongst the authors on the 
level at which the rectum contours should commence and cease. Some only defined 
the organ through the length of the treatment field, while others defined the entire 
organ. This reinforces the recommendation by Beard et al. (1996) that the definitions 
of the organs should be well established so as to minimise contouring uncertainty. 
4.6 Stabilisation and positioning uncertainty 
Implicit in the process of radiation therapy planning is the assumption that either the 
volumes of interest are fixed in space or that the range of motion of these structures 
is both predictable and quantifiable. Although patients are positioned in the same 
manner each day, small changes in patient position and orientation are readily 
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apparent (Beard et al. 1996).  Patient set-up uncertainty relating to stabilisation and 
positioning will be discussed in this section. Organ motion will be discussed in the 
following section (4.7). 
 
It is a complicated matter to ensure a stable and reproducible position of the patient 
during the whole treatment, from the treatment simulation to the first setting-up of 
the patient and then from one treatment session to the next until the end of treatment 
(Dutreix 2000). The first decision that must be made is how to treat the patient; 
whether to treat them supine or prone; what treatment surface to use and the level of 
comfort required. Some centres utilise customised rigid immobilisation devices to 
assist in patient set-up, others utilise very basic standard set up equipment. All of 
these factors, along with body habitus, affect patient set-up accuracy. 
 
There are several different methods by which set-up uncertainty can be measured. 
Because patient set-up accuracy is measured relative to bony landmarks, port films 
and EPI can both be used to assess uncertainty. Repeat CT scans can also be used, 
although these studies have previously been performed with a limited number of 
repeat CT scans due to the time and inconvenience of repeating the scan in the 
planning department. With EPI and CT imaging, the translation required to align the 
pelvic bones between planning and treatment images is accurately calculated by 
software programs. As explained earlier, sequential images can be used to break 
down set-up uncertainty into random and systematic components. Hurkmans et al. 
(2001) completed a systematic review of set-up verification for prostate techniques 
and found that systematic error ranged from 1.0-3.8mm (1SD) and random error 
ranged from 1.2-3.5mm (1SD). Systematic errors identified in these types of studies 
can be corrected and reduce the total uncertainty of patient set-up.  
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Previous studies have reported that set-up error is compatible with the assumption 
that it is normally distributed around zero for all three directions (Balter et al. 1993; 
Rudat et al. 1996). However Antolak et al. (1998) found that in prostate cancer the 
AP direction can be skewed negatively towards the posterior, hence moving the high 
dose region close to the rectum. 
4.6.1 Patient position 
4.6.1a Supine vs. prone 
The first decision to be made regarding patient setup is whether the patient should be 
treated supine or prone. McLaughlin et al. (1999) postulated that the prone position 
would lead to better stabilisation than the supine position as the prostate would rest 
against the bony symphysis rather than the less rigid, less stable rectum and pelvic 
soft tissues. They did find that rectal sparing was improved for patients in the prone 
position, however patient position was not found to influence prostate motion. The 
effect of patient position on prostate motion will be discussed in detail later. Weber 
et al. (2000) also found that the prone position was associated with a better dose 
distribution to the rectum and/or bladder, but reported higher systematic errors 
associated with the prone position resulting in increased set-up variation. This 
increase in systematic errors for patients in the prone position was also reported by 
Tinger et al. (1998). Patient comfort and RT satisfaction and convenience has been 
reported to favour the supine position compared to the prone position (Bayley et al. 
2004). However Cox and Davison (2005) found no significant difference in comfort 
levels between the two positions and concluded that “selection between the prone 
and supine positions may be made without considering comfort” (p. 109) 
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The difficulty in interpreting recent articles comparing treatment positions and 
immobilisation techniques lies in the fact that many authors now perform on-line 
pre-treatment corrections, thus a review of images comparing positions show no 
statistically significant difference in isocentre positioning error or total positioning 
error, however the number of pre-treatment corrections required is sometimes 
reported as a method of comparing techniques (Bayley et al. 2004; Weber et al. 
2000). The research generally indicates that the prone position requires more pre-
treatment isocentre corrections and results in significantly more prostate motion 
(Bayley et al. 2004).  
4.6.1b Mylar vs. rigid table top 
A common source of systematic error in the AP direction has historically been the 
flexible Mylar window of the treatment couch which allowed sag compared to the 
CT/Sim couch used for planning. To minimise the effect of Mylar sag and eliminate 
the potential for a systematic error, carbon fibre couch tops are now being fitted to 
most new treatment machines, and many old machines are having their Mylar 
replaced with rigid inserts (Bieri et al. 1996; Catton et al. 1997).  CT scanners being 
installed in radiation therapy departments are now also being adapted to more 
closely resemble the treatment couch.  
4.6.2 Immobilisation Devices 
The advantages of delivering conformal RT are limited by the ability to deliver the 
prescribed dose accurately and reliably to the target volume over a protracted 
treatment course. The effectiveness of an immobilisation system will help determine 
the width of margins required around the CTV. 
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The most common patient set-up used for target localisation in the pelvis is to align 
triangulation tattoos or skin markings consisting of an anterior (or posterior for 
prone patients) midline and coplanar right and left lateral positioning tattoos with an 
external laser system, as this is the closest way to align external marking with 
internal anatomy. This method can be used with or without immobilisation devices.   
 
There have been mixed results on whether immobilisation reduces the number of 
isomoves required. Rosenthal et al. (1993), Soffen et al. (1991) and Malone et al. 
(2000) found immobilisation significantly reduced errors, Catton et al. (1997) found 
that non-customised leg immobilisation reduced the number of set-up variations 
greater than 5mm from 17% with no immobilisation to 8%. Soffen et al. (1991) and 
Bentel et al. (1994) found improvements only in the AP direction, while Song et al. 
(1996) found no improvement in reproducibility could be demonstrated. The number 
of isomoves obviously depends on the action level that is chosen and therefore this 
should be considered when deciding on the appropriate stabilisation and 
immobilisation device. 
 
There are many stabilisation methods that have been reported; including Alpha 
Cradles which contour the posterior and posterior-lateral surfaces of the patient from 
mid-thigh to lower thoracic (Bentel et al. 1994; Chandra et al. 2003; Rosenthal et al. 
1993; Fiorino et al. 2002; Lattanzi et al. 1999; Soffen et al. 1991; Tinger et al. 1998; 
Yan et al. 1998) and thermal body casts such as Hipfix (Malone et al. 2000). In 
studies of patient set-up uncertainty a comparison is commonly made against 
patients ‘without rigid immobilisation’ which basically meant patients had a 
standard wedge, foot stocks or bolster under their knees (Bieri et al. 1996; Catton et 
al. 1997; Dehnad et al. 2003; Miralbell et al. 2003b; Nederveen et al. 2003; Stroom 
et al. 1999; Weber et al. 2000; Wong et al. 2005). Most of these studies have been 
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conducted using serial portal images to assess the patient positioning accuracy 
compared to bony landmarks. The magnitude of set-up uncertainty depends on the 
type of immobilisation used (Antolak et al. 1998). This can be clearly seen in Table 
4-2. 
Table 4 - 2: Set-up errors using various forms of immobilisation device. 
Set up error (mm) Mean (mm) SD (mm) 
Author Year Notes SI AP RL SI AP RL 
                  
Rosenthal 1993 alpha cradle 0.2 0.3         
    without immobilisation 0.4 0.4         
Dawson 1998 No immobilisation device  1.7 -1.1 -1 3.3 5.5 2.3 
Tinger 1998 Alpha cradle -0.4 1.4 0 2.1 3 3.1 
Rudat 1996 No immobilisation device        5.4 4.9 3.1 
Malone 2000 Hipfix  2.6 2.3 1.9 1.8 1.8 1.4 
    alpha cradle  3.2 3.2 2.7 2.2 2.7 2.4 
    
foam leg support (non-
rigid)  3.4 3.2 3.2 2.9 2.5 2.9 
    
"reported estimates for 
non-immobilised " 
1.6 - 
5.4 
2.4 - 
4.9 
2.8 - 
3.4       
Bayley 2004 supine (Vac-loc device)   -0.1 -0.1   3.6 3.3   
    prone (Hip-fix device)   0.1 0   4.3 3.7   
Fiorino 1998 Alpha cradle - pelvis only -1.5 2.4 0.3 3.3 4.4 3.6 
    Alpha cradle - Legs also -1.2 0.9 0.4 2.7 2.6 2.4 
Chung 2004 
supine - vacloc mm (prior 
to corrections) -0.5 -0.3   2.5 3.2   
Hurkmans 2001 
Review of published 
articles  a SD of 2.5mm is considered state of the art 
                  
    Average (mm) 0.66 1.05 1.07 3.10 3.42 2.65 
 
Pelvic rotation can also be minimised by appropriate immobilisation devices. 
Although commercially available EPI software will now calculate pelvic rotation, 
adjusting for this rotation in practice has proved difficult unlike translational 
misalignments which can be corrected by simple couch shifts. Even the use of CT 
matching does not explicitly account for axial plane rotation, however the 
superposition of pelvic bones showed rotations of less than 1.5º (Melian et al. 1997). 
van Herk et al. (1995) showed pelvic bone rotation compared to the femora and the 
treatment couch, were up to 3.7º, however there is no indication on how these 
patients were immobilised.  
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Ankle blocks are often used to minimise pelvic rotation (Morr et al. 2002). This is 
supported by van Herk et al. (1995) who found differences in the width of leg 
opening correlated with differences in bladder volume. Patients with large bladder 
volumes tended to reduce the angle of leg opening which in turn correlated with 
rotations of the pelvis around the RL axis. As a result van Herk et al. (1995) advised 
that leg rotation should be limited. Lower leg immobilisation, from knees to ankles, 
has been reported to ensure a reproducible set up with respect to the angle of hip 
flexion and degree of pelvic tilt (Crook et al. 1995). Using this set-up, pelvic rotation 
was reported as being 1.63º (SD= 1.55º) in the AP and 2.09º (SD= 1.81º) in the RL 
directions (Crook et al. 1995). 
 
The cost of fabricating personalised, rigid immobilisation devices is also another 
factor that needs to be considered, especially since simple non-customised devices 
have been shown to improve immobilisation.  
 
Patient habitus also needs to be considered. Bieri et al. (1996) found that patient 
weight and thickness did not influence the reproducibility of patient set-up using 
only non-rigid immobilisation. However Song et al. (1996) found that although 
patient set-up errors are greatest in the AP and SI directions, increased amounts of 
RL movement are seen in patients with pelvic circumference >105cm. Richards and 
Buchler (1977) also reported a relationship between patient weight and isocentre 
placement.  
 
Various immobilisation and positioning devices (footstocks, knee bolsters, alpha 
cradles) and patient positions (prone vs. supine) have been evaluated in view of 
optimising treatment set-up but there is a lack of consensus on the method that 
minimises patient set-up uncertainty. The conflicting nature of the results indicates 
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that with careful attention to patient positioning excellent setup reproducibility can 
be achieved without rigid immobilisation. So the question still remains as to whether 
immobilisation reduces set-up error. Hence no firm recommendations regarding the 
optimal position or stabilisation device for patients receiving radiation therapy for 
prostate cancer have been developed. However as higher doses are prescribed using 
techniques with increased conformity and clinical practices move towards routine 
implementation of pre-treatment on-line corrections, rigid immobilisation devices 
are likely to be increasing utilised to minimise intra-fraction patient motion rather 
than for improving inter-fraction setup reproducibility. 
4.7 Organ Motion uncertainty 
Whilst bony anatomy can be used to assess patient set-up uncertainty and rigid 
patient immobilisation may be comforting to the RO and RT it ignores target motion 
within the patient. There is an abundance of literature demonstrating prostate motion 
during a course of radiation therapy, both intra- and inter- fraction. Treatment 
delivery without additional adjustments to account for anatomical changes can result 
in target under-dosing and over-dosing of sensitive structures with respect to the 
original plan. Even with a perfect patient set-up, motion of the internal organs may 
significantly impair the intended precision.  
 
The location of the prostate relative to the bladder and rectum, means that changes in 
their volumes can potentially displace the prostate with respect to the high dose 
region (Miralbell et al. 2003b). Changes in organ volume and position within the 
pelvis lead to variations in dose distribution during treatment, thus casting doubt on 
the reliability of the predictive models for NTCP based on DVH data obtained at the 
time of planning. If the rectal volume changes are significant during a course of 
treatment, the reliability of the predictive model based on a single DVH estimation 
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is compromised. Volume changes compared to the planning CT are a result of 
differential bladder and rectal filling. Methods of reproducing the planning volumes 
have included providing the patient with instructions on what to eat and drink, along 
with more invasive methods. Changes in volume also alter the pressure exerted on 
the prostate, resulting in different prostate rotation and deformation. 
 
The amount of organ motion experienced by the prostate (CTV) due to organ filling 
and respiration affects the margin that needs to be applied to derive the PTV. If the 
mean position for prostate motion across a treatment course is zero, i.e. the prostate 
is exactly at the mean position during the planning CT, the impact of motion is 
minimised, effectively reducing the steep dose gradient at the margins due to 
random uncertainty. However if the mean motion varies significantly from zero, i.e. 
the position of the prostate during the planning CT is significantly different to the 
mean position during treatment, the impact on accuracy of the delivered treatment 
can be substantial due to a large systematic error being introduced, resulting in a 
geographic miss.  
 
This was observed by Nederveen et al. (2003) who were surprised by their results 
which showed that in some cases systematic error increased after the patient’s 
position was verified based on bony anatomy. This was because the prostate position 
relative to the bony anatomy at planning was an outlier and therefore a systematic 
error was introduced after bony anatomy corrections were made. This demonstrates 
that, without the complete picture being considered, in some cases correcting for one 
error introduces a larger error than if no correction had been applied! This is the 
rationale for on-line imaging. On-line imaging can account for organ motion and 
therefore the CTVÆ PTV margin can be reduced. This will be discussed in detail 
later in section 5. 
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Organ motion can also be affected by several factors other than organ volume. If a 
patient has had previous surgery he may have reduced prostate motion due to 
tethering and scar tissue minimising the mobility of surrounding tissues. The staging 
at the time of diagnosis may also affect prostate motion. Although Crook et al. 
(1995) did not find significant differences in the mean motion between early and 
locally advanced prostate cancer, recurrence can potentially reduce the mobility of 
the prostate by tethering the gland to adjacent tissues. 
4.7.1 Methods used to monitor organ motion 
For CT based studies, there are two methods to calculate organ motion described in 
the literature. One method measures from a reference point to each edge of the organ 
of interest in all three orthogonal directions. Whilst this method provides 
information on any changes to the shape of the organ, it is a time consuming 
process. More commonly COV co-ordinates, also referred to as centre of mass 
(COM) are used to represent the overall organ position (Tinger et al. 1998). Planning 
computer software can easily calculate the COV co-ordinates of a contoured organ. 
Motion can be measured by comparing the location of the COV during subsequent 
CT scans relative to the planned COV location.  
 
Assessing organ motion using COV co-ordinates minimises the effect of small 
variations in contouring on a slice-by-slice basis, gives one easily definable 
reference point, rather than edge measurements, and will not be affected by organ 
swelling. Implicit in the use of this method is the assumption that motion can 
adequately be described by COV co-ordinates (Roeske et al. 1995).  
 
Implanted fiducial markers in the prostate can also be used to track organ motion on 
EPIs. Using the COV co-ordinates of the markers to assess internal organ motion 
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has similar advantages to those previously explained. It is common to use 3 or more 
implanted markers to minimise the impact of possible marker migration. Using 
simulated values Pouliot et al. (2003) found a maximum estimate of marker 
migration of 1.16mm (SD= 0.86mm), with most scenarios less than 1mm.  
4.7.2 Organ motion studies 
Prostate motion during radiation therapy has been well documented with techniques 
such as serial planning CT scans, on-line or off-line EPI of implanted fiducial 
markers or on-line ultrasound scanning.  
 
EPI is the typical imaging system employed on a linear accelerator. Real time portal 
imaging using EPI may correct for patient positioning errors, however to assess 
internal organ motion fiducial markers need to be used because there is no direct 
target visualisation due to the lack of soft tissue visualisation. This is an invasive 
technique, not without complications. Ultrasound can also be used to localise the 
prostate but there is evidence that the pressure of the ultrasound probe may in fact 
displace the prostate further (Serago et al. 2002). Both EPI and ultrasound lack the 
ability to assess position variability in all directions, and implanted markers have the 
potential for migration. 
 
Complete investigation of the impact of target motion on the accuracy of treatment 
planning and treatment delivery requires a measure of target position at every 
treatment. CT based studies provide excellent spatial resolution for assessing organ 
motion, however access to a CT scanner to enable re-assessment is often difficult. 
For practical reasons this has resulted in previous studies using sampling methods 
using limited CT scans. Therefore many of the previous studies are based on only 2 
CT study sets with small patient numbers, which would not adequately detect the 
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influence of random and systematic uncertainty on prostate motion. Care needs to be 
taken when analysing these studies, however the results have demonstrated that 
motion was significant enough to warrant further investigation.  
 
A review of published data shows the mean prostate motion to be 5-10mm in the AP 
direction, 1-2mm in the RL direction and about 10mm in the SI direction (Bayley et 
al. 2004). This contradicts the summary of prostate motion data presented in Table 
4-3. The distribution of motion in this table tends to cluster around relatively small 
changes of 5mm or less. However the review by Bayley et al (2004) included only 
eight studies compared to the fifteen studies used to calculate the average prostate 
motion in Table 4-3 making Bayley et al’s (2004) calculation of prostate motion less 
accurate because it would be more significantly influenced by a study with a large 
degree of motion, such as the study by Rudat et al (1996) where a maximum prostate 
displacement of up to 6cm was recorded. Frequency distributions of prostate motion 
show movement in the AP and RL directions were normally distributed (Roeske et 
al. 1995; Rudat et al. 1996). Despite Rudat et al. (1996) showing that movement is 
also normally distributed in the SI direction, Roeske et al. (1995) found it was more 
randomly distributed. Prostate motion has been shown to be consistent during a 
course of treatment (Bayley et al. 2004). One explanation for asymmetric shifts in 
prostate position is that people have different side effects. 
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Table 4 - 3: Results of prostate motion studies 
Internal organ motion (mm) Mean (mm) SD (mm) 
Author Year Notes SI AP RL SI AP RL 
Melian 1997 average COV motion  0.4 -0.7 0.3 3.1 4 1.2 
Zelefsky 1999 prostate COM displacements -0.5 -1.2 -0.6 3.3 2.9 0.8 
Dawson 1998 Internal organ motion - prostate  -0.6 -0.8 0.7 2.5 2.3 1.8 
Tinger 1998 prostate motion  1.5 0.5 0 3.9 2.6 0.9 
Roeske 1995 prostate COM (range)       
0.8-
4.3 
0.8-
4.4 0-1.0 
Rudat 1996 prostate - CA slice only         3.7 1.9 
Antolak 1998 CTV motion        3.6 4.1 0.9 
    prostate motion        3.6 3.6 0.7 
Althof 1996 prostate motion       1.7 1.5 0.8 
McNair 2004 interfraction prostate movement 2.9 0.7 -0.2 3.1 2.3 1.2 
    intrafraction prostate movement 1.3 0.9 0 3.4 2.8 1.6 
Dawson 2000 due to breathing - prone  
0.9-
5.1 
up to 
3.5         
    due to breathing - supine  <1 <1         
    deep breathing (prone)  
3.8-
10.5           
    
deep breathing (supine) - hard 
table top 
2.0-
7.3           
Bayley 2004 supine  0 0.1   3.5 3.6   
    prone  0.7 0.7   3.7 4   
Crook 1995 Supine  -5.9 -5.6   -4.5 4.1   
McLaughlin 1999 supine COM    6.1 range (2.2-11.6mm)   
    prone (COM)   6.2 range (2.2-10.5mm)   
van Herk 1995 prostate       1.7 2.7 0.9 
Stroom 1999 Supine        2.8 2.8 0.6 
    Prone        1.70 2.10 0.50 
    Average (mm) -0.02 0.63 0.03 2.47 3.07 1.06 
 
The inter-institutional variability in prostate motion as shown on Table 4-3 may be 
explained by differences in patient set-up conditions, different patient treatment 
preparation, different techniques to define the prostate (for instance MRI), and 
different methodological and statistical approaches.  
 
The effect of different methodological approaches is seen when reviewing one of the 
most comprehensive studies on organ motion (van Herk et al. 1995). The authors 
assessed SDs and correlation coefficients for nearly 182 combinations of motion 
parameters and volume differences. Although this study was able to quantify 
correlations between motion and volume, the methodology they used does not 
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necessarily reflect a clinical scenario. In this study they combined the data gathered 
during 4 CT scans, where in a clinical situation the initial position is used as a 
reference and then subsequent CT data sets compared to this ‘planned’ position to 
assess relative organ motion. Therefore from this study they were unable to identify 
any time trends, or assess the impact these variations would have on the planned 
dose. Using this methodology the authors have calculated random errors and their 
correlation, however if the location of the prostate during the planning CT was not in 
the mean location, or if the prostate motion changes as a function of time, they will 
not have accounted for any systematic errors. 
 
When considering previous studies that have used CT verification to examine organ 
motion, it is important thing to note that most of these studies have been done with a 
small sample size and used a methodology that may have limited their ability to 
accurately reflect treatment conditions. Most of the articles do not mention the 
timing of the CT relative to treatment delivery and therefore these studies are only 
representative of what may be occurring on a daily basis. 
4.7.3 Volume changes 
Variations in bladder and rectal filling have been shown to affect prostate position 
within the pelvis (Beard et al. 1996; Bentel et al. 2000; Melian et al. 1997). It is 
commonly accepted that random changes in rectal volume are the most influential 
factor affecting isocentre displacement relative to the prostate, although bladder 
volume has also been associated with prostate motion. The literature regarding 
rectum and bladder volume changes, and their combined effect, will be presented in 
the following sections. 
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4.7.3a Rectum 
It has been demonstrated that rectal distension shifts the prostate in an anterior-
superior direction. Melian et al (1997) used 30cc of air to demonstrate prostate shifts 
of up to 3.0cm in the AP direction, and up to 1.5cm in the RL direction. These 
results in the AP direction were consistent with those of van Herk et al. (1995) who 
demonstrated a significant relationship (R= 0.62) between rectal volume and 
prostate translations in the AP direction. Crook et al. (1995) also demonstrated an 
AP shift, however RL displacement was not observed. It is thought that the rectum 
becomes progressively less distended during a course of radiation therapy and 
therefore the predominant motion of the prostate throughout the treatment course is 
in the inferior-posterior direction. 
 
One explanation for shifts in prostate position is the physiological changes in organ 
volume due to radiation induced side effects as discussed earlier. Radiation induced 
diarrhoea has been linked to inferior-posterior shifts in the location of the prostate 
due to reductions in rectal volume and radiation induced proctitis has been linked to 
patients tensing their pelvic muscles, causing an anterior-superior prostate shift 
(Dawson et al. 1998). However flatulence often increases during radiation therapy 
and the presence of gas may increase the overall rectal volume. The randomness of 
rectal volume was demonstrated during a study where patients were repeatedly CT 
scanned over a period of 90 minutes. It was reported that rectal fullness changed 
with time and that rectal gas position was gravity dependent (Bentel et al. 2000).  
 
Contrary to these previous studies Miralbell et al. (2003b) found that there was a 
trend towards increasing rectal volumes during treatment, especially if their initial 
rectal volume was <75cc.  As a consequence patients with small planned rectal 
volumes are likely to have a much larger volume treated to a high dose and thus 
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DVHs established at simulation are likely to underestimate the risk of rectal toxicity. 
This is consistent with findings by Fiorino et al. (2002), where small rectal volumes 
at simulation correlated with late rectal bleeding. However Lebesque et al. (1995) 
concluded that since NTCP variation did not correlate with rectal filling, the NTCP 
estimates from the initial scan are representative of the whole treatment. 
4.7.3b Bladder 
Studies have shown that a constant bladder volume is not achievable when patients 
are treated with a full bladder. When a patient maintains continence with a full 
bladder, contraction of the pelvic floor muscles may significantly change the 
position of the prostate (Dawson et al. 1998). Crook et al. (1995) showed, using 
post-voiding data, that there was a posterior-inferior shift of the prostate. This may 
be due the contraction of pelvic floor musculature to maintain voluntary continence 
pulling the prostate superiorly. Relaxation of the pelvic floor muscles after voiding 
may allow the prostate to move posteriorly and inferiorly (Crook et al. 1995). 
However van Herk et al. (1995) found that the bladder had a much weaker 
relationship to prostate translation than the rectum did in the same direction (R= 
0.26). 
 
Other reasons why patients may not be able to maintain a full bladder include 
radiation induced side effects. Prostate cancer patients frequently have problems 
with micturition prior to commencing treatment and in addition to irritations caused 
by treatment, alterations in bladder capacity and micturition frequency may occur. 
Radiation induced cystitis may also lead to decreased bladder capacity (Rudat et al. 
1996) or the tensing of pelvic muscles, once again causing an anterior-superior 
prostate shift (Dawson et al. 1998). However bladder volume has also been 
demonstrated in one study to increase with time (Bentel et al. 2000). Once again this 
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highlights the difficulty in predicting the effect of organ volumes during a treatment 
course. 
4.7.3c Combined effects 
A statistically significant correlation exists between shifts in the SI & AP directions 
(R= -0.37), suggesting that the internal prostate position is likely to be affected by a 
combination of changes in bladder and rectal volumes, resulting in a diagonal shift 
in the SI/AP direction (Chandra et al. 2003). This displacement along the posterior-
inferior direction was also reported by Crook et al. (1995). However, to further 
complicate the relationship between organ motion and organ volume, it has been 
demonstrated that despite changes in the size and location of the prostate, bladder 
and rectum occurring during treatment, these variations are only partly explained by 
changes in physiological volume of the bladder and rectum because these variations 
in prostate position are also observed between scans with no measurable changes in 
the volumes of either the bladder or rectum (Roeske et al. 1995). The influence of 
other factors on prostate position was studied by van Herk et al. (1995) who 
demonstrated a complicated relationship between leg opening, leg roll (related to 
patient immobilisation) and rectal volume on prostate translation (R= 0.75). 
 
The more recent studies looking at prostate motion and their relationship to bladder 
and rectal filling have been done using patients receiving conformal RT. Perhaps the 
conformal techniques decreased the incidence and severity of radiation proctitis and 
cystitis so that there was no consistent effect on rectal and bladder filling and the 
direction of prostate movement was random (Crook et al. 1995). Therefore organ 
motion may be less predictable and more complex than originally thought. 
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4.7.4 Treatment instructions – volume reproducibility 
As has already been discussed, prostate motion caused by the variable filling of the 
bladder and rectum has been demonstrated through numerous studies using 
sequential CT scans or by imaging the displacement of radio-opaque markers. One 
method of minimising prostate motion is to minimise the variation in bladder and 
rectal filling by giving patients specific ‘treatment instructions’. For the purpose of 
this discussion the instructions and/or advice given to prostate cancer patients 
regarding bladder filling/emptying, rectal filling/emptying and diet will all be 
considered ‘treatment instructions’.   
 
The treatment instructions given to prostate cancer patients receiving radiation 
therapy vary significantly. In the literature there is no consensus on whether patients 
should be treated with a full or empty bladder and rectum. Table 4-4 lists the author 
and year of the relevant published literature, along with the treatment position, 
immobilisation device. It also lists whether the patients were instructed to have an 
empty or full bladder, or a combination of both (E&F), and whether any rectum 
instructions or other contrast methods were used. If authors did not specify the 
patient preparation instructions in the article this has been denoted with a question 
mark (?). 
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Table 4 - 4: Combinations of organ filling as published in the literature 
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Melian 1997 prone immobilised E&F air 13 
Zelefsky 1999 prone immobilised empty air 50 
Michalakos 2002 prone mold empty air 50 
Miralbell 2003 supine none empty ? 9 
Dawson 1998 supine none empty ? 6 
Tinger 1998 supine cradle full none 8 
Roeske 1995 supine cast full ? 10 
Lebesque 1995 supine ? full none 11 
Zellars 2000 supine 7 immobilised full ? 24 
Beard 1996 supine immobilised empty contrast 30 
Rudat 1996 supine none empty empty 27 
Chandra 2003 supine cradle full empty 147 
Antolak 1998 ? ? full ? 17 
Lattanzi 1999 supine cradle full ? 23 
Morr 2002 supine leg immob. full ? 23 
O’Doherty 2003 supine ankle & knee full ? 25 
Dehnad 2003 supine knee bolster ? ? 10 
Nederveen 2003 supine knee bolster ? ? 23 
Miralbell 2003 supine knee bolster empty ? 9 
Bayley 2004 sup/pron ? E&F empty 28 
Crook 1995 supine leg immob. full none 55 
Balter 1993 ? ? ? ? 12 
Balter 2000 sup/pron 4 types     4 
Rudat 1994 supine none ? ? 17 
McLaughlin 1999 sup/pron none empty none 10 
Catton 1997 supine leg & none ? ? 61 
Weber 2000 sup/pron knee bolster empty ? 18 
van Herk 1995 ? ? full contrast 11 
Fiorino 1998 supine Alpha - 2 types full ? 52 
Stroom 1999 sup/pron knee/bellyboard full empty 30 
Muren 2004 ? ? empty ? 19 
Wong 2005 supine leg sponge none none 108 
Mubata 1998 supine some Vacfix full ? 36 
Chung 2004 supine Vac-loc full empty 17 
 
The results of this literature review are reflected in the results of a survey throughout 
Australia & NZ that found there is no gold standard set of instructions for prostate 
cancer patients having Radiation therapy (Knight, 2005). The rationale behind 
giving patients treatment instructions for bladder and rectal filling are presented 
below.   
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4.7.4a Bladder filling 
There are two schools of thought when it comes to patient treatment instructions for 
bladder filling. The first is that to minimise prostate motion and therefore eliminate 
the uncertainty in prostate position due to bladder filling, patients should be treated 
with an empty bladder and accept that there will be less displacement of normal 
tissues out of the high dose region (Dawson et al. 1998). The second is that patients 
should be instructed to have a comfortably full bladder during treatment.  
 
There is an obvious advantage in using a full bladder to reduce normal tissue 
toxicity by displacing the anterior bladder wall and small bowel away from the high 
dose volume. However, the degree to which patients are able to follow instructions 
regarding bladder filling is difficult to assess without additional investigations 
(Althof, Hoekstra & Te Loo (1996). Bladder volume may vary on a daily basis 
depending on the weather (heat versus cold), treatment reactions (de-hydration due 
to onset of diarrhoea), timing of each treatment appointment (am verses pm, and 
therefore how much fluid has been consumed during the day) and how the patient 
measures the amount of fluid drunk each day (consistent water bottle or size of cup). 
 
Kenesei et al (1989, cited in Rudat et al. 1996) used daily ultrasound measurements 
of the bladder of patients who were asked, and reminded daily, to present for 
treatment with a completely full bladder to reveal that no constant bladder volume 
could be achieved and that there was no consistency between the patients’ personal 
impression and measured bladder filling. Contrary to these findings, O’Doherty et 
al. (2003) found good correlation between measured bladder volume and patient 
response. However, there have been no studies that can reliably conclude whether 
treating these patients with an empty bladder is more useful than treating patients 
with a full bladder, and vice versa. 
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4.7.4b Rectal filling 
Standardising rectal filling is a second problem and in practice is not one that can be 
resolved by instructions alone (Althof, Hoekstra & Te Loo 1996). In the survey of 
centres in Australia and New Zealand, most advise their patients to follow a low 
residue, high fibre diet. Some centres also require that patients drink a fibre 
supplement during their treatment based on the hypothesis that this will maintain a 
consistent rectal volume during radiation therapy. However there is a distinct lack of 
evidence on which these assumptions are made. It appears that each prescribing RO 
has developed their own personal preference as to what instructions should be given 
to prostate patients based on experience rather than evidence (Knight, 2005). 
 
Nutritional status is important for patients being treated with radiation therapy. Good 
nutrition will assist in the body’s ability to repair healthy cells damaged by 
irradiation. However a lack of research specifically assessing how diet and fibre 
supplements affect daily rectal volumes is one reason for the absence of a standard 
approach to patient treatment instructions. To compound this issue further, unlike 
the bladder volumes where ultrasound can be used, there are no reliable methods for 
confirming on a daily basis that each patient has conformed to the instructions for 
maintaining rectal filling.  
4.7.5 Patient position: supine vs. prone 
Althof, Hoekstra and Te Loo (1996) found that for patients treated in the supine 
position the prostate was least mobile in the RL direction, but more mobile in the AP 
and SI directions. Bayley et al. (2004) found that prostate motion in the AP direction 
was statistically less in the supine position compared to the prone position, however 
there was no difference in SI prostate motion. Stroom et al. (1999) also examined 
prostate motion of patients treated in the supine and prone positions. They found that 
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the prone position was associated with smaller random errors, but had larger 
systematic errors.  
 
One possible explanation for the larger prostate motion in the prone position is an 
inability to completely empty the bladder prior to treatment (Bayley et al. 2004), as 
prone patients are commonly treated with an empty bladder, while supine are treated 
with a full bladder. This is supported by Stroom et al. (1999) who found that in the 
prone position prostate displacement correlated with bladder volume, whereas in the 
supine position it correlated with changes in rectal volume. In addition, patients who 
find the prone position more uncomfortable may move more and tense their 
abdominal and pelvic muscles which would also affect prostate position (Crook et 
al. 1995). 
 
It has been hypothesised that rectal air or suspension of the rectum by ligaments 
might affect prostate motion (Antolak et al. 1998; Bentel et al. 2000; van Herk et al. 
1995). McLaughlin et al. (1999) and Zelefsky et al. (1997) found that when treating 
patients in the prone position the distance between the prostate and rectum increased 
and therefore the dose to the rectum was minimised. These findings should support a 
hypothesis of decreased motion in the prone position, however it is the opposite of 
what has been observed in the previously mentioned studies (Bayley et al. 2004, 
Stroom et al. 1999).  
 
This increased distance between the rectum and prostate for patients positioned 
prone is contrary to the results of Bentel et al (2000) who found that in both the 
supine and prone positions the prostate remained adjacent to the rectal wall. When 
analysing the study by Zelefsky et al. (1997), where they found a dosimetric 
improvement to the rectum in the prone patients, the same CTVÆ PTV margins 
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were used for both positions. However, if prostate motion is increased in the prone 
position, the CTVÆ PTV margin should be increased to account for this. If a larger 
margin was used on prone patients it is unclear whether the rectal dose benefit 
compared to supine patients would still be present (Bayley et al. 2004). 
 
Bentel et al. (2000) tested the hypothesis that changes in organ location that have 
previously been attributed to patient position, were actually due to changes in 
pressure on the soft tissues of the buttocks or abdomen due to the table top, rather 
than gravitational induced changes in organ position as a result of patient position. 
They were unable to definitively conclude that table pressure was the reason for 
changes in the relative position of the pelvic organs because changes in bladder and 
rectal filling were also observed during the 90 minute session. However they were 
able to demonstrate that the pressure from the table top is in part responsible for 
changes in organ location. 
4.7.6 Intra-fraction motion 
Intra-fraction motion can be a result of patient and organ motion. Even with image 
guidance, intra-fraction motion will potentially limit the accuracy of treatment 
delivery. Although it is generally accepted that intra-fraction motion in the pelvis is 
minimal, it is especially important for treatment sites where the tumour is mobile 
during respiration. 
 
Intra-fraction patient motion is related to patient comfort and stability. For patients 
immobilised in a body cradle it has been reported that movement of the patient on 
the treatment table during a RT session was negligible and could therefore be 
ignored (Tinger et al. 1998).  
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For prostate cancer there is some evidence indicating that the prostate gland may 
experience intra-fraction motion due to respiration. Dawson et al. 2000 and Balter et 
al. 2000 reported the effect of patient position on respiratory movement of the 
prostate. They compared four treatment positions (2 supine, 2 prone) using 
fluoroscopy to track fiducial markers and found that respiratory movement of the 
prostate during normal breathing was substantial in the prone position, up to 5.1mm 
SI and 3.5mm AP directions, compared to supine positions (<1mm), possibly due to 
increased abdominal compression in the prone position. RL motion for all four 
treatment positions was less than 1mm. Prostate motion was shown to double when 
patients were instructed to use deep respiration. They also found that deep 
respiration resulted in AP skeletal movements of up to 13.1mm in the prone position 
compared to the supine position where skeletal movement was negligible. Therefore 
deep respiration introduced patient set-up uncertainty as well as internal organ 
motion for patients in the prone position. 
 
Other studies indicate that intra-fraction prostate movement is not of grave concern 
(Chandra et al. 2003). Nederveen et al. (2003) stated that intra-fraction motion has 
been shown to be less than 1mm, which is consistent with the findings of Dawson et 
al. (2000) & Balter et al. (2000) for patients positioned supine. With the introduction 
of 4D imaging into the planning process, the uncertainty associated with intra-
fraction motion will be able to be reduced further. 4D imaging is already available 
commercially and involves collecting 3D images at multiple time points to assess 
tumour motion. It allows planning to be done at different phases of the respiratory 
cycle. As long as this respiratory cycle can be monitored at the time of treatment, the 
beam can be controlled to deliver treatment when the tumour is within the field by 
the process of gating. 
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4.7.7 Rotation & deformation 
Prostate rotation can occur due to the differential filling of the rectum and bladder. 
Rotational uncertainties are generally reported as less than 2º (Antolak et al. 1998). 
Rudat et al. (1996) found that no rotation errors greater than 1º were detected, 
however van Herk et al. (1995) did find rotations of up to 4º around the RL axis 
when comparing prostate position to bone. The other axes were less than 2.1º.  
Lebesque et al. (1995) estimated rotation of the prostate around the RL axis as 1.7º 
as a result of rectal filling and van Herk et al. (1995) showed prostate rotation 
around the RL axis as result of rectal filling was statistically significant (R = 0.65). 
 
To minimise the effect of rotation, it has been suggested that patients should be re-
scanned if their rectal volume is >150cc. However, for the purposes of deriving an 
appropriate PTV from the CTV, prostate rotation is less important because organ 
rotation does not lead to target misses unless the organ is very irregularly shaped 
(Antolak et al. 1998).  The prostate is generally considered a regular, almost 
cylindrical shape, although its shape may be deformed by the pressure of other 
internal organs. Deformation of the prostate volume can also be caused by tumour 
growth or regression, together with the swelling and inflammatory reaction of the 
prostate in response to treatment (Dehnad et al. 2003). There have been very few, if 
any, studies in which the deformation of the prostate has been studied and is an area 
for future research.  
 
Since accurately measuring this rotation and deformation is difficult without the use 
of in-room CT scanning and image fusion software, historically rotation and 
deformation of the prostate has not been accounted for, only translational shifts. 
Even if this information was available, accounting for it in a routine clinical setting 
would be challenging. Realistically prostate rotation and deformation is unlikely to 
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be corrected for on a daily basis, similar to pelvic rotation that is ignored when using 
EPI images. 
4.8 Dosimetric consequences: 
Despite the abundance of information on patient set-up variation and internal organ 
motion, there are a limited number of studies where the effect of these uncertainties 
on dose have been assessed and there have been none that have evaluated the 
uncertainties of dose distribution within the target volume on a daily basis.  
 
Most of the published research has been based on a small number of patients, using 
a limited number of CT scans. This is because, prior to the introduction of in-room 
CT scanners, collecting this information has required an additional trip to the 
planning CT, therefore requiring the patient to be repositioned for imaging and also 
creating resource implications.  
 
Changes in location of the prostate and normal tissues during radiation therapy have 
dosimetric consequences that may impact on tumour control and NTCP. Movement 
of radiosensitive structures into high dose regions can push the CTV out of the high 
dose region. By incorporating total error and re-calculating the DVH, a reduction in 
TCP of 8.3% was found (Rudat et al. 1996). Miralbell et al. (2003a) used skin 
markings to re-calculate DVHs, to assess organ motion and set-up errors. Other 
studies have matched bony anatomy and therefore ignored set-up error. 
 
The dosimetric consequences of treating patients prone compared to supine were 
reported by Bayley et al. (2004). Due to the increased prostate motion observed in 
the prone position, the PTV was expanded to account for this motion and thus 
increased dose to critical organs. Using DVH analysis they found a statistically 
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significant increase in the dose delivered to the bladder, rectal wall and small bowel 
compared to the supine position. 
 
In order to ensure that the planned dose is delivered to the CTV, the geometric 
margin placed around the CTV to achieve a PTV must account for all the 
uncertainties that have been discussed previously, although it is common practice to 
ignore intra-fraction patient motion as it is considered negligible for prostate patients 
who are adequately stabilised. To achieve prostate doses above 75Gy there is a 
greater need to use tighter margins, especially posteriorly around the rectum to 
reduce complications.  
4.8.1 Margin calculations 
3D imaging using CT and MRI provides a reasonably precise localisation of the 
GTV for prostate cancer patients. The GTV for early stage prostate cancer is the 
entire prostate gland although, as discussed earlier, the inclusion of seminal vesicles 
is contentious. Varying windows and levels can be used on each slice to obtain the 
best subjective appreciation of the organ’s borders. 
 
The location of microscopic extension around the GTV remains uncertain, and 
therefore a CTV around the GTV allows for microscopic disease. To reduce margins 
the uncertainty of microscopic disease (GTVÆCTV) and/or the uncertainty in 
patient positioning (CTVÆPTV) must be reduced. Reducing the uncertainty of 
microscopic extension is difficult and will rely on improvements in biological 
imaging systems. Therefore not surprisingly there has been a wealth of work 
published by RTs, physicists and ROs on methods of reducing the CTVÆPTV 
margins, especially for prostate cancer patients.  
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A full understanding of all geometric uncertainties should lead to objective choices 
for treatment margins (van Herk et al. 2000). An additional 3mm margin on the 
CTVÆPTV can affect the volume of the PTV by up to 25% (Rosenthal et al. 1993). 
Geometric uncertainties including set-up accuracy, organ motion and the accuracy of 
target volume delineation have already been explained previously. It is generally 
accepted that systematic errors are larger than random errors and that they have a 
greater effect on the dose distribution due to the displacement of the high dose 
region relative to the CTV. 
 
Up until the 2000 publication by van Herk et al. (2000) there had been no clear 
guidelines indicating the statistical method that should be used to choose treatment 
margins. In this article they proposed a model that could be used to derive the 
margin required between the CTV and PTV based on probability distributions for 
the dose delivered. The probability distributions were based on the following 
estimates of error.  
Systematic error  AP= 4.1mm SI= 3.6-4.5mm RL= 3.2mm 
 Random error  AP = 3.2mm SI= 2.5mm  RL= 2.2mm 
Prior to implementing this model, individual institutions should assess their own 
errors, and if they are significantly different from those used to generate this model 
the model should be adjusted. The final result is a simplified solution that does not 
require complicated Monte Carlo simulations or other advanced computer programs 
to calculate. Based on their results van Herk et al. (2000) recommend using a margin 
recipe that ensures 95% minimum dose for 90% of patients in 3D. Using these 
confidence levels, the margin recipe formula is: 
CTV Æ PTV margin = 0.7SD of random error + 2.5SD of systematic error. 
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Although it is possible to substitute different values for different confidence and 
dose levels, their recommendation has become the most recognised method for 
calculating CTVÆPTV margins. This formula is based on the probability that a 
point on the edge of the CTV is enclosed by the PTV 95% of the time. Despite using 
these margins there will still be some part of the CTV outside the PTV for the 
majority of treatments, however it will not be the same part of the CTV each time 
and therefore the effect on dose to the CTV is minimised. van Herk et al. (2000) also 
recommended the PTV definition be changed to include the fact that a PTV margin 
is based on a probability that the CTV will receive a clinically acceptable dose. 
 
The formula of van Herk et al. (2000) to calculate CTV Æ PTV margins is 
comparable to other studies. However most previously published margin recipes 
have ignored systematic errors. Since systematic errors have much more impact on 
the dose delivered to the CTV, it is essential that they are treated separately.  
 
It is impossible to eliminate all uncertainty in radiation therapy, therefore margins 
will never be zero and confidence levels will never be 100%. With growing evidence 
that local control is correlated with the dose of radiation delivered and that normal 
tissue toxicity is correlated with both the radiation dose and volume of normal tissue 
that is irradiated, accurate knowledge of target position variability may increase the 
therapeutic ratio of radiotherapy by allowing margins to be large enough to avoid a 
geographic miss, but small enough to minimise normal tissue toxicity. 
 
Unless the source and magnitude of each type of error can be identified and 
minimised, dose escalation would be counterproductive due a larger volume of the 
rectum being included in the high dose region. The best method to account for the 
magnitude and direction of patient set-up uncertainty and organ motion (including 
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organ deformation) is to perform on-line corrections rather than using mathematical 
derived margins (Roeske et al. 1995). Additional CT information during treatment 
would give a better representation of the mean prostate position and allow the 
assessment of any systematic errors that were present during the planning CT. It 
would also increase the knowledge of the relationship of the target position to rectal 
volume and bladder filling. Incorporating on-line CT based corrections for all 
uncertainties is a very unrealistic option in a busy clinical RT department. Instead 
many centres have opted for the middle ground, accounting for patient set-up 
uncertainty and organ motion using EPI, with or without fiducial markers. However 
for highly conformal treatments, particularly IMRT where steep dose gradients are 
used, daily verification of the location of the CTV using Image Guided Radiation 
Therapy (IGRT) is warranted.  
 
5. Treatment Verification 
5.1 Introduction 
To ensure that treatment is accurately delivered to the planned volume, regular 
treatment verification is required. The Faculty of Radiation Oncology Genito-urinary 
Group (FROGG, 2002) state: “As a minimum it is recommended that an isocentre 
check using AP and Lateral films is acquired at least weekly during treatment, and 
ideally daily during the first week of treatment. If available, daily localisation with 
fiducial markers or ultrasound / CT imaging is preferred.” (Skala et al, 2004) 
 
This section will give an overview of the principles of off-line and on-line treatment 
corrections, followed by the variety of techniques available for treatment 
verification.  
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5.1.1 Off-line corrections 
Off-line corrections are the traditional way of correcting for patient set-up errors. 
Off-line corrections involve assessing portal images (either port films or EPI) post-
treatment and can therefore only correct for systematic errors. The off-line 
correction technique needs more than one image to enable an assessment of whether 
a variation in patient set-up is a result of systematic or random errors. Many 
publications have discussed the question of how many images are needed to ensure 
that the systematic error is representative of the systematic error that is occurring 
across a whole course of treatment. This question is also relevant to on-line 
treatment verification protocols. 
5.1.2 On-line corrections 
On-line corrections are performed prior to treatment delivery and are therefore able 
to correct for random and systematic errors. Depending on the technique used, on-
line corrections have the potential to minimise patient set-up errors (EPI) and 
isocentre displacements due to organ motion (EPI with fiducial markers or CT). 
Although on-line corrections still do not account for intra-fraction motion, it is 
recognised that on-line verification has the potential to reduce margins by up to half 
and reduces the inter-fraction positioning uncertainty substantially compared to 
current standards (Dehnad et al. 2003). 
 
On-line corrections are a timely exercise. Once systematic errors are accounted for, 
random errors will only blur the dose distribution. To minimise the clinical workload 
without decreasing accuracy researchers return to the question ‘how many images 
are needed to assess and correct for systematic errors?’. However implementing an 
on-line treatment verification protocol for only a few fractions requires a good 
 - 68 -
 
understanding of random errors. If systematic error can be corrected for after the 
first three fractions, then on-line imaging for the remainder of treatment can be used 
to correct for random errors in the AP direction only due to the presence of the 
rectum in this plane, thus reducing the total treatment time.  
5.2 Non-CT based verification 
Historically, treatment verification has been performed off-line using film or 
Electronic Portal Imaging (EPI). However these methods are limited to assessing 
patient position relative to bony landmarks. To overcome this limitation, radio-
opaque fiducial markers inserted into the prostate have become popular. These 
markers are visible on EPI and are therefore able to track prostate motion. The 
insertion of fiducial markers into the prostate requires a highly invasive procedure 
and has limited applicability to sites outside the pelvis (Mackie et al. 2003). Urethral 
catheters containing markers have also been used to more precisely locate the 
prostate (Bergström, Löfroth & Widmark, 1998; Fransson et al. 2003). 
 
Ultrasound images were the first technique used to determine internal anatomy at the 
time of treatment (Mackie et al. 2003). Ultrasound imaging is a non-invasive 
procedure that is relatively easy to use and is conducted in real time; however the 
pressure exerted on the probe can cause significant displacement of the prostate of 
up to 5mm in some patients (Serago et al. 2002). The use of ultrasound for treatment 
verification is limited in its application to sites outside of the pelvis and abdomen 
due to limited penetration through fat, bone and lung. The accuracy of patient 
positioning based on ultrasound images is also dependent on the skills and 
interpretation of the operator (Serago et al. 2002). 
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5.3 Out-of-room CT scanning for treatment verification 
Until the recent introduction of in-room CT technology, studies assessing soft tissue 
verification have been performed outside the treatment room. Although EPI and 
ultrasound have increased the precision of radiation therapy treatment delivery, only 
CT imaging has the ability to assess translation, rotation, deformation and motion, 
and thus increases the precision with which treatment can be delivered, therefore 
increasing the therapeutic ratio for patients.  
 
There have been a large number of studies published that have used a methodology 
of periodically repeating planning CT scans to assess differences in bladder and 
rectal volumes and their effect on prostate position. However these studies have 
assessed organ volume over a treatment course using a limited number of CT scans.  
 
Those that have used larger numbers of scans have generally had small cohorts of 
patients. Even using weekly CT scans, only 15-20% of all treatment sessions are 
observed. Although this provides a representative sample of the range and frequency 
of volume and motion variations, it does not equal the statistical validity of daily 
imaging.  
 
Table 5-1 shows that some of these studies only repeated the CT scan once or twice 
during the course of treatment, up to a maximum of 1 CT scan per week, and hence 
have a large risk of random error.  
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Table 5 - 1: Studies using repeat CT scans outside treatment room 
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Melian 1997 13 3     X X X 
Martinez 2001 150 4 X   X   X 
Zelefsky 1999 50 3     X X   
Mechalakos 2002 50 3     X X   
Stroom 2000 15 3     X     
Miralbell 2003 9 weekly     X X X 
Dawson 1998 6 weekly X X X X   
Tinger 1998 8 weekly X X X X   
Roeske 1995 10 weekly     X X   
Lebesque 1995 11 3       X X 
Zellars 2000 24 1     X X   
Beard 1996 30 1     X X   
Rudat 1996 27 weekly X   X   X 
Antolak 1998 17 3 X   X X   
Lattanzi 1999 23 daily for boost   X       
Dehnad 2003 10 3     X X   
Miralbell 2003 9 weekly       X   
Crook 1995 55 1     X     
Bentel 2000 9 4     X X   
McLaughlin 1999 10 1     X   X 
Weber 2000 18 1 X         
van Herk 1995 11 3           
Stroom 1999 30 3     X     
Fokdal 2004 15 4     X X   
Muren 2004 19 weekly     X     
 
 
No studies published use daily CT verification technology throughout an entire 
treatment course to assess these volumes. Mechalakos et al. (2002) concluded that 
more than four scans per patient were needed to better understand time trends and 
more closely examine organ motion. When utilising CT scanners outside of the 
treatment room patients are required to attend a separate appointment. This had 
implications on clinical time and resources and also on the validity of the CT 
findings in relation to the organ positions in the treatment position. 
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From these studies a large range of effects caused by volume changes were 
observed. As discussed earlier rectal volume has a large influence on the prostate 
position and there is some evidence of the influence of bladder volumes on prostate 
motion. Differences in patient set-up practices, contrast injections, patient treatment 
instructions and the timing of the repeat CT scans are all variables that contribute to 
the difficultly in interpreting these previous studies.  
5.4 In-room CT verification 
In-room CT verification has only been a recent development but eliminates many of 
the limitations of the methodology used in studies using out-of-room CT scanners. 
Daily in-room CT localisation is a precise method to improve daily target 
localisation in prostate cancer (Lattanzi et al. 1999) and the introduction of these 
scanners has enabled on-line Image Guided Radiation Therapy (IGRT) to be 
implemented into clinical practice. The goal of IGRT is to facilitate dose escalation 
and maintain tolerable dose to the surrounding organs by reducing CTV Æ PTV 
margins. Pouliot et al. (2004) suggests that the following steps are necessary for 
IGRT: 
1. Image acquisitionÆ 2. ReconstructionÆ 3. RegistrationÆ 4. Patient alignment. 
 
During in-room CT verification the patient is scanned in the treatment position 
immediately prior to treatment delivery. The speed of the process has also meant the 
inconvenience for the patient and staff of repeating CT scans has been minimised. 
Although hypothetically other imaging systems could eventually be fitted into the 
treatment room, IGRT is unlikely to consist of systems other than CT, for many of 
the reasons discussed in section 3.4 , making it the modality of choice for planning. 
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There are three approaches to in-room CT scanners available for IGRT. The type 
used for this study utilises a ‘stand alone’ diagnostic quality, traditional CT scanner 
inside the treatment room. The others use the standard features of a linear accelerator 
to produce either MV or kV cone beam images.  
 
In theory, in-room CT scanners allow on-line verification and correction for patient 
set-up errors and organ motion. However, in practice IGRT capabilities cannot be 
fulfilled without image analysis software to generate the corrections necessary to 
reposition the patient. The ability to fuse in-room verification CT scans with the 
planning CT scan using automatic and manual fusion techniques will allow accurate 
and speedy assessments of the patient position.  
 
The most time consuming part of IGRT will be segmentation or contouring. It is 
unrealistic to expect ROs to repeat their contouring on a daily basis, therefore 
automated tools are necessary to segment relevant volumes on the treatment CT 
using the planning CT as a template for auto-segmentation. However, computers 
cannot be expected to automatically generate these contours accurately and they will 
rely on an operator verifying the contours.  
 
On-line CT verification will move the emphasis off patient localisation, and on to 
immobilisation. Because many of the uncertainties that are currently being 
accounted for in the CTVÆ PTV margin will be minimised, there will be an 
increased need to guarantee that the patient does not move during treatment. The 
uncertainty of auto-segmentation and operator interpretation will also need to be 
accounted for when calculating treatment margins. 
 
One of the issues that in-room CT imaging has raised is quantifying the increased 
dose delivered. When comparing the dose delivered by CT and EPI, CT correction 
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was shown to actually reduce patient dose, although EPI irradiates a smaller volume 
(Remeijer et al. 2004). 
 
The time, cost and effect on patient waiting lists will ultimately limit the widespread 
application of daily CT verification and IGRT. IGRT is most likely to be used in 
cases where increased accuracy is required (IMRT) or limited to a number of 
fractions. For example, only during a boost phase instead of an entire course. A 
disadvantage of not using IGRT on a daily basis was observed during the 
introduction of the BAT ultrasound system. The introduction of this new verification 
technology resulted in therapists paying less attention to the initial set-up using the 
skin marks as they relied more directly on the technology for the final positioning 
(Chandra et al. 2003).  
5.4.1 Stand alone CT scanner 
The stand alone CT scanner integrates existing imaging technology and therapy. The 
stand alone approach offers diagnostic quality volumetric imaging, whilst 
maintaining the reference between verification and treatment by using a pivoting 
patient couch. The linac and the CT gantry are positioned at opposite ends of the 
couch so that, by rotating the treatment couch, treatment or CT scanning can be 
performed (Figure 5-1). The rotational axis of the linac gantry is coaxial with that of 
the CT gantry, and the position of the linac isocentre on the couch matches the 
origin of the co-ordinate system for the CT scanning when the couch is rotated 180º 
toward the CT side.  
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Figure 5 - 1: Primatom ‘stand alone’ CT scanner 
 
 
To eliminate patient movement and displacement while the couch is moving and to 
minimise errors caused by flexures in the treatment couch, the CT gantry itself 
moves along rails for scanning rather than the table as in conventional CT. This 
decreases the risk of errors due to mechanical movement, as the only movement is 
the rotation of the couch. The side rails also ensure exact horizontal movement of 
the gantry (Kuriyama et al. 2003). 
 
The positional accuracy of the common couch was tested by Kuriyama et al. (2003) 
and they found that it was 0.20mm, 0.18mm and 0.39mm in the lateral, longitudinal 
and vertical directions. They also found that the scan-positioning accuracy was less 
than 0.4mm in all directions. Uematsu et al. (1996) who were the first to introduce 
this technology also reported that the rotational accuracy of the couch was within 
0.5mm. Since CT verification minimises set-up and organ motion variations, the 
introduction of a 0.5mm uncertainty due to rotational accuracy is more than 
sufficient for most treatment sites, including stereotactic cranial irradiation 
(Kuriyama et al. 2003). 
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There are 3 main advantages of the stand alone in-room CT scanner: 
1. The patient does not have to be moved between the CT and linac 
2. Treatment position can be verified easily and accurately. After setting up the 
patient according to their skin markings, the patient can be CT scanned and the 
isocentre position adjusted by moving the couch top. After the accurate 
position is determined the couch is rotated to allow treatment.  
3. The self-moving CT gantry eliminates reduction in accuracy due to flexures in 
the couch with movement. 
 
To date there has only been one publication with results using in-room CT 
verification for prostate cancer patients (Wong et al. 2005). This research originated 
at Morristown Memorial Hospital and utilised a stand alone CT scanner (Primatom), 
which is the same combination used in this study. Although this study has used the 
largest sample size (108) of any publication using CT scanning to verify organ 
motion only the last 5 fractions of treatment were CT scanned. This study reported 
results of variations in prostate position and the number of isomoves that were 
required but did not quantify bladder and rectal volume data, instead focusing on the 
feasibility of introducing such methods. It also gave a hypothetical scenario of the 
effect of prostate motion on dose. However CTs were only performed on the last 5 
fractions and therefore their study cannot assess prostate motion over an entire 
treatment course.  
6.  Aims 
Despite there being a wealth of information on set-up uncertainty and organ motion, 
to date there have been no published studies that have documented the relationship 
of these uncertainties to the dose delivered on a daily basis for the duration of a 
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patient’s treatment. This study aims to collect this information on a cohort of 
patients so that it can achieve the following: 
6.1 Aim 1 
Increase knowledge of the variations in bladder and rectal volumes for prostate 
patients using the current treatment instructions by collecting daily CT images. 
6.2 Aim 2 
Assess the relationship of bladder and or rectal volumes to field placement 
corrections. 
6.3 Aim 3 
Assess the effect the variation in these volumes has on the planned rectal and target 
volume doses. 
6.4 Aim 4  
Examine the effect this deviation has on the patient population who do not have the 
benefit of modern technology, as in current practice. 
6.5 Aim 5  
Examine the current patient treatment instructions and assess the need for review in 
light of research findings. 
6.6 Aim 6  
To examine the potential of these results to influence the prescribed dose or margins 
used. 
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7. Research Methodology 
7.1 Ethics Approval 
Approval to conduct this study was obtained in July 2003 from the Human Research 
and Ethics Committees (HREC) at the Peter MacCallum Cancer Centre, protocol 
number 03/47 and the Epworth Hospital, study number 24503 (Appendices 1-1 & 1-
2). The University of Sydney HREC approval was granted in August 2003 
(Appendix 1-3). 
 
The extra radiation dose delivered to the patients enrolled in this study was 
considered during the ethics approval process. The Physical Sciences department at 
Peter Mac calculated the approximate additional dose received by the patient as 
1.2Gy over 37 fractions. Although this dose is not negligible, the potential benefit 
was deemed to justify any risks. 
7.2 Patient recruitment 
7.2.1 Sample size 
This study was designed to recruit 25 patients undergoing radical radiation therapy 
for prostate cancer. The method for determining the number of patients needed for 
statistical significance was reviewed in association with the Statistical Centre at the 
Peter MacCallum Cancer Centre (PMCC) as a requirement for Human Research 
Ethics Committee approval. The sample size estimation was based on the ability of 
the study to have adequate power to detect a clinically significant change in rectal 
volume (hypothesis 1) from baseline, at the time of planning, to completion of 
radiotherapy. To facilitate this calculation an estimate of the change in rectal volume 
that would be clinically significant was made. Due to the lack of literature, two 
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scenarios were proposed that might influence tumour control and complication rate. 
It was proposed that this study considered both a 10% and 30% change in rectal 
volume as being clinically significant.  
 
An estimate of the SD was also necessary and was calculated using previous PMCC 
data. In this previous study, the average rectal volume at baseline was 101cc and 
after treatment was 92cc with an average difference of 9cc (SD= 45cc). However 
these results were based on a very small number of patients (n=7).  Also the patients 
were not instructed to drink a fibre supplement to regulate the contents of the 
rectum, so it might be expected that the SD of change in rectal volume would be 
smaller in the proposed study. 
 
Using this available data the sample size for the study was originally computed as 
127 patients, which would provide 80% power to detect a mean decrease in rectal 
volume (from baseline to completion of radiotherapy) of 10cc assuming a SD of 
difference of 45cc , using a paired t-test with a 0.05 one-sided significance level. 
However because this estimate was based on a very small number of patients and 
using the smaller of the two estimates of clinical significance (10%), the original 
estimate of sample size was revised to 46 patients (80% power to detect a mean 
difference of 15cc assuming a SD of difference of 40cc , using a paired t-test with a 
0.05 one-sided significance level). 
 
Due to the assumptions that were necessary to estimate the sample size needed for 
this study, it was suggested an interim review to re-estimate the final sample size 
should be conducted after the data were collected for the first 20 patients, when there 
would be a clearer understanding of the SD for patients in this study. 
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In September 2004 the interim review in association with the Statistical Centre at the 
PMCC was conducted using data from the first 20 patients to complete treatment. 
The difference in rectal volume from baseline to completion of radiotherapy ranged 
from 40.53cc to 114.10cc, with a SD of difference of 45.45cc. This indicated that the 
original SD of difference used to calculate the sample size was an underestimate and 
therefore in order to detect a 15cc decrease in rectal volume the sample size needed 
was 59 patients. However, if the larger estimate of clinical significance, a decrease 
in rectal volume of 30%, was used in the calculation, the sample size for this study 
would have reduced to only 16 patients.  
 
Based on these estimates of sample size, the investigators involved in this study felt 
that stopping patient recruitment at 25 patients was justified because of the improved 
methodology and increased amount of data that was collected in this study compared 
to previously published research. The implications and limitations of this power 
analysis will be discussed further in the research findings. 
7.2.2 Recruitment process 
Patients eligible for entry into this study were identified at the time of their initial 
clinic appointment. The design of this study enabled the recruitment of patients from 
any of PMCC’s Radiation Oncology consulting clinics, provided that their treatment 
was to be performed at the Tattersall’s Cancer Centre where CT verification was 
possible. 
 
Patient recruitment commenced in September 2003 and a convenience sample was 
selected sequentially from patients prescribed treatment at the Tattersall’s Cancer 
Centre over a period of 11 months. Only one patient declined entry into the study, 
and all patients completed their prescribed course of external beam radiation 
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therapy, without any breaks in treatment. During this time there were no changes to 
the planned study protocol. 
7.3 Consent Process 
Patients were required to give informed consent prior to being enrolled into this 
study. The consultant RO offered eligible patients entry into the study at the time of 
prescribing their external beam radiation therapy. The RO, the Principle Investigator 
(PI) or a co-researcher then provided an explanation of the study.  
 
Patients were provided with two copies of the patient information and consent forms 
(version 2 July 2003; Appendix 2). Patients were asked to read this information 
package and invited to discuss the study with family, friends or other health 
professionals. Patients who agreed to participate in the study were asked to bring the 
signed consent form with them at the time of their planning appointments.  
7.4 Eligibility criteria 
Patients who presented for treatment to the Tattersall’s Cancer Centre with stage 
T1c, T2 a/b/c and T3a prostate cancers were eligible for participation in this study. 
Patients participating in this study received the same prescribed dose and treatment 
technique as those not enrolled in the study. The following dose and fraction 
schedule was used for each stage.  
Stage T1c, T2a/b N0 M0  
1. EBRT alone. 
• Phase 1: 50.00Gy in 25Fx’s @ 5/wk  
• Phase 2: 20.00Gy in 10Fx’s @ 5/wk Phase 2 maintains the same 
treatment technique as phase 1, however the CTVÆPTV margin is reduced on 
the posterior edge to minimise dose to the rectum.  
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• Total Dose: 70.00Gy in 35 Fx’s 
2. Neo-adjuvant androgen deprivation (if PSA  > 10 or Gleason score > 6), 
followed by EBRT.  
• Phase 1: 50.00Gy in 25Fx’s @ 5/wk  
• Phase 2: 20.00Gy in 10Fx’s @ 5/wk Phase 2 maintains the same 
treatment technique as phase 1, however the CTVÆPTV margin is reduced on 
the posterior edge to minimise dose to the rectum. 
• Phase 3: 4.00Gy in 2 Fx’s @ 5/wk Technique modified to use lateral 
beams only to minimise dose to the rectum. 
• Total Dose: 74.00Gy in 37 Fx’s 
 
Stage T2c N0 M0 and T3a N0 M0  
1. EBRT plus Neo-adjuvant androgen deprivation 
• Phase 1: 50.00Gy in 25Fx’s @ 5/wk  
• Phase 2: 20.00Gy in 10Fx’s @ 5/wk Phase 2 maintains the same 
treatment technique as phase 1, however the CTVÆPTV margin is reduced on 
the posterior edge to minimise dose to the rectum. 
• Phase 3: 4.00Gy in 2 Fx’s @ 5/wk Technique modified to use lateral 
beams only to minimise dose to the rectum. 
• Total Dose: 74.00Gy in 37 Fx’s 
7.5 Planning Process 
The planning processes were consistent with the current PMCC Urology unit 
protocol.  
Patient set up:  
• Supine (hands resting on chest)  
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• 2 blue sponges under head 
• Footstocks under ankles to minimise pelvic rotation. 
Patient instructions:  
• To commence a Fybogel supplement prior to treatment planning, and to 
continue this unless advised by their RO. 
• To have a comfortably full bladder prior to each appointment (advised to 
drink 3-4 glasses of water) 
 
The planning CT was performed on a Siemens Somatom CT scanner. The Somatom 
is fitted with a carbon fibre couch top. Carbon fibre couch tops do not exhibit the 
same sag that is traditionally associated with CT scanners used for diagnostic 
purposes or the sag of Mylar couch tops. This carbon fibre couch top is consistent 
between the planning CT and treatment unit. 
 
Prior to commencing the planning CT scan, the RTs confirmed that the patient had 
been taking the bowel preparation recommended by the RO, and that they had a full 
bladder.  
 
The patient was positioned on the CT couch top with the assistance of an orthogonal 
laser system. The following procedure was performed to obtain the required 
isocentre position (Figure 7-1): 
 
1. A short topogram was used to screen for Upper Border Pubis (UBP) level in 
the SI direction (30kV, 130mAs). The couch was then moved 1.0cm inferior to this 
level and zeroed. This level is referred to as the treatment reference point level: i.e. 
Tmt. Ref. Pt. Level = 1.0 cm inferior to UBP.  
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2. A single 5mm CT slice, known as a control scan, through the Tmt Ref Pt level 
was then taken (130kV, 180mAs). The ruler function on the CT console was used to 
measure 6cm posteriorly to the most anterior edge of the pubic bone. The bed height 
was adjusted so that the coronal lasers corresponded to this required depth. 
Figure 7 - 1:  a) Topogram &   b) Control slice 
 
 
3. The sagittal lasers were used to align with the patient’s bony midline at Tmt 
Ref Pt level and at Tip of Xiphoid level (superiorly), and to the centre of the 
footstocks (inferiorly). 
 
Once the isocentre position was established, external fiducial markers (Ball Bearings 
or BBs) were placed on the skin at the isocentre and a helical CT data set was 
obtained from +12cm to –10cm, using a 5mm slice width and a pitch of 1.5 (130kV, 
180mAs). The patient set-up was recorded, along with measurements of: 
1. UBP to Base of Penis 
2. UBP to Tip of Xiphoid process of sternum.  
 
Permanent tattoos using Indian ink were then placed on the patients’ skin at the 
following points, corresponding to the external fiducial marker positions: 
1. Anterior midline @ 1cm inferior to UBP (Tmt Ref Pt level) 
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2. Coplanar Right and Left laterals @ D=6cm post to the anterior edge of the 
pubis @ 1.0cm inferior to UBP (Lateral Tmt Ref Pts). 
3. Tip of Xiphisternum in ML 
Points 1 & 2 can be referred to as triangulation tattoos as they locate the isocentre in 
the same plane in all 3 directions. Point 3 is to assist in patient positioning. 
 
These images were then sent to the XIO planning computer for volume marking by 
the RO. Once the required anatomy was contoured, the RT produced a treatment 
plan using the following constraints as per PMCC’s Urology unit protocols: 
  
Isocentre Location:  
A standard isocentre position is used for all prostate patients treated at the PMCC: 
 1.0cm Inferior to UBP 
 In ML 
 D=6cm post to Ant Edge Pubis @1.0cm inferior to UBP 
This isocentre location should represent the origin (0,0,0 co-ordinate) of the 
planning CT scan (because the isocentre location was screened using the process 
outlined above).  
Field Arrangement:  
Depending on the preference of the prescribing RO a three or four field technique 
was used consisting of the following field arrangements: 
Four-field technique: Anterior, Posterior, Right & Left Laterals 
Three-field technique: Anterior, Right & Left Laterals 
Energy:   
18MV photon beams were used for both techniques.  
Compensation: 
Virtual Wedges were used on the lateral beams for the three field technique. 
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No compensation was used in the SI direction. 
T.D: 
The dose was prescribed to the isocentre.  
Computer Data:  
A DVH showing the composite dose for all phases was used to assess the 
acceptability of the plan by the RO. 
Dose constraints:  
Rectal Volume:  
V50 = 50Gy; 50% of the rectal volume (solid) to receive no more than 
50Gy  
V30 = 60Gy; 30% of the rectal volume (solid) to receive no more than 
60Gy 
 Femurs: max 50Gy 
Ancillary Equipment: 
1.0cm leaf Multi-Leaf Collimators (MLCs) using a leaf insertion equal to 50% were 
set with a margin of 1.0cm around the PTV.  
7.6 Additional Planning & Data collection 
Once the treatment plan was accepted by the RO, and checked by the planning 
supervisor, a copy of the patient’s CT images and treatment plans was transferred to 
the research database located on the XIO planning computer system.  
The following sections (7.6-7.9) detail the data that was collected during this 
research, however due to the large number of analyses performed in the results 
section (8.0), the descriptions of each of these analyses are presented with the 
relevant results for clarity rather than being detailed in the research methodology 
section.  
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7.6.1 Patient File Maintenance Æ Contouring 
Once the patient image set was copied into the research database their file was 
opened and the original contours drawn by the RO were deleted. The PI, to eliminate 
inter-observer contouring variation, then drew contours of the following structures 
using the following definitions. As recommended by Beard et al. (1996), the 
definitions were documented prior to the commencement of the study in an attempt 
to minimise contouring uncertainty. 
a) Prostate CTV 
It is institute practice to equate GTV to CTV. The CTV was defined as the entire 
prostate gland and excluded the seminal vesicles. For the primary purpose of this 
research, assessing prostate motion, the inclusion of the seminal vesicles while 
contouring for the study was unnecessary, as it would have added variables (eg: 
seminal vesicle angle) that were not pertinent to the study hypotheses.  
b) Rectum 
As discussed previously, there are many different variations on the definition of the 
rectum. To allow a comprehensive assessment of the results from this research to 
those found in the literature several different rectal structures were contoured: 
1. Anal Canal: The anal canal was defined with a standard 3cm in length, 
extending from the slice above the anal verge. It was contoured around the exterior 
wall of the anal canal, including any faeces or air contents. 
2. Rectum Solid: The rectum solid commenced on the slice 0.5cm superior to the 
junction with the anal canal and was contoured around the exterior wall of the 
rectum. It extended superiorly to one slice below the slice where the rectum turned 
into the sigmoid colon. The rectum solid included faeces and gas within the contour. 
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3. Rectum Internal: When there was gas or faeces present in the rectum, the 
internal wall of the rectum was also contoured. The rectum internal could then be 
subtracted from the rectum solid to calculate the rectal wall volume. 
c) Bladder: The entire anatomical organ, contoured on the most external edge of the 
bladder wall, therefore including the wall and bladder filling. 
 
These structures were drawn on each individual axial slice of each CT dataset by the 
PI (Figure 7-2). 
 
Figure 7 - 2: Contours shown on Axial Slice 
Blue = Bladder, Green = Prostate, Red = Rectum 
 
In order to obtain a PTV the auto-margin feature was selected. A 1.0cm margin was 
applied around the contoured prostate volume. The auto-margin feature with a 0cm 
margin was applied to the Rectum and Anal Canal in order to obtain the overall 
volume of these two structures. 
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7.6.2 Teletherapy 
Once the contours were completed the volumes for the contoured structures were 
obtained using the report function in the ‘Teletherapy’ program of XIO. Volumes for 
the following structures were recorded on the patient data collection forms 
(Appendix 3). 
1. Prostate 
2. Bladder 
3. Rectum (solid) 
4. Rectum (internal) 
5. Anal Canal 
6. Rectum + Anal Canal 
 
In Teletherapy a marker was placed at the COV for each structure. A marker was 
also placed at the isocentre. Then using the report function, the co-ordinates for each 
marker (X, Y, Z) were printed and recorded on the patient data collection forms. 
 
Templates using the original treatment fields were created for each phase of the 
treatment plan so that it could be applied to the daily treatment verification CTs. 
This template saved the planned information regarding field arrangement, field size 
and isocentre location. In order to apply the MLC arrangement to the subsequent CT 
scans, the MLC file for each field was saved as an aperture. This process was 
documented in detail in the XIO manual (Appendix 4). 
 
Finally the planned dose to each of the structures was recorded on the patient data 
collection sheets. The prescription point was selected as the isocentre marker and the 
prescribed dose for each phase (phase 1 = 50Gy, phase 2 = 20Gy, phase 3 = 4Gy) 
was entered into the monitor unit function.  
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The ‘DVH- cursor volume method’ was used to record the doses in selected volumes 
of interest, as explained in Appendix 4. 
 
The following doses were collected from the DVH: 
1. PTV dose:  
a. V100 = the dose received by 100% of the PTV 
b. V95 = the dose received by 95% of the PTV 
c. V90 = the dose received by 90% of the PTV 
2. Prostate dose (CTV): 
a. V100 = the dose received by 100% of the prostate volume 
b. V95 = the dose received by 95% of the prostate volume 
c. V90 = the dose received by 90% of the prostate volume 
3. Rectum (solid): 
a. V50 = the dose received by 50% of the rectum solid volume 
b. V30 = the dose received by 30% of the rectum solid volume 
4. Anal Canal: 
a. V50 = the dose received by 50% of the anal canal volume 
b. V30 = the dose received by 30% of the anal canal volume 
5. Rectum (Solid) – Rectum (Internal) = Rectal Wall: 
a. V50 = the dose received by 50% of the rectal wall volume 
b. V30 = the dose received by 30% of the rectal wall volume 
The statistical reporting function on XIO was also used to obtain the following 
statistical information on the dose delivered:  
1. PTV:  
a. Mean Dose 
b. Minimum Dose 
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2. Prostate: 
a. Mean Dose 
b. Minimum Dose 
3. Rectum (solid): 
a. Mean Dose 
4. Anal Canal: 
a. Mean Dose 
5. Rectum (solid) – Rectum (internal) = Rectal Wall: 
a. Mean Dose 
6. Bladder: 
a. Mean Dose 
7.7 Treatment Process, CT verification 
For patients enrolled into this study, a daily verification CT was performed for each 
fraction prior to treatment, using the Siemens Primatom Linear Accelerator as 
discussed previously.  
 
For each treatment, the RTs followed the instructions set out in the ‘Primatom CT 
Verification: Prostate Volume Study Instruction Manual’ (Appendix 5). 
 
Prior to taking the patient into the treatment room, the RTs checked patient 
compliance with the treatment instructions by asking the patients if they had drunk 
their water and if they had been taking their fibre supplement. 
 
The RTs then positioned, localised and marked up each patient on the treatment 
couch as per standard treatment protocol. BBs were placed on the patient’s skin at 
the isocentre while the couch was still located under the linac. The digital couch 
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readout was ‘zeroed’ at this planned isocentre position to give a ‘relative’ digital 
couch readout.  
 
Once the clearance of the CT over the patient was confirmed by the RTs, the CT was 
zeroed at the central axis so that the CT lasers intersected the BBs placed on the 
patient skin whilst under the linac. 
 
Due to the rotation mechanism of the couch the couch height dropped 0.45cm during 
rotation. This was investigated prior to the commencement of the study. It was 
confirmed that the height of the CT scanner origin and linac isocentre were correctly 
aligned when they were installed. Further investigation found that as the couch 
rotated 180 degrees, the height of the couch lowered by 0.45cm due to the cork 
screw mechanism of the couch stand. It was also confirmed prior to commencing the 
study that there was no associated change in couch tilt when the CT was rotated 180 
degrees. This change in height meant that the CT lasers in the coronal plane did not 
intersect the BBs placed on the skin when the couch was under the linac. Therefore a 
correction for the difference between CT origins was applied to the planning data on 
the patient data collection sheets. 
 
Using the BBs placed on the patient’s skin at the isocentre, the CT was reviewed for 
positional accuracy using the same topogram and control slice process used during 
the planning process. 
 
The cross hairs function was used to align the BBs placed on the patient’s skin. 
Using the measuring tool (ruler) on the CT console, the position of the isocentre in 
relation to the reference landmarks, was measured. The location of the isocentre was 
assessed according to the current unit policy. Variations of <0.5cm required no pre-
treatment correction. The co-ordinates of the isocentre were recorded on the 
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patient’s research data sheet so patient set-up accuracy and the incidence of pre-
treatment isomoves could be determined (Appendix 3). 
 
If the isocentre placement was outside the accepted tolerance (FP the isocentre 
was adjusted to fit within unit policy. The RTs used the digital couch readout inside 
the treatment room to move the required distance. The BBs were then adjusted on 
the patient’s skin to reflect this change in isocentre position. All isocentre 
movements (isomoves) were recorded on the patient’s research data sheet. 
 
Once the isocentre position was established, a helical CT data set was obtained from 
+12cm to –10cm, using a 5mm slice width and a pitch of 1.5 (130kV, 180mAs).  
 
The couch was then rotated back 180º and the radiation treatment was delivered. 
Once treatment was completed the axial CT images were exported back to the XIO 
planning computer system for data collection. 
7.8 Data Collection using XIO 
7.8.1 Patient File Maintenance Æ Contouring 
Images transferred from the Primatom CT were imported into the research database.  
For each fraction the PI drew the same contours generated on the planning CT scan. 
Contouring reliability will be discussed later in section 7.9. 
7.8.2 Teletherapy 
Once the patient was imported into XIO and contoured, a new plan was created by 
importing the appropriate patient template. Three different isocentres were used to 
analyse the effect of IGRT on the planned dose Figure 7-3 demonstrates the three 
isocentres which will be described further in the following sections. 
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Figure 7 - 3: Three different isocentres used to analyse effect of IGRT on dose 
 
 
7.8.2a ‘Actual’ Isocentre: 
The ‘Actual’ isocentre was defined as the isocentre where the treatment was 
delivered for that fraction. This was almost always (0,0,-0.45) reflecting the 
difference in couch height between the planning and Primatom CT scanners. The co-
ordinates of this ‘actual’ isocentre were checked to ensure that they corresponded 
with the BBs placed on the patient’s skin. If necessary the co-ordinates were 
adjusted to match the placement of the BBs. The apertures for each beam were 
imported individually and converted back into MLC settings. A report of structure 
volumes and marker positions (COV co-ordinates) was printed and the information 
recorded on the patient data collection sheets (Appendix 6). 
 
Dose data were generated by prescribing the fractional dose 200cGy (2Gy) to the 
isocentre. A DVH and the dose statistics functions were used to document the dose 
delivered to the same points of interest recorded during planning (section 7.6.2). 
These were recorded on the patient data collection sheets.  
Planned isocentre location 
= D6cm post to pubis bone 
Actual Iso: 
<0.5cm from planned iso – 
relative to bony landmarks 
(no on-line corrections) 
Uncorrected Iso:  
>0.5cm from planned iso -
relative to bony landmarks 
(iso location prior to on-
line corrections.) 
Future Iso: 
Distance between 
planned COV prostate 
location and planned iso 
maintained 
 Pubis   Bone 
 0.5cm radius 
Right 
Posterior 
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7.8.2b ‘Original’ Isocentre 
A second plan was created for each fraction that had had a pre-treatment isocentre 
move, i.e.: an isomove made as a result of the CT verification process. This 
‘Original’ isocentre represents the isocentre that would have been treated if the 
patient had not had pre-treatment CT verification. For example; if a pre-treatment 
isomove was made 0.5cm posterior as a result of the CT verification, the dose 
delivered to the ‘Original’ isocentre was calculated 0.5cm anterior to the ‘Actual’ 
isocentre. To demonstrate the impact CT verification had on dose, the fractional 
dose (2Gy) was prescribed to the ‘Original’ isocentre and the same dose data was 
collected. 
7.8.2c ‘Future’ Isocentre 
Another ‘Future’ plan was created for all fractions regardless of whether pre-
treatment corrections were performed. This ‘Future’ isocentre maintained the 
relationship between the isocentre and the COV of the prostate at the time of 
planning, therefore correcting for internal organ motion. For example if at the time 
of planning the isocentre co-ordinates were (0,0,0) and the COV of the prostate were 
(0.3,0.5, -1.2), to maintain this relationship during treatment, the isocentre is always 
going to be 0.3cm to the right, 0.5cm inferior and 1.2cm anterior (-0.3, -0.5, 1.2) 
from the COV of the prostate. The magnitude and direction of this ‘offset’ was 
recorded on the data collection sheet so that it could easily be applied to each 
treatment fraction.  
 
For each treatment fraction the ‘offset’ calculated was applied to the prostate COV 
co-ordinates. For example if during treatment the COV prostate co-ordinates were 
(0.7, -0.5, -0.2), to maintain the planned relationship between the COV prostate an 
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offset of (-0.3, -0.5, 1.2) is applied resulting in a ‘Future’ Isocentre location of (0.4, -
1.0, 1.0). 
 
To demonstrate the dosimetric impact of accounting for COV prostate motion using 
CT, the fractional dose (2Gy) was prescribed to the ‘future’ isocentre. The dose data 
information was collected and recorded on the patient data collection sheets.  
7.9 Intra-observer contouring variation 
Intra-observer contouring variation, or repeatability, was monitored throughout the 
twelve months of this study. 
 
The CT datasets of five de-identified prostate cancer patients undergoing Radiation 
Therapy at the Tattersall’s Cancer Centre were copied into the research database and 
saved under a unique number and date for completion. This was copied fourteen 
times resulting in 15 copies of the same file, each with 5 different CT datasets. 
These identical CT datasets were used to monitor contouring variation: initially 
repeating measurements weekly, then monthly for the remainder of the study 
duration. 
 
On each contouring occasion the following contours, using these definitions, were 
drawn:  
• Prostate (entire gland, excluding seminal vesicles) 
• Bladder (entire organ) 
• Anal Canal (3cm in length from anus) 
• Rectum solid (including air/faecal contents) – one slice inferior to the sigmoid-
rectum junction & one slice superior to the end of anal canal. 
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After contouring each of these structures, a structure volume report was generated 
and printed with the COV of each structure.  
8. Results 
Twenty five patients who presented to the Tattersall’s Cancer Centre, Epworth 
Hospital, for radical radiotherapy for prostate cancer were recruited into this study 
over a period of twelve months (October 2003-04). During this time 816 on-line 
treatment verification CT scans were performed. Only one of the 816 data sets 
obtained was incomplete and therefore no volume or dose data was possible 
although assessment of patient set-up uncertainty was possible. There were also 87 
treatment fractions where CT verification was not performed due to a machine 
breakdown or unavailability. The raw data for each patient are accessible in 
Appendix 7.  
 
Where relevant, the statistical analysis for these results has been based on linear 
regression and any conclusions have been drawn using 95% confidence intervals 
(95%CI) unless stated otherwise. 
8.1 Patient Characteristics 
8.1.1 Descriptive Characteristics 
Patient ages ranged from 55 to 77 years (mean= 70.5 years, SD= 5.8 years).  Nine 
(9) patients presented with stage T1c prostate cancer, twelve (12) patients with stage 
T2a-c, and four (4) patients with stage T3a..Gleason scores ranged from five (5) to 
nine (9), with scores of six and seven accounting for 18/25 patients. Eleven (11) 
patients were prescribed a treatment schedule of 70Gy in 35 fractions, and fourteen 
(14) patients were prescribed 74Gy in 37 fractions. Descriptive characteristics for 
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the twenty five patients recruited are shown in Table 8-1 including whether or not 
the patient underwent a course of hormone treatment prior to commencing radiation 
therapy. Hormone treatment has previously been associated with an observed 
decrease in prostate volume throughout a radiation therapy treatment course (Pouliet 
et al. 2003)  
Note: the Gleason scores have been recorded directly from the patient’s medical 
history. The format used to document the Gleason Score differs between Radiation 
Oncologists. Some documented the histological grade, clinical stage and the overall 
score, whereas others only documented the overall Gleason score. 
Table 8 - 1: Patient Characteristics 
Patient Age  Staging Gleeson 
Dose 
Level 
Hormone 
treatment? 
1 72 T1c 3+2 = 5 70Gy No 
2 70 T2a 4+5 = 9 74Gy No 
3 76 T1c 7 74Gy No 
4 67 T1c 6 70Gy No 
5 74 T2a 6 70Gy No 
6 70 T1  3+4 = 7 74Gy Yes 
7 65 T1c 3+3 = 6 74Gy No 
8 76 T2c 3+4 = 7 74Gy Yes 
9 71 T2b 3+3 = 6 70Gy No 
10 71 T2a 6 70Gy No 
11 73 T2c 4+3 = 7 74Gy Yes 
12 72 T2a 3+3 = 6 70Gy No 
13 71 T2b 3+4 = 7 74Gy Yes 
14 61 T2b 8 70Gy No 
15 57 T3a 3+4 = 7 74Gy No 
16 77 T2b 8 74Gy Yes 
17 55 T1c 3+3 = 6 70Gy No 
18 72 T3a 4+4 = 8 70Gy Yes 
19 66 T1c 5 74Gy Yes 
20 75 T1c 7 70Gy Yes 
21 74 T3a 7 74Gy Yes 
22 74 T2b 4+3 = 7 74Gy No 
23 74 T3a 9 74Gy Yes 
24 76 T1c 6 74Gy No 
25 74 T2a 3+3 = 6 70Gy No 
Mean 70.5     
S.D. 5.8     
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8.1.2 Patient Symptoms 
During this research study patients were reviewed according to the standard Peter 
Mac Urology unit treatment review policy. According to this policy patients are 
reviewed by the RO during weeks 1, 4 and 7 of their treatment. For the remaining 
weeks patients are reviewed by a nurse, however patients are encouraged to seek 
assistance for any symptoms that may arise between reviews. The unit policy does 
not require the reporting of specified symptoms according to grade, although this 
policy is in a process of change that will see the introduction of a toxicity template 
for the regular recording of symptoms, or absence of, during a patient’s treatment. 
 
Tables 8-2 & 8-3 demonstrate the urinary and rectal symptoms documented in the 
treatment notes for all 25 patients. The absence of any note was interpreted as no 
symptom reported by the patient. 
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Table 8 - 2: Urinary symptoms reported 
   frequency/urgency    
   dysuria - painful uriniation    
   micturia - difficulty voiding    
   
incontinence - inability to control 
micturation 
   
   nocturia - night    
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1 
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w
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-
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-
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-
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2                 
3                 
4               
5                 
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8                 
9                 
10                     
11                 
12                 
13                     
14                     
15                   
16                     
17               
18                       
19                         
20                 
21                 
22                     
23                     
24                     
25                 
 
 
 
 
 
 
 
 
 
 
 - 100 -
 
Table 8 - 3: Rectal symptoms reported 
  diarrhoea - watery stools    
  proctitis - rectal inflammation   
  perineal irritation   
  anal/rectal discomfort   
  constipation - difficulty passing stools   
  haemorrhoids   
pa
tie
n
t  
w
ee
k 
1 
(1-
5) 
w
ee
k 
2 
(6-
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) 
w
ee
k 
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-
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(21
-
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-
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-
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1       resolved    slightly 
2               resolved 
3                 
4                 
5                 
6             reduced increased  
7              
8                 
9                 
10      slight       
11                 
12             
13               improved 
14                 
15                 
16               
17                 
18                 
19                 
20                 
21                 
22               
23                 
24                 
25                 
 
8.2 Contouring uncertainty 
8.2.1 Intra-observer contouring uncertainty 
This research study was designed so that all contouring was performed by a single 
observer, using a standard slice thickness for all CT scans, as well as pre-determined 
structure definitions (described in section 7.6.1), in an attempt to minimise 
contouring variation. An assessment of intra-observer contouring uncertainty, or 
contouring repeatability, was performed over a period of twelve months. 15 sets of 
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repeat measurements were performed on the data set of 5 patients for 4 structures. 
The complete data set for each structure is available for viewing on the CD-ROM 
(Appendix 8). 
 
Using the volume and COV information, the repeatability of the contouring by the 
PI was assessed for the following structures: 
a) Rectum 
b) Bladder 
c) Prostate 
d) Anal Canal 
8.2.1a Rectum 
i) Volume Variation 
Table 8-4 summarises the mean and SD for the rectum volume for each patient.  
Table 8 - 4: Rectum volume statistics 
Patient Mean Volume (cc) SD (cc) 
1 186.2 5.2 
2 54.5 3.9 
3 50.8 1.3 
4 64.3 6.0 
5 45.5 2.8 
Average 80.3 3.8 
 
The rectum volume contouring variations for each patient over the twelve month 
period of this study are demonstrated in Figures 8-1(a-e) along with the linear line of 
best fit equation and the coefficient of determination (R²). Note the different scale 
used on patient 1 due to a large difference in volume.  
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Figure 8 - 1 (a-e): Rectum volumes variations 
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Patient 3: Rectum
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Patient 5: Rectum
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Regression statistics, including the Pearson correlation coefficient (R), 95%CI range 
and p-values for these graphs are shown in Table 8-5. 
Table 8 - 5: Rectum contours: Regression statistics 
Patient R 95%CI range p-value 
1 0.33 -0.28 to 1.03 0.24 
2 0.66 0.18 to 0.97 0.01 
3 0.31 -0.26 to 0.08 0.27 
4 0.35 -0.28 to 1.22 0.20 
5 0.40 -0.09 to 0.60 0.14 
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The repeatability of contouring of the rectum volume was assessed by normalising 
the data. Normalisation was performed by subtracting the mean rectum volume for 
each patient from the volume at each measurement occasion. Figure 8-2 
demonstrates the distribution of rectum volume variations after normalisation.  
Figure 8 - 2: Normalised rectum volume histogram 
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The 75 normalised contouring measurements demonstrated in Figure 8-2 resulted in 
a SD of 4.1cc. An analysis for normal distribution was performed resulting in a 
Kurtosis value of 0.31 and a Skewness value of 0.13. Both of these values indicate a 
normal distribution. 
 
ii) Centre of Volume (COV) motion 
To assess whether the small changes in volume affected the location of the COV of 
the rectum the data was normalised relative to the mean COV location. The SD of 
each COV relative to the mean COV location is shown in Table 8-6.  
Table 8 - 6: Rectum COV variation (cm) relative to the mean COV location 
  x y z 
SD (cm) 0.08 0.29 0.11 
 
 
The normalised distributions for each direction are shown on the histograms in 
Figures 8-3(a-c). The polarity of the coordinate system relates to the convention 
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used by the XIO planning system used to collect data. The X coordinate relates to 
the location of the COV relative to the mid-plane (midline) of the patient, where the 
left of the patient is positive X and the right negative X. The Y coordinate locates 
the volume in the SI direction with positive Y towards the patient’s head (superior) 
and negative Y inferior. The Z co-ordinate locates the COV in the AP direction, with 
positive Z located anteriorly and negative Z posteriorly for a supine patient. 
Figure 8 - 3 (a-c): Distribution of COV location normalised to the mean 
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The Kurtosis and Skewness values for each direction are shown in Table 8-7. 
Kurtosis in the X and Y directions indicates that the distribution is not normal. 
Table 8 - 7: Normal distribution data for COV motion 
Direction Kurtosis Skewness 
x 2.77 0.47 
y 2.66 1.31 
z 0.49 -0.24 
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iii) Effect of volume expansion 
To assess the potential for small variations in contouring to make large differences 
in volume, on five occasions a 0.1cm margin and a 0.2cm margin were applied to the 
original contours using the automatic expansion function on the planning computer 
system. To assess the effect of increasing the UL of the rectum by one CT slice 
(0.5cm), the contour was also expanded 0.5cm in the superior direction with no 
expansion in the other dimensions. The resulting average volume is demonstrated in 
Table 8-8.  
Table 8 - 8: Rectum volume (cc) as a result of expansion 
Expansion Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
Original 186.2 54.5 50.8 64.3 45.5 
0.1cm + 206.1 61.5 60.3 76.5 52.9 
0.2cm + 225.0 70.3 67.8 86.9 59.9 
0.5cm UL 213.9 68.7 63.3 80.4 60.9 
 
8.2.1b Bladder 
i) Volume data 
Table 8-9 summarises the mean and SD for the bladder volume for each patient.  
Table 8 - 9: Bladder volume statistics 
Patient Mean Volume (cc) SD (cc) 
1 532.9 5.8 
2 291.4 6.8 
3 120.1 3.0 
4 347.2 8.9 
5 234.3 5.2 
Average 305.2 6.0 
 
The bladder volume contouring variations for each patient over the twelve month 
period of this study are demonstrated in Figures 8-4(a-e) along with the linear line of 
best fit equation and the R² values. Note that the scale used on all graphs is different, 
although the volume range displayed on the Y-axis of each graph is 40cc. The R 
value, 95%CI range of the slope and p-value are shown in Table 8-10.  
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Figure 8 - 4(a-e): Bladder volume variations 
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Table 8 - 10: Bladder contours: Correlation coefficients, 95% CI range and p-values 
Patient R 95%CI range p-value 
1 0.08 -0.68 to 0.88 0.79 
2 0.58 0.15 to 1.63 0.02 
3 0.28 -0.20 to 0.57 0.32 
4 0.63 0.33 to 2.19 0.01 
5 0.56 0.07 to 1.24 0.03 
 
The repeatability of contouring the bladder volume was assessed by normalising the 
data to the mean as shown in Figure 8-5.  
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Figure 8 - 5: Normalised bladder volume histogram 
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Descriptive statistics of the 75 normalised contoured volumes used to generate this 
histogram (Figure 8-5) resulted in a SD of 6.1cc. An analysis for normal distribution 
resulted in a Kurtosis value of 0.36 and a skewness value of -0.11 indicating that the 
steepness and symmetry of this distribution is normal. 
 
ii) Centre of volume (COV) motion 
To assess whether the small changes in volume affected the location of the COV of 
the bladder the data was normalised relative to the mean COV location. The SD of 
each COV relative to the mean COV location is shown in Table 8-11. 
Table 8 - 11: Bladder COV variation relative to the mean COV location 
  x y z 
SD (cm) 0.04 0.12 0.06 
 
The normalised distributions for each direction are shown in Figures 8-6(a-c) 
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Figure 8 - 6(a-c): Distribution of COV location normalised to the mean 
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Z co-ordinates - normalised (mean)
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Kurtosis and Skewness values for each direction are shown in Table 8-12 and 
indicate a normal distribution. 
Table 8 - 12: Normal distribution data for COV motion 
Direction Kurtosis Skewness 
x -0.25 0.09 
y 0.35 0.21 
z -0.08 -0.13 
 
 
iii) Effect of volume expansion 
To assess the effect small variations in contouring had on volume, on five occasions 
a 0.1cm margin and a 0.2cm margin were applied to the original contours. The 
resulting effect on volume is demonstrated in Table 8-13.  
Table 8 - 13: Bladder volume (cc) as a result of expansion 
Expansion Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
Original 532.9 291.4 120.1 347.2  234.3 
0.1cm + 566.7 310.4 130.1 367.6 250.3 
0.2cm + 593.9 327.4 138.6 387.2 264.1 
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8.2.1c Prostate 
i) Volume Data 
Table 8-14 summarises the mean and SD for the prostate volume for each patient.  
Table 8 - 14: Prostate volume statistics. 
Patient Mean Volume (cc) SD (cc) 
1 100.9 4.4 
2 31.0 4.8 
3 28.9 3.8 
4 67.2 9.7 
5 40.9 2.7 
Average 53.8 5.1 
 
The prostate volume contouring variations for each patient over the twelve month 
period are demonstrated in Figures 8-7(a-e) along with the linear line of best fit 
equation and the R² values. The R value, 95%CI of the slope and p-value are shown 
in Table 8-15.  
Figure 8 - 7(a-e): Prostate volume variations 
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Patient 5: Prostate
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Table 8 - 15: Prostate contours: correlation coefficients, 95% CI and p-values 
Patient R 95%CI range p-value 
1 0.83 -1.14 to -0.49 0.00 
2 0.94 -1.23 to -0.81 0.00 
3 0.86 -0.99 to -0.48 0.00 
4 0.86 -2.53 to -1.19 0.00 
5 0.88 -0.70 to -0.35 0.00 
 
The repeatability of contouring the prostate volume was assessed by normalising the 
data. Figure 8-8 demonstrates the distribution of prostate volume variations after 
normalisation. 
Figure 8 - 8: Normalised prostate volume histogram. 
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For 75 contouring occasions the prostate contours had a SD of 5.5cc. The analysis 
for normal distribution resulted in a Kurtosis value of 0.21 and a Skewness value of 
0.16. These results indicate that the distribution is normal 
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ii) Centre of volume (COV) motion 
To assess whether the change in volume affected the location of the COV of the 
prostate the data was normalised relative to the mean COV location. The SD of each 
COV relative to the mean COV location is shown in Table 8-16. 
Table 8 - 16: Prostate COV variation relative to the mean COV location 
  x y z 
SD (cm) 0.07 0.16 0.10 
 
The normalised distributions for each direction are shown below (Figure 8-9a-c) 
Figure 8 - 9(a-c): Distribution of COV location normalised to mean 
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Z coordinates - normalised (mean)
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These histograms for COV were assessed for normal distribution. The Kurtosis and 
Skewness values for each direction are shown in Table 8-17 and indicate a normal 
distribution. 
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Table 8 - 17: Normal distribution data for COV motion 
Direction Kurtosis Skewness 
x 1.82 -1.04 
y 0.59 0.35 
z -0.39 0.05 
 
iii) Effect of volume expansion 
To assess the effect variations in contouring had on volume, on five occasions a 
0.1cm margin and a 0.2cm margin were applied to the original contours. To assess 
the effect of increasing the UL of the rectum by one CT slice (0.5cm), the contour 
was also expanded 0.3cm in the superior direction with no expansion in the other 
dimensions. The resulting effect on average volume is demonstrated in Table 8-18.  
Table 8 - 18: Prostate volume (cc) as a result of expansion 
Expansion Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
Original  100.9 30.9 28.9 67.2 40.9 
0.1cm + 112.9 38.7 35.2 81.9 47.8 
0.2cm + 123.3 43.7 39.7 90.3 53.0 
0.3cm UL 119.6 42.1 39.6 86.4 52.7 
 
 
8.2.1d Anal Canal 
i) Volume Data 
Table 8-19 summarises the mean and SD for the anal canal volume for each 
patient. 
Table 8 - 19: Anal Canal volume statistics 
Patient Mean Volume (cc) SD (cc) 
1 10.4 1.2 
2 15.7 1.1 
3 14.3 0.8 
4 11.0 2.1 
5 11.5 1.2 
Average 12.6 1.3 
 
The anal canal volume contouring variations for each patient over the twelve months 
are demonstrated in Figures 8-10(a-e) along with the linear line of best fit equation 
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and R² values. The R value, 95%CI of the slope and p-value are shown in Table 8-
20. 
Figure 8 - 10(a-e): Anal Canal volume variation 
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Patient 3: Anal Canal
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Patient 5: Anal Canal
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Table 8 - 20: Anal Canal contours: Correlation coefficients, 95% CI and p-values 
Patient R 95%CI range p-value 
1 0.01 -0.16 to 0.15 0.98 
2 0.04 -0.14 to 0.16 0.88 
3 0.15 -0.08 to 0.14 0.60 
4 0.76 -0.54 to -0.18 0.00 
5 0.16 -0.20 to 0.12 0.57 
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The repeatability of contouring the anal canal was assessed by normalising the data. 
Figure 8-11 demonstrates the distribution of rectum volume variations after 
normalisation. 
Figure 8 - 11: Normalised anal canal volume histogram 
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The histogram in Figure 8-11 demonstrates that from the 75 contouring occasions 
the SD for anal canal contouring is 1.3cc. An analysis for normal distribution 
resulted in a Kurtosis value of 0.13 and a Skewness value of 0.05 indicating a 
normal distribution. 
 
ii) Centre of volume (COV) motion 
To assess whether changes in volume affected the location of the COV of the anal 
canal, the data was normalised relative to the mean COV location. The SD of each 
COV relative to the mean COV location is shown in Table 8-21. 
Table 8 - 21: Anal Canal COV variation relative to mean COV location 
  x y z 
SD (cm) 0.07 0.16 0.11 
 
The normalised distributions for each direction are shown in histograms below 
(Figures 8-12a-c). 
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Figure 8 - 12 (a-c): Distribution of normalised COV location. 
X coordinates - normalised (mean)
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Y coordinates - normalised (mean)
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These histograms for COV motion can also be assessed for normal distribution. The 
Kurtosis and Skewness values for each direction are shown in Table 8-22 and 
indicate a normal distribution. 
Table 8 - 22: Normal distribution data for COV motion 
Direction Kurtosis Skewness 
x -0.13 0.36 
y 0.92 0.49 
z -0.76 0.05 
 
iii)Effect of volume expansion 
To assess the effect volume variations in contouring on five occasions a 0.1cm 
margin and a 0.2cm margin were applied to the original contours. The resulting 
effect on average volume is demonstrated in Table 8-23. 
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Table 8 - 23: Anal canal volume (cc) as a result of expansion 
Expansion Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
Original  10.4  15.7 14.3 11.0 11.5 
0.1cm + 13.2 19.0 17.4 14.7 14.6 
0.2cm + 15.9 22.1 20.4 17.6 17.4 
 
8.2.2 Inter-observer contouring uncertainty 
Although this research was conducted using a single observer, an assessment of 
reproducibility compared to a qualified RO was completed to ensure that the 
structures were identified correctly. Inter-observer contouring uncertainty was 
assessed by comparing contours drawn on the same five patients by a consultant RO 
on one occasion against the contours drawn by the PI. The same structures were 
assessed as those discussed previously during the intra-observer contouring 
uncertainty section. 
8.2.2a Rectum 
i) Volume variations 
The mean rectum volume from the intra-observer study was used to assess inter-
observer contouring uncertainty by comparing it to the volume contoured by the RO 
(Figure 8-13).  
Figure 8 - 13: Comparison of mean rectum volume vs. RO contoured volume 
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The mean rectum volume, SD and 2SDs for each patient calculated during the intra-
observer study along with the volume contoured by the RO are reported in Table 8-
24. RO volumes that fall outside the range of 2SD from the mean are shaded in grey. 
Table 8 - 24: Rectum Inter-observer variation (cc) 
Rectum Mean SD 2SD RO 
Patient 1 186.2 5.2 10.3 185.0 
Patient 2 54.5 3.9 7.8 63.7 
Patient 3 50.8 1.3 2.7 65.4 
Patient 4 64.3 6.0 12.0 57.0 
Patient 5 45.5 2.8 5.7 43.3 
 
 
ii) COV variation 
COV variations for the rectum are shown in Table 8-25. Once again the mean COV 
location, SD and 2SDs calculated during the intra-observer study are tabulated along 
with the location of the COV from the ROs contouring. Any COV coordinates of the 
RO that fall outside the range of 2SDs from the mean are shaded grey.  
Table 8 - 25: Rectum COV variations (cm) 
X Mean SD 2SD RO 
Patient 1 0.95 0.12 0.24 0.88 
Patient 2 0.03 0.05 0.10 0.32 
Patient 3 -1.02 0.25 0.50 -1.05 
Patient 4 -0.77 0.07 0.14 -0.75 
Patient 5 0.59 0.08 0.16 0.62 
Y         
Patient 1 0.97 0.19 0.38 1.50 
Patient 2 0.43 0.35 0.70 0.75 
Patient 3 0.27 0.06 0.12 1.00 
Patient 4 1.55 0.36 0.72 3.00 
Patient 5 -0.12 0.39 0.78 0.50 
Z         
Patient 1 -4.49 0.13 0.26 -4.25 
Patient 2 -5.25 0.17 0.34 -5.51 
Patient 3 -4.19 0.09 0.18 -4.47 
Patient 4 -4.55 0.11 0.22 -4.58 
Patient 5 -3.97 0.05 0.10 -3.97 
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8.2.2b Bladder 
i) Volume variations 
The mean bladder volume from the intra-observer study was used to assess inter-
observer contouring uncertainty by comparing it to the volume contoured by the RO 
(Figure 8-14).  
Figure 8 - 14: Comparison of mean bladder volume vs. RO contoured volume 
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The mean bladder volume, SD and 2SDs for each patient calculated during the intra-
observer study along with the volume contoured by the RO are reported in Table 8-
26. RO volumes that fall outside the range of 2SD from the mean are shaded in grey. 
Table 8 - 26: Bladder Inter-observer variation (cc) 
Bladder Mean SD 2SD RO 
Patient 1 532.9 5.8 11.7 531.1 
Patient 2 291.4 6.8 13.6 292.2 
Patient 3 120.1 3.0 6.0 128.4 
Patient 4 347.2 8.9 17.9 345.8 
Patient 5 234.3 5.2 10.5 218.4 
 
ii) COV variation 
COV variations for the bladder are shown in Table 8-27. Once again the mean COV 
location, SD and 2SDs calculated during the intra-observer study are tabulated along 
with the location of the COV from the ROs contouring. Any COV coordinates of the 
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RO that fall outside the range of 2SDs from the mean are shaded grey. In the event 
that the SD calculated is equal to zero, it too is shaded grey. 
Table 8 - 27: Bladder COV variations (cm) 
X Mean SD 2SD RO 
Patient 1 0.71 0.04 0.08 0.76 
Patient 2 -0.31 0.05 0.10 -0.34 
Patient 3 -0.22 0.06 0.12 -0.15 
Patient 4 -0.65 0.04 0.08 -0.77 
Patient 5 0.54 0.04 0.08 0.57 
Y         
Patient 1 5.07 0.11 0.22 5.25 
Patient 2 3.13 0.16 0.32 3.00 
Patient 3 1.75 0.00 0.00 2.00 
Patient 4 4.68 0.11 0.22 5.00 
Patient 5 2.83 0.15 0.30 3.00 
Z         
Patient 1 3.12 0.04 0.08 3.14 
Patient 2 2.30 0.05 0.10 2.38 
Patient 3 1.52 0.06 0.12 1.51 
Patient 4 2.72 0.05 0.10 2.67 
Patient 5 1.71 0.09 0.18 1.61 
 
 
8.2.2c Prostate 
i) Volume variations 
The mean prostate volume from the intra-observer study was used to assess inter-
observer contouring uncertainty by comparing it to the volume contoured by the RO 
(Figure 8-15).  
 
The mean prostate volume, SD and 2SDs for each patient calculated during the intra-
observer study along with the volume contoured by the RO are reported in Table 8-
28. No RO volumes fall outside the range of 2SD from the mean. 
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Figure 8 - 15: Comparison of mean prostate volume vs. RO contoured volume 
Prostate inter-observer volume comparison
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Table 8 - 28: Prostate Inter-observer variation (cc) 
Prostate Mean SD 2SD RO 
Patient 1 100.9 4.4 8.8 94.0 
Patient 2 31.0 4.8 9.7 23.9 
Patient 3 28.9 3.8 7.6 28.3 
Patient 4 67.2 9.7 19.4 63.4 
Patient 5 40.9 2.7 5.4 41.1 
 
 
ii) COV variation 
COV variations for the prostate are shown in Table 8-29. Once again the mean COV 
location, SD and 2SDs calculated during the intra-observer study are tabulated along 
with the location of the COV from the ROs contouring. Any COV coordinates of the 
RO that fall outside the range of 2SDs from the mean are shaded grey.  
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Table 8 - 29: Prostate COV variations (cm) 
X Mean SD 2SD RO 
Patient 1 1.12 0.05 0.10 1.10 
Patient 2 -0.20 0.10 0.20 -0.11 
Patient 3 -0.70 0.06 0.12 -0.72 
Patient 4 -0.90 0.07 0.14 -0.93 
Patient 5 0.81 0.05 0.10 0.68 
Y         
Patient 1 0.27 0.06 0.12 0.50 
Patient 2 -0.68 0.18 0.36 -0.50 
Patient 3 -0.92 0.15 0.30 -1.00 
Patient 4 0.65 0.26 0.52 0.75 
Patient 5 -0.43 0.11 0.22 0.00 
Z         
Patient 1 -1.27 0.07 0.14 -1.25 
Patient 2 -0.93 0.14 0.28 -0.63 
Patient 3 -0.87 0.09 0.18 -0.97 
Patient 4 0.10 0.11 0.22 0.31 
Patient 5 -0.24 0.08 0.16 -0.38 
 
8.2.2d Anal Canal 
i) Volume variations 
The mean anal canal volume from the intra-observer study was used to assess inter-
observer contouring uncertainty by comparing it to the volume contoured by the RO 
(Figure 8-16).  
Figure 8 - 16: Comparison of mean anal canal volume vs. RO contoured volume 
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The mean anal canal volume, SD and 2SDs for each patient calculated during the 
intra-observer study along with the volume contoured by the RO are reported in 
Table 8-30. RO volumes that fall outside the range of 2SD from the mean are shaded 
in grey. 
Table 8 - 30: Anal Canal Inter-observer variation (cc) 
Anal Canal Mean SD 2SD RO 
Patient 1 10.4 1.2 2.4 12.6 
Patient 2 15.7 1.2 2.3 15.0 
Patient 3 14.3 0.8 1.6 11.0 
Patient 4 11.0 2.1 4.2 17.4 
Patient 5 11.5 1.2 2.4 11.9 
 
 
ii) COV variation 
COV variations for the anal canal are shown in Table 8-31. Once again the mean 
COV location, SD and 2SDs calculated during the intra-observer study are tabulated 
along with the location of the COV from the ROs contouring. Any COV coordinates 
of the RO that fall outside the range of 2SDs from the mean are shaded grey. In the 
event that the SD calculated is equal to zero, it too is shaded grey. 
Table 8 - 31: Anal Canal COV variations 
X Mean SD 2SD RO 
Patient 1 1.36 0.06 0.12 1.26 
Patient 2 -0.13 0.06 0.12 -0.18 
Patient 3 -0.53 0.05 0.10 -0.55 
Patient 4 -0.56 0.09 0.18 -0.66 
Patient 5 0.61 0.07 0.14 0.57 
Y         
Patient 1 -6.53 0.13 0.26 -6.00 
Patient 2 -4.00 0.00 0.00 -4.00 
Patient 3 -4.50 0.00 0.00 -4.75 
Patient 4 -4.83 0.24 0.48 -3.00 
Patient 5 -4.32 0.24 0.48 -4.00 
Z         
Patient 1 -5.16 0.10 0.20 -4.84 
Patient 2 -3.86 0.12 0.24 -3.42 
Patient 3 -4.04 0.09 0.18 -4.13 
Patient 4 -3.73 0.13 0.26 -3.12 
Patient 5 -2.12 0.11 0.22 -1.90 
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8.3 Patient set-up uncertainty 
Patient set-up uncertainty will be presented using several different measures: 
1) Number of isomoves. 
2) Timing of isomoves & changes to isocentre recorded in treatment sheet. 
3) Direction of isomoves 
4) Magnitude of isomoves 
5) Relationship between the number of shifts and patient habitus 
6) Systematic variation 
7) Random variation 
8) Total set-up uncertainty 
The data used to assess patient set-up uncertainty is available in appendix 9. 
8.3.1 Number of isomoves 
During this study 816 pre-treatment verification CT scans were performed. On one 
treatment occasion the CT data set was incomplete and therefore could only be used 
to assess isocentre position. According to department protocol, an isomove was 
performed when the location of the treatment isocentre was FP IURP WKH
planned isocentre using bony landmarks. The frequency of isomoves was recorded 
for each patient and demonstrated in Figure 8-17.  
 
The total number of occasions where an isomove was required for the patient 
population was 82, equating to 10.1% of all fractions. On average 3.3 isomoves were 
required per patient treatment course. Patient 19 demonstrated the greatest number 
of isomoves (12 out of 35 treatments), while five patients had no isomoves 
throughout their entire treatment course. There was also no time trend across the 
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research project, from patient 1 to patient 25, associated with the number of 
isomoves required (R= 0.08).  
Figure 8 - 17: Number of isomoves per patient 
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8.3.2 Timing of isomoves 
Table 8 - 32: Pre-treatment isomoves and adjustments to treatment sheet 
Pa
tie
n
t N
o
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 TO
TA
L
1 A A 1
2 PR P R R 3
3 A A A A A A A 6
4 A P P P 4
5 A L L A P P P 5
6 A L I I I L A A 8
7 A A A 2
8 0
9 A A P P P 3
10 A A S 2
11 A A L L L L L 6
12 A A A I I P 4
13 0
14 L 1
15 0
16 P I I 3
17 A A 2
18 AL AL PL L 4
19 IR IPR A P P P P P P P S S A P 12
20 A A A S R P R P P P 10
21 SA SA S A A 3
22 0
23 A P 1
24 I I S 2
25 0
Legend
Notes
Patient 18: Fx 6. treatment sheet altered (AL)
pre-treatment correction (L)
Patient 19: Fx 3. treatment sheet altered (IR) 
pre-treatment correction (A)
Patient 20: Fx7. treatment sheet altered (A)
pre-treatment correction (S)
Moved in 2 directions
Pre-treatment isoshift performed
Change in isocentre recorded in treatment sheet (as a result of constant moves)
No CT verification performed due to machine breakdown
Patients who were treated to 70Gy in 35Fx (i.e no Fx no 36 or 37)
Pre-treatment isoshift performed + change in isocentre in treatment sheet (see notes)
Fraction
Moved in 3 directions
A = ANT; P = POST
S = SUP; I = INF
R = RIGHT; L = LEFT
IR = INF & RIGHT; PR= POST&RIGHT; SA = SUP & ANT
IPR = INF, POST & RIGHT
Moved in AP direction
Moved in SI direction
Moved in RL direction
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The timing of the isomoves is shown in Table 8-32, along with the timing of 
changes to the isocentre recorded in the treatment sheet. Changes to the initial 
treatment isocentre were permitted when two consecutive on-line corrections were 
performed. This was to minimise repeated corrections for systematic variation. 
 
8.3.3 Direction of isomoves 
Of the isomoves demonstrated in Table 8-32, 21 moves were in the RL (X) 
direction, 16 in the SI (Y), and 54 in the AP (Z) direction (Figure 8-18). On 8 
occasions there was an isomove made in more than one direction, with one of these 
occasions requiring a move in all 3 directions (Figure 8-19). 14/21 moves were in 
the left (+) direction, 9/16 in the inferior (-) direction and 30/54 in the anterior (+) 
direction. 
Figure 8 - 18: Direction of isomoves 
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Figure 8 - 19: Direction of multiple isomoves 
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8.3.4 Magnitude of isomoves 
The average magnitude of an isomove was 5.5mm (RL), 5.8mm (SI) and 6.4mm 
(AP). Figure 8-20 demonstrates the magnitude and direction of shifts.  
Figure 8 - 20: Magnitude direction of isomoves. 
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There was no consistent direction for isomoves in any of the three dimensions as 
indicated by the mean magnitude of the shifts. An analysis for normal distribution 
was also performed for each direction (Table 8-33). 
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Table 8 - 33: Analysis of isomove magnitude (mm) 
  X Y Z 
Mean 1.70 -1.00 0.60 
S.D 5.40 5.90 6.60 
Mode 5.00 5.00 6.00 
Kurtosis -1.55 -2.15 -1.70 
Skewness -0.75 0.25 -0.27 
 
8.3.5 Relationship between patient body habitus and isomoves 
The relationship between patient body habitus and isomoves can be demonstrated by 
plotting the number of isomoves against the patient volume (Figure 8-21). 
Figure 8 - 21: Body habitus vs. isomoves 
Body Habitus vs. isomoves
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The relationship between patient separation in both the AP and lateral directions can 
also be plotted against the number of isomoves required (Figures 8-22 and 8-23). 
Figure 8 - 22: AP separation vs. isomoves 
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Figure 8 - 23: Lateral separation vs. isomoves 
Lateral separation  vs. isomoves
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8.3.6 Isocentre systematic variation 
The isocentre systematic error is the difference between the planned isocentre 
location and the mean isocentre location during treatment.  
     _ 
SE (patient) = Xk – Xk0    (Rosenthal et al. 1992) 
      
_
 
    Where Xk = mean location of the isocentre 
     Xk0= planned location of the isocentre  
 
Since the planned isocentre location was zero (0,0,0) the systematic error for each 
patient was simply the mean of all treatment isocentre locations (816 data points). 
The systematic set-up error for each direction is demonstrated in Table 8-34. 
            _ 
SE (all fractions) = Xk  
Table 8 - 34: Systematic set-up error (mm) 
  Systematic error 
X (R-L) -0.5 
Y (Sup-Inf)  0.3 
Z (Ant-Post) -0.4 
 
8.3.7 Isocentre random variation 
The isocentre random error is the mean deviation of all points from their mean 
position during treatment and is therefore the SD of the treatment isocentre location. 
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Using the data from the 816 data points the random error for all fractions (Table 8-
35). 
  RE (all fractions) = ¥>(Xjk – Xj) ²]   (Rosenthal et al. 1992) 
                m      
Table 8 - 35: Random Error (mm) 
  Random error 
X (R-L) 2.00 
Y (Sup-Inf) 2.00 
Z (Ant-Post) 2.50 
 
8.3.8 Total set-up uncertainty 
The total set-up uncertainty, the overall difference between the treatment and 
planned isocentre position, for all fractions was calculated and reported in Table 8-
36. 
(TU) ² = (RE) ² + (SE) ²   (Rosenthal et al. 1992) 
Table 8 - 36: Total set-up uncertainty (mm) 
  Total uncertainty 
X (R-L) 2.06 
Y (Sup-Inf) 2.02 
Z (Ant-Post) 2.53 
 
The frequency distribution for set-up uncertainty for all fractions, including those 
below the action threshold, can also be used to assess whether total set-up 
uncertainty follows a normal distribution (Figure 8-24 a-c). Table 8-37 demonstrates 
that these distributions are normal. 
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Figure 8 - 24 a-c: Distribution of set-up uncertainty 
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0
50
100
150
200
250
-
1
-
0.
9
-
0.
8
-
0.
7
-
0.
6
-
0.
5
-
0.
4
-
0.
3
-
0.
2
-
0.
1 0
0.
1
0.
2
0.
3
0.
4
0.
5
0.
6
0.
7
0.
8
0.
9 1
Magnitude (cm) and direction
N
u
m
be
r 
o
f o
cc
u
rr
en
ce
s
Distribution of set-up uncertainty - SI
0
50
100
150
200
250
300
-
1
-
0.
9
-
0.
8
-
0.
7
-
0.
6
-
0.
5
-
0.
4
-
0.
3
-
0.
2
-
0.
1 0
0.
1
0.
2
0.
3
0.
4
0.
5
0.
6
0.
7
0.
8
0.
9 1
Magnitude (cm) and direction
N
u
m
be
r 
o
f o
cc
u
rr
en
ce
s
 
Distribution of set-up uncertainty - AP
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Table 8 - 37: Analysis for normal distribution of overall set-up uncertainty 
  Kurtosis Skewness 
X 0.18 -0.14 
Y 1.32 -0.04 
Z 1.89 0.01 
 
8.4 Organ volume variations 
8.4.1 Hypothesis 1: Rectal volumes decrease 
Hypothesis 1, that rectal volumes decrease across a course of radiation therapy, was 
assessed using the following three structures: Rectum solid, Rectal Wall and Anal 
Canal. The definitions used for these structures were stated previously (section 
7.6.1). The data used to assess rectum organ volumes is available in appendix 10. 
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8.4.1a) Rectum solid 
Table 8-38 demonstrates the variations observed in rectum solid volumes for each 
individual patient during a course of radiation therapy. For each individual patient 
this table demonstrates the planned rectum solid volume, the mean treatment 
volume, the SD of the treatment volume (which also equates to the random error), 
the R value, the t-value, the p-value and indicates the direction of the trend. The 
patients who demonstrate statistically significant p-values (<0.05) have been shaded 
grey along with the R value.  
Table 8 - 38: Organ volume variations - Rectum Solid 
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1 36.12 39.70 8.20 0.02 0.13 0.90 Not significant 
2 124.93 88.20 35.70 0.36 -2.28 0.03 Decrease 
3 46.81 71.71 15.34 0.44 2.88 0.01 Increase 
4 108.33 79.53 38.53 0.14 -0.81 0.42 Not significant 
5 40.67 43.52 13.49 0.42 -2.52 0.02 Decrease 
6 89.39 96.33 41.01 0.60 -4.31 0.00 Decrease 
7 37.94 57.18 20.97 0.08 0.48 0.64 Not significant 
8 38.63 43.05 4.20 0.45 2.28 0.03 Increase 
9 57.55 69.75 17.33 0.45 2.37 0.03 Increase 
10 144.17 59.79 14.24 0.28 -1.22 0.24 Not significant 
11 138.14 66.34 17.08 0.08 -0.40 0.69 Not significant 
12 156.68 83.42 33.83 0.49 -3.17 0.00 Decrease 
13 44.13 44.32 9.64 0.06 0.30 0.77 Not significant 
14 49.51 79.97 33.33 0.48 -2.98 0.01 Decrease 
15 170.79 109.51 30.85 0.06 0.37 0.72 Not significant 
16 188.66 92.42 26.55 0.36 -2.19 0.04 Decrease 
17 36.47 48.82 5.62 0.16 -0.91 0.37 Not significant 
18 95.53 93.34 12.99 0.32 -1.91 0.07 Not significant 
19 79.52 60.86 20.41 0.01 -0.06 0.96 Not significant 
20 82.32 68.30 22.61 0.25 -1.47 0.15 Not significant 
21 98.92 65.31 23.88 0.14 -0.80 0.43 Not significant 
22 115.74 87.83 14.18 0.24 -1.42 0.17 Not significant 
23 54.51 53.03 24.88 0.50 -3.40 0.00 Decrease 
24 96.67 64.88 17.65 0.12 -0.70 0.49 Not significant 
25 102.88 98.28 23.00 0.01 -0.06 0.95 Not significant 
mean 89.4 70.6      
SD 45.7 19.7      
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The mean planned rectum solid volume was 89.4cc with a SD of 45.7cc. The mean 
treatment rectum solid volume was 70.6cc (SD= 19.7cc).  
 
The rectum solid volumes for all fractions of all patients were normalised against the 
original planning volume and then expressed as a percentage. For each fraction these 
values were then averaged and plotted to assess for time trends (Figure 8-25). The p-
value for the slope of Figure 8-25 is <0.05 (p= 0.00) and R is 0.66 indicating a trend 
for decreasing volume over time.  
Figure 8 - 25: Average change in Rectum solid volume 
Average change in Rectum (solid) Volume
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Systematic error can be used to assess the variation between planned rectum solid 
volume and the volumes observed during treatment. The systematic error shown in 
Figure 8-26 was calculated by subtracting the mean treatment volume from the 
planned volume. 
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Figure 8 - 26: Systematic error for Rectum Solid volumes 
Systematic error: Rectum Solid
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The relationship between planned volume and systematic error is shown in Figure 8-
27. A regression analysis on the slope of this graph results in R= 0.91 and a p-value 
of p= 0.00 indicating a statistically significant relationship.  
Figure 8 - 27: Planned rectum solid volume vs. systematic error. 
Planned Rectum Solid volume vs. systematic error
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Random error is calculated as the SD of the treatment volumes (Figure 8-28). The 
relationship between random errors and planning volume can also be assessed 
(Figure 8-29). 
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Figure 8 - 28: Random error for Rectum Solid volumes 
Random error: Rectum Solid
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Figure 8 - 29: Planned rectum solid volume vs. random error. 
Planned Rectum solid volume vs. random error
y = 0.1051x + 11.629
R2 = 0.2217
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Regression statistics were performed on the relationship between planned volume 
and random error and resulted in p= 0.02, R= 0.47 indicating a relationship between 
the two variables, although not as strong as that observed for systematic error.  
 
The maximum and minimum rectum solid volume as a percentage of the planned 
volume experienced during treatment for each patient are demonstrated in Table 8-
39. Patients who demonstrated a maximum fluctuation of less 100% or a minimum 
fluctuation of greater than 100% are shaded grey. 
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Table 8 - 39: Maximum & minimum treatment volume (% of planned volume). 
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1 221.29% 71.90% 
2 154.39% 30.71% 
3 250.18% 73.72% 
4 184.50% 34.77% 
5 206.42% 64.96% 
6 248.89% 48.67% 
7 329.92% 85.42% 
8 133.08% 84.13% 
9 201.06% 77.98% 
10 61.23% 26.79% 
11 83.59% 27.81% 
12 134.92% 29.78% 
13 172.81% 73.85% 
14 341.75% 83.80% 
15 100.09% 33.46% 
16 85.85% 32.25% 
17 192.87% 112.15% 
18 135.77% 78.21% 
19 177.82% 46.08% 
20 148.62% 51.30% 
21 118.74% 35.78% 
22 113.34% 60.85% 
23 281.47% 62.12% 
24 125.52% 49.59% 
25 157.83% 65.94% 
mean 174.5% 57.7% 
 
 8.4.1b) Rectal wall 
Table 8-40 demonstrates the variations observed in rectal wall volumes for each 
individual patient during a course of radiation therapy. For each individual patient 
this table demonstrates the planned rectal wall volume, the mean treatment volume, 
the SD of the treatment volume (which also equates to the random error), the R 
value, the t-value, the p-value and indicates the direction of the trend. The patients 
who demonstrate statistically significant p-values (<0.05) have been shaded grey 
along with the R value. 
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Table 8 - 40: Organ volume variations: Rectal Wall 
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1 31.74 34.81 3.23 0.14 0.82 0.42 Not Significant 
2 38.19 37.94 3.79 0.37 -2.37 0.02 Decrease 
3 44.02 54.87 7.97 0.23 1.42 0.16 Not Significant 
4 46.96 41.65 6.63 0.04 -0.23 0.82 Not Significant 
5 35.59 28.23 4.76 0.19 -1.08 0.29 Not Significant 
6 34.88 51.23 8.92 0.81 8.02 0.00 Increase 
7 36.34 36.56 5.97 0.31 1.95 0.06 Not Significant 
8 36.74 40.72 4.05 0.64 3.76 0.00 Increase 
9 46.12 52.71 9.40 0.65 4.03 0.00 Increase 
10 43.80 45.95 6.65 0.38 1.70 0.11 Not Significant 
11 39.99 44.32 5.74 0.30 -1.53 0.14 Not Significant 
12 41.67 48.16 8.59 0.40 2.46 0.02 Increase 
13 33.92 36.09 2.89 0.24 1.32 0.20 Not Significant 
14 32.35 39.37 4.51 0.34 1.97 0.06 Not Significant 
15 34.17 42.09 5.51 0.62 4.64 0.00 Increase 
16 61.89 62.19 7.29 0.75 6.54 0.00 Increase 
17 29.70 44.81 4.29 0.42 2.52 0.02 Increase 
18 66.89 76.15 5.93 0.71 5.61 0.00 Increase 
19 50.81 44.47 5.59 0.20 -1.15 0.26 Not Significant 
20 34.66 35.40 5.30 0.01 0.04 0.97 Not Significant 
21 45.04 44.14 8.29 0.22 -1.27 0.21 Not Significant 
22 60.25 69.68 5.73 0.43 2.71 0.01 Increase 
23 30.02 36.58 2.49 0.20 1.20 0.24 Not Significant 
24 35.63 49.38 4.48 0.35 2.24 0.03 Increase 
25 68.68 72.36 6.00 0.01 -0.05 0.96 Not Significant 
mean 42.4 46.8      
SD 11.3 12.2      
 
The mean planned Rectal Wall volume was 42.4cc with a SD of 11.3cc. The mean 
treatment rectal wall volume was 46.8cc (SD= 12.2). 
 
The rectal wall volumes for all fractions of all patients were normalised against the 
original planning volume and then expressed as a percentage. For each fraction these 
values were then averaged and plotted to assess for time trends (Figure 8-30). The p-
value of the slope for Figure 8-30 is <0.05 (p= 0.00) and R is 0.79 indicating an 
increase in rectal wall volume over time. 
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Figure 8 - 30: Average change in rectal wall volume. 
Average change in Rectal Wall Volume
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Systematic error can be used to assess variation between the planned rectal wall 
volume and the volumes observed during treatment. The systematic error shown in 
Figure 8-31 was calculated by subtracting the mean treatment volume from the 
planned volume. 
Figure 8 - 31: Systematic error for rectal wall volumes 
Systematic error: Rectal wall
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The relationship between the planned volume and systematic error is shown in 
Figure 8-32. A regression analysis on the slope of this graph results in R= 0.12 and 
p= 0.16, indicating that there is no statistically significant relationship between the 
two variables. 
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Figure 8 - 32: Planned rectal wall volume vs. systematic error. 
Planned Rectal wall volume vs. systematic error
y = -0.0673x + 7.2453
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Random error is calculated as the SD of the treatment volume (Figure 8-33). The 
relationship between random error and planning volume can also be assessed (Figure 
8-34).  
Figure 8 - 33: Random error for rectal wall volume 
Random error: Rectal wall
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Figure 8 - 34: Planned rectal wall volume vs. random error 
Planned Rectal wall volume vs. random error
y = 0.0658x + 2.9685
R2 = 0.1563
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Regression statistics were performed on the relationship between the planned 
volume and random error resulting in p= 0.045 and R= 0.40 indicating a statistically 
significant relationship between the two variables. 
 
The maximum and minimum rectal wall volume during treatment as a percentage of 
the planned volume for each patient are demonstrated in Table 8-41. Patients who 
demonstrated a minimum fluctuation of greater than 100% are shaded grey.  
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Table 8 - 41: Maximum & minimum treatment volume (% of the planned volume) 
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1 125.71% 75.43% 
2 118.96% 79.47% 
3 176.15% 76.81% 
4 131.22% 62.22% 
5 117.76% 56.50% 
6 192.63% 92.80% 
7 139.98% 53.47% 
8 135.63% 83.56% 
9 158.98% 86.21% 
10 128.64% 78.08% 
11 142.21% 82.90% 
12 173.46% 72.55% 
13 127.62% 83.34% 
14 142.01% 89.55% 
15 144.54% 84.90% 
16 121.55% 77.48% 
17 172.93% 112.73% 
18 130.90% 94.96% 
19 122.22% 71.52% 
20 151.07% 80.21% 
21 175.51% 75.36% 
22 139.25% 99.52% 
23 141.47% 96.94% 
24 160.93% 111.56% 
25 126.31% 88.02% 
mean 143.9% 82.6% 
 
8.4.1c) Anal Canal 
Table 8-42 demonstrates the variations observed in anal canal volumes for each 
individual patient during a course of radiation therapy. For each individual patient 
this table demonstrates the planned anal canal volume, the mean treatment volume, 
the SD of the treatment volume (which also equates to the random error), the R 
value, the t-value, the p-value and indicates the direction of the trend. The patients 
who demonstrate statistically significant p-values (<0.05) have been shaded grey 
along with the R value. 
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Table 8 - 42: Organ volume variations: Anal Canal 
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1 12.72 9.62 3.39 0.16 -0.89 0.38 Not significant 
2 7.17 8.33 1.08 0.28 -1.70 0.10 Not significant 
3 10.80 10.59 1.31 0.24 -1.44 0.16 Not significant 
4 16.19 13.34 1.65 0.48 -3.07 0.00 Decrease 
5 17.76 10.83 2.23 0.66 -4.84 0.00 Decrease 
6 9.75 9.56 1.40 0.13 0.72 0.47 Not significant 
7 6.94 9.67 1.35 0.33 2.08 0.05 Increase 
8 9.51 9.07 1.44 0.06 0.29 0.78 Not significant 
9 9.31 7.29 1.03 0.49 -2.62 0.02 Decrease 
10 12.60 10.03 1.47 0.42 1.92 0.07 Not significant 
11 7.38 7.54 1.22 0.25 1.22 0.24 Not significant 
12 10.16 11.67 1.90 0.60 4.25 0.00 Increase 
13 8.44 7.25 0.85 0.45 -2.70 0.01 Decrease 
14 6.52 6.09 0.63 0.10 0.52 0.61 Not significant 
15 7.82 7.31 0.85 0.14 0.80 0.43 Not significant 
16 9.45 9.14 1.40 0.15 -0.88 0.38 Not significant 
17 6.86 6.42 0.72 0.30 1.75 0.09 Not significant 
18 5.79 6.13 1.08 0.37 2.25 0.03 Increase 
19 5.17 6.46 0.94 0.26 -1.58 0.12 Not significant 
20 7.50 8.12 1.15 0.40 2.48 0.02 Increase 
21 5.08 5.53 0.87 0.38 2.38 0.02 Increase 
22 6.69 6.58 0.83 0.12 0.71 0.48 Not significant 
23 3.42 3.21 0.52 0.47 -3.15 0.00 Decrease 
24 17.54 11.66 1.49 0.35 2.23 0.03 Increase 
25 10.67 12.42 1.95 0.19 1.08 0.29 Not significant 
mean 9.3 8.6      
SD 3.8 2.4      
 
The mean planned anal canal volume was 9.3cc with a SD of 3.8cc. The mean 
treatment rectal wall volume was 8.6cc (SD= 2.4). 
 
The anal canal volumes for all fractions of all patients were normalised against the 
original planning volume and then expressed as a percentage. For each fraction these 
values were then averaged and plotted to assess for time trends (Figure 8-35). The p-
value of the slope for Figure 8-35 is <0.05 (p= 0.00) and R is 0.21, indicating that 
the anal canal volume increases over time. 
 
 - 142 -
 
Figure 8 - 35: Average change in anal canal volume. 
Average change in Anal Canal Volume 
y = 0.0006x + 0.9691
R2 = 0.0447
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Systematic error can be used to assess variation between the planned rectal wall 
volume and the volumes observed during treatment. The systematic error shown in 
Figure 8-36 was calculated by subtracting the mean treatment volume from the 
planned volume. 
Figure 8 - 36: Systematic error for anal canal volumes 
Systematic error: Anal Canal
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The relationship between the planned volume and systematic error is shown in 
Figure 8-37. A regression analysis on the slope of this graph results in a p-value of 
p= 0.00 and R= 0.79, indicating a statistically significant relationship between the 
variables. 
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Figure 8 - 37: Planned anal canal volume vs. systematic error. 
Planned Anal Canal volume vs. systematic error
y = -0.4656x + 3.6113
R2 = 0.6186
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Random error is calculated as the SD of the treatment volume (Figure 8-38). The 
relationship between random error and planning volume can also be assessed (Figure 
8-39). 
Figure 8 - 38: Random error for anal canal volume 
Random error: Anal Canal
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Figure 8 - 39: Planned anal canal volume vs. random error 
Planned Anal Canal volume vs. random error
y = 0.1072x + 0.3191
R2 = 0.4391
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Regression statistics were performed on the relationship between the planned 
volume and random error resulting in a p-value= 0.00 and R= 0.66 indicating a 
significant relationship between the variables. 
8.4.2 Hypothesis 2: Bladder volumes fluctuate 
Hypothesis 2, that bladder volume alters or fluctuates during a radical course of 
radiotherapy was tested on the data collected during this study. The data used to test 
hypothesis 2 is available in appendix 11. 
 
Table 8-43 demonstrates the variations observed in bladder volumes during a course 
of radiotherapy. For each individual patient this table demonstrates the planned 
bladder volume, the mean treatment volume, the SD of the treatment volume (which 
also equates to the random error), the R value, the t-value, the p-value and indicates 
the direction of any trend. The patients who demonstrate statistically significant p-
values (<0.05) have been shaded grey along with the R value. 
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Table 8 - 43: Organ volume variation: Bladder 
pa
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1 480.10 195.00 64.02 0.26 1.55 0.13 Not significant 
2 138.80 121.90 60.39 0.15 -0.87 0.39 Not significant 
3 260.72 287.57 85.65 0.23 -1.40 0.17 Not significant 
4 173.43 515.67 172.05 0.06 0.35 0.73 Not significant 
5 90.49 88.59 23.10 0.13 -0.71 0.49 Not significant 
6 322.36 198.08 73.62 0.54 -3.70 0.00 Decrease 
7 157.60 144.21 38.21 0.40 -2.55 0.02 Decrease 
8 95.63 103.34 24.71 0.14 -0.62 0.54 Not significant 
9 429.91 181.21 112.13 0.09 -0.42 0.68 Not significant 
10 176.14 178.28 97.44 0.36 -1.61 0.13 Not significant 
11 254.47 104.37 39.38 0.01 -0.04 0.97 Not significant 
12 160.32 127.50 51.87 0.01 0.04 0.97 Not significant 
13 59.42 136.87 25.85 0.10 -0.55 0.58 Not significant 
14 204.56 176.64 52.51 0.05 -0.28 0.78 Not significant 
15 269.73 203.74 77.80 0.14 -0.81 0.42 Not significant 
16 77.95 95.99 15.92 0.07 -0.38 0.70 Not significant 
17 91.51 211.42 89.73 0.02 0.11 0.91 Not significant 
18 96.43 111.44 30.00 0.20 -1.12 0.27 Not significant 
19 122.10 198.83 161.74 0.37 -2.27 0.03 Decrease 
20 116.22 172.32 76.40 0.12 -0.72 0.48 Not significant 
21 237.99 231.85 104.42 0.17 -0.99 0.33 Not significant 
22 132.80 137.30 42.68 0.46 -2.98 0.01 Decrease 
23 160.29 134.29 54.15 0.38 -2.45 0.02 Decrease 
24 150.67 115.14 79.63 0.10 -0.59 0.56 Not significant 
25 163.39 212.59 78.57 0.01 0.07 0.94 Not significant 
mean 184.9 175.4      
SD 105.1 86.4      
 
The mean planned bladder volume was 184.9cc with a SD of 105.1cc. The mean 
treatment volume as 175.4cc (SD = 86.4). 
 
The bladder volumes for all fractions of the 25 patients were normalised against the 
original planning volume and then expressed as a percentage. For each fraction these 
individual values were then averaged and plotted to assess for time trends (Figure 8-
40). The p-value of the slope in Figure 8-40 is <0.05 (p=0.00) and R= 0.56, 
indicating that there is a decrease in bladder volume over time. 
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Figure 8 - 40: Average change in Bladder volume 
Average change in Bladder Volume
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Systematic error can be used to assess the variation between the planned bladder 
volume and the volumes observed during treatment. The systematic error shown in 
Figure 8-41 was calculated by subtracting the mean treatment volume from the 
planned volume. 
Figure 8 - 41: Systematic error for bladder volumes. 
Systematic error: Bladder volumes
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The relationship between planned volume and systematic error is shown in Figure 8-
42. A regression analysis on the slope of this graph results in R= 0.71 and p= 0.00, 
indicating that there a significant relationship between bladder volume and 
systematic error. 
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Figure 8 - 42: Planned bladder volume vs. systematic error 
Planned Bladder volume vs. systematic error
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Random error, which is calculated as the SD of the treatment volumes, is plotted in 
Figure 8-43. The relationship between random errors and planning volume can also 
be assessed (Figure 8-44). 
Figure 8 - 43: Random error for bladder volumes 
Random error: Bladder volumes
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Figure 8 - 44: Planned bladder volume vs. random error 
Planned Bladder volume vs. random error
y = 0.1026x + 50.302
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A regression analysis was performed on the relationship between the planned 
bladder volume and random error and resulted in p= 0.00 and R= 0.27 indicating a 
statistically significant relationship. 
 
The maximum and minimum bladder volumes as a percentage of the planned 
volume observed during treatment for each patient are demonstrated in Table 8-44. 
Patients who demonstrated a maximum fluctuation of less 100% or a minimum 
fluctuation of greater than 100% are shaded grey. 
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Table 8 - 44: Maximum & minimum treatment volumes (% of the planned volume) 
pa
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1 68.02% 16.33% 
2 254.72% 46.85% 
3 193.25% 46.85% 
4 468.82% 115.86% 
5 144.36% 53.48% 
6 118.81% 29.45% 
7 158.96% 56.27% 
8 157.31% 64.64% 
9 107.22% 8.01% 
10 278.99% 50.81% 
11 85.73% 20.39% 
12 176.30% 45.68% 
13 334.50% 145.44% 
14 157.36% 52.52% 
15 183.18% 31.22% 
16 175.48% 94.41% 
17 430.59% 67.51% 
18 188.64% 77.08% 
19 515.62% 55.37% 
20 283.75% 58.31% 
21 173.07% 12.69% 
22 191.95% 61.53% 
23 178.10% 45.81% 
24 256.67% 31.66% 
25 253.97% 45.87% 
mean 221.4% 53.4% 
 
8.4.3 Prostate volume variations 
The prostate volumes were contoured on each CT scan set and prostate volume 
across the treatment course was assessed. Table 8-45 demonstrates the volumes 
observed for each individual patient including the planned prostate volume, the 
mean treatment volume, the SD of the treatment volume (or random error), the R 
value, the t-value, the p-value and the direction of any statistically significant time 
trend. The patients who demonstrate statistically significant p-values (<0.05) have 
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been shaded grey along with the R value. The prostate volume data is available in 
appendix 12. 
Table 8 - 45: Organ volume variations –Prostate 
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1 43.57 35.29 5.82 0.83 -8.45 0.00 Decrease 
2 32.11 23.58 5.63 0.72 -6.15 0.00 Decrease 
3 56.28 51.41 8.41 0.82 -8.49 0.00 Decrease 
4 41.83 37.30 3.63 0.37 -2.21 0.03 Decrease 
5 32.65 24.54 3.13 0.67 -4.94 0.00 Decrease 
6 35.90 37.77 2.77 0.46 -2.96 0.01 Decrease 
7 33.83 36.43 3.81 0.28 1.71 0.10 Not significant 
8 41.36 46.05 3.03 0.06 0.27 0.79 Not significant 
9 42.21 36.74 3.23 0.76 -5.48 0.00 Decrease 
10 36.70 34.00 2.96 0.59 -3.05 0.01 Decrease 
11 26.67 25.37 2.83 0.63 3.88 0.00 Increase 
12 42.51 40.44 3.23 0.10 -0.59 0.56 Not significant 
13 16.31 16.25 1.21 0.47 -2.88 0.01 Decrease 
14 26.47 24.94 1.88 0.41 2.45 0.02 Increase 
15 21.55 19.97 1.60 0.13 -0.76 0.45 Not significant 
16 25.29 25.08 1.49 0.02 -0.11 0.91 Not significant 
17 24.25 25.97 1.57 0.72 -5.70 0.00 Decrease 
18 25.59 25.06 1.79 0.47 -2.94 0.01 Decrease 
19 14.13 15.26 1.23 0.21 -1.21 0.24 Not significant 
20 26.31 26.02 1.99 0.67 5.15 0.00 Increase 
21 18.62 18.93 1.18 0.55 -3.80 0.00 Decrease 
22 47.79 48.08 3.54 0.70 -5.68 0.00 Decrease 
23 68.78 72.44 3.54 0.60 -4.49 0.00 Decrease 
24 23.75 26.17 1.47 0.18 -1.06 0.30 Not significant 
25 37.83 36.60 2.83 0.47 -3.02 0.00 Decrease 
mean 33.7 32.4      
SD 12.7 12.8      
 
The mean planned prostate volume 33.7cc with a SD of 12.7cc. The mean treatment 
volume was 32.4cc (SD= 12.8cc). 
 
The prostate volumes for all patients for all fractions were normalised against the 
original planned volume and then expressed as a percentage. For each fraction these 
values were averaged and plotted to assess for an average time trend (Figure 8-45). 
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The p-value for the slope of Figure 8-45 is <0.05 (p= 0.00) and R= 0.83, indicating a 
statistically significant decrease in prostate volume over time. 
Figure 8 - 45: Average change in prostate volume 
Average change in Prostate Volume
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Systematic error can be used to assess variation between planned and treatment 
prostate volumes (Figure 8-46). 
Figure 8 - 46: Systematic error for prostate volumes 
Systematic error: Prostate
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The relationship between systematic error and planned volume is demonstrated in 
Figure 8-47. A regression analysis on the slope of this relationship results in a p-
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value= 0.57 and R= 0.12 indicating that there is no statistically significant 
relationship between the two variables. 
Figure 8 - 47: Planned prostate volume vs. systematic error. 
Planned Prostate volume vs. systematic error
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Random errors for the prostate volume of each individual patient are presented in 
Figure 8-48. The relationship between random errors and planning volume are 
shown in Figure 8-49. 
Figure 8 - 48: Random error for prostate volumes 
Random error: Prostate
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Figure 8 - 49: Relationship between planned prostate volume and random error 
Planned Prostate volume vs. random error
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Regression analysis was performed on the slope of Figure 8-49 resulting in a p-
value= 0.00 and R= 0.70, indicating that there is a statistically significant 
relationship between the planned prostate volume and random error. 
 
The maximum and minimum prostate volumes as a percentage of the planned 
volume for each patient are shown in Table 8-46. Patients who demonstrated a 
maximum fluctuation of less 100% are shaded grey. 
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Table 8 - 46: Maximum & minimum treatment volumes (% of the planned volume) 
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1 103.95% 58.71% 
2 104.80% 46.22% 
3 121.86% 72.23% 
4 103.35% 72.20% 
5 93.81% 56.45% 
6 118.22% 92.92% 
7 131.51% 84.95% 
8 122.41% 94.68% 
9 104.95% 73.96% 
10 105.56% 78.69% 
11 117.21% 78.03% 
12 108.84% 79.98% 
13 113.43% 84.43% 
14 111.52% 79.64% 
15 105.71% 78.75% 
16 112.77% 86.16% 
17 118.60% 95.42% 
18 111.25% 82.57% 
19 125.62% 86.69% 
20 114.33% 86.01% 
21 115.36% 87.86% 
22 113.79% 86.92% 
23 113.45% 92.56% 
24 125.14% 97.94% 
25 113.61% 79.94% 
mean 113.2% 80.6% 
 
 
8.4.4 Relationship between volume variations and symptoms 
The relationship between patient reported gastrointestinal symptoms and variations 
in the rectum solid volume are demonstrated in Table 8-47.  
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Table 8 - 47: Relationship between GI symptoms & rectum solid volume trend. 
Symptom Time trend 
Number of 
patients 
Diarrhoea Decrease 5 
  Increase 1 
  Not significant 13 
Constipation Decrease 0 
  Increase 0 
  Not significant 2 
Neither Decrease 2 
  Increase 2 
  Not significant 2 
 
The relationship between patient reported urinary symptoms and variations in the 
bladder volume are demonstrated in Table 8-48.  
Table 8 - 48: Relationship between urinary symptoms & bladder volume trend. 
Symptom Time trend 
Number of 
patients 
Frequency Decrease 4 
  Increase 0 
  Not significant 16 
Retention Decrease 0 
  Increase 0 
  Not significant 2 
Neither Decrease 1 
  Increase 0 
  Not significant 2 
 
8.5 Organ motion uncertainty 
The COV coordinates for all structures were recorded on a daily basis. Variation of 
the COV was used to calculate the magnitude and direction of organ motion on a 
daily basis. Initially organ motion for each organ has also been broken down to 
include an assessment of random, systematic and total uncertainty. An assessment of 
the relationship between volume and motion is then presented. Organ motions 
uncertainty data is available in Appendix 13. 
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8.5.1 Rectum 
8.5.1a Rectum Solid organ motion 
The COV rectum co-ordinates for each fraction were recorded. The COV rectum 
was then normalised by subtracting the COV for each fraction from the planned 
COV rectum location to calculate the organ motion for that fraction. The mean COV 
co-ordinates in each direction were calculated to determine the systematic error, and 
a calculation of the SD of these co-ordinates results in the random error associated 
with rectum motion. Table 8-49 and Figure 8-50 demonstrate the mean systematic, 
random and total uncertainty for internal organ motion of the rectum.  
Table 8 - 49: Internal organ motion (cm): Rectum Solid 
  
Systematic COV 
uncertainty 
Random COV 
uncertainty 
Total COV  
uncertainty 
  x y z x y z x y z 
Mean -0.01 0.07 -0.10 0.32 0.37 0.24 0.45 0.52 0.35 
SD 0.35 0.40 0.30 0.08 0.12 0.08 0.15 0.19 0.19 
 
Figure 8 - 50: Internal organ motion: Rectum 
Average internal organ motion - rectum solid
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8.5.1b Effect of rectal volume on rectal COV location 
The effect of rectum solid volume on rectal COV location was assessed. Initially an 
assessment of the relationship between the initial planned volume and systematic 
error was calculated in all 3 directions (Table 8-50). 
Table 8 - 50: Systematic error vs. planned rectum solid volume. 
  R t-value p-value 
x 0.30 1.50 0.15 
y 0.35 -1.77 0.09 
z 0.15 -0.74 0.47 
 
The relationship between the initial planned volume and random error was also 
calculated (Table 8-51). 
Table 8 - 51: Random error vs. planned rectum solid volume. 
  R  t-value p-value 
x 0.11 0.54 0.60 
y 0.29 1.44 0.16 
z 0.04 -0.20 0.84 
 
To assess the relationship between volume and COV motion the normalised COV 
rectum co-ordinates for each direction were plotted against the normalised rectum 
volume for each fraction, with the normalised rectum solid volume reported as the 
percentage change in volume from the planned volume (Figure 8-51, 8-52 & 8-53). 
Figure 8 - 51: Rectum COV motion (X) vs. % change in rectum volume 
Rectum COV motion (x) vs. % change in rectum 
volume
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Figure 8 - 52: Rectum COV motion (Y) vs. % change in rectum volume 
Rectum COV motion (y) vs. % change in rectum 
volume
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Figure 8 - 53: Rectum COV motion (Z) vs. % change in rectum volume 
Rectum COV motion (z) vs. % change in rectum 
volume
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A regression analysis was performed on the data shown in Figures 8-51, 8-52 and 8-
53. The R value, t-value and p-value for each direction are shown in Table 8-52. 
Only the Y direction demonstrated a statistically significant relationship between 
changes in rectum volume and COV motion. 
Table 8 - 52: Regression statistics for Rectum COV vs. change in Rectum volume 
  R t-value p-value 
x 0.09 -2.68 0.01 
y 0.21 6.12 0.00 
z 0.00 -0.12 0.91 
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8.5.1c Anal Canal 
Table 8-53 and Figure 8-54 demonstrate mean the anal canal systematic, random and 
total COV uncertainty. 
Table 8 - 53: Internal organ motion (cm): Anal canal 
  
Systematic COV 
uncertainty 
Random COV 
uncertainty 
Total COV  
uncertainty 
  x y z x y z x y z 
Mean -0.01 0.13 -0.17 0.25 0.31 0.43 0.33 0.43 0.58 
SD 0.25 0.32 0.34 0.12 0.08 0.38 0.17 0.18 0.37 
 
Figure 8 - 54: Internal organ motion: Anal Canal 
Average internal organ motion - anal canal
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8.5.1d Effect of anal canal volume on anal canal COV location 
The effect of anal canal volume on anal canal COV location was assessed. 
The relationship between the initial planned volume and systematic error was 
calculate in all three directions (Table 8-54) 
Table 8 - 54: Systematic error vs. planned anal canal volume 
  R t-value p-value 
x 0.12 -0.58 0.57 
y 0.00 0.02 0.99 
z 0.08 0.38 0.71 
 
The relationship between the planned volume and random error was also calculated 
(Table 8-55). 
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Table 8 - 55: Random error vs. planned anal canal volume. 
  R  t-value p-value 
x 0.02 -0.10 0.92 
y 0.18 0.89 0.38 
z 0.24 -1.18 0.25 
 
8.5.2 Bladder 
8.5.2a Bladder organ motion 
Table 8-56 and Figure 8-55 demonstrate the mean bladder systematic, random and 
total COV uncertainty. 
Table 8 - 56: Internal organ motion (cm): Bladder 
  
Systematic COV 
uncertainty 
Random COV 
uncertainty 
Total COV  
uncertainty 
  x y z x y z x y z 
Mean 0.01 0.08 -0.13 0.24 0.55 0.39 0.35 0.86 0.61 
SD 0.29 0.82 0.52 0.06 0.20 0.12 0.14 0.51 0.26 
 
Figure 8 - 55: Internal organ motion: Bladder 
Average internal organ motion - bladder
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8.5.2b Effect of bladder volume on bladder COV location 
The effect of bladder volume on bladder COV location was assessed. 
The relationship between the initial planned volume and systematic error was 
calculate in all three directions (Table 8-57) 
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Table 8 - 57: Systematic error vs. planned bladder volume 
  R t-value p-value 
x 0.04 -0.21 0.83 
y 0.61 -3.72 0.00 
z 0.13 -0.61 0.55 
 
The relationship between the planned volume and random error was also calculated 
(Table 8-58). 
Table 8 - 58: Random error vs. planned bladder volume. 
  R  t-value p-value 
x 0.07 0.33 0.75 
y 0.31 1.54 0.14 
z 0.24 -1.18 0.25 
 
To assess the relationship between volume and COV motion, the normalised COV 
bladder co-ordinates for each direction were plotted against the percentage change in 
bladder volume for each fraction (Figures 8-56, 8-57 & 8-58). 
Figure 8 - 56: Bladder COV motion (X) vs. % change in bladder volume 
Bladder COV motion (x) vs. % change in bladder 
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Figure 8 - 57: Bladder COV motion (Y) vs. % change in bladder volume 
Bladder COV motion (y) vs. % change in bladder 
volume
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Figure 8 - 58: Bladder COV motion (Z) vs. % change in bladder volume 
Bladder COV motion (z) vs. % change in bladder 
volume
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A regression analysis was performed on Figures 8-56, 8-57 and 8-58. The R value, t-
value and p-value for each direction are shown in Table 8-59. These indicate that 
there is a statistically significant relationship between a change in bladder volume 
and COV motion in all three directions. 
Table 8 - 59: Regression statistics for Bladder COV vs. change in bladder volume. 
  R t-value p-value 
x 0.11 3.04 0.00 
y 0.77 34.38 0.00 
z 0.15 4.18 0.00 
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8.5.3 Prostate 
8.5.3a Prostate motion 
Table 8-60 and Figure 8-59 demonstrate the mean prostate systematic, random and 
total COV uncertainty. 
Table 8 - 60: Internal organ motion (cm): Prostate 
  
Systematic COV 
uncertainty 
Random COV 
uncertainty 
Total COV 
uncertainty 
  x y z x y z x y z 
Mean 0.00 0.16 -0.20 0.22 0.25 0.31 0.30 0.37 0.52 
SD 0.23 0.27 0.43 0.06 0.07 0.09 0.12 0.18 0.23 
 
Figure 8 - 59: Internal organ motion: Prostate 
Average internal organ motion - prostate
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Prostate motion was assessed for any significant relationship between motion in two 
dimensions. Figures 8-60 to 8-62 demonstrate the relationship between prostate 
motion in the AP and SI, the RL and SI and the RL and AP directions respectively. 
Table 8-61 summarises the results of a regression analysis on these figures. There 
was only a statistically significant relationship demonstrated in the AP-SI direction. 
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Figure 8 - 60: Prostate motion in 2D: AP vs. SI 
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Figure 8 - 61: Prostate motion in 2D: RL vs. SI 
Prostate COV (x) vs. Prostate COV (y) motion 
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Figure 8 - 62: Prostate motion in 2D: RL vs. AP 
Prostate COV (x) vs. Prostate COV (z) motion 
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Table 8 - 61: Regression analysis - prostate motion in 2 dimensions 
  t-value p-value R 
Ant-Post vs. Sup-Inf 9.45 0.00 0.31 
RL vs. Sup-Inf -0.26 0.80 0.01 
RL vs. Ant-Post 0.40 0.69 0.01 
 
8.5.3b Effect of rectal volume on prostate COV location 
The effect of rectum solid volume on prostate COV location was assessed. 
The relationship between the initial planned rectum solid volume and systematic 
COV prostate error was calculated in all three directions (Table 8-62). 
Table 8 - 62: Systematic COV prostate error vs. planned rectum solid volume. 
  R t-value p-value 
x 0.15 0.74 0.47 
y 0.02 -0.10 0.93 
z 0.53 -2.98 0.01 
 
 
The relationship between the planned rectum solid volume and random COV 
prostate error was also calculated (Table 8-63). 
Table 8 - 63: Random COV prostate error vs. planned rectum solid volume 
  R t-value p-value 
x 0.09 0.41 0.69 
y 0.27 1.32 0.20 
z 0.31 1.58 0.13 
 
 
To assess the relationship between rectum volume and prostate COV motion the 
normalised COV co-ordinate for each direction was plotted against the normalised 
rectum solid volume (Figures 8-63, 8-64 & 8-65). 
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Figure 8 - 63: Prostate COV motion (X) vs. % change in rectum solid volume 
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Figure 8 - 64: Prostate COV motion (Y) vs. % change in rectum solid volume 
Prostate COV motion (y) vs. % change in rectum 
volume
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Figure 8 - 65: Prostate COV motion (Z) vs. % change in rectum solid volume 
Prostate COV motion (z) vs. % change in rectum 
volume y = 0.3574x + 1.0043
R2 = 0.1776
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A regression analysis was performed on Figures 8-63, 8-64 and 8-65. The R value, t-
value and p-value for each direction are shown in Table 8-64. A statistically 
significant relationship was demonstrated between prostate motion in all directions 
and changes in rectum volume. 
Table 8 - 64: Regression statistics for Prostate COV vs. % change in rectum solid volume. 
  R t-value p-value 
x 0.12 -3.39 0.00 
y 0.16 -4.61 0.00 
z 0.42 13.25 0.00 
 
8.5.3c Effect of bladder volume on prostate COV location 
The effect of bladder volume on prostate COV location was assessed. 
The relationship between the initial planned bladder volume and systematic COV 
prostate error was calculated in all three directions (Table 8-65). 
Table 8 - 65: Systematic COV prostate error vs. planned bladder volume 
  R  t-value p-value 
x 0.32 -1.61 0.12 
y 0.09 0.43 0.67 
z 0.14 0.67 0.51 
 
The relationship between the planned bladder volume and random COV prostate 
error was also calculated. 
Table 8 - 66: Random COV prostate error vs. planned bladder volume 
  R  t-value p-value 
x 0.07 0.35 0.73 
y 0.10 -0.49 0.63 
z 0.08 -0.37 0.71 
 
To assess the relationship between bladder volume and prostate COV motion the 
normalised COV co-ordinate for each direction was plotted against the normalised 
bladder volume (Figures 8-66, 8-67 & 8-68). 
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Figure 8 - 66: Prostate COV motion (X) vs. % change in bladder volume 
Prostate COV motion (x) vs. % change in bladder 
volume
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Figure 8 - 67: Prostate COV motion (Y) vs. % change in bladder volume 
Prostate COV motion (y) vs. % change in bladder 
volume
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Figure 8 - 68: Prostate COV motion (Z) vs. % change in bladder volume 
Prostate COV motion (z) vs. % change in bladder 
volume y = 0.057x + 1.1473
R2 = 0.0014
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A regression analysis was performed on Figures 8-66, 8-67 and 8-68. The R value, t-
value and p-value for each direction are shown in Table 8-67. There was a 
significant relationship between prostate motion and changes in bladder volume in 
the RL and SI directions. 
Table 8 - 67: Regression statistics for Prostate COV vs. %change in bladder volume. 
  R t-value p-value 
x 0.13 3.72 0.00 
y 0.15 4.36 0.00 
z 0.04 1.08 0.28 
 
8.6 Dose variations 
The mean dose for each fraction was summed to compare the dose delivered at the 
actual isocentre, uncorrected isocentre and the future isocentre. The total mean dose 
delivered for each isocentre was then expressed as a percentage of the planned mean 
dose. The mean individual patient doses were then averaged over the twenty five 
patients to determine the average percentage of the mean dose delivered to each 
structure. 
 
An analysis was then conducted to assess the effect of organ volume changes on the 
rectum solid, bladder and PTV mean dose. Although mathematically mean doses are 
the only doses that can be added together, the dose delivered to predefined volumes 
of interest for each fraction can be compared to the planned dose per fraction to 
further assess the effect of organ volume.  
 
In addition to analysing the effect of bladder and rectal volume variations on PTV 
dose, the effect of bladder and rectum COV motion on PTV dose was also 
considered. The data used to analyse dose deviations is available in appendix 14. 
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8.6.1 Rectum 
8.6.1a Rectum Solid 
The percentage of the planned dose delivered to the rectum solid for the 25 patients 
is demonstrated Table 8-68. Figure 8-69 demonstrates the average dose delivered to 
the rectum solid as a percentage of the planned dose. 
Table 8 - 68: Mean rectal dose as a % of the planned dose for each patient 
Patient Actual Uncorrected Future 
1 109.23% 109.59% 113.14% 
2 107.24% 106.97% 109.16% 
3 106.30% 108.26% 108.19% 
4 95.76% 96.39% 108.99% 
5 92.97% 92.55% 96.08% 
6 95.81% 96.16% 92.80% 
7 88.62% 90.00% 97.41% 
8 98.48% 98.48% 93.62% 
9 94.40% 93.88% 90.40% 
10 101.72% 101.76% 108.72% 
11 121.34% 121.38% 134.01% 
12 86.82% 88.31% 113.88% 
13 91.84% 91.84% 100.18% 
14 107.06% 107.06% 96.29% 
15 106.29% 106.29% 117.10% 
16 103.25% 103.23% 117.71% 
17 103.67% 104.91% 92.30% 
18 104.01% 106.16% 102.86% 
19 108.50% 106.37% 107.90% 
20 85.90% 85.52% 92.94% 
21 101.77% 102.72% 104.87% 
22 93.74% 93.74% 100.35% 
23 95.08% 94.84% 97.84% 
24 94.79% 94.77% 103.63% 
25 81.91% 81.91% 90.00% 
Average 99.1% 99.3% 103.6% 
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Figure 8 - 69: Mean dose delivered to the rectum solid - 3 isocentre locations 
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8.6.1b Rectal Wall 
The percentage of the planned dose delivered to the rectal wall for the 25 patients is 
demonstrated Table 8-69.  
Table 8 - 69: Mean rectal wall dose as a % of the planned dose for each patient 
Patient Actual Uncorrected Future 
1 107.89% 108.22% 111.30% 
2 103.66% 103.41% 104.69% 
3 106.91% 108.82% 107.94% 
4 72.73% 73.31% 82.23% 
5 92.39% 91.94% 95.44% 
6 101.72% 102.55% 98.33% 
7 90.57% 92.14% 103.19% 
8 97.72% 97.72% 92.97% 
9 95.42% 95.00% 91.17% 
10 108.56% 108.60% 116.20% 
11 104.65% 104.75% 114.26% 
12 85.55% 86.62% 108.57% 
13 92.61% 92.61% 100.43% 
14 105.48% 105.46% 94.87% 
15 98.47% 98.47% 108.81% 
16 97.40% 97.33% 110.76% 
17 97.59% 98.74% 86.87% 
18 107.41% 109.54% 106.31% 
19 107.47% 105.64% 103.41% 
20 87.62% 87.19% 94.50% 
21 96.93% 98.09% 100.02% 
22 105.28% 105.28% 112.88% 
23 91.76% 91.52% 94.27% 
24 105.96% 105.94% 115.42% 
25 89.41% 89.41% 98.82% 
Average 98.1% 98.3% 102.2% 
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Figure 8-70 demonstrates the average dose delivered to the rectal wall as a 
percentage of the planned dose. 
Figure 8 - 70: Mean dose delivered to the rectal wall - 3 isocentre locations 
Dose delivered to the Rectal wall
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8.6.1c Anal Canal 
Figure 8-71 demonstrates the average dose delivered to the anal canal as a 
percentage of the planned dose. 
Figure 8 - 71: Mean dose delivered to the anal canal - 3 isocentre locations 
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The percentage of the planned dose delivered to the anal canal for the 25 patients is 
demonstrated Table 8-70.  
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Table 8 - 70: Mean anal canal dose as a % of the planned dose for each patient 
Patient Actual Uncorrected Future 
1 80.62% 80.97% 82.18% 
2 105.36% 105.19% 94.47% 
3 135.48% 135.84% 98.92% 
4 108.52% 109.40% 109.75% 
5 138.72% 137.14% 148.09% 
6 159.20% 157.62% 138.97% 
7 111.71% 112.87% 159.74% 
8 133.62% 133.62% 111.92% 
9 81.59% 81.39% 66.70% 
10 106.42% 108.17% 128.18% 
11 95.19% 94.91% 74.00% 
12 142.19% 141.42% 113.76% 
13 91.37% 91.37% 90.64% 
14 71.10% 71.10% 58.44% 
15 93.11% 93.11% 93.25% 
16 82.33% 80.99% 105.25% 
17 85.31% 86.20% 75.43% 
18 97.71% 99.20% 101.40% 
19 162.62% 157.12% 104.79% 
20 82.24% 82.45% 87.74% 
21 119.26% 122.93% 126.68% 
22 128.68% 128.68% 137.35% 
23 107.52% 107.41% 92.36% 
24 92.25% 92.13% 99.25% 
25 113.55% 113.55% 144.84% 
Average 109.0% 109.0% 105.8% 
 
8.6.1d Hypothesis 3: Reduced rectal volumes lead to increased rectal dose. 
Hypothesis three was based on the findings in the literature that indicated that the 
majority of patients would experience a decrease in rectal volumes over a course of 
treatment. From the results presented earlier only 7 patients demonstrated a time 
trend of decreasing rectum volumes, 1 patient demonstrated decreasing rectal wall 
volumes and 5 patients decreasing anal canal volumes. The following tables recap 
the R value, t-value and p-value as well as the direction of any time trend for each 
individual patient, with a decrease shaded grey. Table 8-71 indicates whether there 
was an increase in the mean rectum solid dose for both the actual isocentre and 
future isocentre. 
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Table 8 - 71: Rectum solid; Regression statistics and effect on dose 
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1 0.02 0.13 0.90 Not significant Yes Yes 
2 0.36 -2.28 0.03 Decrease Yes Yes 
3 0.44 2.88 0.01 Increase Yes Yes 
4 0.14 -0.81 0.42 Not significant   Yes 
5 0.42 -2.52 0.02 Decrease     
6 0.60 -4.31 0.00 Decrease     
7 0.08 0.48 0.64 Not significant     
8 0.45 2.28 0.03 Increase     
9 0.45 2.37 0.03 Increase     
10 0.28 -1.22 0.24 Not significant Yes Yes 
11 0.08 -0.40 0.69 Not significant Yes Yes 
12 0.49 -3.17 0.00 Decrease   Yes 
13 0.06 0.30 0.77 Not significant   Yes 
14 0.48 -2.98 0.01 Decrease Yes   
15 0.06 0.37 0.72 Not significant Yes Yes 
16 0.36 -2.19 0.04 Decrease Yes Yes 
17 0.16 -0.91 0.37 Not significant Yes   
18 0.32 -1.91 0.07 Not significant Yes Yes 
19 0.01 -0.06 0.96 Not significant Yes Yes 
20 0.25 -1.47 0.15 Not significant     
21 0.14 -0.80 0.43 Not significant Yes Yes 
22 0.24 -1.42 0.17 Not significant   Yes 
23 0.50 -3.40 0.00 Decrease   Yes 
24 0.12 -0.70 0.49 Not significant     
25 0.01 -0.06 0.95 Not significant     
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Table 8-72 indicates whether there was an increase in the mean rectum wall dose for 
both the actual isocentre and future isocentre. 
Table 8 - 72: Rectum wall; Regression statistics and effect on dose 
pa
tie
n
t N
o
 
R
 
t-v
al
u
e
 
p-
v
al
u
e 
Ti
m
e 
Tr
en
d?
 
In
c
re
as
e
 
in
 
m
ea
n
 
re
ct
al
 
w
al
l d
o
s
e 
(ac
tu
a
l i
s
o
)?
 
In
c
re
as
e
 
in
 
m
ea
n
 
re
ct
al
 
w
al
l d
o
s
e 
(fu
tu
re
 
is
o
)?
 
1 0.14 0.82 0.42 Not Significant Yes Yes 
2 0.37 -2.37 0.02 Decrease Yes Yes 
3 0.23 1.42 0.16 Not Significant Yes Yes 
4 0.04 -0.23 0.82 Not Significant     
5 0.19 -1.08 0.29 Not Significant     
6 0.81 8.02 0.00 Increase Yes   
7 0.31 1.95 0.06 Not Significant   Yes 
8 0.64 3.76 0.00 Increase     
9 0.65 4.03 0.00 Increase     
10 0.38 1.70 0.11 Not Significant Yes Yes 
11 0.30 -1.53 0.14 Not Significant Yes Yes 
12 0.40 2.46 0.02 Increase   Yes 
13 0.24 1.32 0.20 Not Significant   Yes 
14 0.34 1.97 0.06 Not Significant Yes   
15 0.62 4.64 0.00 Increase   Yes 
16 0.75 6.54 0.00 Increase   Yes 
17 0.42 2.52 0.02 Increase     
18 0.71 5.61 0.00 Increase Yes Yes 
19 0.20 -1.15 0.26 Not Significant Yes Yes 
20 0.01 0.04 0.97 Not Significant     
21 0.22 -1.27 0.21 Not Significant   Yes 
22 0.43 2.71 0.01 Increase Yes Yes 
23 0.20 1.20 0.24 Not Significant     
24 0.35 2.24 0.03 Increase Yes Yes 
25 0.01 -0.05 0.96 Not Significant     
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Table 8-73 indicates whether there was an increase in the mean anal canal dose for 
both the actual isocentre and future isocentre. 
Table 8 - 73: Anal Canal; Regression statistics and effect on dose 
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1 0.16 -0.89 0.38 Not significant     
2 0.28 -1.70 0.10 Not significant Yes   
3 0.24 -1.44 0.16 Not significant Yes   
4 0.48 -3.07 0.00 Decrease Yes Yes 
5 0.66 -4.84 0.00 Decrease Yes Yes 
6 0.13 0.72 0.47 Not significant Yes Yes 
7 0.33 2.08 0.05 Increase Yes Yes 
8 0.06 0.29 0.78 Not significant Yes Yes 
9 0.49 -2.62 0.02 Decrease     
10 0.42 1.92 0.07 Not significant Yes Yes 
11 0.25 1.22 0.24 Not significant Yes Yes 
12 0.60 4.25 0.00 Increase Yes Yes 
13 0.45 -2.70 0.01 Decrease     
14 0.10 0.52 0.61 Not significant     
15 0.14 0.80 0.43 Not significant     
16 0.15 -0.88 0.38 Not significant   Yes 
17 0.30 1.75 0.09 Not significant     
18 0.37 2.25 0.03 Increase   Yes 
19 0.26 -1.58 0.12 Not significant Yes Yes 
20 0.40 2.48 0.02 Increase     
21 0.38 2.38 0.02 Increase Yes Yes 
22 0.12 0.71 0.48 Not significant Yes Yes 
23 0.47 -3.15 0.00 Decrease Yes   
24 0.35 2.23 0.03 Increase     
25 0.19 1.08 0.29 Not significant Yes Yes 
 
Since the number of patients in this study did not demonstrate the expected time 
trend for decreasing rectal volumes, to test the hypothesis that reducing rectal 
volume leads to increasing rectal radiation dose, the percentage change in rectal 
volume for all 815 IGRT occasions were plotted against the percentage change in 
dose to the rectum solid. The anal canal and rectal wall have not been calculated as 
the changes in volume were not as large as those observed in the rectum solid 
volume. 
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To assess the effect a change in rectum solid volume had on the planned dose, the 
rectum solid volume for each fraction, as percentage of the planned volume, was 
plotted against the dose delivered to the ‘actual’ isocentre as a percentage of the 
planned dose. Figure 8-72 demonstrated the effect of volume change on the mean 
dose, Figure 8-73 demonstrates the effect on V50 and Figure 8-74 demonstrates the 
effect on V30. 
Figure 8 - 72: Effect of changing rectum solid volume on mean dose delivered to the rectum 
solid – actual isocentre 
% change in Rectum Solid volume vs. % change in 
mean rectum solid dose - actual isocentre
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Figure 8 - 73: Effect of changing rectum solid volume on V50 dose delivered to the rectum solid 
– actual isocentre 
% change in Rectum Solid volume vs. % change in 
V50% rectum solid dose - actual isocentre
y = -0.0497x + 1.0261
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Figure 8 - 74: Effect of changing rectum solid volume on V30 dose delivered to the rectum solid 
– actual isocentre 
% change in Rectum Solid volume vs. % change 
in V30% rectum solid dose - actual isocentre
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The results for the uncorrected isocentre will not be presented in this thesis as there 
was minimal variation between it and the actual isocentre. This is not unexpected 
since the pre-treatment isomoves were performed on only 10% of treatment 
fractions. This data has been included in Appendix 14. 
 
To assess what effect a change in rectum solid volume would have on the planned 
dose, despite corrections for internal organ motion, the rectum solid volume for each 
fraction, as percentage of the planned volume, was plotted against the dose delivered 
to the ‘future’ isocentre as a percentage of the planned dose. Figure 8-75 
demonstrated the effect of volume changes on the mean dose, Figure 8-76 
demonstrates the effect on V50 and Figure 8-77 demonstrates the effect on V30. 
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Figure 8 - 75: Effect of changing rectum solid volume on mean dose delivered to the rectum 
solid – future isocentre 
% change in Rectum Solid volume vs. % change in 
mean rectum solid dose - future isocentre
y = -0.1584x + 1.1862
R2 = 0.2394
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Figure 8 - 76: Effect of changing rectum solid volume on V50 dose delivered to the rectum solid 
– future isocentre 
% change in Rectum Solid volume vs. % change in 
V50% rectum solid dose - future isocentre
y = -0.1793x + 1.1854
R2 = 0.1818
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The two outliers on Figures 8-76 and 8-77 have been deleted. Patient 16 had a 
planned dose per fraction during phase 3 of 0.1Gy (V50%) and 0.2Gy (V30%). The 
dose delivered to the anal canal using the future isocentre for fraction 36 and 37 of 
this patient’s treatment was 1.02 and 1.36Gy resulting in a % change in dose of in 
excess of 1000%. Therefore the 2 points have been deleted. 
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Figure 8 - 77: Effect of changing rectum solid volume on V30 dose delivered to the rectum solid 
– future isocentre 
% change in Rectum Solid volume vs. % change in 
V30% rectum solid dose- future isocentre
y = -0.1497x + 1.1611
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Table 8-74 summarises the relationships between rectum dose and rectum volume 
for both the actual and future isocentres. 
Table 8 - 74: Relationship between rectum solid volume and dose 
  Mean Rectum Dose V50% Rectum Dose V30% Rectum Dose 
  Actual Future Actual Future Actual Future 
R 0.13 0.49 0.08 0.43 0.02 0.39 
t-value -3.71 -16.00 -2.25 -13.42 0.67 -11.88 
p-value 0.00 0.00 0.03 0.00 0.51 0.00 
 
8.6.2 Bladder 
8.6.2a Bladder  
The percentage of the planned dose delivered to the bladder for the 25 patients is 
demonstrated Table 8-75. Figure 8-78 demonstrates the average dose delivered to 
the bladder as a percentage of the planned dose. 
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Table 8 - 75: Mean bladder dose as a % of the planned dose for each patient 
Patient Actual Uncorrected Future 
1 164.91% 164.62% 165.52% 
2 99.62% 99.71% 104.75% 
3 88.53% 87.71% 91.86% 
4 45.13% 45.05% 52.54% 
5 118.04% 117.89% 112.31% 
6 107.72% 108.46% 120.29% 
7 115.49% 114.97% 83.15% 
8 79.55% 79.55% 83.77% 
9 182.32% 182.96% 202.27% 
10 124.21% 122.94% 115.42% 
11 154.39% 154.32% 163.23% 
12 108.41% 108.50% 108.56% 
13 65.19% 65.19% 72.26% 
14 91.10% 91.03% 98.70% 
15 134.08% 134.08% 137.51% 
16 103.35% 103.94% 95.20% 
17 69.54% 69.21% 74.06% 
18 92.01% 91.44% 90.90% 
19 51.92% 52.25% 89.11% 
20 77.15% 76.81% 77.89% 
21 96.67% 95.27% 94.20% 
22 104.30% 104.30% 101.69% 
23 100.76% 100.88% 101.78% 
24 117.97% 117.77% 119.45% 
25 94.46% 94.46% 77.70% 
Average 103.5% 103.3% 105.4% 
 
Figure 8 - 78: Mean dose delivered to the bladder - 3 isocentre locations 
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8.6.2b Effect of Bladder volume on bladder dose 
To assess the effect a change in bladder volume had on the planned dose the bladder 
volume for each fraction, as percentage of the planned volume, was plotted against 
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the dose delivered to the ‘actual’ isocentre as a percentage of the planned dose. 
Figure 8-79 demonstrated the effect of volume change on the mean dose at the actual 
isocentre, Figure 8-80 demonstrates the effect on mean dose at the future isocentre. 
Figure 8 - 79: Effect of changing bladder volume on mean dose delivered to the bladder – actual 
isocentre 
% change in Bladder volume vs. % change in 
mean Bladder dose - actual isocentre
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Figure 8 - 80: Effect of changing bladder volume on mean dose delivered to the bladder – 
future isocentre 
% change in Bladder volume vs. % change in 
mean Bladder dose - future isocentre
y = -0.5229Ln(x) + 1.0001
R2 = 0.7768
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8.6.3 Prostate 
8.6.3a Prostate CTV and PTV 
The percentage of the planned dose delivered to the prostate CTV, for the three 
different isocentres is demonstrated in Figure 8-81. No further analysis on the dose 
delivered to the prostate will be presented. Instead the dose delivered to the PTV 
will be analysed since the aim of treatment is to deliver 95% of the prescribed dose 
to the PTV, remembering that the CTV Æ PTV margin is applied to allow for all 
sources of uncertainty (as described in section 4.4) to ensure that the prescribed dose 
is delivered to the CTV. 
Figure 8 - 81: Mean dose delivered to the prostate using the 3 isocentre locations 
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The percentage of the planned dose delivered to the PTV for the 25 patients is 
demonstrated Table 8-76. Figure 8-82 demonstrates the average dose delivered to 
the bladder as a percentage of the planned dose. 
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Table 8 - 76: Mean PTV dose as a % of the planned dose for each patient 
Patient Actual Uncorrected Future 
1 99.74% 99.77% 100.34% 
2 100.10% 100.08% 100.25% 
3 99.42% 99.40% 99.69% 
4 99.03% 99.09% 100.36% 
5 99.37% 99.16% 100.01% 
6 99.70% 99.66% 99.87% 
7 96.90% 96.96% 99.25% 
8 99.25% 99.25% 99.19% 
9 99.17% 99.15% 99.02% 
10 97.99% 99.77% 100.34% 
11 98.50% 98.48% 99.91% 
12 97.47% 97.57% 100.62% 
13 99.08% 99.08% 99.87% 
14 99.63% 99.63% 99.58% 
15 98.46% 98.46% 100.94% 
16 98.17% 98.15% 99.72% 
17 99.91% 99.97% 99.18% 
18 99.42% 99.47% 99.61% 
19 97.09% 97.48% 99.88% 
20 98.85% 98.79% 100.10% 
21 99.56% 99.68% 100.02% 
22 98.81% 98.81% 99.66% 
23 99.03% 99.02% 99.31% 
24 99.08% 99.04% 100.86% 
25 98.91% 98.91% 99.88% 
Average 98.9% 99.0% 99.9% 
 
Figure 8 - 82: Mean dose delivered to the PTV using the 3 isocentre locations 
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8.6.3b Effect of rectal volume on PTV dose 
The effect of rectal volume on PTV dose was assessed by plotting the percentage 
change in rectum solid volume against the percentage change in mean PTV dose. 
Figure 8-83 demonstrates the effect on the mean dose at the actual isocentre, and 
Figure 8-84 demonstrates the effect on the dose delivered to V95% at the actual 
isocentre. 
Figure 8 - 83: Relationship between rectum solid volume and mean PTV dose – actual isocentre 
% change in Rectum solid volume vs. % change in 
mean PTV dose - actual isocentre
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Figure 8 - 84: Relationship between rectum solid volume and V95% PTV dose – actual 
isocentre 
% change in Rectum solid volume vs. % change in 
V95% PTV dose - actual isocentre
y = 0.0368x + 0.9084
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When the isocentre was corrected for internal organ motion, the future isocentre, the 
effect of rectum solid volume variation on dose should be eliminated. Figure 8-85 
demonstrates the effect on the mean dose at the future isocentre, and Figure 8-86 
demonstrates the effect on the dose delivered to V95%. 
Figure 8 - 85: Relationship between rectum solid volume and mean PTV dose – future isocentre 
% change in Rectum solid volume vs. % change in 
mean PTV dose - future isocentre
y = -0.0062x + 1.0048
R2 = 0.1842
70%
75%
80%
85%
90%
95%
100%
105%
0% 100% 200% 300% 400%
% change in rectum solid volume
%
 
c
ha
n
ge
 
in
 
m
e
a
n
 
PT
V 
do
s
e
 
 
Figure 8 - 86: Relationship between rectum solid volume and V95 PTV dose – future isocentre 
% change in Rectum solid volume vs. % change in 
V95% PTV dose - future isocentre
y = -0.0179x + 1.0097
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8.6.3c Effect of bladder volume on PTV dose 
The effect of bladder volume on PTV dose was assessed by plotting the percentage 
change in bladder volume against the percentage change in mean PTV dose. Figure 
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8-87 demonstrates the effect on the mean dose at the actual isocentre, and Figure 8-
88 demonstrates the effect on the dose delivered to V95% at the actual isocentre. 
Figure 8 - 87: Relationship between bladder volume and mean PTV dose – actual isocentre 
% change in Bladder volume vs. % change in 
mean PTV dose - actual isocentre
y = 0.0007x + 0.9883
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Figure 8 - 88: Relationship between bladder volume and V95 PTV dose – actual isocentre 
% change in Bladder volume vs. % change in 
V95% PTV dose - actual isocentre
y = 0.0063x + 0.9355
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Once again, when the isocentre was corrected for internal organ motion the effect of 
bladder volume variation on dose should be eliminated. Figure 8-89 demonstrates 
the effect on the mean dose at the future isocentre, and Figure 8-90 demonstrates the 
effect on the dose delivered to V95%. 
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Figure 8 - 89: Relationship between bladder volume and mean PTV dose – future isocentre 
% change in Bladder volume vs. % change in 
mean PTV dose - future isocentre
y = -0.0003x + 0.9993
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Figure 8 - 90: Relationship between bladder volume and V95 PTV dose – future isocentre 
% change in Bladder volume v’s % change in 
V95% PTV dose - future isocentre
y = -0.0012x + 0.9943
R2 = 0.0018
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8.6.3d Effect of rectum solid COV motion on PTV dose 
The normalised COV location of the rectum solid was plotted against the percentage 
change in mean PTV dose for each of the three directions at the actual isocentre. The 
same graphs were plotted for the V95 dose. These figures are not presented in the 
body of this thesis, but are available for viewing in Appendix 14. A regression 
analysis was performed on each of these graphs to analyse the relationship between 
rectum COV motion and the effect on the percentage of the planned dose that was 
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delivered to the actual isocentre. The results of this analysis indicate that rectum 
motion in the AP direction is significantly related to PTV dose (Table 8-77).  
Table 8 - 77: Regression analysis: Effect of rectum motion on PTV dose – actual isocentre 
  Mean PTV Dose V95% PTV Dose 
  x y z x y z 
R 0.04 0.05 0.16 0.08 0.02 0.16 
t-value -1.14 -1.33 4.47 -2.14 -0.48 4.72 
p-value 0.26 0.18 0.00 0.03 0.63 0.00 
 
 
The same graphs were plotted and a regression analysis performed to assess the 
relationship between rectum motion and PTV dose at the future isocentre (Table 8-
78). These results indicate that there is now a relationship between the variables in 
the SI direction. 
Table 8 - 78: Regression analysis: Effect of rectum motion on PTV dose – future isocentre 
  Mean PTV Dose V95% PTV Dose 
  x y z x y z 
R 0.08 0.10 0.01 0.14 0.17 0.00 
t-value -2.22 -2.91 0.34 -3.88 -4.86 -0.13 
p-value 0.03 0.00 0.73 0.00 0.00 0.90 
 
 
8.6.3e Effect of bladder COV motion on PTV dose 
A regression analysis was performed on the relationship between bladder COV 
motion and the effect on the percentage of the planned dose that was delivered to the 
actual and future isocentres. Both the mean dose and the dose delivered to 95% of 
the PTV (V95%) were considered. The graphs have not been included in this results 
section, but are available for viewing in Appendix 14. The results of this analysis are 
presented in Tables 8-79 and 8-80. These results indicate that there is a significant 
relationship in the AP direction for both the actual and future isocentres. 
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Table 8 - 79: Regression analysis: Effect of bladder motion on PTV dose – actual isocentre 
  Mean PTV Dose V95% PTV Dose 
  x y z x y z 
R 0.00 0.01 0.18 0.03 0.03 0.20 
t-value -0.09 0.21 5.06 -0.95 0.70 5.67 
p-value 0.93 0.84 0.00 0.34 0.48 0.00 
 
Table 8 - 80: Regression analysis: Effect of bladder motion on PTV dose – future isocentre 
  Mean PTV Dose V95% PTV Dose 
  x y z x y z 
R 0.00 0.05 0.22 0.04 0.13 0.29 
t-value 0.10 -1.36 -6.45 -1.00 -3.77 -8.51 
p-value 0.92 0.17 0.00 0.32 0.00 0.00 
 
8.6.3f Effect of prostate COV motion on PTV dose 
The effect of prostate COV motion on the PTV dose has been assessed using the 
actual and future isocentres. Both the mean dose and the dose delivered to 95% of 
the PTV (V95%) have been presented. 
 
Figures 8-91 through to 8-93 demonstrate the effect prostate COV displacement 
from the planned location has on the mean PTV dose at the actual isocentre in each 
of the three directions. Figures 8-94 through to 8-96 demonstrate the effect of 
prostate COV displacement from the planned location has on the V95 PTV dose at 
the actual isocentre in each of the three directions. Polynomial trend lines have been 
used on the graphs demonstrating the relationship between prostate COV 
displacement and the effect on the PTV dose using the ‘actual’ isocentre.  
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Figure 8 - 91: Effect of prostate displacement in the RL direction on the mean PTV dose – 
actual isocentre 
Prostate COV (X) displacement vs. % change in 
mean PTV dose - actual isocentre
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Figure 8 - 92: Effect of prostate displacement in the SI direction on the mean PTV dose – actual 
isocentre 
Prostate COV (Y) displacement vs. % change in 
mean PTV dose - actual isocentre
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Figure 8 - 93: Effect of prostate displacement in the AP direction on the mean PTV dose – 
actual isocentre 
Prostate COV (Z) displacement vs. % change in 
mean PTV dose - actual isocentre
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Figure 8 - 94: Effect of prostate displacement in the RL direction on the V95 PTV dose – actual 
isocentre 
Prostate COV (X) displacement vs. % change in 
V95% PTV dose - actual isocentre
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R2 = 0.0024
35.00%
55.00%
75.00%
95.00%
115.00%
-1.50 -1.00 -0.50 0.00 0.50 1.00 1.50
Prostate COV displacement (X - cm)
%
 
ch
an
ge
 
in
 
V9
5%
 
PT
V 
do
se
 
 
Figure 8 - 95: Effect of prostate displacement in the SI direction on the V95 PTV dose – actual 
isocentre 
Prostate COV (Y) displacement vs. % change in 
V95% PTV dose - actual isocentre
y = -0.1215x2 + 0.0581x + 0.9579
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Figure 8 - 96: Effect of prostate displacement in the AP direction on the V95 PTV dose – actual 
isocentre 
Prostate COV (Z) displacement vs. % change in 
V95% PTV dose - actual isocentre
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Figures 8-97 through to 8-99 demonstrate the effect of prostate COV displacement 
from the planned location has on the mean PTV dose at the future isocentre in each 
of the three directions. Figures 8-100 through to 8-102 demonstrate the effect of 
prostate COV displacement from the planned location has on the V95 PTV dose at 
the future isocentre in each of the three directions. Linear trend lines have been used 
on the graphs demonstrating the relationship between prostate COV displacement 
and the effect on the PTV dose using the ‘future’ isocentre. This is because once 
corrections are made for internal organ motion using IGRT, there should no longer 
be a relationship between the degree of displacement and the dose that would be 
delivered after corrections. 
Figure 8 - 97: Effect of prostate displacement in the RL direction on the mean PTV dose –
future isocentre 
Prostate COV (X) displacement vs. % change in 
mean PTV dose - future isocentre
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Figure 8 - 98: Effect of prostate displacement in the SI direction on the mean PTV dose –future 
isocentre 
Prostate COV (Y) displacement vs. % change in 
mean PTV dose - future isocentre
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Figure 8 - 99: Effect of prostate displacement in the AP direction on the mean PTV dose –future 
isocentre 
Prostate COV (Z) displacement vs. % change in 
mean PTV dose - future isocentre
y = -0.0041x + 0.9982
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Figure 8 - 100: Effect of prostate displacement in the RL direction on the V95 PTV dose –future 
isocentre 
Prostate COV (X) displacement vs. % change in 
V95% PTV dose - future isocentre
y = -0.0062x + 0.993
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Figure 8 - 101: Effect of prostate displacement in the SI direction on the V95 PTV dose –future 
isocentre 
Prostate COV (Y) displacement v’s % change in 
V95% PTV dose - future isocentre
y = 0.0077x + 0.992
R2 = 0.0207
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Figure 8 - 102: Effect of prostate displacement in the AP direction on the V95 PTV dose –future 
isocentre 
Prostate COV (Z) displacement vs. % change in 
V95% PTV dose - future isocentre
y = -0.0156x + 0.9898
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8.7 Hypothesis 4: Current preparation instructions are 
inadequate to maintain the planned dose distribution. 
The results presented previously in section 8.6 will be used during the discussion to 
evaluate whether the current patient preparation instructions are inadequate to 
maintain the planned dose distribution to each of the contoured structures.  
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9. Discussion: 
Until now there have been no studies assessing volume, organ motion and the effect 
on dose on a daily basis using CT scanning of the radiotherapy patient. Weekly CT 
scans have been used to observe the patient in 15-25% of treatment sessions 
(Dawson et al. 1998; Miralbell et al. 2003a, 2003b; Tinger et al. 1998; Roeske et al. 
1995; Rudat et al. 1996) thus providing a representative sample of the range and 
frequency of volume and motion variations. This study on IGRT has allowed a 
comprehensive assessment of these variables on a larger patient population than 
most studies reported in the literature. 
9.1 Patient Characteristics 
9.1.1 Descriptive characteristics of the sample population 
The patients recruited into this study are a representative sample of the early stage 
prostate cancer patient population (refer to section 3.1). The only previous study 
using daily in-room CT verification reported patients with the same clinical staging 
T1c-T3 and similar Gleason scores (range 5-8) (Wong et al. 2005). Martinez et al 
(2001), whose study into organ motion, set-up error and the effect on dose has the 
largest patient population reported in the literature, also studied patients with the 
same clinical characteristics. No mean age was reported for either study. A review of 
the other articles reported in the literature found patient age is seldom reported. 
9.1.2 Patient Symptoms 
There was no hypothesis related to the connection between patient symptoms and 
organ volume. However documentation of patient reported symptoms was collated 
retrospectively in the hope that the presence of symptoms may be able to explain the 
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variations in organ volume demonstrated in section 8.4 of the results. Unfortunately 
the irregular reporting of patient symptoms as demonstrated in Table 8-2 & 8-3 
make it difficult to interpret any relationship between organ volume and the onset or 
presence of symptoms. These figures do indicate that symptoms were more 
commonly reported during weeks 4 and 7/8. It is unlikely that the symptoms are 
actually worse in those weeks, and may reflect the fact that patients more accurately 
report their symptoms to the Doctor compared to the nurse or because the Doctors 
ask more specific questions about their symptoms. 
 
The change in unit policy to document patient reported toxicities according to the 
RTOG grading system on a more regular basis will make the correlation between 
symptoms and organ volume easier to interpret and is one area for future 
investigation highlighted during this research.  
9.2 Contouring Uncertainty 
Contouring uncertainty is a function of many factors, including the partial volume 
effect, poorly defined anatomy on CT scans, variations in contouring and operator 
misinterpretation (Tinger et al. 1998). Contouring uncertainty for this study will be 
broken down into intra and inter observer contouring uncertainty. 
9.2.1 Intra-observer contouring uncertainty 
Intra-observer contouring variation is a measure of repeatability. It is the variation 
observed between operations done by the same observer, with the same sample of 
patients, using the same planning computer system. In this study, five patient CT 
data sets were copied 15 times to test repeatability over a 12 month period.  
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9.2.1a Rectum 
i) Volume uncertainty 
The mean rectal volumes contoured by the PI in this study range from 45.5 to 
186.2cc, with a SD of 1.3cc to 6.0cc (Table 8-4). The SD as a percentage of the 
mean volume averaged 4.7% (maximum of 9.3%). The rectal volume for one patient 
was three times larger than that of the other four patients in this study. When this 
was investigated patient 1 was shown to have faecal contents and air still in his 
rectum (Figure 9-1). Although all patients were given instructions to drink a fibre 
supplement, the volume demonstrated by patient 1 indicates that these instructions 
were either not followed correctly or the fibre supplement did not have the desired 
effect. 
Figure 9 - 1: Patient 1 demonstrates large rectal volume due to faeces and air 
 
 
Linear lines of best fit can be assessed for time trends to determine whether the 
contouring by the PI changed over time (Figure 8-1 a-e). Only one patient out of five 
has a p-value of <0.05 and therefore patient 2 is the only patient for whom we can 
conclude with 95% confidence that there is a time trend for increasing contoured 
volume (Table 8-5). The 95% CI range of the slope also indicates that only patient 2 
demonstrates a real trend, as the remaining patients’ 95%CI ranges include zero. 
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The lack of consistent trends in contouring the same datasets indicates difficulties in 
delineating the rectum on each occasion rather than a change in contouring practices 
over time. Therefore to assess the repeatability of the measurements the rectum 
volumes were normalised by subtracting the mean anal canal volume for each 
patient from the volume at each measurement occasion (Figure 8-2).  
 
An analysis for normal distribution of the normalised rectum volume was performed 
with Kurtosis and Skewness values reported. “Kurtosis characterises the relative 
peakedness or flatness of a distribution compared with the normal distribution. 
Positive kurtosis indicates a relatively peaked distribution. Negative kurtosis 
indicates a relatively flat distribution.” (Microsoft Excel XP, 2002). “Skewness 
characterises the degree of asymmetry of a distribution around its mean. Positive 
skewness indicates a distribution with an asymmetric tail extending toward more 
positive values. Negative skewness indicates a distribution with an asymmetric tail 
extending toward more negative values” (Microsoft Excel XP, 2002). The Kurtosis 
and Skewness values of a normal distribution are defined to be zero, with values of 
two or greater considered indicators of non-normal distribution. Therefore the 
Kurtosis value of 0.31 and a Skewness value of 0.13 for the rectum volume 
histogram indicates that the data is relatively outlier-free and that the data is 
distributed symmetrically around the mean.  
 
The histogram in Figure 8-2 demonstrates that the 75 normalised rectum volumes 
resulted in a SD of 4.1cc. This SD represents the uncertainty in contouring the 
rectum. Two SDs (8.1cc) represents the degree of uncertainty at the 95%CI. This 
estimate of uncertainty can be used as the width of the error bars for the rectum 
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volumes when analysing volume variations for the 25 study patients in the main 
study. 
 
The gastrointestinal (GI) tract is the most difficult structure in the pelvis to define. 
Unlike the prostate or bladder that are discrete organs, the extent of each section of 
the GI tract, and therefore the CT slice where it starts and stops, is subject to 
interpretation by the observer. As discussed in the introduction, the lowest section of 
the GI tract, the anal canal, is commonly defined as a length of 3cm, and the rectum 
ends on the CT slice prior to this. The start of the rectum, at the sigmoid-rectal 
junction, is commonly determined by its movement inferiorly-posteriorly on the CT 
scan (Figure 9-2).  
Figure 9 - 2: Sagittal DRR showing sigmoid-rectum junction 
 
Figure extracted from Fleckenstein & Tranum-Jensen, 1993 p. 287 
 
Changing this junction by only 1 CT slice creates a change in the COV by 0.25cm, 
or half the slice thickness. The effect on volume was demonstrated by expanding the 
volume by 0.5cm at the upper level. By expanding the volume by the equivalent of 
Rectum 
Sigmoid Colon 
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one slice the average increase in rectum volume was 22.6cc. The average increase in 
volume for four out of five patients when the UL was expanded by 0.5cm was at 
least 3 times the SD of the mean volume, indicating that at the 99%CI the variation 
in volume was due to less than 0.5cm variation in defining the UL or LL (Table 8-
8). Although the increase in volume by expanding the UL by 0.5cm for the 
remaining patients did not exceed 3SD, the CI for concluding that volume variations 
are due to less than 1 CT slice is still high (patient 4, increase = 2.9SDs of the mean 
volume) 
 
ii) COV uncertainty. 
The COV variation around the mean COV location in all three directions was less 
than 3mm. COV variation was greatest in the SI (Y) direction, SD= 0.29cm, 
compared to the AP (Z), SD= 0.08cm, and RL (X) directions, SD= 0.11cm.  The 
increased uncertainty in the Y direction is was expected as CT slice thickness affects 
the resolution in this plane and therefore compounds the difficulty in delineating the 
UL and LL of the rectum. As explained earlier in this section, increasing the UL by 
one CT slice or decreasing the LL by one slice, results in a change in the Y COV 
coordinate by 0.25cm. A CT slice thickness of less than 0.5cm, which is becoming 
more commonly used in radiation therapy practice, may decrease the uncertainty in 
this direction to a similar magnitude demonstrated in the other 2 planes. The 
difficulty in defining the upper edge of the rectum will also affect the COV value. 
 
An analysis for normal distribution of the normalised rectum volume was performed 
with Kurtosis and Skewness values reported in Table 8-7. These values indicate that 
for the rectum COV location the data is relatively outlier-free, although the X and Y 
directions show more variation, and that the data is distributed symmetrically around 
the mean.  
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The SD of the COV coordinates represents the uncertainty in locating the rectum. 
Two SDs (X= 0.16cm, Y= 0.58cm, Z= 0.22cm) represents the degree of uncertainty 
associated with rectum location at the 95% CI and can be used as the width of the 
error bars for the rectum COV locations for the 25 study patients. 
 
iii) Effect of volume expansion. 
Table 8-8 demonstrated a 1mm increase in the rectum contour resulted in an average 
increase in volume of 12.3cc (SD = 6.1cc), which is over three times the average 
variation in volume of the individual patients observed during the 12 month 
reproducibility study (SD= 3.8cc) and three times the uncertainty of the normalised 
data (SD= 4.1cc). As discussed earlier, an increase in overall length of the volume 
by the equivalent of one CT slice (0.5cm), also results in an average increase in 
volume three times the SD of the planned volume. This indicates that we can 
conclude with 99% confidence (3SD) the volume variation observed was the result 
of less than 1mm variation in contours drawn on each axial slice or by an increase in 
the length of the volume by one CT slice. It would be unrealistic to expect that 
accuracy of less than 1mm would be possible due to limitations of the computer 
system such as pixel size and the accuracy of the mouse, however increased 
accuracy in the Y direction should hypothetically be possible with decreased CT 
slice thickness. This explanation is supported by Stroom et al. (1999) who quote that 
the maximum accuracy due to pixel size is 2mm, and by Muren et al. (2004) who 
found a discrepancy of 2-3mm between landmarks when performing anatomy 
matching. 
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9.2.1b Bladder 
i) Volume uncertainty 
The mean bladder volume contoured by the PI in this study ranged from 120.1cc to 
532.9cc, with a SD of 3.0cc to 8.9cc (Table 8-9). The average SD as a percentage of 
the average mean is less than 2% and reflects the relative ease at which the bladder 
can be visualised on a CT scan compared to the surrounding structures (Figure 9-3). 
However it is obvious from the range in mean volumes from these five patients that 
the volume of a ‘full’ bladder can vary significantly between patients. 
Figure 9 - 3: Bladder is an easily identified pelvic structure 
 
 
Linear lines of best fit can be assessed for time trends to determine whether the 
contouring by the PI changed over time (Figure 8-4 a-e). Patients 2, 4 and 5 have a 
p-value of <0.05 and therefore we can conclude with 95% confidence that there is a 
time trend for increasing contoured volume (Table 8-10). However any trend seen in 
contouring practice needs to be assessed over a 2 month period, rather than a 12 
month period, to more accurately assess the uncertainty for each of the 25 patients in 
the main IGRT study. This is because the contouring for the patients enrolled in the 
IGRT study was completed over a period of approximately two months, where as 
the trend for increasing volume in this contouring uncertainty investigation was 
observed over a twelve month period.  
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It is also obvious from visual observation that a linear line of best fit does not 
accurately summarise the fluctuations that are seen during each contouring occasion. 
Therefore to assess the repeatability of the measurements the bladder volumes were 
normalised. An analysis for normal distribution resulted in a Kurtosis value of 0.36 
and a skewness value of -0.11 indicating that the steepness and symmetry resembles 
a normal distribution. Descriptive statistics of the 75 normalised contoured volumes 
resulted in a SD of 6.1cc. This SD represents the uncertainty associated with 
contouring the bladder. Two SDs (12.2cc) represents the degree of uncertainty at the 
95% CI and can be used as the width of the error bars for the bladder volumes of the 
25 study patients.  
 
ii) COV uncertainty 
The COV variation around the mean COV location in all three directions for the 
bladder was smaller than that seen for the rectum (Table 8-11). This decrease can be 
attributed to the improved visualisation of the bladder discussed earlier. However the 
largest COV variation is still observed in the SI direction (SD = 0.12cm) and as 
discussed earlier would be affected by the CT slice thickness.  
 
An analysis for normal distribution of the normalised bladder volumes was 
performed. The Kurtosis and Skewness values shown in Table 8-12 indicate that 
despite the Y direction having a couple of outliers, all three directions follow a 
normal distribution. 
 
The SD of the COV coordinates represents the uncertainty in locating the bladder. 
Two SDs (X= 0.08cm, Y= 0.24cm, Z= 0.12cm) represents the degree of uncertainty 
associated with the bladder location at the 95%CI and can be used as the width of 
the error bars for the bladder COV locations for the 25 study patients. 
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iii) Effect of volume expansion 
Table 8-13 demonstrates that a 1mm expansion of the bladder volume related to an 
average increase in volume of 22.2cc (SD= 8.5cc), which is over 3 times the average 
variation in volume observed (SD= 6.0cc) and more than three times the uncertainty 
of the normalised data (SD= 6.1cc). This indicates that the contouring uncertainty 
for the bladder is less than 1mm. As discussed previously, it is unrealistic to expect 
accuracy of less than 1mm due to limitations of the computer system and CT slice 
thickness. 
9.2.1c Prostate 
i) Volume uncertainty. 
The mean volume for the prostate ranged from 28.9cc to 100.9cc, with a SD of 
between 2.7cc and 9.7cc (Table 8-14). The SD for Patient 4 is over double the 
variation observed for the other four patients. On further investigation it was found 
that the prostate for patient 4 was poorly visualised with respect to surrounding 
anatomy compared to the patients who had lower intra-observer variation, even 
when the window levels were optimised as demonstrated in Figure 9-4.  
Figure 9 - 4: Patient 4 on the left, Patient 1 on the right. 
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Linear lines of best fit can be assessed for time trends. All 5 patients have a p-value 
<0.05 leading to the conclusion that there is a time trend for decreasing contoured 
prostate volume over time (Table 8-15). Unlike the previous structures where the 
time trend was not completely explained by a linear trend, the prostate volumes 
show a significantly strong R value indicating that there was a change in contouring 
practice over the twelve months when looking at prostate volumes. However once 
again the effect of the change in contouring practice over the 12 months does not 
necessary reflect the change in contouring for each individual patient on the main 
IGRT study since the contouring of these patients was completed over a much 
shorter period (approximately 2 months).  
 
To assess the repeatability of measurements the prostate volumes were normalised. 
The resulting volumes followed a normal distribution (Figure 8-8). Two SDs of this 
normalised data (10.9cc) represents the degree of uncertainty in prostate volume at 
the 95%CI and can be used as an estimate of uncertainty for the prostate volumes for 
the 25 study patients. 
 
There is limited published information on the degree of uncertainty in contouring the 
prostate and therefore the amount of variation expected was unknown. In a research 
study protocol recently approved at the PMCC, the statistical endpoints for the 
validation of an automated segmentation tool were that the volume of the prostate 
identified by the program is within +/- 10% of the volume outlined by an operator 
and that the centre of mass (or COV) of the prostate identified by the program is 
within +/- 3mm in all three cardinal directions of the COV of the structure outlined 
by the operator (Kron et al, 2005). This research is being conducted in collaboration 
with Siemens Medical Systems and if the program is validated it will be introduced 
as a clinical tool for IGRT.  
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Using the criteria suggested by Kron et al (2005), the variation observed in patients 
1, 2 and 5 are less than 10%, however they are greater for patients 3 and 4. An 
explanation of the increased variation observed in patient 4 has already been 
suggested and is applicable to patient 3 also. The effect for patient 3 is also 
compounded by the fact that this patient has the smallest mean prostate volume. 
When the effect on volume of increasing the volume by 1mm in the AP and RL 
directions is assessed, almost 90% of the variation can be explained because the 
1mm expanded volume equates to 1.65SDs and 1.52SDs for patient 3 and patient 4 
respectively. Furthermore, an increase in the UL by 3mm, which is less than one 
slice thickness, is able to explain 95% of the variation. 
  
ii) COV uncertainty 
The largest COV variation around the mean was again observed in the SI direction 
due to the effect of CT slice thickness and the inherent difficulty in assessing the UL 
of the prostate at its junction with adjacent vascular tissue (Table 8-16). The 
variation around the normalised mean prostate COV location confirms a normal 
distribution (Table 8-17). 
 
If we assess the variation in COV location according to the criteria suggested by 
Kron et al (2005), at the 95%CI (2SDs) the location of the COV in the X and Z 
directions are within expected variations (X= 0.14cm, Z= 0.20cm). Although the Y 
direction demonstrates variation slightly larger than expected (Y= 0.32cm), this 
would be expected to decrease if a smaller CT slice thickness was used. These 
degrees of uncertainty in each direction can be used as the width of the error bars for 
the prostate COV locations for the 25 study patients. 
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The COV variation demonstrated in this study is comparable to that reported in the 
published literature. As discussed in the literature review (section 4.5.1), variability 
of PTV contours, which are derived from the prostate volume, resulted in an 
estimate of reproducibility of 1mm in the COV position (Melian et al. 1997). The 
uncertainty associated with COV co-ordinates was also reported as1.6mm in the AP 
and Lat directions by Roeske et al. (1995) and as 2mm (AP) and 1mm (RL) by 
Beard et al. (1996). They also acknowledged that larger uncertainties may be present 
in the SI measurements due to the slice thickness (0.5cm) and difficulties in 
determining the superior and inferior levels of the prostate on CT.   
 
iii) Effect of volume expansion 
As discussed previously a 1mm expansion of the prostate in the AP and RL 
directions related to an average increase in volume of 8.0cc (SD= 2.9cc) which is 
equivalent to 15% of the mean volume and explains the majority of volume variation 
at the 90%CI (Table 8-18). Increasing the UL of the prostate by less than 1 CT slice 
thickness (3mm) results in an average increase in volume of 14.3cc and is able to 
explain 95% of the variation in the two patients who demonstrated the greatest 
volume variation. 
9.2.1d Anal Canal 
i) Volume uncertainty 
The mean anal canal volume for the five patients in this study was 12.6cc, with a SD 
of 1.3cc (Table 8-19). Linear lines of best fit were applied to the Figures 8-10(a-e) to 
assess for time trends. Only patient 4 has a p-value of <0.05 and is therefore the only 
patient who we can be confident at the 95% CI of a demonstrating a time trend for 
decreasing contoured volume (Table 8-20). 
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The lack of consistent time trends once again indicates the difficulty in delineating 
the structure, rather than a change in practice over time. Any differences in defining 
the anal canal also affected the rectum due to the fixed length of the anal canal 
(3cm). To decrease the variation in the rectum and anal canal contouring, it requires 
further improvement of the definitions of these structures to eliminate variations in 
the SI borders. Increased training and experience using the structure definitions used 
in this study would also decrease contouring variation as they were different from 
those used in clinical practice, to make the results more relevant to current literature. 
Alternatively, the rectum could be defined for the length of the field only thus 
eliminating the subjective decision on where the LL and UL are defined. 
 
To assess repeatability of contouring the anal canal the volumes were normalised. 
An analysis of normalised anal canal volumes confirmed that the distribution of 
variation was normal (Figure 8-11). The average SD for contouring anal canal 
volumes was only 1.3cc. Two SDs (2.7cc) represents the degree of uncertainty at the 
95% CI and will be used as the width of the error bars for the anal canal volumes for 
the 25 study patients. 
 
ii) COV uncertainty 
The COV variations around the mean are comparable to those reported for the three 
previous structures and will be used as the degree of uncertainty, at the 95%CI, 
when assessing anal canal COV locations for the 25 study patients (2SDs: X= 
0.14cm, Y= 0.32cm, Z= 0.22cm). An analysis of the normalised anal canal volume 
histograms (Figure 8-12, a-c) demonstrates that the variation is normally distributed 
(Table 8-22). 
 
 
 - 210 -
 
iii) Effect of volume expansion 
A 1mm expansion of the anal canal volume related to an average increase in volume 
of 3.2cc (SD= 0.3cc), which is approximately 2.5 times larger than the average SD 
for the individual patients (SD= 1.3cc) and the uncertainty of the normalised data 
(SD= 1.3cc) (Table 8-23). Therefore the reported volume variation can be explained, 
with >98% confidence, as result of 1mm variation in the AP and RL directions.  
9.2.2 Inter-observer contouring uncertainty 
Inter-observer contouring variation is a measure of reproducibility. It is the variation 
observed between different observers with the same sample of patients using the 
same planning computer system. Although this research was designed so that the PI 
was responsible for contouring all CT images, contouring of these structures is not 
normally the role of the RT.  Therefore inter-observer contouring uncertainty is 
included in this thesis to demonstrate the ability of the investigator to contour 
structures that are clinically relevant. In this study Dr Andrew See (MBBS, 
FRANZCR) who was a consultant RO at the Tattersall’s Cancer Centre, contoured 
the same five patient CT data sets used in the intra-observer study, on a single 
occasion. These volumes were used as the “gold standard” for comparison with the 
volumes contoured by the PI during the intra-observer study.  
 
As reported earlier in section 8.2.1, the intra-observer study involved 15 contouring 
occasions and provided a mean and SD for each patient and each structure. The RO 
who participated in the inter-observer study only completed one contouring occasion 
and therefore a direct comparison using the means and SDs for each observer was 
not possible. However the SD from the intra-observer study measured how large the 
variations fluctuated around the mean and can be used to assess how close the 
volume contoured by the RO reflects that drawn by the PI. It can be concluded with 
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95% confidence that the two observers have contoured the same structure when the 
volume contoured by the RO falls within +/- 2SDs of the mean volume contoured by 
the PI.  
 
To improve the assessment of inter-observer contouring uncertainty it requires the 
use of multiple observers including both ROs and RTs. It would also be preferable to 
have the all the observers contour the same structures on multiple occasions so that a 
mean volume for each observer could be used and eliminate any random error that 
may be present in this study. A study design taking into consideration these factors 
would more closely represent inter-observer variation that would be observed in a 
clinical department, but beyond the scope of this research.  
9.2.2a Rectum 
i) Volume uncertainty 
In the previous study by Fiorino et al. (2002) on inter-observer contouring variation, 
the mean rectal volume deviation was -5.6cc (SD = 5.3cc), with a maximum of 
10.0cc variation seen between observers. The SD as a percentage of the mean 
volume variation ranged from 10-18%.  This resulted in a maximum dose variation 
of 7-8Gy (SD=2-3Gy). There were systematic differences seen in the anterior edge 
of the rectum as well as the superior limit (UL). Foppiano et al. (2002 & 2003) also 
found deviations at the superior limit of between 0.5-0.8cm. In conclusion they 
stated the use of strict definitions minimises the impact of inter-observer variations; 
however even when strict definitions were used they were still a significant source 
of uncertainty.  
 
In this study the mean deviation was -2.6cc (SD= 9.0cc), with a maximum variation 
between observers of -14.6cc. These results are very similar to those reported in the 
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literature. A more detailed comparison of rectal volumes between the two observers 
demonstrated that the rectal volumes contoured by the RO for three patients were 
within 2SDs of the mean volumes contoured by the PI and therefore it can be 
concluded with 95% confidence that the volumes drawn by the 2 observers are the 
same (Table 8-24). However two of the patients contoured by the RO demonstrated 
variation that exceeded 2SDs which indicates that the there was a difference in 
contouring the rectum despite definitions being provided.  
 
Further investigation showed that for patient 2, the volume contoured by the RO was 
slightly larger than the largest volume contoured by the PI (63.7cc and 63.0cc 
respectively). However the volume contoured by the RO is only slightly larger than 
when the PIs volume was expanded by 1mm (61.5cc) and is less than when it was 
expanded 0.5cm at the upper level (68.7cc). When comparing the variation in COV 
location, patient 2 only demonstrates variation greater than 2SDs in the X direction 
which therefore indicates that the variation between the observers for this patient is 
most likely due to small contouring variation rather than a difference in locating the 
structure within the pelvis (Table 8-25). 
 
For patient 3 there was a much larger variation between the RO volume and the 
largest volume contoured by the PI (65.4cc compared to 53.3cc respectively.) This is 
also reflected by the COV location being greater than 2SDs from the mean in the Y 
and Z directions (Table 8-25). The increased amount of variation in the Y direction 
indicates that there were differences in defining the UL & LL of the rectum. This 
was expected from the literature. 
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ii) COV uncertainty 
The COV comparison indicates that patient 3 is not the only patient where variation 
greater than 2SDs occurs between the observers (Table 8-25). Although the 
confidence of contouring the same volume for patient 1 and 4 was 95%, the COV in 
the Y direction for the RO was consistently more superior to the PI COV. This 
indicates that there was a systematic difference between the PI and the RO in 
defining the rectum within the pelvis. This was confirmed by using sagittal overlays 
taken in the same plane (Figure 9-5). This same analysis was performed using BEVs 
by Fiorino et al. (2002) to confirm systematic deviations in contouring the rectum. 
Figure 9-5 demonstrates that the rectum contours drawn by the RO (solid lines) were 
more superior those of the PI (hashed lines). It should also be noted that the LL, 
which relates to the anal canal contour, is also more superior so the same variation in 
the Y direction will be expected for the anal canal.  
Figure 9 - 5: Demonstrating the variation between the UL and LL for the two observers 
Hashed lines = PI, RO = solid lines 
 
 
Rectum 
Anal Canal 
Sup (+Y) 
Ant (+Z) 
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9.2.2b Bladder 
i) Volume variation 
The variation in bladder volume between the two observers is less than that reported 
for the rectum. The mean deviation was 2.0cc (SD= 8.8cc), with a maximum 
deviation of 15.9cc for patient 5. When this outlier was removed the mean deviation 
reduces to 1.5cc (SD= 4.7cc). This uncertainty (<1% of mean volume) is consistent 
with that reported in the literature. Lebesque et al. (1995) stated that uncertainty of 
up to 2.5% should be expected when contouring the bladder.  
 
When assessing whether at the 95%CI, the RO’s bladder volumes were the same as 
the PI’s, it was found that two patients had RO volumes that were greater than 2SDs 
from the PI’s mean bladder volume (Table 8-26). The largest variation was observed 
for patient 5 with the RO’s volume being 15.9cc less than that of the PI. However, 
the COV locations in all three directions demonstrated variation of less than 2SDs 
(Table 8-27). The most logical explanation for this is that the RO’s contouring is 
approximately 1mm smaller than that of the PI since the results of a 1mm expansion 
result in a 16cc increase in volume. 
 
The other patient who demonstrated a greater than 2SD variation from the mean PI 
volume was patient 3. The RO’s volume is 8.3cc larger than the PI’s mean bladder 
volume, however a 1mm expansion was shown earlier to increase the volume by 
10.9cc and is therefore a reasonable explanation for the variation. There is also a 
0.25cm variation in the Y COV coordinate which may indicate a difference in 
defining the UL or LL by one CT slice, although the SD for this direction was zero. 
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ii) COV uncertainty 
The COV comparison indicates that patients 3 and 4 both had small variations in the 
location of the bladder between observers (Table 8-27). However the SD of the 
mean PI volumes was extremely small for all patients due to the excellent 
repeatability when contouring the bladder. The sagittal and coronal overlays in 
Figure 9-6 confirm how small these variations in bladder contouring were. 
Figure 9 - 6:  a) coronal & b) sagittal overlays 
Hashed lines = PI, solid lines = the RO. 
 
 
 
9.2.2c Prostate 
None of the prostate volumes drawn by the RO are greater than 2SDs away from the 
mean PI prostate volumes (Table 8-28). In fact three of the five volumes fall within 
1SD which may lead to the conclusion that the reproducibility of the prostate 
contours has even greater confidence than the bladder and rectum.  
 
However the intra-observer SD for the prostate volume was large and it is obvious 
from Table 8-28 that the prostate volumes drawn by the PI are consistently larger 
than those drawn by the RO. On average the prostate volume contoured by the RO 
was 3.6cc (SD= 3.4cc) smaller than that of the PI. This equates to a variation of 
SUP (+Y) SUP (+Y) 
Ant (+Z) Right (-X) 
Bladder 
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6.7% of the mean prostate volume. This is consistent with the 6% variability of PTV 
contours (which are derived from the CTV) which was attributed to contouring 
variation by Melian et al. (1997). 
 
ii) COV uncertainty. 
Despite the 6% variation between observers in prostate volume, the COV 
comparison does not show any trend for uncertainty between observers, and again 
the direction with the largest uncertainty is the SI (Y) (Table 8-29).  
9.2.2d Anal Canal 
The results for the anal canal are very similar to those presented for the rectum. 
Because the anal canal was a fixed length of 3cm, any variations in volume or COV 
are not due to the observer contouring a different number of CT slices, but related to 
the location of the anal canal in the pelvis. The two patients highlighted in Table 8-
30 where the RO volume was greater than 2SDs from the mean also have a 
difference in the Y COV coordinate of greater than 2SDs (Table 8-31). Patient 3’s 
RO volume is smaller which corresponds a more inferior (-Y) location. Conversely 
patient 4 RO volume is larger, which corresponds to a more superior (+X) location 
by 1.83cm. This is not surprising as anatomically the anal canal diameter decreases 
as it moves more inferiorly. Therefore a change in the SI direction will have an 
impact on the overall volume.   
9.2.3 Summary of intra and inter-observer uncertainty 
This study confirms the presence of both intra and inter-observer contouring 
uncertainty. Intra and inter-observer uncertainty need to be considered when 
calculating the margins necessary to ensure that the CTV is adequately covered on a 
daily basis. As expected from the limited literature available on contouring variation, 
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inter-observer contouring variation was larger than intra-observer variation 
(Foppiano et al. 2002 & Fiorino et al. 2002). Fiorino et al. (2002) also reported that 
intra-observer contouring variation increased the mean dose to the rectum by 2Gy, 
however the increase in the maximum dose to the rectum was only 0.1Gy. This 
amount of variation in dose will have minimal clinical implications. 
 
In this study the bladder had the lowest intra and inter-observer variation due to its 
relatively easy visualisation on CT imaging of the pelvis, whereas the other 
structures demonstrated larger variation due to the difficulty distinguishing them 
from surrounding structures. However it was demonstrated that the majority of these 
volume variations were explained by a variation in contouring of less than 1mm. 
This is supported by the results of Dehnad et al. (2003) who found that error in 
delineation of the prostate was a result of less than 2mm variation in contouring. The 
volume variation observed in this study also resulted in minimal effects on the COV 
location except in the Y (SI) direction, which was affected by the 0.5cm CT slice 
thickness. The degree of the uncertainty at the 95%CI derived from this data that 
will be applied to the 25 study patients, is shown in Table 9-1. 
Table 9 - 1: Volume and COV uncertainty 
  Volume COV 
Structure Uncertainty (cc) 2SD Uncertainty (cm) 2SD 
  (after normalisation) X Y Z 
Rectum 8.14 0.16 0.58 0.22 
Bladder 12.18 0.08 0.24 0.12 
Prostate 10.94 0.14 0.32 0.2 
Anal Canal 2.66 0.14 0.32 0.22 
 
These results support the conclusions by previous authors that although contouring 
variations exist, their effect on dose is less than for set-up errors and organ motion 
(Fiorino et al. 2002). However in the future when daily IGRT is being used to 
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correct for set-up error and organ motion, contouring variations will become a 
significant source of remaining uncertainty. 
 
The results of this study have validated the methodology to use only one 
investigator, the PI, for contouring throughout this research. However it does not 
solve the problem of how to account for this variation in clinical practice. Despite 
using written definitions, the practical application of such definitions has proven 
difficult. Potentially the definition of the rectum and anal canal could be simplified 
to minimise the SI variation, along with the use of a smaller CT slice thickness. In 
some centres, including PMCC, it is standard practice to contour the rectal volume 
for the length of the field only. Although the DVH will not be for the entire organ, 
this definition would allow an assessment of the effect of rectal diameter on dose, 
rather than having different lengths. 
 
It could be hypothesised that once the technology is available to import the original 
planning contours onto the verification CT, rather than having to draw them on each 
slice, the volume variation would reduce. This is because a <1mm variation in 
structure definition is unlikely to be detected by the operator, and therefore the 
contour will be left unaltered. Further research is needed to assess the variation seen 
in volumes and COV position, when an automated computer contouring tool is 
available. This research commenced at PMCC in conjunction with Siemens Medical 
Systems in early 2006 using the CT scans of the 25 patients in this study. If this tool 
proves to be more accurate it will decrease the reliance on treatment RTs to 
accurately contour structures and increase the feasibility of performing on-line organ 
motion corrections in clinical practice. However at the current stage of development, 
automated contouring of the prostate accepts variations larger than those presented 
here. 
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Until this automated technology has proved effective and is commercially available, 
centres planning on correcting for internal organ motion may wish to consider the 
use of fiducial markers as a surrogate for organ contouring. Alternatively, prior to 
clinical implementation, centres should provide increased education and training 
programs and consider competency testing for a group of clinical contouring 
‘experts’ to perform this role, especially considering that RTs typically have limited 
experience in contouring these structures. This is supported by Rybovic, Halkett and 
Williams (2005) who found that although there was no correlation between accuracy 
of anatomy contouring and years of experience or formal training, frequent exposure 
to performing in this role was important. 
9.3 Patient set-up uncertainty 
The comprehensive analysis of patient set-up uncertainty is important for assessing 
the variations experienced by patients who do not have the benefit of daily on-line 
imaging. Although this study has been a much more comprehensive assessment of 
treatment reproducibility using CT verification than has been performed previously, 
patient set-up accuracy studies have been adequately performed using EPI with 
larger patient populations than reported in this study.  
 
However, hypothesis 4 of this research is that the current instructions are inadequate 
to maintain the planned dose distribution. Set-up uncertainty is one of the factors 
that affect the planned dose distribution, remembering that Antolak et al. (1998) 
found that set-up accuracy was negatively skewed towards the prostate hence 
moving the high dose region towards the rectum. By assessing random, systematic 
and total uncertainty informed decisions can be made regarding margins needed 
during planning and verification protocols. 
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Despite using non-customised stabilisation, the reproducibility of patient set-up was 
very effective when an action level of 0.5cm for the isocentre location was used with 
only 10.1% of isocentre set-ups needing adjustment (Figure 8-17). The largest 
number of isomoves was 12 for patient 19 and 5 patients required no isocentre 
adjustments throughout the course of their treatment. On average 3.3 isomoves were 
required per patient over their entire treatment course.  
  
Previous researchers looking at the incidence of isomoves have reported an increase 
in the number of shifts over time and hypothesised that this was due to increased 
reliance on the imaging technology by the treatment RTs (Chandra et al. 2003). 
There were no time trends observed in the number of isomoves performed over the 
duration of twelve month period of the study from patient 1 to patient 25 (R= 0.08) 
(Figure 8-17).  
 
As an indicator of the set-up accuracy required in other prostate research studies, the 
Trans-Tasman Radiation Oncology Group (TROG) have a current trial (TROG 
03.04, RADAR protocol, 2004) that requires an institution to demonstrate that 90% 
of treatment isocentres coincide within 5mm of the planned isocentre along each of 
the orthogonal axes, for patients receiving 70-74Gy. For this study 93.4% of the 
isocentres were located within 5mm in the AP direction with 97.4% and 98% within 
this limit in the RL and SI directions respectively. If the action level was decreased 
further, it would be expected that the number of isomoves would increase. If the 
department was considering dose escalation or reducing the CTVÆ PTV margins, it 
may be beneficial to review the percentage of isocentres that are within 3mm of the 
planned isocentre position. According to the RADAR protocol, increasing the dose 
to 78Gy requires 90% of treatments to be within 3mm and if this could not be 
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achieved using the current patient stabilisation system, alternative methods that 
minimise set-up uncertainty and hence the number of pre-treatment shifts should be 
considered.  
 
The timing of the isomoves as visualised in Table 8-32 was also interesting. 
Although 37% (30/82) occurred in the first five fractions and 51% occurred during 
the first two weeks, there were isomoves scattered throughout the entire treatment 
course, with 28% occurring after week 4. This indicates the need for regular 
verification of the isocentre position even after any initial systematic errors are 
corrected.  
 
The timing of the changes to the treatment isocentre position to correct for 
systematic errors was also interesting (Table 8-32). RTs were instructed to alter the 
isocentre in the treatment sheet if a shift was performed with the same magnitude 
and direction on consecutive days, i.e. a change made for the 3rd day. However the 
RTs also used their professional experience to make changes that fell outside the 
original instructions. Patients 1, 2, 10, 11 & 23 all had adjustments made to their 
treatment sheet isocentre, despite the fact that there were not 2 consecutive days 
where moves were made. On further investigation this judgement was made because 
the RTs could see that although the action level was not reached there was a 
systematic error present. For example: patient 11, Fx 12 was 0.3cm post, Fx 13 was 
0.4cm post and Fx 14 was 0.5cm post, therefore the staff made a judgment to correct 
the treatment sheet isocentre. This was obviously a justifiable decision as no more 
corrections were needed in this direction for the remainder of the patient’s treatment. 
However there was also one example of where the isocentre in the treatment sheet 
was adjusted for the same reason, however the move was recorded in the wrong 
direction. This resulted in 2/3 of the next fractions requiring moves, before the 
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treatment isocentre was recorded correctly. The use of daily verification minimised 
the impact of isocentre transcription errors in the treatment sheet. 
 
The majority of isomoves were performed in the AP direction (54), whilst the fewest 
were in the SI direction (16), with the 21 shifts in the RL direction (Figure 8-18). 
There were also 8 occasions where the isocentre was corrected in more than one 
direction (Figure 8-19). The average magnitude of these isomoves were 6.4mm 
(AP), 5.8mm (SI) and 5.5mm (RL). When direction is also considered the mean set-
up variation in the AP direction is 0.6mm (SD= 6.6), SI is -1.0mm (SD= 5.9) and RL 
is 1.7mm (SD= 5.4). An analysis for normal distribution demonstrates that the 
magnitude and direction of the shifts was normally distributed in the RL and AP 
directions, but the distribution in the SI direction is non-normal (Table 8-33).  
 
The magnitude of set-up errors calculated during this research can be compared to 
those reported in the literature (Table 9-2). 
Table 9 - 2: Set up errors reported in the literature 
    Set up error (mm) Mean SD 
Author Year Notes SI AP RL SI AP RL 
Rosenthal 1993 immobilisation (alpha cradle) 0.2 0.3         
    without immobilisation 0.4 0.4         
Dawson 1998 No immobilisation device 1.7 -1.1 -1 3.3 5.5 2.3 
Tinger 1998 Cradle -0.4 1.4 0 2.1 3 3.1 
Rudat 1996 none       5.4 4.9 3.1 
Antolak 1998 ?       2.3 5.1 4 
Dawson 2000 
skeletal motion due to breathing - 
prone   
2.7-
13.1         
    
skeletal motion due to breathing - 
supine negligible       
Bieri 1996 non-rigid immobilisation (median)   0 5 0       
Malone 2000 Hipfix  2.6 2.3 1.9 1.8 1.8 1.4 
    alpha cradle 3.2 3.2 2.7 2.2 2.7 2.4 
    foam leg support (non-rigid)  3.4 3.2 3.2 2.9 2.5 2.9 
    
"reported estimates for non-
immobilised patients" 
1.6-
5.4 
2.4-
4.9 
2.8-
3.4       
Bayley 2004 supine Vac-loc device -0.1 -0.1   3.6 3.3   
    prone Hip-fix device 0.1 0   4.3 3.7   
Weber 2000 prone 0.8 -1.3   5.4 4.7   
    supine -knee bolster 1.7 -1.8   3.8 4.2   
Fiorino 1998 Pelvis immobilisation (mm) -1.6 2.5 0.4       
    Leg immobilisation (mm) -1.2 0.6 0.3       
    No immobilisation (mm) -1.4 1.1 -0.6       
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The results of the current study demonstrate a smaller mean uncertainty in only the 
SI and AP direction, compared to most studies that utilised rigid immobilisation 
devices such as alpha cradles and hip fix devices, however the SD is larger for all 3 
directions. Two possible explanations for these results being comparable to those 
reported for rigid immobilisation devices, include the use of a rigid couch top and 
using a fixed couch height. Bieri et al. (1996) also reported that a carbon fibre table 
top produced results comparable to rigid immobilisation devices due to the 
elimination of Mylar sag.  It has also been hypothesised that the movement of skin 
in the AP direction can be reduced by setting a fixed couch height and therefore 
reducing the uncertainty (Mubata et al. 1998). It is also possible that variation in the 
AP direction is due to weight loss, although the information necessary to confirm 
this relationship was not collated for our study. 
 
There was no correlation between patient habitus and the number of pre-treatment 
isomoves relative to bony anatomy seen in the results (Figure 8-21). Patient 
separation in the AP and Lateral directions also showed no relationship to the 
number of isomoves required (Figures 8-22 and 8-23). Therefore it does not seem 
possible to predict the patient population who may experience increased set-up 
variation and therefore need increased attention to the stabilisation method used for 
treatment. This is consistent with the results of Bieri et al. (1996) who found that 
weight and thickness did not influence set-up reproducibility, but contradicts the 
results of Song et al. (1996) who found increased lateral movement in larger 
patients. 
 
Although the calculation of systematic and random error is not one of the specific 
research questions of this thesis, the data collated from the daily set-up records 
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enabled these to be calculated. A detailed analysis of the causes of these errors is not 
be discussed in this thesis, but these calculations will assist in the discussion of 
hypothesis four in section 9.7 regarding whether the current instructions were 
adequate to maintain the planned dose distribution.  
 
The systematic setup error reported was very small, with the largest variation 
observed in the RL direction (-0.5mm) followed by the AP (-0.4mm) and SI 
(0.30mm) directions (Table 8-34). This low systematic error reflects the 
compatibility of the treatment couch and the couch used for the planning CT. The 
Tattersall’s Cancer Centre was only opened in 2004 and was equipped with state of 
the art equipment that had been designed for compatibility between planning and 
treatment.  
 
As expected the random error for this study was greatest in the AP direction 
(2.5mm) followed by the SI (2.0mm) and RL (2.0mm) directions (Table 8-35). The 
relatively larger random error in the AP direction resulted in the increased number of 
isomoves in this plane as reported earlier. However despite the RL direction having 
the largest systematic error, because the random component was small, the number 
of isomoves in the RL direction was less than the AP direction. This resulted in only 
5 more isomoves than the SI direction which had the lowest systematic but a similar 
random component.  
 
Hurkmans et al. (2001) completed a systematic review of set-up verification 
literature and found that systematic error ranged from 1-3.8mm (1SD) and random 
error ranged from 1.2-3.5mm. Table 9-3 demonstrates the systematic and random 
error reported in a selection of the articles reviewed by the author. When comparing 
the values reported in the literature and those reviewed by Hurkmans et al. (2001) 
 - 225 -
 
the systematic error in this study is lower than reported, possibly due to the carbon 
fibre tables used in both planning and treatment, but the random component falls 
within the reported range. 
Table 9 - 3: Systematic and Random errors as reported in the literature. 
 
 
Total set-up uncertainty, which combines systematic and random error in quadrature, 
was greatest in the AP direction (2.2-2.56mm) and very similar in the SI and RL 
direction. From the literature, systematic error was expected to be the largest 
component of total set-up uncertainty; however in all directions it was random error 
that was the largest component. This is important to consider for patients not having 
daily verification, because although systematic error may be minimised by having 
compatible equipment, random error will still occur. 
 
The frequency distribution for set-up uncertainty was normally distributed around 
zero (Table 8-37), which is consistent with the assumptions made in previous studies 
that set-up error is normally distributed in all directions (Rudat et al. 1996, Balter et 
al. 1993). Contrary to the findings of Antolak et al. (1998) we did not find the set-up 
accuracy in the AP direction to be negatively skewed. This may be due to the use of 
    
Random & Systematic error 
(mm)    Systematic   Random 
Author Year breakdowns of set-up errors SI AP RL SI AP RL 
Yan 1997 no immbilisation  3.8   3 1.5   1.6 
Nederveen 2003 Knee bolster 2.1 4.4 2.1 1.7 2.2 1.8 
McNair 2004 Beam Cath  <2 <2 <2 2.8 3.2 1.8 
Catton 1997 No knee support   
Mean = 2.9mm 
(range 0.5-8.8) 
Mean = 3mm (range 
0.2-8.4) 
    soft knee support  
Mean = 1.8mm 
(range 0-4.8) 
Mean = 2mm (range 
0-10.2) 
Weber 2000 Prone  4.1 2.7   3.7 4   
    Supine  2.2 1.9   3.3 3.6   
Fiorino 1998 Pelvis immobilisation (mm) 1.9 3.5 2.8 2.5 3.1 2.4 
    Leg Immobilisation 0.7 2.1 1.7 1.8 1.8 1.6 
    No immobilisation 2.5 2.7 3 1.8 2.5 2 
Stroom 1999 Supine (mm) 1.4 1.5 1.3 1.5 2.2 1.6 
    Prone (mm) 0.8 0.8 0.8 2.4 2.4 2.7 
    Average (mm) 2.17 2.45 2.10 2.30 2.78 1.94 
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a fixed couch height that minimises the effect of skin sag, and the use of a rigid table 
top. This study demonstrated excellent set-up reproducibility using a non-
customised stabilisation method.  
9.4 Aim 1: To increase knowledge of volume variations  
Authors of the published literature agree that the bladder and rectum volumes at the 
time of planning are merely a snapshot in time and that reproducibility of these 
volumes is becoming increasingly important as we reduce margins and introduce 
dose escalation. However there is much debate over the degree of volume variations 
and their effect on the overall treatment plan. The aim of this section is to examine 
the variations in bladder and rectal volumes for prostate cancer patients using the 
current treatment instructions, followed by an assessment of their effect on organ 
motion in section 9.5. Section 9.6 discusses the implication of volume variation on 
dose. Variations in prostate volume have also been presented in this section (9.4). 
 
During this study organ volumes were contoured on each CT data set by the PI and 
the absolute volume of each structure was recorded. The first aim of this thesis is to 
quantify the variations in bladder and rectal volumes for prostate cancer patients 
over an entire course of radiation therapy. No previous study is known where 
volume information has been collected on a daily basis. Although Wong et al. 
(2005) used the same equipment to perform daily verification of patients during their 
last five treatment fractions, variations observed in bladder and rectum volumes have 
not yet been published. Therefore this daily CT verification study over the entire 
course of treatment for 25 patients, provides new insight into the variations in 
volume that can be expected.  
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Patients in this study were asked to adhere to the current treatment instructions given 
to all prostate cancer patients treated at the five different PMCC sites. These 
instructions are the same as those used prior to the planning process which require 
them to drink 1L of water 30 minutes prior to their treatment, to continue a daily 
routine of taking a fibre supplement and to consume bland food only. These 
instructions have been described in detail previously in section 7.5.  
 
Although as discussed contouring variation can be significant, previously published 
studies into organ volume variation have neglected to incorporate estimates of 
contouring uncertainty into their results. To overcome this limitation this discussion 
has used the assessment of contouring uncertainty presented earlier to determine 
whether we can be confident that any of the volume variations observed are real.  
9.4.1 Hypothesis 1: Rectal volumes decrease 
There has been an abundance of literature published on the differences in rectal 
volume between planning and treatment (Melian et al. 1997; Miralbell et al. 2003a). 
Most demonstrate an observed decrease in rectal volumes over a course of radiation 
therapy (Antolak et al. 1998; Lebesque et al. 1995; Roeske et al. 1995; Zellars et 
al.2000). However much of this literature has been based on the periodic assessment 
of rectal volumes, not a daily analysis. Most of the studies reported in the literature 
also required the patient to attend an additional measurement session, raising 
questions over the application of these results to the volumes at the time of 
treatment. The three rectal structures contoured for this study; rectum solid, rectal 
wall and anal canal, will be discussed separately. 
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9.4.1a Rectum Solid 
The rectum solid volume was contoured around the external wall of the rectum and 
includes faecal contents and air. Table 8-38 demonstrated the rectum volume 
variations for the 25 patients recruited into this study. From this table the mean 
planned rectum solid volume was 89.4cc, with a SD of 45.7cc. The mean treatment 
rectum solid volume was 70.6cc with a SD of 19.7cc. This volume range is 
consistent with those reported in the literature. Roeske et al. (1995) reported the 
mean rectal volume for their series of patients was 79.2cc (range= 35-182cc), Tinger 
et al. (1998) reported a 76ml mean volume (SD= 34ml) and Lebesque et al. (1995) 
reported an average rectal volume of 94cc (SD= 31cc, range= 58-157cc). The 
variation in volume observed in this study is also consistent with the observations 
reported by Miralbell et al. (2003a), who found large variations in the rectum 
volume between planning and treatment (ratio =1.17, SD= 0.56) and by Melian et al. 
(1997) who reported significant variations in rectal volume between CT scans 
repeated weekly. 
 
Uncertainties due to contouring were estimated by Roeske et al. (1995) as at 8% of 
the average rectal volume, mainly due to inconsistencies in determining the SI 
borders. The contouring uncertainty results presented previously (section 8.2 & 9.2) 
reported that the 95% CI for contouring rectum volumes was ±8.1cc (2SD), which 
correlates to a variation of between 9.1% (planned volume) and 11.5% (mean 
treatment volume). When this uncertainty is applied to the mean planned (89.4cc 
±8.1cc) and treatment volume (70.6cc ±8.1cc) it does not account for all of the 
variation observed. Therefore it can be concluded that the difference between the 
planning volume and the mean treatment volume is as a result of a change in rectal 
volume rather than as a result of contouring uncertainty.  
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Table 8-38 also demonstrates the p-value for the slope of the graph that plots volume 
versus time for each individual patient. The p-value was used to test the null 
hypothesis that the slope is equal to zero. Seven out of the 25 patients experienced a 
statistically significant (p= <0.05) time trend for decreasing rectum solid volumes 
and therefore the null hypothesis that the slope is equal to zero can be rejected. 
However the R value, which quantifies the strength of the relationship, ranges 
between 0.36 and 0.60, indicating that at best only 36% (if R= 0.60, R²= 0.36) of the 
variation can be explained by a linear line of best fit. This is demonstrated by the 
volume variation observed in patient 6. Figure 9-7 demonstrates the difference 
between the planning and treatment rectum solid volumes over his course of 
radiation therapy. This figure demonstrates that the relationship is probably not 
linear, but is certainly difficult to extrapolate. 
Figure 9 - 7: Patient 6: The difference between planning and treatment rectum solid volumes. 
Patient 6: Difference between planning and 
treatment volumes: rectum solid  
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A decrease in rectum volume over time was not unexpected. The hypothesis that 
rectal volumes decreased was based on results published in the literature. The 
mechanism for decreased volumes during treatment is widely hypothesised as a 
result of radiation induced irritation. Lebesque et al. (1995) reported a time trend for 
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reducing rectal volumes of approximately 6% per week due to decreased rectum 
filling. Roeske et al. (1995) reported 70% of patients demonstrated a net decrease in 
rectal volume over the course of treatment. Zellars et al. (2000) reported a mean 
decrease in rectal volume to 82% of the pre-treatment volume on patients who were 
re-scanned during week 4-5. Antolak et al. (1998) found that rectum volumes 
decreased between the pre-treatment planning scan and the first on-treatment CT 
scan. However Antolak et al. (1998) repeated the on-treatment scans on three 
occasions and found that the rectum volume remained consistent on all the treatment 
scans. 
 
Three patients experienced a statistically significant time trend for increasing rectum 
solid volumes (p= <0.05). The R value for these patients were either 0.44 or 0.45, 
indicating once again that not all the variation can be described by a linear line of 
best fit. This is demonstrated by the volume variation observed in patient 3. Figure 
9-8 demonstrates the difference between the planning and treatment rectum solid 
volumes over his course of radiation therapy.  
Figure 9 - 8: Patient 3: Difference between planning and treatment rectum solid volumes 
Patient 3: Difference between planning and 
treatment volumes: Rectum solid
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Further investigation into the patients who demonstrated these trends for increasing 
volume found that patient 8 and 9 both had a reduced number of data points, 22 and 
24 fractions respectively. Data collection for Patient 8 was completed after fraction 
22. Patient 9 did not commence data collection until fraction 11 due to a machine 
breakdown (Figure 9-9 a & b). Therefore patient three was the only patient to 
demonstrate a time trend over the entire treatment course. Although the trends for 
the other two patients were statistically significant, caution should be used when 
interpreting their results as it is unclear what influence the remaining fractions would 
have had on the significance of their trends.  
Figure 9 - 9 a) Patient 8 b) Patient 9: Difference between planning and treatment volume: 
Rectum solid 
Patient 8: Difference between planning 
and treatment volume: Rectum Solid
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Patient 9: Difference between planning and 
treatment volume: Rectum Solid
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Although it was unexpected that three patients would demonstrate a statistically 
significant trend for increasing rectal volume, further investigation of the published 
literature found two articles that had also reported this observation. The previously 
discussed literature has reported that late in treatment the rectum tends to be empty 
and collapsed due to irradiation, however McLaughlin et al. (1999) who completed a 
study of 10 patients who had not been given specific bowel preparation instructions, 
also found that scans performed late in treatment consistently demonstrate large 
rectal volumes expanded by gas. Miralbell et al. (2003b) who performed weekly CT 
scans on 9 patients, found that patients with an initial rectal volume of <75cc 
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demonstrated a trend towards increasing rectal volumes. All three patients who 
demonstrated increasing volumes in this study had a planning rectum volume of 
<75cc. However so did 3 of the patients who demonstrated a time trend for 
increasing volume and 4 patients who demonstrated no statistically significant time 
trend. Therefore it cannot be concluded that a planning volume of <75cc will always 
lead to increasing volumes.  
 
The remaining 15 patients had p-values >0.05 and therefore we cannot be confident 
that the slope is equal to zero. For these 15 patients it can be concluded that no time 
trend for rectum solid volumes during their course of radiotherapy was 
demonstrated. It should also be noted that patients 10 and 11 were also affected by 
the prolonged machine breakdown and therefore had a reduced number of data 
points. Although these patients did not demonstrate significant trends, once again it 
is unclear whether this missing data has affected any trends.  
 
The normalised rectum solid volumes for each patient were combined to calculate 
the average rectum solid volume and then plotted as a function of time (Figure 8-
25). With a p-value = 0.00 and R= 0.66, it can be concluded that for this group of 
patients there was an average decrease in rectal volume over a course of radiation 
therapy. 
 
The results of this IGRT study do not conclusively prove that the rectum solid 
volumes decrease over a course of radiation therapy. Compared to the literature, 
only 28% of our patients demonstrated a statistically significant decrease in volume 
over time compared to Roeske et al. (1995) who reported that 70% of patients 
demonstrated a net decrease in rectal volume over the course of treatment. Unlike 
Lebesque et al. (1995), who reported a 6% decrease in rectum filling per week, we 
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only observed an average decrease of approximately 20% during treatment, which 
was similar to that reported by Zellars et al. (2000). Unexpectedly, 60% of our 
patients did not demonstrate any statistically significant time trends of changing 
rectum solid volumes. It is hypothesised that the decreased variation observed in our 
patients occurred as a result of the bowel preparation instructions given to the 
patient, something that was not reported in the three previously mentioned published 
articles. The bowel preparation taken by the patients was a fibre supplement which 
was expected to minimise the rectal volume by ‘de-bulking.’ Since it has been 
reported that rectal volumes were decreased at the end of treatment, using a de-
bulking agent at the time of planning to reduce the rectum volume should 
hypothetically minimise the volume variations observed during treatment. Our 
results seem to support this hypothesis. 
 
The decrease in volume during treatment compared to the planning volume is 
demonstrated by comparing the mean treatment volume (70.6cc, SD = 19.7) to the 
mean planned volume (89.4cc, SD= 45.8). This comparison indicates that there is a 
systematic difference between the rectum solid volume at the time of planning and 
the volume during treatment (Figure 8-26). If a contouring uncertainty of ±8.1cc is 
once again, considered Figure 8-26 indicates that 17 of 25 patients had a systematic 
volume variation that could not be attributed to contouring uncertainty alone. This 
result is supported by the findings of Lebesque et al. (1995). They reported that the 
planning CT overestimates rectum filling during treatment, with the largest 
treatment variation seen in patients with large initial rectum volumes. According to 
their findings patients with volumes greater than approximately 200cc were 
considered large and resulted in increased variation. 
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The relationship between systematic error and planned volume was investigated. 
Although it is recognised that variations in the volume of interest size are a result of 
pathophysiological changes, and as such are not necessarily an error that can be 
controlled, from a statistical viewpoint these variations will be referred to as 
systematic errors throughout this thesis.  
 
A regression analysis on the slope of Figure 8-27 resulted in R= 0.91 and p= 0.00. 
These results indicate that there is a very strong relationship between the planned 
volume and systematic error. When a systematic error of zero is substituted into the 
line of best fit equation it results in a planning rectum solid volume of 62.8cc. The 
contouring uncertainty can be applied around this volume (62.8cc ± 8.1cc) to 
calculate a range that represents the ideal planning rectum solid volume. Planning 
volumes that fall outside this range have an increased probability of systematic 
errors in rectum volume during treatment.  
 
This concept was raised by Tinger et al. (1998) who suggested that planning 
radiation therapy treatments on CT scans that demonstrate organs with extreme 
filling, should be avoided. Instead they recommended that the planning scan be 
repeated. However they gave no guidelines on what volume was considered 
extreme. Another reason to reduce planning rectal volumes is that Zelefsky et al. 
(1999) found that a rectal volume >60cc was a predictor of systematic deviations in 
prostate motion of greater than 3mm. Their findings support the conclusion drawn 
from our results that patients who have volumes smaller than 54.6cc or larger than 
70.9cc, are expected to have large systematic errors. In clinical practice if patients 
have planned rectum volumes that fall outside this range they should be re-scanned 
to confirm the volumes. 
 
 - 235 -
 
The change in volume during treatment is quantified by calculating the random 
error. Random error is the SD of the mean treatment volume. Figure 8-28 
demonstrates the random error for each patient. If a contouring uncertainty of ±8.1cc 
is once again considered, Figure 8-28 indicates that 23 of 25 patients had random 
volume variation that could not be attributed to contouring uncertainty alone. 
 
The relationship between random error and planned volume was also investigated. A 
regression analysis was performed on the slope of Figure 8-29. There was a 
statistically significant linear relationship between planned volume and random error 
(p= 0.02) however the strength of this relationship is much weaker than that seen for 
systematic error (R= 0.47).  
 
Another measure of variation is the maximum and minimum rectum solid volumes 
observed during treatment for each patient (Table 8-39). The average maximum and 
minimum rectum solid volumes indicate that the treatment volume ranged between 
174% and 58% of the planned volume. Roeske et al. (1995) also reported individual 
volume fluctuations of up to 50% of the average volume. However the extreme 
fluctuations in volume for patients in this IGRT study ranged from 342% (patient 
14) to 27% (patient 10) of the planned volume. Table 8-39 also demonstrates that 
patients 10, 11 and 16 had a planning rectum solid volume larger than all treatment 
volumes and patient 17 had a planned volume smaller than all treatment volumes. 
This was expected since all these patients demonstrate large systematic error (Figure 
8-26). 
9.4.1b Rectal Wall 
Table 8-40 demonstrates the rectal wall volume variations for the 25 patients 
enrolled in this study. The mean rectal wall volume was 42.4cc with a SD of 11.3cc. 
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The mean treatment volume was 46.8cc (SD= 12.2cc). Lebesque et al. (1995) 
reported an average rectal wall volume of 44cc (SD= 10cc, range = 29-58cc).  
 
The contouring uncertainty results presented previously (section 8.2 & 9.2) did not 
include an assessment for the rectal wall. If the 8% contouring uncertainty for the 
rectum solid was applied to the rectal wall, it would result in an uncertainty of 3.4-
3.8cc. There is limited literature on the uncertainty associated with rectal wall 
volumes. Lebesque et al. (1995) reported only a 1% difference between the planning 
scan and average volume and this was potentially attributed to contouring 
uncertainty. However Lebesque et al. (1995) only compared the volumes for an 
additional 3 CT scans performed periodically during treatment, which is not as 
reliable as the patient data sets for this study which include up to 37 additional CT 
scans per patient.  
 
Table 8-40 contains the statistical results for the graphs which plotted volume versus 
time for each individual patient. The p-value was used to test the null hypothesis that 
the slope was equal to zero. One out of twenty five patients experienced a time trend 
(p = <0.05) for decreasing rectal wall volumes and 10 patients demonstrated 
increasing rectal wall volumes throughout their course of treatment. The remaining 
14 patients had p-values >0.05 and therefore it could not be concluded that the slope 
was equal to zero.  
 
The R value quantifies the strength of the relationship ranged between 0.35 and 0.81 
for patients who had a p-value <0.05, indicating that not all the variation can be 
explained by a line of best fit. This is demonstrated best in Figure 9-10 which plots 
the difference in rectal wall volume between each treatment fraction and the initial 
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planned volume for patient 6. Patient 6 showed the strongest time trend yet only 
66% of the variation can be explained by a linear line of best fit (R²= 0.66). 
Figure 9 - 10: Patient 6: The difference between planning and treatment rectal wall volumes. 
Patient 6: Difference in volume between planning 
and treatment y = 0.6561x + 4.016
R2 = 0.6609
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Once again patients 8 and 9 who had a decreased number of observations 
demonstrated an increase in volume over time. However unlike the rectum solid, 
there are 8 other patients who also demonstrate this trend. Therefore even if the 
results of these two patients may not be as reliable as those patients who had 
observations for their entire course of treatment, there still appears to be a trend for 
increasing volume over time.  
 
The increase in volume observed in the individual patient is confirmed by Figure 8-
30 which plots the average normalised rectal wall volume for all 25 patients as a 
function of time. This figure shows that for this group of patients there was a 
statistically significant increase in volume over time, p-value =0.00, R= 0.79. This 
finding of increasing volumes is not supported by the literature. Lebesque et al. 
(1995) reported that rectal wall volumes were relatively consistent during treatment 
and were not biased by the amount of rectal filling. They observed no increase or 
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decrease in rectal wall volume, only a 1% difference between the planning scan and 
average volume which was attributed to contouring uncertainty. 
 
The increase in rectal wall volume is also demonstrated by the systematic error 
between the planning volume and average treatment volume (42.4cc compared to 
46.8cc). Figure 8-31 demonstrated the systematic error for each individual patient. If 
we assume that the contouring uncertainty for the rectal wall is the same as the 
rectum solid (8%), Figure 8-31 demonstrates that 17 of 25 patients had systematic 
variation of greater than 3.7cc. Therefore we can be 95% confident that the variation 
seen in these 17 patients cannot be attributed to contouring uncertainty alone. 
 
The relationship between systematic and planned volume was investigated. Unlike 
the rectum solid, there was no significant relationship between the planned rectal 
wall volume and the probability of systematic error.  
 
The change in volume during treatment is quantified by calculating the random 
error. Figure 8-33 demonstrated the random error for each patient. If a contouring 
uncertainty of 3.7cc is once again considered, then 22 of 25 patients demonstrated a 
random variation that cannot be explained by contouring uncertainty alone. 
 
The relationship between random error and planned volume was also investigated. A 
regression analysis on the slope of Figure 8-34 resulted in a p-value of 0.045 and R= 
0.40. Although we can conclude with 95% confidence that there is a relationship 
between the two, the strength of this relationship is weak. However it does indicate 
that smaller rectal wall volumes have a decreased probability of random error, which 
supports the discussion earlier that the rectum solid volume should be minimised to 
reduce the probability of systematic errors. 
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The final measure of rectal wall variation presented in the results was the maximum 
and minimum volumes experienced during treatment for each patient (Table 8-41). 
Unlike Lebesque et al. (1995) who reported only a 1% difference between the 
planning scan and average volume, the variation in this study ranged from 144% to 
83% of the planned volume. On the basis of their results Lebesque et al. (1995) 
concluded that DVH analysis should be conducted on rectal wall volumes to reduce 
the effect of rectal filling. Despite the increased variation observed in this IGRT 
study compared to Lebesque et al. (1995), it is still less than that observed for the 
rectum solid (174% to 58%), therefore if the rectum wall volume is used for 
calculating the planning DVH it may more accurately represent the dose delivered 
during treatment.  
9.4.1c Anal Canal 
Table 8-42 demonstrated the anal canal volume variations for the 25 patients 
enrolled in this IGT research study. From this table the mean planned anal canal 
volume was 9.3cc with a SD of 3.8cc. The mean treatment anal canal volume was 
8.6cc (SD = 2.4cc). Unlike the rectum solid and rectal wall there were no published 
articles found on the variation that could be expected for the anal canal volumes 
during treatment. 
 
The uncertainty associated with contouring the anal canal was 2.7cc (2SD) as 
reported in sections 8.2 and 9.2. When this is applied to the mean planned volume 
(9.3cc ±2.7cc) and the mean treatment volume (8.6cc ±2.7cc) more than 95% of the 
variation can be attributed to contouring uncertainty. 
 
Table 8-42 also demonstrates the p-value for the slope of the graphs that plot volume 
verses time for each individual patient. The p-value was used to test the null 
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hypothesis that the slope was equal to zero. 6 patients demonstrated a statistically 
significant (P <0.05) time trend for increasing anal canal volumes and 5 patients 
demonstrated a trend for decreasing volumes, but there was an overall increase in 
volume. The remaining 14 patients did not demonstrate any significant time trends. 
 
Once again the strength of the trends seen varies (R ranging from 0.33 to 0.66). The 
strongest trend was observed in patient 5 where 44% of the relationship was 
explained by a linear time trend (Figure 9-11, R²= 0.44), although this patient is not 
representative of the overall increase in average volume. 
Figure 9 - 11: Patient 5: The difference between planning and treatment anal canal volumes. 
Patient 5: Difference in volume between planning 
and treatment y = -0.1457x - 4.4113
R2 = 0.4387
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A weaker correlation between time and volume was observed when the normalised 
volumes for each patient were plotted (Figure 8-35). Unlike the rectum solid and 
rectal wall, the average anal canal volume showed a statistically significant increase 
in volume over time (p= 0.00) however only 5% of the variation could be explained 
by a linear relationship (R²= 0.05). 
 
The increase in anal canal volumes over a course of treatment can be demonstrated 
by comparing the mean treatment volume to the planned volume. This measure of 
systematic error was plotted for each individual patient (Figure 8-36). If a 
 - 241 -
 
contouring uncertainty of 2.7cc is considered, at the 95%CI, 20 patients experience a 
systematic error that can be explained solely by contouring uncertainty. Similarly 24 
of 25 patients had random variation less than the reported contouring uncertainty 
(Figure 8-38). Therefore it can be concluded with 95% confidence that the variation 
in anal canal volumes observed during this study was a result of contouring 
uncertainty and not as a result of changes in volume during treatment.  
9.4.2 Hypothesis 2: Bladder volumes fluctuate 
As with the rectum there have been many articles that have published the results of 
studies examining the difference in bladder volume between planning and treatment 
(Antolak et al. 1998; Beard et al. 1996; Fokdal et al. 2004; Lebesque et al. 1995; 
Mechalakos et al. 2002; McLaughlin et al. 1999; McNair 2004; O’Doherty et al. 
2003; Roeske et al. 1995; Tinger et al. 1998; Zellars et al. 2000). However unlike the 
rectum, where the majority of the literature supported the hypothesis that volumes 
decreased throughout a course of radiation therapy, there is no consensus in the 
literature on whether bladder volumes follow time trends. Antolak et al. (1998), 
O’Doherty et al. (2003), McNair (2004), McLaughlin et al. (1999) and Lebesque et 
al. (1995) reported that patients experience a decrease in bladder volume. Roeske et 
al. (1995) also reported that one in two patients demonstrated a time trend for 
decreasing bladder volume, whist the remaining authors demonstrated a general 
increase. Fokdal et al. (2004) also reported an increase in bladder volume during 
treatment, whilst Beard et al. (1996) concluded that any changes in bladder volume 
during week 4 of treatment were only small.  
 
As discussed earlier, the rationale behind treating patients with a full bladder is that 
it displaces the dome of the bladder from the target volume and therefore reduces 
treatment related toxicity. Patients enrolled in this study were given the standard 
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treatment instruction that required them to drink 1L of water, 30 minutes prior to the 
treatment appointment. Hypothesis 2 tested whether the bladder volume fluctuated 
during treatment, despite the patient being given instructions to drink a set amount 
of fluid 30 minutes prior to their appointment. Variation in volume is not necessary a 
result of variations in the amount of fluid drunk by the patient, but could also be due 
to the timing of micturition and other fluids drunk throughout the day. A decrease in 
volume over the treatment course may be a result of acute urinary side effects of the 
radiation therapy. 
 
Table 8-43 demonstrated the bladder volume variations for the 25 patients enrolled 
into this IGRT study. From this table the mean bladder volume for this study was 
184.9cc (SD 105.1cc) with a range between 59.4cc and 480.1cc. The mean treatment 
volume was 175.4cc (SD= 86.4cc) and ranged between 88.6cc and 515.7cc. This is 
consistent with the bladder volumes reported in the literature. O’Doherty et al. 
(2003) used weekly ultrasound measurements and found that there was a significant 
decrease in average bladder volume between the planning CT and treatment from 
415ml to 250ml. Tinger et al. (1998) reported a mean bladder volume of 157ml 
(SD= 65ml) for patients who had also been instructed to have a full bladder. McNair 
(2004) reported a mean treatment bladder volume of 260ml (SD= 135ml) compared 
to a mean volume of 279ml during the planning scan. Lebesque et al. (1995) 
reported that an average bladder volume of 220cc with the SD of 89cc (range 94-
317cc). Lebesque et al. (1995) also reported that patients who were requested to 
have a full bladder, demonstrated a 4% decrease in volume over the course of their 
treatment. Zellars et al (2000) reported a mean decrease in bladder volume to 51% of 
the pre-treatment volume on patients who were re-scanned during week 4 or 5 of 
treatment. Roeske et al. (1995) reported a bladder volume range of 70-509cc with an 
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average volume of 187cc for patients with a full bladder. They also reported that 
absolute bladder volumes varied significantly, with a SD of between 25-30% of the 
average volume. In this IGRT study the SD of the treatment volume was nearly 50% 
of the average treatment volume.  
 
Uncertainty associated with contouring the bladder at the 95%CI was reported in 
sections 8.2 and 9.2 as being equivalent to ±12.2cc (2SD). When this uncertainty is 
applied to the mean planned bladder volume (84.9 ±12.2cc) and the mean treatment 
volume (175.4 ±12.2cc), it can be concluded with 95% confidence that the variation 
between the mean volumes is due to contouring uncertainty. 
 
Table 8-43 also demonstrates the p-value for the slope of the graph that plots volume 
versus time for each individual patient. The p-value was used to test the null 
hypothesis that the slope was equal to zero. 5 of 25 patients demonstrated a 
statistically significant (p <0.05) time trend for decreasing bladder volume over a 
course of treatment. The R values for these 5 patients ranged from 0.37 to 0.54, 
indicating that the strength of the relationship was not strong. This is demonstrated 
by the volume variation observed in patient 6 (Figure 9-12). Patient 6 demonstrated 
the strongest correlation, however only 29% of the variation can be explained by a 
linear time trend (R²= 0.29). 
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Figure 9 - 12: Patient 6: The difference between planning and treatment bladder volumes. 
Patient 6: Difference in volume between planning 
and treatment
y = -3.6044x - 56.519
R2 = 0.2927
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The fact that 5 of 25 patients demonstrated a decrease in bladder volume over the 
duration of their treatment, and that no patients demonstrated a statistically 
significant increase in bladder volume, indicates that patients have difficulty in 
maintaining a full bladder during treatment. The hypothesis proposed for this 
observation is that the bladder is emptier as treatment progresses, as a result of 
irritation and the patient’s inability to accurately comply with the treatment 
instructions. It is also possible that those patients with large planning bladder 
volumes, started drinking earlier, or were kept waiting longer, prior to their planning 
appointment when compared to their treatment appointments. Most patients are 
nervous prior to their planning appointment and are anxious to ensure that they have 
drunk enough water. However once they become familiar with the treatment process 
it is possible that they pay less attention to the instructions that they were given.  
 
The normalised bladder volumes for each patient were combined to calculate the 
average change in bladder volume for each fraction and then plotted as a function of 
time (Figure 8-40). When all patients are grouped together the correlation co-
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efficient demonstrates a much stronger relationship for decreasing bladder volumes 
over time than that seen for any of the individual patients (p= 0.00, R= 0.56).  
 
The decrease in bladder volume between treatment and planning is demonstrated by 
analysing the systematic error (Figure 8-41). If a contouring uncertainty of ±12.2cc 
is considered, at the 95%CI, 20 of 25 patients had a systematic variation that could 
not be explained by contouring uncertainty alone. Antolak et al. (1998) also reported 
a systematic error, with the bladder volumes decreasing between the pre-treatment 
planning scan and the first on-treatment CT scan. Although McLaughlin et al. 
(1999) did not provide their patients with any specific treatment instructions, they 
also found that bladder volumes were consistently smaller late in the treatment 
course. Therefore since the volume of the bladder is not reproducible when patients 
are given instructions to have a full bladder or when they are given no instructions at 
all, hypothetically this may lead to the conclusion that patients should be instructed 
to have an empty bladder. By asking patients to void immediately prior to treatment, 
hypothetically it may be possible to more accurately control the volume of the 
bladder. 
 
Several authors have reported that their patients were instructed to have an empty 
bladder. Beard et al. (1996) reported only very small bladder volume changes 
between the planning scan and a single additional scan performed during week 4. 
The study was based on the results of 30 patients who were asked to have an empty 
bladder, however the study does not have the same power to detect variations in 
bladder volume because it had much more limited imaging. We have demonstrated 
that the bladder volume varies on a daily basis, something that could not be 
demonstrated by Beard et al. (1996) who used only one additional CT scan. It is also 
possible that the patients in that study took additional care to follow their bladder 
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filling instructions as they only underwent one additional scanning procedure, 
whereas the patients in our study were being scanned daily during the same session 
as their treatment delivery. It is possible that patients in our IGRT study were less 
likely biased by their need to ‘please’ the researchers as the study was conducted 
over an extended period of time. 
 
Fokdal et al. (2004) also reported results for patients who were instructed to void 
prior to scanning. Of the 15 patients in their study, they found that 87% had a post-
void bladder volume ranging between 10-200ml, with a mean volume of 63ml, and 4 
patients had a residual urine volume of >150ml despite the instructions to empty 
their bladder. They also found using four repeat scans that 54% of patients 
experienced an increase in bladder volume during treatment. Mechalakos et al. 2002 
also found that bladder volume increased compared to the planning scan. They 
hypothesised that this increase in bladder volume may reflect partial urinary 
retention and obstructive urinary symptoms. Mechalakos et al. (2002) also 
recognised that it might be as a result of poor monitoring of adherence to treatment 
instructions. Therefore it appears that patients have difficulty reproducing the 
planned bladder volume despite the instructions they are given. 
 
The relationship between systematic error and planned bladder volume indicates that 
there is a strong relationship between the two (p= 0.00, R= 0.71). It appears from 
Figure 8-42 that a large volume at the time of planning overestimates the bladder 
filling observed during treatment and conversely a small bladder volume at the time 
of planning underestimates the volume during treatment. This is consistent with the 
literature discussed previously. Lebesque et al. (1995) reported the largest patient 
variation was seen with patients with large initial filling volumes. They reported that 
similar to the rectum, the planning CT overestimates bladder filling during 
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treatment, and patients with an initial bladder volume greater than 561cc had a larger 
volume variation during treatment. These results support McLaughlin et al.’s (1999) 
argument against overfilling the bladder at the time of the planning CT, because it 
cannot be reproduced late in treatment. 
 
To minimise the systematic variation seen in bladder volumes, in theory an ideal 
planning volume can be calculated. When a systematic error of zero is substituted 
into the line of best fit equation it results in a planned bladder volume of 173cc. The 
contouring uncertainty can be applied around this volume (173 ± 12.2cc) to calculate 
a range that represents the ideal planning bladder volume. Planning volumes that fall 
outside this range have an increased probability of systematic errors, as 
demonstrated in Figure 8-42. At the time of planning, if the bladder volume is 
outside this specified range, consideration should be given to repeating the planning 
scan and providing the patient with more definitive instructions on bladder filling.  
 
On further analysis of systematic error, patient 4 demonstrates the largest systematic 
error due to the relatively small planned bladder volume (173.4cc) when compared 
to the mean treatment volume (515.67cc). Based on the fact that the planned bladder 
volume was smaller than all of the treatment bladder volumes it would be a 
reasonable assumption that this patient did not follow the instruction to drink 1L of 
water 30 minutes prior to their planning time. If the outlier of patient 4 is removed 
(Figure 9-13), the correlation between planned volume and systematic error 
increases from 50% (R²= 0.50 for Figure 8-42) to 78% (R²= 0.78 for Figure 9-13) of 
the variation explained now by a linear relationship.  
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Figure 9 - 13: Relationship between planned bladder volume and systematic error; Patient 4 
removed. 
Planned Bladder volume vs. systematic error
Patient 4 removed
y = -0.784x + 121.14
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The intercept along the X axis of Figure 8-42 indicated that the ideal bladder volume 
at the time of planning to minimise systematic volume variation was 173cc, however 
after the data point for patient 4 is removed (Figure 9-13), the intercept now 
indicates the ideal planned bladder volume is 155cc. I suggest that patients who have 
a planning bladder volume that falls within a range of 150 – 180cc would minimise 
the systematic variation observed during treatment. 
 
The variation in bladder volume during treatment is quantified by calculating the 
random error. Figure 8-43 demonstrated the random error for each patient. If a 
bladder contouring uncertainty of 12.2cc is once again considered, Figure 8-43 
indicates that all of the patients had random error greater than the uncertainty 
associated with contouring. This indicates that the variations in bladder volume were 
indeed a result of variations in volume, rather than intra-observer contouring 
variation. Melian et al. (1997) also found that total bladder volumes showed marked 
variation from scan to scan when performed weekly. As a result Melian et al. (1997) 
attempted to reduce the variation in bladder volume by asking patients to void prior 
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to the scan, but as discussed already this does not necessarily lead to increased 
bladder volume reproducibility. 
 
The relationship between random error and planned volume was demonstrated in 
Figure 8-44. A regression analysis was performed on this relationship. Although the 
p-value indicates a statistically significant relationship between the two variables 
(p= 0.01) the strength of this relationship is very weak, with only 7% of the variation 
being explained by a linear line of best fit (R= 0.27, R²= 0.07). However when 
looking at Figure 8-44 it is obvious that two outliers affect the strength of the 
relationship between random error and planned volume. 
 
Patient 4 was removed from the systematic variation analysis based on the 
hypothesis that his planned volume was an outlier due to the patient not following 
the instructions to drink 1L of water. However from Figure 8-43 it is clear that 
patient 4 also demonstrated the largest random variation during treatment (172.1cc), 
indicating that the patient was consistently unable to follow these instructions. 
Patient 19 was the other patient with an outlier on Figure 8-44 (R²= 0.07). Whilst 
Patient 19 did not demonstrate a large systematic volume variation, he did 
demonstrate large random bladder volume variations also indicating that he was 
unable to follow the treatment instructions. Figure 9-14 demonstrates the 
relationships between random error and planned volume with the two outliers 
removed (R²= 0.27). Although this increases the linear correlation between the two 
variables from 7% to 27%, the relationship is still weak. 
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Figure 9 - 14: Relationship between Bladder volume and random error with outliers removed 
Planned Bladder volume vs. random error
Patient 4 and 19 removed
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The presence of random errors in this IGRT study does not support the conclusion 
by Antolak et al. (1998) who conducted on-treatment scans on three occasions and 
found that the bladder volume remained consistent on all the treatment scans. 
(Mechalakos et al. (2002) also reported that bladder volumes remained fairly 
constant during treatment. However O’Doherty et al. (2003) reported that patients 
often have difficulty sustaining a full bladder due to a combination of factors 
including previous diagnostic procedures and treatment induced side effects as well 
as a disregard of bladder filling instructions. Interestingly, they also reported a 
strong correlation between the measured bladder volume and patient assessment of 
their bladder filling. They concluded that although patients were unable to comply 
with the bladder instructions, they were accurately able to assess their bladder 
fullness. Improved patient bladder filling instructions and paying more attention to 
the patient’s assessment of their daily bladder filling, may further reduce random 
fluctuations, although this hypothesis will need to be verified by further research. 
 
Of greater clinical significance are the fluctuations in bladder volume seen 
throughout the treatment course, despite the patients being given instructions on the 
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amount of water to consume prior to each appointment. Despite a low mean 
systematic error (-9.6cc) a mean random error of 69.3cc indicates that there are large 
fluctuations in bladder volume during treatment. The mean maximum fluctuation in 
bladder volume was 221%, and mean minimum fluctuation in bladder volume was 
54%, when compared to the planned bladder volume. However there were extreme 
fluctuations in bladder volume seen during this study with patient number 19 
demonstrating a 516% increase in his planned bladder volume and patient number 9 
demonstrating a decrease in his planned bladder volume to 8% of the initial volume. 
Unfortunately due the lack of accurate symptom reporting it is not possible to assess 
whether pre-treatment urinary symptoms or the onset of acute side effects influenced 
bladder volume variation for patients participating in this study.  
 
Despite the results of this IGRT study demonstrating that bladder volumes vary 
significantly on a daily basis, the clinical importance of maintaining a full bladder is 
based on the assumption that bladder volume effects the location of the prostate 
within the pelvis and therefore influences the accuracy with which the planned dose 
can be delivered. The effect that the bladder volume fluctuations observed in this 
study have on prostate COV motion, will be analysed later in section 9.5 and their 
effect on dose will be analysed in section 9.6. Should variations in bladder volume 
prove not to effect the prostate COV location or the dose delivered, perhaps less 
emphasis should be placed on giving patients unnecessary instructions. 
9.4.3 Prostate volume variation. 
Quantifying prostate volume variation was not one of the initial aims of this research 
and therefore there was no hypothesis being tested. However early results indicated 
that the prostate volume was changing over time and warranted further investigation 
as part of this thesis.  
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Table 8-45 demonstrated that the mean planned prostate volume for this study was 
33.7cc (SD= 12.7cc) with a range between 14.1cc and 68.8cc. The mean treatment 
volume was 32.4cc (SD= 12.8cc, range = 15.3cc -72.8cc). The prostate volumes for 
the patients in this study were smaller than those that have been reported in the 
literature. Roeske et al. (1995) reported an average prostate volume of 56cc, with 
individual patients ranging between 30-115cc for the 10 patients in their study that 
used weekly CT images. Zellars et al. (2000) reported a mean prostate volume of 
78.9cc, ranging from 53.4cc to 108.2cc. Although these smaller volumes may 
indicate a systematic underestimation of the prostate volume by the PI, the inter-
observer contouring comparison from section 9.2 contradicted this with the volumes 
by the PI being consistently larger than those of the consultant RO.  
 
The mean planned volume and the mean treatment volume only demonstrate a very 
small change in prostate volume over a course of radiation therapy (1.3cc). Similar 
to this IGRT study, Roeske et al. (1995) and Miralbell et al. (2003a) used weekly CT 
scans to establish that the treatment prostate volume was nearly identical to the 
planning volume. Zellars et al. (2000) also reported a median volume change of only 
-4.6cc in the 24 patients that had a CT scan during the 4-5th week of treatment. 
However there was no scan at the completion of treatment to assess if the prostate 
volume decreased towards the end of treatment.  
 
The certainty with which this trend can be considered as ‘real’ is minimised by the 
same trend being observed during the assessment of contouring uncertainty. During 
the contouring uncertainty assessment, the prostate volume was shown to have 2SDs 
of 10.9cc, which equated to a 95% confidence. This uncertainty is much greater than 
the variation observed between the mean planning volume and mean treatment 
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volume which indicates that the prostate volume variation observed in this study 
occurs as a result of contouring uncertainty. However the initial estimate of 10.9cc 
was also based on an average prostate volume of 53.8cc, whereas the mean prostate 
volume for the 25 patients in this study is only 33.7cc, meaning that contouring 
uncertainty is equivalent to approximately 33% of the volume. Therefore the 
estimate of contouring uncertainty that will be used for this discussion will be 
calculated as a ratio of the difference between the volumes. This still results in an 
uncertainty of 6.9cc, or 20% of the mean volume. Despite this correction to the 
uncertainty associated with prostate contouring, at the 95%CI, the variation in 
prostate volumes still appears to occur as a result of contouring uncertainty and not 
as a result of volume changes. However some of the other results presented 
contradict this conclusion.  
 
The difficulty in assessing contouring uncertainty is compounded by the fact that 
intra-observer uncertainty was measured over a 12 month period, whereas the 
contouring performed on each of the patients in this study was performed over a 
maximum period of two months. When considering the changes in contouring 
demonstrated in section 8.2, it is obvious that the change in volumes from one 
occasion to the next are not as significant as the change from occasion one to 
occasion fifteen. Therefore the trends seen over the 12 month contouring uncertainty 
study may not be applicable to the individual patients. The initial increase in 
volume, followed by a gradual decrease was also not observed during the intra-
observer contouring uncertainty study, which indicates that this increase in volume 
may not be a result of contouring uncertainty.  
 
Despite there being only a small variation between the mean planned and treatment 
volumes 18 of 25 patients demonstrated a statistically significant (p<0.05) time trend 
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for changes in prostate volume. As highlighted on Table 8-45, 15 patients 
demonstrated a trend for decreasing prostate volume whilst 3 patients demonstrated 
increasing prostate volumes. The strength of this relationship is determined by the R 
value variation, between 0.37 and 0.83. Of the patients who demonstrated an 
increase in volume only patient 11 was missing a substantial number of data points 
(fractions 1-11) which may have decreased the validity of the trend. The other 2 
patients offer no obvious explanation for an increase in prostate volume.  
 
A statistically significant (p<0.05) decrease in prostate volume over time was also 
demonstrated when the prostate volumes for all patients were normalised and then 
plotted (Figure 8-45). This figure demonstrates that 69% of the variation in prostate 
volumes can be explained by a linear time trend (R²= 0.69). Instead of following a 
complete linear trend, the slope of Figure 9-15 demonstrates an initial increase in 
prostate volume with a peak at about 2 weeks, then a steady decline before levelling 
off towards the end of treatment. The last 2 fractions do show an increase in volume, 
however some patients only had 35 fractions and therefore there were fewer data 
points and this may have had influence on the slope. This is reflected by a higher 
percentage of the variation being explained by a polynomial trend line using an 
order of 3 (R²= 88%).  
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Figure 9 - 15: Average change in prostate volume 
Average change in Prostate Volume
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The prostate has a slow mitotic rate compared to the rectum and therefore a rapid 
decrease or increase in the number of cells is not expected. However benign 
hyperplasia of the prostate occurs naturally in elderly men. Hyperplasia is not an 
increase in the number of cells but an increase in cell size. One explanation for the 
initial increase in prostate volume may be an increase in hyperplasia as a result of 
exposure to low levels of radiation. Then after 2 weeks, hypothetically, the cells 
slowly shrink reducing the amount of hyperplasia. Another hypothesis is that in the 
first two weeks there is an increase in inflammation and oedema within the prostate. 
These hypotheses cannot be verified without histological analysis and therefore the 
pathological reasons for the change in volume observed are inconclusive. 
 
The fact that this trend for decreasing prostate volumes over time was observed 
during the intra-observer study also appears to confirm the conclusion that the 
variation in prostate volumes observed in the 25 patients was at least partly the result 
of contouring uncertainty, particularly given the relative difficulty in contouring the 
prostate compared with other pelvic structures. However the intra-observer study 
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demonstrated a decrease in volume for all five patients which does not explain why 
3 patients in the IGRT study demonstrated increasing prostate volume.  
 
One explanation is that the contouring in the intra-observer study was performed 
over a period of 12 months compared to a maximum contouring period of only 2 
months for the 25 patients enrolled in this IGRT study. When the intra-observer 
variation results are assessed using only the first 2 months data points (initial and 
repeats 1-5) the strength of the time trend decreases. In fact none of the patients 
demonstrate a statistically significant time trend for decreasing prostate volumes and 
the time trend for patient 1 changed direction (Table 9-4). 
Table 9 - 4: Comparison of intra-observer prostate contouring time trends over 12 and 2 
months. 
 All occassions First 2 months  
Patient R p-value trend R p-value trend 
1 0.83 0.00 decrease 0.42 0.41 increase 
2 0.94 0.00 decrease 0.81 0.05 decrease 
3 0.86 0.00 decrease 0.08 0.88 decrease 
4 0.86 0.00 decrease 0.53 0.28 decrease 
5 0.88 0.00 decrease 0.47 0.35 decrease 
 
Figure 8-45 demonstrated the average prostate volume varied between +5% and -8% 
of the planned volume. Table 8-46 demonstrates that the maximum prostate volume 
for patient 7 was 132% of the planned volume and the minimum prostate volume for 
patient 2 was 46% of the planned volume. On average the maximum and minimum 
prostate volume as a percentage of the planned volume were 113% and 81% 
respectively.  
 
Large variations in prostate volume have been reported previously. In 1995 Roeske 
et al. reported that prostate volumes were observed to vary by an average of ±10% 
during a course of radiation therapy. Among individual patients the range of prostate 
volumes was reported as ±15% of the average volume although they did not observe 
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any time trends. Roeske et al. (1995) estimated uncertainty in the prostate volume 
associated with contouring to be 5% of the average volume which is only one 
quarter of the estimate of contouring uncertainty for this study. However they did 
not offer any hypothesis for the remaining 5% variation in prostate volume.  
 
Although contouring uncertainty in this study accounts for some of the variation 
observed in prostate volumes, like the study by Roeske et al. (1995), it does not 
account for all of the variation. From the results presented it does appear that there is 
a decrease in prostate volume over time. Pouliot et al. (2003) has also previously 
demonstrated a global reduction in prostate volume. They were able to link fiducial 
marker migration to reduction of prostate volumes contoured on CT scans repeated 
midway through treatment. It was hypothesised that this shrinkage was related to the 
effect of both radiation therapy and hormone treatments.  
 
The influence of hormone therapy on prostate volume was investigated for the 
patients in this study. 10 of 25 patients enrolled in this IGRT study had also been 
given hormone treatments. There does not appear to be any correlation between the 
use of hormones and a trend for decreasing prostate volume, with 5 patients who had 
hormone therapy demonstrating a decrease in prostate volume, 3 patients 
demonstrating no significant time trend and the remaining 2 patients demonstrating 
an increase in prostate volume (Table 9-5). Mechalakos et al. (2002) also reported 
that patients receiving neo-adjuvant androgen deprivation did not show any 
difference in prostate volume time trends. 
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Table 9 - 5: Hormone treatments and trends in prostate volume for each patient 
Patient Hormones? 
Trend in prostate 
volume 
1 no Decrease 
2 no Decrease 
3 no Decrease 
4 no Decrease 
5 no Decrease 
6 4 months induction Decrease 
7 no Not significant 
8 androgen deprivation Not significant 
9 no Decrease 
10 no Decrease 
11 6 months induction Increase 
12 no Not significant 
13 6 months induction Decrease 
14 no Increase 
15 no Not significant 
16 Zoladex x2 Not significant 
17 no Decrease 
18 androgen deprivation Decrease 
19 cyproterone Not significant 
20 cyproterone (ceased poor tolerance) Increase 
21 Zoladex 6 months Decrease 
22 no Decrease 
23 Zoladex 6 months Decrease 
24 no Not significant 
25 no Decrease 
 
 
Dehnad et al. (2003) also demonstrated prostate shrinkage between their planning 
CT and a second CT performed before treatment commenced. However they 
reported that there was no significant prostate deformation between subsequent CT 
scans performed during weeks 3 and 6 of their study. They reported that there was 
no clear explanation for their findings and were therefore unable to conclude 
whether previously reported marker migration was a result of shrinkage of the 
prostate or as a result of the markers migrating relative to the prostatic tissue. 
Dehnad et al. (2003) also hypothesised that deformation of the prostate volume 
during radiotherapy can be caused as a result of tumour growth or regression, 
together with swelling and inflammatory reaction as a result of marker insertion and 
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response to radiotherapy. Although the increase in prostate volume for patients in 
this study is not as a result of swelling or inflammation due to marker implantation, 
it is possible that the increase in volume observed in 3 of our patients is due to 
swelling and inflammation in response to the radiation therapy treatment. 
 
van Herk et al. (1995) concluded that intra-patient shape variations of the prostate 
appear to be acceptably low and therefore allow the assumption that they have a 
relatively constant shape. Although this study has demonstrated volume variations, 
as presented earlier a 1mm expansion of the prostate volume in two dimensions, AP 
and Lat, can lead to an average increase in volume of 15% and have little effect on 
the COV. This is important when using the prostate COV instead of a contoured 
volume to assess prostate motion. Prostate motion will be discussed later in section 
9.5.  
 
Similar to what was suggested previously in the contouring uncertainty section, 
Dehnad et al. (2003) suggest that importing contours and then editing them may 
reduce contouring variability and as a consequence small changes in prostate shape 
that fall within the usual delineation variability would not be detected. However they 
also acknowledge that a bias towards detecting no change would be introduced using 
this methodology, but this methodology would be able to indicate whether the 
volume variation observed in this study is smaller than the variability in delineation 
of the prostate. 
 
The results of this study are not able to conclusively determine whether prostate 
volumes decrease over a course of radiation therapy. Whilst strong time trends have 
been observed, the effect of contouring uncertainty reduces the strength of this 
relationship. However these trends appear to be reliable suggesting a need to re-scan 
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patients during treatment with the view of reducing the treatment volume if a 
decrease in prostate size is observed. Care should be taken when interpreting these 
results, but they do indicate that further research into the change in prostate volume 
during treatment is warranted, especially when the technology is available to edit 
imported contours, rather than requiring the observer to contour each CT scan 
individually.  
9.4.4 Correlation between volume variations and symptoms 
Assessing the correlation between patient reported symptoms and volumes is 
extremely complex. The ability to correlate these two variables in this study was 
further reduced by the lack of daily documentation of symptoms in the patient’s 
history. Correlating the relationship between these two variables is not an aim or 
hypothesis for this research, a short discussion on the observations follows. 
9.4.4a Rectum Volume and Gastrointestinal Symptoms 
The patient reported symptoms during this study have already been presented 
(Section 8.1.3) and the limitations of this data have already been discussed. It has 
been suggested in the literature that radiation induced diarrhoea is one of the reasons 
why patients demonstrate a decrease in rectal volumes over a course of treatment. 
Conversely, it could be hypothesised that constipation would result in an increase in 
rectal volumes.   
 
Table 8-47 documents the number of patients who reported either diarrhoea or 
constipation at some stage during their treatment, as well as any time trends 
associated with their rectum solid volume during treatment. The other 
gastrointestinal symptoms including proctitis, perineal irritation, anal discomfort or 
haemorrhoids, were not analysed for a relationship to changes in rectal volume. 
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Of the 19 patients who reported diarrhoea, Table 8-47 demonstrates that 5 of them 
had decreasing rectum solid volumes, 13 had no significant time trend and one 
patient demonstrated a time trend for increasing rectum solid volume. Both of the 
patients who reported constipation at some stage, also reported diarrhoea during 
their treatment and neither demonstrated a statistically significant time trend 
associated with the rectum solid volume. Six of the 25 patients in this study had no 
documentation of either diarrhoea or constipation symptoms in their patient history 
and the time trends for these patients were evenly spread between increase, 
decreasing and insignificant.  
 
These results are unable to conclusively determine whether changes in rectal 
volumes are associated with gastrointestinal symptoms. That 5 of 7 patients who 
demonstrated decreasing rectal volumes, experienced diarrhoea indicates that there 
may be a relationship. The remaining 2 patients who demonstrated a decrease in 
rectal volume did not have any symptoms documented in their patient histories. If 
more detailed symptom data had been collected, minor changes in bowel habits that 
the patients did not report, may have been discovered. However the strength of the 
relationship between volume and symptoms is decreased by the fact that 13 patients 
who experienced either diarrhoea or constipation did not demonstrate any time 
trends. Hypothetically this could be as a result of the fact that these patients only 
experienced low grade symptoms compared to the patients who did demonstrate 
time trends, but without a symptom grading system this cannot be assessed. 
However this hypothesis does not explain why one patient who experienced 
diarrhoea demonstrated an increase in rectal volume. 
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9.4.4b Bladder Volume and Urinary Symptoms 
It has been suggested in the literature that radiation induced symptoms are the reason 
why patients demonstrate variations in bladder volumes over a course of treatment. 
Table 8-48 documents the number of patients who reported either urinary frequency 
or retention at some stage during their treatment along with any time trends 
associated with their bladder volume during treatment. For the purpose of this 
discussion the patient reported symptoms of frequency, nocturia and incontinence 
documented in section 8.1.3 have all been grouped together as frequency symptoms 
and micturia has been classified as a urinary retention symptom.  
 
Only 5 patients in this IGRT study demonstrated a decrease in bladder volume over 
time. Four of these patients reported urinary frequency symptoms and the remaining 
patient had no symptoms documented. 16 patients reported urinary frequency with 
no associated decrease in bladder volumes during treatment, but in the absence of 
symptom grading scores it is not possible to determine whether their symptoms were 
as severe as those patients who did demonstrate a decrease in volume.  
 
Two patients reported urinary retention which hypothetically could lead to 
increasing bladder volumes during treatment, however neither patient demonstrated 
a time trend. Once again this may be because the severity of the symptom was not 
great enough to affect bladder volumes. As with the rectum volume results, these 
results indicate that there may be a relationship between the urinary symptoms and 
bladder volume, but additional symptom grading scores are needed before any 
conclusions on the effect of symptoms on volume are made. 
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9.4.5 Aim 2: Correlation between volumes and field placement 
corrections 
Aim 2, to assess the correlation between bladder or rectal volumes and field 
placement corrections, was included as a result of the PI’s clinical experience of 
treating prostate cancer patients. This experience resulted in anecdotal evidence that 
a large number of isomoves were being performed due to the mobility of the tattoo 
located on the anterior skin surface. It was observed that when a patients’ bladder 
filling varied, the anterior tattoo shifted in the SI direction, relative to the bony 
anatomy visualised on the port films. As a result one of the research questions 
developed for this study was to assess the correlation between bladder, or rectal 
volumes, and field placement corrections, or the incidence of isomoves.  
 
However prior to this study being commenced the set-up processes used at the 
Tattersall’s Cancer Centre were changed to minimise the impact of the anterior 
tattoo variation in the SI direction. The treatment isocentre for patients enrolled in 
this study utilised the lateral tattoos to locate the isocentre in the SI direction. The 
anterior tattoo was only used to locate the isocentre in the lateral direction. A carbon 
fibre couch top was also installed with the Primatom treatment unit and therefore a 
fixed distance to the couch top was used to determine the isocentre location in the 
AP direction.  
 
The RTs at the Tattersall’s Cancer Centre conducted a pilot project to assess the 
variation in the SI location of the lateral and anterior tattoos. They found that the 
lateral tattoos were more reliable in locating the isocentre in the SI direction relative 
to bony landmarks. As a result the set-up protocol used to treat radical pelvis 
patient’s at all five PMCC sites was changed to the method detailed above and 
carbon fibre couch tops have since been installed on all treatment couches. As a 
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result of this change in practice, aim 2 of this study became redundant and will not 
be discussed further. 
9.5 Internal Organ Motion 
Internal organ motion affects the accuracy of treatment delivery. Unlike patient set-
up accuracy where numerous studies have been published using alternative 
verification methods such as EPI, internal organ motion cannot be readily assessed 
using those methods. Although there have been some studies that have used 
implanted fiducial markers in the prostate to monitor prostate motion, those studies 
were unable to quantify rectum and bladder motion. Some published literature is 
available that quantifies rectum and bladder motion, but these utilise only periodic 
assessment of CT scans. Therefore the daily CT scans collected during this study 
have provided a unique opportunity to assess organ motion in greater detail than has 
previously been possible.  
9.5.1 Rectum COV motion 
Rectum motion was assessed in section 8.5.1 using the rectum solid and anal canal. 
These are discussed separately.  
9.5.1a Rectum solid COV motion 
The mean systematic uncertainty associated with the rectum solid COV motion over 
a course of treatment was -0.01cm, 0.07cm and -0.10cm in the RL (X), SI (Y) and 
AP (Z) directions respectively (Table 8-49).  
 
The mean random uncertainty associated with the rectum solid COV motion of a 
course of radiation therapy was 0.32cm(X), 0.37cm(Y) and 0.24cm(Z) (Table 8-49). 
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Unlike the systematic uncertainty where the AP direction demonstrated the greatest 
uncertainty, random rectum solid motion in the Z direction was the smallest. 
 
The mean and one SD for the total uncertainty associated with the rectum solid COV 
motion was -0.45±0.15cm(X), 0.52±0.19cm(Y) and 0.35±0.19cm(Z) (Table 8-49). 
The increased degree of uncertainty in the Y direction was expected when 
considering the results of the intra-observer contouring study. The uncertainty 
associated with the COV of the rectum was previously reported as 0.16cm(X), 
0.58cm(Y) and 0.22cm(Z). Therefore since the uncertainty associated with 
contouring is actually larger than the COV motion observed in this study, it indicates 
that the observed COV motion in the Y direction is most likely the result of 
contouring uncertainty rather than organ motion. Although both the X and Z COV 
co-ordinates are also subject to contouring uncertainty, at the 95%CI we can 
conclude that there was rectum solid COV motion of 0.29cm in the X direction and 
0.13cm in the Z direction. 
9.5.1b The effect of Rectum solid volume on rectum COV motion 
There was no significant relationship between the planned rectal volume and 
systematic error or random error (Tables 8-50 & 8-51). Therefore the planned 
volume cannot be used as a predictor of increased uncertainty in the rectum COV 
motion.  
 
The relationship between rectum volume and rectum COV motion was also assessed 
in each direction. In the RL and AP directions there was no statistically significant 
relationship between the Rectum COV motion and the percentage change in rectum 
volume (Table 8-52). There was a statistically significant relationship in the SI 
direction (p= <0.05). Figure 8-52 demonstrates that as the rectal volume increases, 
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the COV moves more superiorly (positive direction) and vice versa. However, 
despite a statistically significant relationship (p= 0.00), the R² value of 0.04 indicates 
that this relationship is weak, with only 4% of the variation explained by a linear 
trend line. This COV variation would also correlate with an increase in volume as a 
result of contouring uncertainty. As discussed previously the UL of the rectum can 
be difficult to determine and results in increased uncertainty in the SI (Y) direction. 
It is logical that an increase in volume as a result of contouring uncertainty, will also 
correlate with COV motion in the superior direction.  
9.5.1c Anal Canal COV motion 
The mean systematic uncertainty associated with the anal canal COV motion over a 
course of treatment was -0.01cm, 0.13cm and -0.17cm in the RL (X), SI (Y) and AP 
(Z) directions respectively (Table 8-53).  
 
The mean random uncertainty associated with the anal canal COV motion of a 
course of radiation therapy was 0.25cm(X), 0.31cm(Y) and 0.43cm(Z).  
 
The mean and one SD for the total uncertainty associated with the anal canal COV 
motion was 0.33±0.17cm(X), 0.43±0.18cm(Y) and 0.58±0.37cm(Z). At the 95%CI 
the uncertainty associated with the COV of the anal canal was previously reported as 
0.14cm(X), 0.32cm(Y) and 0.22cm(Z). However unlike the rectum solid results, the 
uncertainty associated with contouring is smaller than the anal canal COV motion 
observed in this study. This indicates that although the COV co-ordinates are also 
subject to contouring uncertainty we can conclude the observed anal canal COV 
motion not due to contouring uncertainty, was 0.19cm, 0.11cm and 0.36cm in the X, 
Y and Z directions respectively. 
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9.5.1d The effect of Anal Canal volume on anal canal COV motion 
There was no statistically significant relationship between the planned anal canal 
volume and systematic or random error (Tables 8-54 & 8-55). Therefore the planned 
volume cannot be used to predict whether the anal canal will demonstrate increase 
COV uncertainty. 
 
One question that cannot be answered from these results is what effect do the rectum 
and anal canal outside the levels of the treatment field, have? Although in this study 
the distinction between anal canal and rectum was made, some authors have also 
considered upper and lower rectum volumes and motion. The length of the rectum 
included in the treatment field would potentially move less due to increased fibrosis 
as a result of the radiobiological effects on tissue. 
9.5.2 Bladder COV motion 
The mean systematic uncertainty associated with the bladder COV motion over a 
course of treatment was 0.01cm, 0.08cm and -0.13cm in the X, Y and Z directions 
respectively (Table 8-56).  
 
The mean random uncertainty associated with the bladder COV motion of a course 
of radiation therapy was 0.24cm(X), 0.55cm(Y) and 0.39cm(Z).  
 
The mean and one SD for the total uncertainty associated with the bladder COV 
motion was 0.35±0.14cm(X), 0.86±0.51cm(Y) and 0.61±0.26cm(Z). At the 95%CI, 
the uncertainty associated with the COV of the bladder was previously reported as 
0.14cm(X), 0.32cm(Y) and 0.10cm(Z). Therefore the uncertainty associated with 
contouring is smaller than the bladder COV motion observed in this study. This 
indicates that although the COV co-ordinates are also subject to contouring 
uncertainty, we can conclude that the observed bladder COV motion, due to 
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contouring uncertainty, was 0.21cm, 0.54cm and 0.51cm in the X, Y and Z 
directions respectively. 
9.5.2b The effect of bladder volume on bladder COV motion 
This increased uncertainty in the COV location of the bladder was expected. 
Previous results demonstrated large fluctuations in bladder volume which would 
logically correspond to larger variations the location of the bladder within the pelvis, 
especially in the SI direction. Figure 8-57 demonstrates the strong statistically 
significant relationship between bladder volume and the location of the COV 
bladder in the Y direction (p=0.00, R= 0.77). Although Table 8-59 indicates a 
statistically significant relationship between these two variables in the X and Z 
directions, the strength of their relationships are much weaker. 
 
There was no significant relationship between the planned bladder volume and 
random error (Table 8-58), however there was a statistically significant relationship 
between the planned volume and systematic error in the Y direction (Table 8-57), 
indicating that the planned volume can be used as a predictor of increased 
uncertainty in the bladder COV. Figure 9-16 demonstrates the relationship between 
planned bladder volume and systematic COV error in the Y direction. This figure 
demonstrates that systematic error increases as the bladder volume varies from a 
volume of 191cc. Previous discussions indicated that a volume of between 154cc 
and 173cc was ideal to minimise volume fluctuations. Using this ideal planning 
volume range COV uncertainty in the Y direction would be between 0.23 and 
0.46cm, approximately half the degree of uncertainty observed in the 25 patients 
enrolled in this study.  
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Figure 9 - 16: Systematic error (Y) vs. planned bladder volume 
Systematic error (Y) vs. planned bladder volume
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9.5.3 Prostate COV motion 
The mean systematic uncertainty associated with the prostate COV motion over a 
course of treatment was 0.00cm, 0.16cm and -0.20cm in the X, Y and Z directions 
respectively. The mean random uncertainty associated with the prostate COV 
motion was 0.22cm(X), 0.25cm(Y) and 0.31cm(Z) (Table 8-60).  
 
The mean and SD for the total uncertainty associated with the prostate COV motion 
was 0.30±0.12cm(X), 0.37±0.18cm(Y) and 0.52±0.23cm(Z). The results of the intra-
observer contouring study presented earlier indicate that the COV location as a result 
of contouring was 0.14cm(X), 0.32cm(Y) and 0.20cm(Z). When this uncertainty is 
taken into account it results in a residual COV motion of 0.16cm in the RL, 0.05cm 
in the SI and 0.32cm in the AP directions that we can be confident is a result of 
internal organ motion and not contouring uncertainty. 
 
The increased uncertainty in the AP direction was not unexpected. Zelefsky et al. 
(1999) found that there was a tendency for the prostate to be displaced more 
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posteriorly during treatment compared to the planning scan. The results of our 
systematic error calculation confirm that this also occurred in our cohort of patients 
with the COV of the prostate being on average 2mm more posterior during treatment 
than its location during the planning CT scan. 
 
Wong et al. (2005) used the central CT slice through the prostate to determine the 
isocentre location relative to soft tissue anatomy. Although they did not report a 
mean prostate motion, they did report the number of isomoves based on soft tissue 
anatomy. In their study Wong et al. (2005) found that 46%, 73% and 66% of 
treatment isocentres were less than 3mm from the planned isocentre in the AP, SI 
and RL directions respectively. They also reported that 44% had AP motion greater 
than 0.5cm and 15% had motion in the AP direction of greater than 1.0cm. In our 
study we found that on 31%, 35% and 25% of all treatment occasions prostate 
motion was less than 3mm in the RL, SI and AP directions respectively. In our study 
we had a larger number of fractions where organ motion exceeded 3mm, however 
43% of all fractions had COV motion greater than 5mm and only 14% had AP 
motion greater than 1.0cm (compared to 44% and 15% respectively). Therefore, 
although we observed increased amounts of variation between 3mm and 5mm, 
variations greater than 5mm were very similar. Assessment of the reasons for these 
differences is difficult. Wong et al. (2005) did not report whether patients were 
given treatment instructions and they did not provide volume information for the 
bladder or rectum. They also only scanned patients during their last week of 
treatment, unlike our study which used verification CTs throughout the entire 
treatment course. They may have observed increased variation if the entire treatment 
course was imaged. It is possible that the prostate location is more fixed during the 
final week of treatment due to fibrosis of the surrounding tissues. As discussed 
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earlier in section 4.3.7, signs of fibrosis are visible as early as day 3 of treatment 
(Somosy et al 2002) and therefore it is plausible that by the end of treatment that this 
fibrosis reduces prostate motion. It is also possible that the patients demonstrated 
decreased fluctuations in bladder and or rectum volumes. All of these variables 
would affect COV prostate motion.   
 
The results of the analysis of whether prostate motion in one direction was related to 
another were presented in Figures 8-60, 8-61 and 8-62. Figure 8-60 clearly 
demonstrates that there is a significant relationship between prostate motion in the 
AP direction and prostate motion in the SI direction. The results of the regression 
analysis confirm this with a p-value= 0.00 and R= 0.31 (Table 8-61). When the 
prostate is located more anteriorly within the pelvis, it is also located more 
superiorly. This relationship along the diagonal axis has previously been 
documented in the literature. Zellars et al. (2000) reported that the prostate shifted 
along the axis extending from an anterior-superior to posterior-inferior position. 
They reported an angle of 41º to describe the axis of average motion with respect to 
the Y axis on the graph. The angle observed for our study was 67º meaning that we 
did not observe the same degree of displacement superiorly for a given anterior 
displacement, however we have demonstrated organ motion along the same diagonal 
plane. 
 
One of the limitations of using COV co-ordinates to assess prostate motion is that it 
is not possible to assess changes in prostate shape. However van Herk et al. (1995) 
concluded that shape variations of the prostate appear to be acceptably low and 
therefore allow the assumption that they have a relatively constant shape. This 
means that COV motion can be used during IGRT to correct for internal organ 
motion without corrections for changes in prostate shape. 
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9.5.3b Correlation between Rectal volume and prostate motion 
The correlation between rectal volume and prostate motion was assessed in Section 
8.5.3b. Table 8-62 demonstrates that there is a statistically significant relationship 
between prostate motion in the AP direction and the planned rectum solid volume. 
Although the strength of this relationship is not strong, Figure 9-17 shows that the 
systematic error increases as the prostate volume increases or decreases from the 
intercept volume (78.1cc). This indicates that a planned rectal volume of 78cc would 
minimise the systematic error in prostate COV location. However Beard et al. 
(1996) concluded that the initial volume could not be used as a predictor for organ 
motion despite changes in rectal volume and diameter between the planning scan 
and the scan repeated during week 4 of treatment being correlated with prostate 
motion. There was no relationship found between the planned rectum solid volume 
and systematic error in the other 2 directions in our study. There was also no 
relationship associated with the planned rectum solid volume and random error.  
Figure 9 - 17: Systematic error in prostate COV location vs. planned rectum solid volume. 
Systematic error in prostate COV location (Z) vs. 
planned rectum solid volume
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The relationship between normalised rectum solid volume and prostate COV co-
ordinates in all three directions was also assessed. Although there was a statistically 
significant relationship in all three directions (Table 8-64), visual observation of 
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Figures 8-63, 8-64 indicate that the strength of the relationship in the X and Y 
directions is very weak. However Figure 8-65 demonstrates that there is a definite 
trend with the prostate COV moving more anteriorly when the rectum solid volume 
increases. This is confirmed by R= 0.42. 
 
Numerous authors have also reported a significant correlation between prostate 
motion and rectal volume. Roeske et al. (1995) found the largest COV prostate 
variations in the AP direction (-0.087±0.235cm). Although their mean COV 
displacement was smaller than ours, the SD of their study is very similar to that of 
our study. Roeske et al. (1995) only included 10 patients in their study and this may 
account for the variation observed in the mean COV displacement when compared 
to our study with 25 patients.  
 
Zelefsky et al. (1999) also reported a tendency for the prostate to be displaced more 
posteriorly during treatment compared to the planning scan. Like our study, Zelefsky 
et al. (1999) found that this AP prostate motion correlated with rectal volume 
(p=0.00). Miralbell et al. (2003a) and Melian et al. (1997) also reported that rectal 
filling was associated with a trend for anterior motion of the prostate.  
 
Antolak et al. (1998) reported significant correlation between prostate motion and 
rectal volume. However they reported that although the COV prostate shifted 
anteriorly as the rectum volume increased, it was also associated with a compression 
of the anterior border of the prostate. Kupelian et al. (2005) also reported prostate 
deformation secondary to rectal filling. Compression of the prostate cannot be 
demonstrated in our data, however the anterior shift demonstrated by both Antolak 
et al. 1998 and Kupelian et al. (2005) is consistent with our observations.  
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Zellars et al. (2000) reported a statistically significant relationship between prostate 
motion and rectal volume, with the prostate shifting along a diagonal axis from an 
anterior-superior to posterior-inferior direction. They reported a 1cm shift in the 
COV of the rectum, which resulted in a 0.35cm shift in the COV of the prostate in 
the same direction. Tinger et al. (1998) also found that prostate motion in the AP and 
SI directions correlated with the percentage change in rectal volume. 
 
Figure 9-18 demonstrates the relationship between prostate motion in the AP (Z) and 
SI (Y) directions using the same graphical representation method reported by Zellars 
et al. (2000). This figure demonstrates COV prostate motion in the same anterior-
superior to posterior-inferior direction as that reported by Zellars et al. (2000). A 
regression analysis of the relationship resulted in a statistically significant p-value 
(p= 0.00), t-value= 9.44 and R= 0.32. Although not all motion is explained by this 
trend, it is obvious that there is a relationship between prostate motion in the two 
directions. 
Figure 9 - 18: Prostate motion in the AP direction vs. SI motion. 
Prostate COV (z) vs. Prostate COV (y) motion 
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Unlike our study, Melian et al. (1997) also reported a correlation with rectum 
volume and prostate COV motion in the SI direction, although it was less significant 
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than in the AP direction (R= 0.73, p= 0.04 and R= 0.65, p= 0.00 respectively). 
Patients in that study were treated prone compared to patients in our study who were 
treated supine which may have increased the influence of bladder volume. Melian et 
al. (1997) found a statistically significant relationship between bladder volume and 
prostate motion, which was also observed in our study (section 9.5.3c). Melian et al. 
(1997) conclude that although changes in prostate location in the AP direction are 
equally correlated with rectum and bladder volumes, in the SI direction movement 
appears to be more correlated with bladder volume.  
 
Stroom et al. (1999) hypothesised that the time of the day that a patient is treated 
may affect the location of the prostate. In their study all patients were treated in the 
morning, however they acknowledge that this may not be representative of the 
normal patient population. In our daily CT verification study, patients were not 
treated at a specific time during the day as they were booked in the same fashion as 
all other patients undergoing radiotherapy. The fact that we made no attempt to treat 
our patients at the same time each day may be one explanation why volumes varied 
more, however further investigation is needed.  
9.5.3c Correlation between Bladder volume and prostate motion 
There was no significant relationship observed between the planned bladder volume 
and systematic or random prostate motion for the 25 patients enrolled into this IGRT 
study (Tables 8-65 & 8-66). Therefore the planned bladder volume cannot be used as 
a predictor for increased prostate motion. 
 
The relationship between bladder volume and prostate COV motion was also 
assessed in each direction (Figures 8-66 to 8-68). There was no statistically 
significant relationship between prostate motion in the AP direction and bladder 
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volume (Table 8-67). Zelefsky et al. (1999) found that AP prostate motion did not 
correlate significantly with bladder volume (p= 0.19). Similarly Antolak et al. 
(1998), Beard et al. (1996), Mechalakos et al. (2002), Miralbell et al. (2003a), 
Roeske et al. (1995) and Tinger et al. (1998) also found that there was either a weak 
or no correlation between AP prostate motion and bladder volume. This indicates 
that the AP prostate motion is most likely due to the changes in rectal volume as 
discussed previously. 
 
However there was a statistically significant relationship (p= <0.05) between 
prostate motion in the SI and RL directions, although the strength of these 
relationships is only weak with R= 0.15 and R= 0.13 respectively (Table 8-67). This 
contradicts the finds of Stroom et al. (1999) who reported that in the supine position 
the prostate location was only affected by the rectum volume and not the bladder 
volume. It has been hypothesised that the supine position allows the bladder to 
distend the anterior abdominal wall and lessen the impact of bladder volume 
variation compared to the prone position. 
 
There is evidence in the literature that bladder volume affects the location of the 
prostate in the SI direction, although the effect of bladder volume on lateral 
displacement has not been previously reported. Melian et al. (1997) found 
significant correlation between bladder volume and PTV motion in the AP and SI 
directions for patients treated prone. Larger bladder volumes were associated with 
more posterior and inferior PTV positions (R= 0.77 and R= 0.73 respectively, with 
probability p<0.0001). However the influence of bladder volume on prostate 
position may be increased in comparison to patients treated supine due to the limited 
room for bladder expansion anteriorly, forcing the bladder to expand posteriorly as 
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well as inferiorly. This may explain why in our study variation was only observed in 
the SI direction. 
 
Contrary to our findings, Zellars (2000) reported patients with large bladder volumes 
late in treatment, are strongly associated with posterior prostate displacement. They 
found that patients instructed to have a full bladder in the hope of decreasing bladder 
and small bowel toxicity, demonstrated a trend for prostate motion. They reported a 
1cm shift in the COV of the bladder which resulted in a 0.33cm shift in the COV of 
the prostate in the same direction. They also reported a correlation between volume 
and prostate shift, with a 1cc change in volume resulting in a 0.003cm prostate shift. 
To make this equation more clinically relevant, a 100cc change in volume would 
result in a 3mm prostate shift. However this study by Zellars et al. (2000) was based 
on 24 patients with only 1 repeat CT scan during week 4-5, which demonstrated a 
significant decrease in bladder volume to 51% of the pre-treatment volume. It has 
already been reported that our study did not demonstrate a decrease in bladder 
volume, although there were significant volume fluctuations, and therefore 
conclusions based on the results of Zellars et al’s (2000) study are much less reliable 
than our study which utilised 815 verification CT scans.  
9.6 Aim 3: Effect of volume variations on the planned dose 
Aim 3 was to assess the effect volume variations had on the planned rectal and target 
volume doses. DVHs are the most common way of comparing treatment plans, 
however they do not provide the information necessary to determine where the dose 
is being delivered within the structure. In routine treatment planning this limitation 
of DVHs is accepted as radiobiological dose constraints are usually defined as the 
dose delivered to a percentage of the structure, with minimal consideration on where 
this dose is occurring. An estimate of uncertainty is rarely associated with the dose 
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delivered to patients (Dutreix 1984). Published dose-effect relationships are based 
on the initial planned dose which assumes that the absorbed dose delivered was 
exactly as planned. However when multiple CT scans are used to assess dose, the 
location of the dose distribution within the structure will vary, making the 
comparison of the plans much more complex and limiting the utility of a DVH. 
When a DVH is calculated on multiple CT scans of the same patient, variations in 
the results may be due to variation in the shape and volume of the structure between 
scans, variation in the position of the structure between scans, as well as contouring 
uncertainty. 
 
Therefore, although in this study dose information was collected for pre-determined 
volume percentages, eg: V90 = the dose delivered to 90% of the volume, we were 
unable to add together the dose delivered to these volumes for each fraction to 
compare the dose delivered to the planned dose, as the dose may have been 
delivered to a different part of the volume each day and there was no way of 
assessing this using a DVH. To overcome this limitation the mean dose for each 
fraction has been added together to compare the mean dose delivered to the mean 
planned dose, since the mean dose is not affected by the distribution of the dose 
within the structure. 
 
Although the doses from each fraction cannot be added together, the dose delivered 
to each of these interest points on a daily basis can be compared to the dose that was 
planned to be delivered per fraction. Variations in this fractional dose can be 
assessed for correlations between volume variations and, or, organ motion. 
 
The effect of treatment uncertainties on the dose delivered to a patient during a 
course of radiation therapy has not been performed on this scale previously. 
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Although it is acknowledged that the effect of uncertainties on dose is an important 
clinical problem, modelling the effect of uncertainties on dose is difficult. Published 
literature has been based on studies using only a small number of repeat CT scans 
(Balter et al. 1993; Bayley et al. 2004; Lebesque et al. 1995; Melian et al. 1997, 
Miralbell et al. 2003a) or on theoretical dose modelling using only the one CT scan 
(Goiten & Busse 1975; Martinez et al. 2001; Partridge, Ebert & Hesse 2002; Rudat 
et al. 1996; Rudat et al. 1994, van Herk et al. 2000, Wong et al. 2005). However, 
according to Partridge, Ebert & Hesse (2002), the accurate reconstruction of dose 
delivery requires high-quality anatomical information acquired at the time of 
treatment. Wong et al. (2005) who, as discussed previously, have conducted the 
study that most closely resembles our study, only reported shift magnitudes and 
hypothetical effects on dose. In this study we have used all the in-room CT 
information gathered to assess the effects on the dose delivered to the patient 
throughout their entire treatment course. 
 
The effect on dose can be as a result of all of the variables that have been presented 
in this thesis. The effect of patient set-up uncertainty has been considered by 
comparing the dose delivered using the actual isocentre, to the dose delivered to the 
uncorrected isocentre. The difference in dose between these two isocentres is a result 
of on-line corrections actioned when the location of the treatment isocentre was 
displaced from the planned isocentre by a distance of equal to or greater than 0.5cm, 
relative to the patient’s bony anatomy. 
 
The effects of organ volume and internal organ motion on the planned dose were 
assessed by comparing the dose delivered to the actual isocentre to the future 
isocentre.  
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9.6.1 Rectum 
9.6.1a Rectum Solid dose reproducibility 
The mean dose delivered to the rectum solid for the actual and uncorrected isocentre 
was between 99.1% and 99.3% of the planned mean dose (Table 8-68). However 
when internal organ motion was corrected for using the future isocentre, the mean 
dose delivered to the rectum solid increased to 103.6% of the planned mean dose. 
This 4% increase in mean rectum solid dose is expected since the COV motion 
results indicated that there was a systematic displacement of the prostate. The 
treatment location of the prostate was systematically more posterior than the planned 
location, therefore once the isocentre is corrected to account for this motion, it is 
logical that the dose to the rectum solid will increase. It is important to note that the 
average mean dose for the future isocentre exceeds the planned mean dose.  
 
Mubata et al. (1998) also reported variations in rectum dose as a result of set-up 
uncertainty. They calculated the degree of set-up uncertainty using portal imaging to 
calculate the theoretical effect on dose using DVHs. They reported that a 2.5mm 
shift in patient set-up in the AP direction can increase the volume of the rectum 
receiving 60Gy by about 10%. Consistent with our findings, Mubata et al. (1998) 
concluded that the AP set-up variation compared to the SI and RL directions has the 
most significant influence on rectal dose. However this study is only hypothetical, 
being based on the original planning scan and therefore does not have the ability to 
assess the effect of organ motion or filling. 
9.6.1b Rectal wall dose reproducibility 
The mean dose delivered to the rectal wall for the actual and uncorrected isocentre 
was between 98.1% and 98.3% of the planned mean dose (Table 8-69). When 
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internal organ motion was corrected for using the future isocentre, the mean dose 
delivered to the rectal wall increased (102%) similar to that observed for the rectum 
solid.   
 
In a previous study Melian et al. (1997) found that the percentage of the prescribed 
dose delivered to V30, or the dose delivered to 30% of the rectal wall, varied by 5-
32% when they imported the original treatment plan onto three subsequent CT 
scans. Although we did not find the same degree of variation in the average mean 
rectal wall dose, individual patients in our study did show variation in the planned 
rectal wall dose of between 72.7% (patient 4) and 108.6% (patient 10) indicating 
that although the average change in dose is minimal, individual patients can 
demonstrate much larger variations in dose. 
9.6.1c Anal canal dose reproducibility 
The mean dose delivered to the anal canal for the actual and uncorrected isocentre 
was 109% of the planned mean dose (Table 8-70). When internal organ motion was 
corrected for using the future isocentre the mean dose delivered to the anal canal 
decreased. Hypothetically this is due to the future isocentre correcting for systematic 
variation in the SI direction. The location of the future isocentre corrects for the 
more superior location of the prostate during treatment in comparison with location 
at the time of planning. This results in a small decrease in dose to the anal canal.   
9.6.1d Hypothesis 3: That reduced rectal volumes lead to increased rectal 
dose 
The results of this study did not demonstrate the expected time trend for decreasing 
rectal volumes that had previously been reported in the literature. Table 8-71 
demonstrates that although 7 patients had statistically significant time trends for 
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decreasing rectum solid volumes, only 3 of these demonstrated an increase in mean 
dose when the actual isocentre was used for dose calculations. The sole patient who 
demonstrated a time trend for increasing rectum solid volumes also demonstrated an 
increase in rectum solid dose, along with 8 patients who had no observed time trend 
associated with their volume. When the future isocentre was considered there still 
was no relationship between patients who demonstrated time trends for rectal 
volume and the incidence of increased rectal volume dose. 
 
The results presented in Tables 8-72 and 8-73 also indicate that there was no 
relationship between increasing mean dose and time trends for the rectal wall or anal 
canal. 
 
Since the number of patients who demonstrated time trends for decreasing rectum 
volumes was less than expected, it was decided that further investigation was 
necessary by comparing the relationship between dose and volume for each 
individual fraction rather than basing conclusion only on time trends. 
 
Therefore to further assess the relationship between variations in rectum volume and 
the effect on dose, the volume as a percentage of the planned volume was plotted 
against the dose delivered as a percentage of the planned dose, for both the actual 
and future isocentres (Figures 8-72 to 8-77). Only the rectum solid was initially 
considered for this section of the results as it was the rectal volume that 
demonstrated the largest volume variations previously. 
 
The results of a regression analysis performed on these plots was summarised in 
Table 8-74. These results demonstrate that there is a statistically significant 
correlation between the rectum solid volume and mean dose and V50 dose delivered 
to the rectum when using the actual isocentre. However the strength of the 
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relationship is weak (R< 0.13). Table 8-74 also demonstrates that there is a 
statistically significant correlation between the rectum solid volume and dose 
delivered to the rectum at all three dose points considered (mean, V50 and V30), 
when using the future isocentre. Visual observation of Figures 8-75, 8-76 and 8-77 
confirm that as the rectal volume decreases, the mean dose delivered to the rectum 
solid increases. The strength of these relationships can also be considered significant 
with R values of between 0.481 and 0.37. 
 
Fokdal et al. (2004) also found that an increasing rectum volume resulted in a larger 
percentage of the rectum being irradiated at 4 pre-defined dose levels on a DVH. 
Muren et al. (2004) suggest that a planning organ at risk volume (PRV) be used to 
account for anatomical and geometric variability caused by rectum volume 
variations and organ motion during treatment. The PRV would incorporate a margin 
that encompasses the span of rectum motion around the organ at risk, similar to the 
margin placed around the CTV to create the PTV. Hypothetically the DVH 
calculated on the PRV during planning would better present that dose delivered over 
the entire treatment course. However this hypothesis needs to be tested to see 
whether there is a correlation between adverse effects and PRV DVH data before a 
PRV can be used to predict the risk of treatment induced side effects. 
 
The results presented in section 8.6.1d only considered the effect of rectum solid 
volumes on dose. This volume was the only volume considered initially due to the 
larger variation observed in the rectum solid volumes compared to the rectal wall 
and anal canal. However when reviewing the literature Lebesque et al. (1995) found 
that the planning rectal wall DVH, more accurately represented the dose delivered to 
the rectum throughout the course of treatment, because there was no correlation 
between dose and filling. They concluded that since rectal wall volumes do not 
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demonstrate time trends, they should be used for DVH analysis. Since no time trends 
in the rectal wall volumes were found in our study either it was decided that the 
relationship between rectal wall volume and dose should be tested using the same 
tests that were performed for the rectum solid, however only the mean dose was 
considered for this analysis. The graphs used for this analysis are demonstrated in 
Figure 9-19 for the actual isocentre and Figure 9-20 for the future isocentre. Table 9-
6 summarises the regression analysis statistics for these two graphs. 
Figure 9 - 19: Effect of changing rectal wall volume on the mean dose delivered to the rectal 
wall – actual isocentre 
% change in Rectal wall volume vs. % change in 
mean rectal wall dose - actual isocentre
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Figure 9 - 20: Effect of changing rectal wall volume on the mean dose delivered to the rectal 
wall – future isocentre 
% change in Rectal wall volume vs. % change in 
mean rectal wall dose - future isocentre
y = -0.0321x + 1.0606
R2 = 0.0037
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Table 9 - 6: Relationship between rectal wall and dose 
Mean Rectal wall  
dose 
  Actual Future 
R 0.05 0.06 
t-value 1.39 -1.75 
p-value 0.16 0.08 
 
The results of the regression analysis in Table 9-6 indicate that there is no 
statistically significant relationship between the mean rectal wall dose and the rectal 
wall volume, using either the actual or future isocentres. This is contrary to the 
results for the rectum solid where the dose was related to the volume, but supports 
the conclusion by Lebesque et al. (1995) that the rectum wall volumes should be 
used at the time of planning. Lebesque et al. (1995) found that rectal filling 
differences were equally distributed within and outside the high dose region. They 
reported that DVH variation was not related to rectal filling. As the rectum volume 
increased, the outer rectum contour expanded both inside and outside the high dose 
region, in such a way that the increase in the high dose region was nearly 
proportional to the increase of the whole organ. 
9.6.2 Bladder 
9.6.2a Bladder dose reproducibility 
The mean dose delivered to the bladder using all three isocentres results in less than 
a 2% variation, however the dose delivered is consistently higher than the initial 
planned dose. Despite this relatively small increase in average mean treatment dose 
compared to the planned dose, individual patients demonstrate large variations in the 
dose delivered to the bladder. Patient 9 demonstrates that the dose delivered to the 
bladder is 202% of the initial planned dose, whilst patient 4 received only 52.5% of 
the planned dose to the bladder. The results of the bladder volume variation analysis 
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in section 8.4.2 show that patient 4 had the largest degree of random and systematic 
uncertainty and patient 9 had the third largest of each. Therefore it appears that 
bladder volume does affect the dose delivered to the bladder and this relationship 
was tested further. 
9.6.2b Effect of bladder volume on bladder dose 
To assess the relationship between bladder volume and dose, the percentage change 
in planned bladder volume was plotted against the percentage change in the planned 
mean bladder dose for the actual isocentre and future isocentre for each of the 815 
CT scans. A logarithmic trend line was then applied to Figures 8-79 and 8-80. From 
these figures there is an obvious statistically significant relationship between volume 
and dose delivered to the bladder. This finding is supported by Lebesque et al. 
(1995) who found that both bladder and bladder wall doses decrease as bladder 
filling increases. Unlike the rectum where the rectal wall dose was more reliable for 
reporting dose, Lebesque et al. (1995) found that there is no advantage in reporting 
bladder wall dose over the dose delivered to the entire volume. It was hypothesised 
that as bladder filling progressed, the bladder expanded partly within the high dose 
region, but mainly outside as it expanded superiorly within the pelvis. As a result, 
they conclude that the clinical implication of this bladder expansion is that patients 
should be treated with a full bladder. They also conclude that bladder DVHs 
performed at the time of planning can only be representative of the whole treatment 
if the bladder filling can be kept constant. This relationship has been demonstrated 
by our results and highlights the need to solve the problem of how to maintain a 
consistent bladder volume on a daily basis.  
 
Fokdal et al. (2004) reported that an increasing bladder volume resulted in a 
decrease in the volume of rectum irradiated, thus indicating that a full bladder may 
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push the rectum out of the treatment volume. An analysis for this correlation was not 
performed during this study, but demonstrates the large number of factors that may 
affect the dose delivered. 
9.6.3 Prostate & PTV dose reproducibility 
9.6.3a Prostate (CTV) and PTV 
This study used the prostate gland alone to define the CTV. The effect of patient set-
up uncertainty and organ motion on the dose delivered to the prostate (CTV) is 
demonstrated in Figure 8-81. The use of an on-line correction protocol to locate the 
treatment isocentre within 5mm of the planned isocentre using bony landmarks, 
demonstrated no improvement in the percentage of the planned dose delivered. 
Corrections for prostate motion on a daily basis only result in an average increase in 
the mean dose of 0.4%. This indicates that the CTVÆPTV margin applied at the 
time of planning has adequately accounted for the geometrical uncertainties 
associated with this cohort of patients. In fact, by demonstrating no improvement in 
dose between the actual and uncorrected isocentre locations, it indicates that the 
margins are too generous. The minimal improvement in dose between the actual and 
future isocentres could be interpreted as a result of only small variations in the 
location of the prostate with respect to the bony anatomy. However prostate motion 
has already been demonstrated, thus reinforcing the assumption that the CTVÆPTV 
margins used were too large to observe the expected improvement in dose, with 
corrections for patient set-up uncertainty or internal organ motion. 
 
The mean dose delivered to the PTV as a percentage of the planned dose is 
demonstrated in Table 8-76 and Figure 8-82. Consistent with the results observed for 
the prostate, there is no difference between the mean dose delivered to the PTV 
 - 288 -
 
using the actual or uncorrected isocentres. There is a greater difference observed 
between the actual and future isocentres, although when this internal organ motion is 
accounted for, it still only results in an average increase in dose of 1%. Miralbell et 
al. (2003a) in a study of 9 patients who underwent weekly CT scanning during 
treatment, also found that despite large variations in rectum and bladder volumes 
there was good reproducibility of the dose delivered to the prostate. They did 
however report that dose reproducibility was less optimal for the seminal vesicles. 
The seminal vesicles were not contoured during our study and therefore further 
investigation is necessary to assess dose reproducibility for patients who have the 
seminal vesicles included in their CTV. 
 
These findings are contrary to the results of Melian et al. (1997) who found that 
when the original treatment plan was used to calculate DVHs on scans with different 
bladder and rectal volumes, the dose delivered to V95 of the PTV ranged from 79-
100% of the planned dose. Their study was based on only 3 additional CT scans and 
although they had a 1cm margin in most planes, they only applied a 0.6cm margin 
posteriorly. Since prostate motion is greatest in the AP direction it is not surprising 
that Melian et al. (1997) found more variation in the PTV dose than our study where 
1cm margins were used.  
 
It could be concluded, based on our results, that the prescribed dose is accurately 
delivered during treatment. However before discussing hypothesis 4, that the current 
treatment instructions are inadequate to maintain the planned dose distribution, it is 
necessary to examine the relationship between organ motion and PTV dose in more 
detail. 
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9.6.3b Effect of rectal volume on PTV dose 
The effect of rectal volume on PTV dose was assessed by plotting the percentage 
change in rectum solid volume against the percentage change in both the mean PTV 
dose and the V95 PTV dose for the actual isocentre (Figures 8-83 & 8-84). A 
regression analysis resulted in p-values for these figures that were both statistically 
significant (p= 0.00), however the low R values, 0.14 and 0.19 respectively, reflect 
the poor linear correlation between rectal volume and PTV. In an attempt to explain 
the relationship better, logarithmic trend lines were applied to these figures, resulting 
in R values of 0.19 and 0.24 respectively. Therefore a logarithmic trend line does not 
offer a more conclusive explanation of the relationship between rectum solid volume 
and PTV dose. 
 
The effect of rectal volume on PTV dose was also assessed using the future isocentre 
(Figures 8-85 & 8-86). As expected, when prostate motion is accounted for, the data 
points on the graphs visually clustered around the 100% line on the Y axis. This is 
expected since any corrections for internal organ motion should eliminate the 
relationship between rectum volume and dose. However there is still a residual trend 
on both graphs. The trend line demonstrating the relationship between the mean 
PTV dose and rectum volume is statistically significant (p= 0.00) with R= 0.43. The 
trend line for the V95 PTV dose is also statistically significant (p= 0.00) and has a 
slightly reduced correlation (R= 0.36). This indicates that even when corrections for 
internal organ motion are made, the dose to the PTV is still affected by the rectum 
volume, with larger volumes slightly reducing the dose delivered to the PTV. 
9.6.3c Effect of bladder volume on PTV dose 
The effect of bladder volume on PTV dose was assessed by plotting the percentage 
change in bladder volume against the percentage change in both the mean PTV dose 
 - 290 -
 
and the V95 PTV dose for the actual isocentre (Figures 8-87 & 8-88). A regression 
analysis resulted in p-values for these figures that were both not statistically 
significant (p= 0.36 and p= 0.10 respectively), indicating that there is no relationship 
between bladder volume and PTV dose using the actual isocentre. Once again, in an 
attempt to explain the relationship better, logarithmic trend lines were applied to 
these figures resulting in R values of 0.017 and 0.01 respectively. Therefore a 
logarithmic trend line does not offer a more conclusive explanation of the 
relationship between bladder volume and PTV dose. 
 
The effect of bladder volume on PTV dose was also assessed using the future 
isocentre (Figures 8-89 & 8-90). As expected, corrections for internal organ motion 
decrease the relationship between bladder volume and dose. The trend line 
demonstrating the relationship between the mean PTV dose and bladder volume is 
not statistically significant (p= 0.36, R= 0.03). The trend line for the V95 PTV dose 
is no longer statistically significant either (p= 0.23, R= 0.04) and thus indicates that 
when using the future isocentre, there is no relationship between the bladder volume 
and the dose delivered to the PTV.  
9.6.3d Effect of rectum solid COV motion on PTV dose 
The effect of rectum COV motion on PTV dose was assessed by plotting the 
normalised COV location against the percentage change in PTV dose (mean and 
V95). This was done in all 3 directions and for both the actual and future isocentres. 
 
When considering the actual isocentre (Table 8-77), the mean PTV dose has a 
statistically significant relationship to the location of the rectum solid COV in only 
the AP direction (p< 0.05), although the R value is low (<0.16). The regression 
analysis of the relationship between the rectum COV and the dose delivered to 95% 
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of the PTV (V95) indicates that there is also a statistically significant relationship in 
the RL and AP directions, but not in the SI direction. It was anticipated that there 
would be a relationship between rectum COV in the AP direction and PTV dose 
when using the actual isocentre based on our previous results. We have already 
demonstrated that as the rectum COV moves more anteriorly within the pelvis it 
correlates with a shift in the location of the prostate COV in the same direction. 
Therefore if corrections for internal organ motion are not made it is expected that it 
will affect the dose delivered.  
 
When the future isocentre is considered (Table 8-78), there is no longer a 
statistically significant relationship between rectum COV in the AP direction and 
PTV dose. This is because the dislocation of prostate volume, caused by a change in 
the location of the rectum, is corrected for. Unexpectedly, there are now statistically 
significant relationships remaining in the other two directions, despite corrections 
for internal organ motion, although the strength of these relationships are weak as 
shown in Figure 9-21. Figure 9-21 demonstrates the relationship between the rectum 
COV motion in the SI direction and its effect on dose delivered to the 95% of the 
PTV using the future isocentre. Although there is a statistically significant 
relationship (p= 0.00), the strength of this relationship is only weak (R= 0.17), which 
is obvious from the scattered nature of the data points on the graph. 
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Figure 9 - 21: Relationship between rectum COV motion in the Y direction and the change in 
dose delivered toV95 of the PTV 
Rectum solid COV motion (y) vs. % change in V95% PTV 
dose - future isocentre
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9.6.3e Effect of bladder COV motion on PTV dose 
The effect of bladder COV motion on PTV dose was assessed by plotting the 
normalised COV location against the percentage change in PTV dose (mean and 
V95). This was done in all 3 directions for both the actual and future isocentres. 
 
When considering the actual isocentre (Table 8-79), the mean PTV dose and V95 
PTV dose both have a statistically significant relationship to the location of the 
bladder COV in the AP directions (p< 0.05), with R= 0.22 and R= 0.29 respectively 
(Figure 9-22). This indicates that when the actual isocentre is used, bladder COV 
location affects the dose delivered to the PTV, with a more anterior location 
resulting in an increased dose. 
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Figure 9 - 22: Relationship between bladder COV motion in the Z direction and the change in 
V95 dose delivered to the PTV 
Bladder COV motion (z) vs. % change in V95% PTV dose - 
actual isocentre
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However there was no statistically significant relationship in the SI direction. 
Previous authors have reported that a full bladder pushes the prostate inferiorly 
within the pelvis and therefore it was expected that there would be a relationship 
between COV motion in the SI direction and dose delivered to the PTV. However 
our results do not support this hypothesis. 
 
When the future isocentre is considered (Table 8-80), there is still a statistically 
significant relationship between bladder COV in the AP direction and PTV dose (p= 
0.00), with R= 0.22 (mean) and R= 0.29 (V95).  There is also a relationship between 
the dose delivered to 95% of the PTV and the SI location of the bladder COV 
(p=0.00), although the strength of this relationship is weaker than for the AP 
direction (R=0.13). Therefore despite corrections for internal organ motion, there is 
still a relationship between bladder COV and PTV dose as demonstrated in Figure 9-
23. This figure demonstrates a residual relationship between bladder COV motion 
and PTV dose, with the dose delivered to 95% of the PTV increasing as the bladder 
COV moves more posteriorly. Since bladder COV is affected by the degree of 
bladder filling, this finding reinforces the need to maintain a constant bladder 
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volume in order to minimise COV motion and therefore minimise its effect on PTV 
dose. 
Figure 9 - 23: Effect of bladder COV (Z) on PTV dose 
Bladder COV motion (z) vs. % change in V95% PTV dose - 
future isocentre
y = -0.0097x + 0.9919
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9.6.3f Effect of prostate COV motion on PTV dose 
The effect of prostate COV motion, which can be a result of changes in bladder and 
rectum filling and COV motion, on PTV dose was presented in sections 9.6.3b-e. 
Figures 8-91 through to 8-96 demonstrated the variation in both the mean PTV dose 
and V95 PTV dose for each of the 3 directions, by plotting the normalised prostate 
COV location against the dose delivered to the PTV, for each of the 815 in-room CT 
verification scans. Polynomial trend lines were fitted as it appears that as the 
distance away from the zero normalised prostate COV location increased, in both the 
positive and negative directions, the dose to the PTV decreased. The strength of this 
relationship was weakest in the RL direction, which was expected since prostate 
motion in this direction is least effected by the filling or motion of other pelvic 
organs. The strongest relationship was observed in the AP direction with R= 0.68 for 
the mean PTV dose and R= 0.69 for the V95 PTV dose. These results confirm that 
prostate motion in the AP and to a lesser extent the SI direction have a significant 
influence on the dose delivered. 
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Using polynomic equations to calculate the relationships demonstrated in Figures 8-
91 to 8-96, the effect of prostate motion on PTV dose can be assessed. Table 9-7 
demonstrates the effect a displacement of 0.5cm and 1.0cm has on the dose 
delivered to the PTV, expressed as a percentage of the planned dose. 
Table 9 - 7: Effect of prostate displacement on PTV dose 
  Mean PTV dose V95 PTV dose 
Dislocation 0.5cm 1cm 0.5cm 1cm 
Right (-) 98.94% 99.18% 94.38% 96.03% 
Left (+) 98.99% 98.96% 94.90% 97.09% 
Sup (+) 99.13% 97.84% 95.66% 89.45% 
Inf (-) 98.11% 95.80% 89.85% 77.83% 
Ant (+) 99.35% 97.76% 97.15% 89.48% 
Post (-) 98.95% 96.96% 94.21% 83.60% 
 
From this table it is clear that 0.5cm variations in prostate location have a minimal 
effect on the mean PTV dose, with less than 2% variation in the planned dose. A 
0.5cm variation has a greater effect on the dose delivered to 95% of the PTV, with a 
10% decrease in dose when the prostate is located 0.5cm inferiorly to its planned 
location. A 1cm prostate displacement would result in an even more significant 
decrease in the dose delivered to the PTV, especially if this displacement was in the 
inferior or posterior directions. 
 
The same analysis was conducted for the dose delivered using the future isocentre. 
Figures 8-97 to 8-102 confirm that once internal organ motion is corrected for, there 
is no longer a relationship between prostate COV displacement and the dose 
delivered to the PTV. This is why using IGRT to correct for soft tissue anatomy 
offers improved accuracy compared to previous verification protocols. 
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9.7 Hypothesis 4: Current treatment instructions are 
inadequate to maintain the planned dose 
It was hypothesised that the currently used patient preparation instructions were 
inadequate to maintain the planned dose distribution (Hypothesis 4). Much of the 
literature presented in this thesis supported the hypothesis that variations in bladder 
and rectal volumes, and their COV locations, adversely effected the planned dose 
distribution. This hypothesis is based on the assumption that these volumes are able 
to be entirely controlled by the patient and the bladder and bowel preparations. Since 
it was anticipated that this study would prove that patients were unable to maintain 
the planned volumes of these organs, it was logical that hypothesis 4 should test the 
theory that the treatment instructions given to the patients in this study were 
inadequate. 
 
The assessment of the effect of geometric uncertainties on the dose delivered during 
an entire course of radiation therapy for prostate cancer conducted during this study, 
is the most comprehensive assessment conducted to date. No published literature 
could be located that demonstrated the effect of internal organ motion and patient 
set-up uncertainty on more than four repeat CT scans. 
 
The results discussed thus far have demonstrated that, despite daily variations in 
patient set-up, organ filling and internal organ motion, only minimal variation was 
observed in the average mean dose delivered to the PTV (Figure 8-82), rectum solid 
(Figure 8-69), rectal wall (Figure 8-70), anal canal (Figure 8-71) and the bladder 
(Figure 8-78) between the actual and future isocentres. This could lead to the 
conclusion that the treatment instructions given to the patients enrolled in this study 
were adequate to maintain the planned dose. The almost negligible difference 
 - 297 -
 
between the actual and uncorrected isocentres could also be used to conclude that 
the current immobilisation and set-up practices enable accurate patient position 
reproducibility, or it could just be because of large margins. Therefore this 
conclusion is only valid when the same patient set-up and CTV Æ PTV margins are 
used. PMCC has recently followed the lead of many other institutions and decreased 
the CTV Æ PTV margin to 7-8mm. It is expected that with a decrease in margin 
daily uncertainties will have a greater effect on the dose delivered if not corrected 
for using IGRT. 
 
It has also been demonstrated in this analysis that, although there was minimal 
variation in the average mean dose delivered to any of the structures of interest, 
variations in dose observed on a daily basis were related to organ filling and motion. 
A summary of the findings are listed below: 
 
Rectum: 
i) There was a weak statistically significant correlation between rectum solid 
volume and rectum solid dose using the actual isocentre (Figures 8-72 to 8-74). 
ii) The relationship between rectum solid volume and dose was stronger for the 
future isocentre (Figures 8-75 to 8-79). 
iii) A weak statistically significant correlation exists between rectum solid volume 
and PTV dose using the actual isocentre (Figures 8-83 & 8-84). 
iv) Despite corrections for internal organ motion (future isocentre) there was a 
stronger correlation between rectum solid volume and PTV dose, compared to 
the actual isocentre (Figure 8-85 & 8-86). 
v) There was a statistically significant relationship between rectum COV and 
PTV dose using the actual isocentre (Table 8-77). 
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vi) After corrections for internal organ motion, there was no longer a relationship 
between rectum COV and PTV dose (Table 8-78). 
vii) There was no statistically significant relationship between rectal wall volume 
and rectal wall dose for either the actual or future isocentres (Figures 9-20 & 9-
21; Table 9-6). 
The clinical implication of these results is that the rectum volume needs to be 
maintained between planning and treatment to ensure that the dose to the rectum and 
PTV is accurately delivered by minimising volume variation and COV motion. 
Although while the dose variations observed in this study were small, if dose is 
escalated, even small variations will become important. 
 
These results also indicate that the rectal wall volume could be considered for 
planning DVHs as it is not affected by rectal filling and is therefore more 
representative of the dose received during treatment. Alternatively the use of 
planning organ at risk volumes (PRV) as suggested by Muren et al. (2004) could be 
investigated further to test whether a dose-volume relationship can be determined. 
 
Bladder: 
viii) There was a logarithmic trend observed between bladder volume and bladder 
dose (Figure 8-79 & 8-80). 
ix) There was no relationship observed between PTV dose and bladder volume 
(Figures 8-87 to 8-90). 
x) There was a statistically significant relationship between bladder COV and 
PTV dose for both the actual and future isocentres (Table 8-79 & 8-80). 
The results of this study indicate that a full bladder is preferred during treatment to 
minimise the dose to the bladder. Although there was no relationship between PTV 
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dose and bladder volume, there was a relationship between bladder COV and PTV 
dose. Patients who have a large bladder volume at the time of planning and who are 
unable to maintain a full bladder during treatment, demonstrate an increase in 
bladder dose from the original plan. Figures 8-76 and 8-77 demonstrate that if the 
bladder is not full, there is an exponential increase in dose, which will increase the 
risk of exceeding the tolerance dose. Therefore the planned bladder volume need to 
be accurately reproduced during treatment for the planning DVH to be 
representative of the dose delivered during treatment. 
 
PTV 
xi) There was no improvement in the average mean PTV dose despite corrections 
for bony anatomy or soft tissue anatomy (Figure 8-82). 
xii) As the distance of prostate displacement from its normalised mean location 
increases, the dose delivered to the PTV also increases when patients are 
treated without corrections for internal organ motion (Figures 8-91 to 8-96). 
These results indicate that for the patients enrolled in this study the margins 
adequately accounted for the majority of patient set-up and organ motion 
uncertainty, therefore resulting in only a minor improvement in dose when using the 
actual and future isocentres. However a decrease in dose delivered to the PTV when 
the prostate is displaced within the pelvis has been demonstrated. These results 
indicate that patients who have on-line corrections could have their CTVÆPTV 
margins reduced to maximise the therapeutic benefit of IGRT. 
 
Therefore on the basis of the results it can be concluded that the planned dose was 
accurately delivered to the 25 patients observed in this study. However as 
CTVÆPTV margins decrease and dose increases, it will be important to further 
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minimise the variations in bladder and rectal volumes in order to ensure that the 
planned dose distribution is maintained. 
 
9.8 Aim 4: To examine the effect of uncertainties on the general 
patient population.  
Organ volume variations, organ motion and patient set-up uncertainty will continue 
to affect the accuracy of the dose delivered to patients who do not have the benefit of 
on-line corrections for soft tissue anatomy. If on-line corrections are performed 
using methods such as EPI, although set-up uncertainties can be corrected, patients 
will still not have corrections for internal organ motion unless they agree to have 
fiducial markers implanted into their prostate. However until the validity of using 
fiducial markers as a surrogate for prostate position, including deformations as a 
result of bladder and rectum volumes is established, IGRT using CT verification is 
the only way that we can be certain that the dose to the prostate is accurately 
delivered.  
 
Patients who have daily on-line corrections using IGRT will have any displacement 
of the prostate corrected for and the planned dose delivered to the PTV will be 
maintained as demonstrated in section 9.6.3f. Although once on-line corrections for 
prostate motion are applied the dose delivered is not related to whether patients are 
able to maintain the same bladder and rectum filling, a full bladder has been 
demonstrated to still decrease the dose to the dome of the bladder (section 9.6.2b) 
and variations in rectal volume will still affect the dose delivered to the rectum 
(section 8.6.1d). Therefore in order to maintain the planned dose distribution to not 
only the PTV but also the critical structures, it is important that the organ volumes at 
the time of planning can be maintained. 
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For patients who do not have access to IGRT technology, which is currently the 
majority of patients undergoing radiation therapy, these results have the potential to 
improve the accuracy of their treatment through an increased understanding of the 
uncertainties associated with an entire course of radiation therapy and their effect on 
dose. These results have demonstrated that, using the current treatment instructions 
and margins, the planned dose can be delivered accurately. Clinically this is very 
reassuring. However the most important outcome of these results for non-IGRT 
patients is that the information collected will inform clinical practice. As the desire 
to decrease margins and escalate dose in order to improve the therapeutic ratio 
continues to be important, these results will ensure that this can be done without 
increasing the risk of the geographically missing the target.  
9.9 Aim 5: Examine the current patient treatment instructions 
and assess the need for review 
Patients in this study demonstrated significant variations in bladder and rectum 
volumes despite being instructed to drink 1 litre of water 30 minutes prior to their 
treatment appointment, take a fibre supplement daily and being advised to follow a 
low residue diet. It was not possible to ascertain whether patients on this study were 
unwilling to follow these instructions, however since they were asked by the 
treatment staff on a daily basis whether they had followed these instructions it would 
have to be assumed that observed variations in volume were as a result of the 
patients inability to follow the instructions rather than a disregard for the instructions 
themselves. It is therefore possible that treatment setup would be improved if the 
instructions given to patients were reviewed and made easier for them to follow. 
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Although the effect on the mean prescribed dose delivered to the PTV was clinically 
insignificant, bladder and rectal volume have been shown to influence the dose these 
organs receive. Therefore if the planned volumes are not maintained, the DVH 
calculated at the time of planning will not accurately reflect the dose delivered 
during treatment and hence may increase the risk of radiation induced side effects. 
 
It has been demonstrated in this study that the rectum COV affects the PTV dose if 
on-line corrections are not performed for soft tissue anatomy. The bladder COV also 
affects the PTV dose.  As the rectum and bladder COVs shift as a result of 
differential filling, the prostate is displaced within the pelvis thus resulting in 
changes to the dose delivered to the PTV.  
 
In current practice the bladder and rectum volumes on the planning CT are assessed 
by the RTs and ROs using subjective measures. If the RT notices that the patient’s 
bladder is not ‘full enough’ they will talk to the patient in an attempt to elicit how 
much fluid they have drunk. To ensure that the instructions have been followed, the 
RT may then request the patient empties his bladder, drinks the required amount of 
fluid, and then undergoes another planning CT in approximately 30 minutes. 
However no attempt is made to determine whether the bladder is ‘too full’ and 
whether the patient will be able to maintain this volume during treatment, especially 
if there are any delays in entering the treatment room.  
 
Similarly RTs are encouraged to consider the size of the rectum at the time of 
acquiring the CT scans, although not all staff are confident in assessing these images 
without a RO present. As a general rule, if the width of the rectum is greater than 
that of the prostate it is an indication that it is unusually large, which may be due to 
bowel gas or faeces. Using this scan may give misleading DVH information. 
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Patients may be asked to empty their bowels and an additional planning CT will be 
performed during the same planning session. If the patient is unable to empty his 
bowel, or the rectum is still ‘large’ on the second planning scan, the patient may be 
given further instructions regarding fibre supplements and asked to return for 
another planning scan in approximately one week.  
 
In clinical practice all of the measures used to determine whether the volumes at the 
time of planning are representative of those expected during treatment, are 
subjective. From this study we have demonstrated that the ideal planning bladder 
volume is approximately 154-172cc, and the ideal planning rectum volume is 
approximately 62cc ± 8cc in order to minimise systematic and random volume 
fluctuations. It is suggested that patients who are being planned for radical prostate 
radiotherapy and have volumes that fall outside this range on their planning CT 
scan, should be considered for an additional planning scan prior to commencing 
treatment to verify these volumes. If the volumes are not consistent, these patients 
should have daily CT verification to ensure that prostate motion as a result of organ 
filling, is corrected for prior to treatment delivery. 
 
There are only a couple of published trials that have examined both full and empty 
bladders on the same group of patients (Fiorino et al. 2002; Bayley et al. 2004). 
However these studies focussed on the effect of bladder volume on prostate location 
rather than on the reproducibility of bladder volumes on a daily basis. No known 
studies have examined rectum volume variability between patients who have been 
given a fibre supplement and those who have not. 
  
In 1999 a trial conducted at the PMCC collected data from 17 patients undergoing 
radical radiation therapy for prostate cancer. These patients had a weekly CT in both 
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the supine and prone positions, and the bladder and rectal volumes were contoured. 
The instructions given to the patients in 1999 differ slightly to those currently used 
at the PMCC. Unlike 1999, where the patients were given no instructions to take a 
fibre supplement, current patients are instructed to commence the supplement one 
week prior to simulation, and continue throughout the course of their treatment.  
However, the instructions to patients regarding the need to have a comfortably full 
bladder (achieved by drinking 1 Litre of water at least 15 minutes prior to their 
treatment commencing) and to follow a low residue / high fibre diet, have not 
changed. Unfortunately the results of this study are yet to be published, however it 
may be possible to compare their volume variation analysis to the results from this 
current study.  
 
9.10 Application of results:  
Although there are other image guided methods clinically available, a diagnostic 
quality CT scanner arguable makes the comparison with planning images easier, and 
allows for accurate dose calculations. Patients treated with daily IGRT for this study, 
were initially allocated an additional 20 minutes for their treatment appointment, 
resulting in a total appointment time of 30 minutes. This was largely as a result of a 
lack of commercially available software programs that automatically calculate the 
magnitude of isomoves required. As the study progressed and the treatment staff 
became more familiar with the verification process, the total appointment time was 
decreased to 20 minutes. The study by Wong et al. (2005), who used a similar 
method of daily IGRT for the last five fractions of treatment, reported that they 
added 20 minutes to the patient’s regular treatment time, however this time also 
included corrections for soft tissue anatomy. Once corrections for soft tissue 
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anatomy are performed at the Tattersall’s Cancer Centre it is likely that the total 
treatment time will once again increase to 30 minutes.  
 
However the use of CT verification for IGRT is unlikely to become standard 
practice for all prostate cancer patients due to workload limitations and 
infrastructure costs. If it can be proven that fiducial markers accurately represent the 
location of the prostate, it is foreseeable that IGRT will be performed using on-line 
EPI matching. Since EPI is now a standard feature on most linear accelerators and is 
relatively more time efficient, fiducial markers have a greater potential for 
verification of all prostate cancer patients. IGRT using CT will then become 
reserved for verification of patients who need to have their dose accurately 
reconstructed, for example patients undergoing dose escalation or IMRT. Future 
IGRT research using in-room CT scanning will focus on the clinical viability of on-
line adaptive radiation therapy (ADRT), where the treatment fields can be optimised 
on a daily basis to deliver the planned dose exactly by accounting for interfraction 
changes in the position and shape of the target without the need for extensive 
calculations (Court et al. 2005), and to comprehensively assess treatment plan 
reproducibility for tumour sites other than the prostate. 
 
9.10.1 Aim 6: Will these results influence the margins or prescribed 
dose? 
The results of this study have provided the information necessary to review the 
accuracy with which radiation therapy for prostate cancer patients can be delivered. 
This study shows that all patients experience some degree of set-up uncertainty and 
organ motion during their treatment. Despite these uncertainties, the dose delivered 
to the patient was accurately delivered, even without daily corrections for set-up 
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uncertainty or internal organ motion. The increased knowledge of patient set-up 
variation, organ motion and their effect on the planned dose will enable a review of 
the margins used during treatment planning. The results of this study indicate that a 
1.0cm margin around the CTV is very generous especially when on-line corrections 
minimise some, but not all, of the geometric uncertainties that the CTV Æ PTV 
margin is designed to account for. The results of this study also indicate that it is 
possible to reduce this margin even for patients who will not be having daily on-line 
corrections since there was only a marginal improvement in the dose when 
corrections were applied. If smaller margins had been used during this IGRT study 
there is little doubt that the effect of the uncertainties discussed in section 4.4 on the 
dose delivered to the actual isocentre when compared to the future isocentre, would 
have been greater.  
 
Calculating the ideal CTV Æ PTV margin is not within the scope of this thesis, 
however the data is available to complete this assessment at a later date. Since the 
planned dose was accurately delivered, if the CTVÆ PTV margins are decreased 
there is no reason why we cannot confidently escalate the prescribed dose without an 
increased risk of radiation induced side effects, especially if internal organ motion is 
monitored using one of the available IGRT methods. 
9.11 Limitations 
Although every attempt was made to make this study as comprehensive as possible, 
there are still a few limitations that need to be considered when assessing the results.  
 
a) Contouring for this study was performed on each individual CT dataset and 
introduced increased potential for intra-observer contouring uncertainty. 
Software that allows the initial planning contour to be overlayed onto the new 
 - 307 -
 
treatment CT scans may reduce the amount of intra-observer contouring 
variation. 
 
b) The assessment of inter-observer contouring variation was limited by the use 
of only one additional observer, on only one occasion. An increased number of 
occasions would have allowed the calculation of a mean RO volume and 
therefore reduced the influence of random errors. A larger number of observers 
would have more accurately reflected the clinical environment where multiple 
ROs and RTs would be involved in on-line corrections. Software that enables 
the original contours to be imported onto subsequent CT scans would therefore 
minimise the effect of intra-observer contouring uncertainty also. 
 
c) This study has not addressed rotation, only basic translation variations. 
Rotation was unable to be assessed due to a lack of software that allowed an 
analysis of both bony and internal organ rotations. 
 
d) Intra-fraction motion was not assessed. The results reported in this thesis 
assume no patient movement or organ motion between CT scanning and 
treatment delivery. Although there was no formal study completed to test this 
assumption, anecdotal evidence suggests that the RTs experienced no 
discrepancies between the locations of the BBs relative to the laser system, 
once the patient was rotated back under the linac gantry. There were also no 
additional isomoves requested as a result of the routine EPIs that were taken 
during treatment, suggesting that patient movement between the CT scan and 
treatment delivery was minimal. 
 
e) This study only assessed the reproducibility and motion of the prostate gland. 
If the seminal vesicles are to be included in the CTV, further investigation is 
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needed to assess how the uncertainties reported in this study effect the dose 
delivered. 
 
f) The assessment for organ motion and dose analysis for this study was 
performed off-line. For IGRT to be fully functional in a clinical environment 
these functions need to be available at the treatment console and they need to 
be able to be performed in a timely manner. Until this can be assessed it is 
unknown whether IGRT or ADRT, will be feasible.  
 
g) Co-morbidities were not reported for patients enrolled in this study. Co-
morbidities, such as previous bowel surgery, may potentially affect organ 
motion. Due to this lack of information in the present study, an analysis to test 
whether co-morbidities affect organ motion could not be performed. Although 
these results still give a comprehensive assessment of organ motion, care needs 
to be taken when interpreting the degree of motion until future research can 
determine whether co-morbidities affect organ motion. 
 
Despite these limitations, this IGRT study using daily in-room CT verification to 
document the uncertainties associated with the delivery of radiation therapy for 25 
radical prostate cancer patients, is the most comprehensive assessment of treatment 
plan reproducibility known.  
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10. Summary of IGRT research: 
This IGRT research is the first known study that has been performed on a daily basis 
throughout an entire treatment course. This study of 25 patients is also larger than 
many previously published studies, resulting in a comprehensive data set. Because 
this study was performed using a single treatment couch and the CT scans were 
performed immediately prior to treatment delivery, uncertainty was minimised 
compared to previously published out-of-room CT verification studies. The focus of 
this study has been to quantify the daily variation in organ volumes, the associated 
COV motion, and ultimately the effect on dose. The most important results have 
been presented with explanations for these findings, including a detailed discussion 
of their relevance to the published literature.  
 
Some of the data collected during this study has not been analysed as it was not 
within the scope of this thesis. Including an analysis of these results would have 
increased the size of the thesis, thus prohibiting the detailed discussion already 
presented. It is the intention of the investigator to analyse this additional data at a 
later date and publish the results. 
10.1 Patient set-up uncertainty 
Total patient set-up uncertainty, as well as the systematic and random components, 
are presented. The patient set-up uncertainty results were normally distributed. 
Systematic uncertainty was found to be very low, less than 0.5mm, however random 
uncertainty was up to 2.5mm. These results indicate that the basic patient 
stabilisation method utilised was adequate for patient set-up reproducibility. This 
was reflected by the low number of treatments that required on-line corrections for 
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isocentre displacements (10.1%). There was no relationship found between patient 
body habitus and the incidence of on-line isocentre corrections. 
10.2 Organ Volumes Variations 
This is the first known study where organ volume variations for the bladder, rectum 
and prostate have been documented throughout an entire treatment course. 
 
The average rectum solid volume was shown to decrease over time, however only 7 
patients demonstrated a statistically significant time trend and therefore our results 
were unable to conclusively prove that rectum volumes decrease over time 
(Hypothesis 1). There was a relationship found between the planned rectum volume 
and systematic error, with a planned volume of approximately 63cc being the ideal 
volume to minimise both systematic and random error. Rectum wall volume and 
anal canal volumes were also analysed. 
 
The average bladder volume was demonstrated to decrease over a course of 
treatment. However extreme fluctuations in bladder volume during treatment were 
confirmed (Hypothesis 2). An ideal volume of the bladder of approximately 155cc-
180cc at the time of planning, reduces the magnitude of systematic and random 
errors. Large bladder volumes have a high risk of large systematic errors that have 
been demonstrated to affect the dose delivered to the bladder and the PTV. 
 
Although quantifying prostate volume variation was not an original aim, prostate 
volumes were shown to decrease during a course of radiation therapy. The certainty 
with which this trend can be considered real is affected by intra-observer contouring 
uncertainty. However supporting evidence of prostate volume shrinkage has been 
published. These results indicate that patients should be rescanned during treatment 
to confirm the volume of the prostate has not changed.  
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10.3 Organ motion 
The rectum solid demonstrated a low mean systematic organ motion (<0.10cm) 
although it exhibited much higher mean random motion (0.24-0.37cm). Similar 
motion was observed in the anal canal volumes. Rectum COV motion was 
demonstrated to be statistically significantly related to rectum volume in the SI and 
RL directions only. 
 
Bladder organ motion also had a low mean systematic uncertainty (<0.13cm) and 
higher mean random uncertainty, up to 0.55cm in the SI direction. High systematic 
error in the SI direction was statistically significant with larger planned bladder 
volumes. Bladder motion in all directions was found to be significantly related to 
changes in bladder volume. 
 
The mean location of the prostate at the time of the planning CT was 0.2cm more 
posterior than during treatment. There was a statistically significant relationship 
demonstrated between systematic COV prostate error in the AP direction and the 
planned rectum volume. There was also a significant relationship demonstrated 
between prostate COV motion in all three directions and changes in rectum volume, 
and also between prostate COV motion and bladder volume in the RL and SI 
directions. 
10.4 Dose delivered 
The results from this study indicate that the dose delivered to the patient accurately 
reflected the planned mean dose to all structures of interest even without on-line 
corrections for patient set-up errors. In addition there was no clinically significant 
improvement in the mean dose delivered when off-line corrections for internal organ 
motion were considered.  
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There was a statistically significant relationship demonstrated between the rectum 
dose and rectum volume, even when corrections for prostate motion were 
performed. However there was no significant relationship between rectal wall dose 
and rectal wall volume. A logarithmic relationship was demonstrated between 
bladder dose and bladder volume.  
 
A change in rectal or bladder volume was not related to a change in PTV dose, 
although prior to corrections for internal organ motion PTV dose was significantly 
related to rectum and bladder motion in the AP direction. Once internal organ 
motion was corrected for there was no longer a relationship between rectum COV 
motion and dose in the AP direction, however bladder COV motion in the AP and SI 
directions still significantly affected PTV dose.   
 
Prostate COV motion was demonstrated to have a large effect on the planned dose 
delivered to the PTV. Polynomial trend lines demonstrated that the dose delivered to 
the PTV decreased as the prostate displacement increased in the AP and SI 
directions. Minimal effects on dose were observed in the RL direction. As expected 
once corrections for internal organ motion were made, the relationship between 
prostate COV motion and PTV dose was eliminated. 
 
From these results there appears to be no justification to routinely perform daily CT 
verification for patients being treated using the current treatment protocol. The 
results of this study also indicate that a CTVÆ PTV margin of 1.0cm is too large 
and if reduced could minimise the dose delivered to critical organs without 
compromising the dose to the CTV. It is expected that the patient set-up error and 
organ motion demonstrated in this study would have a greater effect on the dose 
delivered for patients treated with reduced margins. Any further margin reductions 
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or dose escalation may justify the use of daily CT verification, for example when a 
reduced margin is used to deliver a boost. The effects of patient set-up error and 
organ motion will also have a much larger effect on dose for patients receiving 
IMRT where steep dose gradients are used to avoid critical structures. 
10.5 Conclusion 
The focus of this study has been to quantify the daily variation in organ volumes, the 
associated COV motion, and ultimately the effect on dose. The results of this study 
showed that the treatment plan reproducibility for patients in this study was good. 
Using this information we will be able to assess how these factors affect current 
clinical practices, make suggestions for further investigation (section 10.5.1) and 
recommendations to improve treatment plan reproducibility (section 10.5.2).  
10.5.1 Suggestions for further investigation 
As a result of this research the following suggestions for further investigation are 
made: 
a) Inter-observer contouring variation needs to be quantified in more detail prior 
to the clinical implementation of on-line internal organ motion corrections 
using IGRT so that it can be incorporated into the margin calculations. The 
development and testing of software that allows planning contours to be 
imported would potentially decrease the uncertainty involved with assessing 
internal organ motion and decrease the time taken on the treatment unit. 
b) With the increased knowledge in treatment uncertainties, further research 
needs to test the uncertainty related to defining the GTV and CTV. The use of 
biological imaging modalities, that more accurately locate the tumour cells 
within the prostate, may lead to a decrease in the size of the treatment volume.  
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c) Further investigation into the effect of organ filling is still required. A 
randomised control trial to compare the effect of a full or empty bladder on 
dose is required. A trial designed to assess rectal volumes in conjunction with 
specific dietary intake would also be beneficial, although this would be a large 
study and would need the assistance of nutritional experts. 
d) Future research into the effect of smaller margins on dose could be conducted 
using the data set collected during this study.  
10.5.2 Recommendations 
The following recommendations have been made based on the results of this 
comprehensive assessment of treatment plan reproducibility. 
a) Uncertainty in the location of the pelvic organs at the time of planning can be 
reduced by completing additional planning scans to check for systematic 
errors, however resources prohibit this in most radiation therapy departments. 
Similarly, many departments would find the time and resources necessary for 
daily CT verification for all patients prohibitive, especially without computer 
software to assist in organ contouring. Therefore it is recommended that 
patients who have rectum or bladder volumes outside the ranges specified 
earlier in section 10.2 at the time of their planning CT be re-scanned to 
minimise the risk of systematic errors and increase the clinician’s confidence 
that the planned DVH is accurately delivered. 
b) Use MRI fusion at the planning stage to minimise the uncertainty in 
delineating the CTV and then import these contours onto the subsequent 
verification CT data sets. 
c) For centres intending to implement on-line organ motion corrections using CT 
verification, it is recommended that the isocentre be located at the COV of the 
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prostate so that any corrections are easily performed without having to 
calculate an offset. This will minimise the risk of a calculation error. 
d) That the margins applied to the CTV are appropriate for the type of verification 
the patient is going to have performed. 
e) Education and training programs are necessary for RTs prior to the 
implementation of internal organ motion corrections to minimise inter-
observer contouring variations. Ideally, a specialist RT, or group of experts, 
qualified to perform on-line corrections, would reduce contouring uncertainty. 
f) It is recommended that couch movements be enabled at the treatment console 
allow minor on-line corrections from outside the treatment room. This would 
decrease the time necessary for the IGRT procedure and decrease the chance of 
patient movement.  
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12. Appendices 
Appendix 1: Ethics certificates 
Human Research Ethics Committee (HREC) approval certificates for the conduct for 
this research for the following institutions are attached: 
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Appendix 2: Consent form 
A copy of the Participant Information and Consent Form (PICF) is available for 
viewing on the CD-ROM included at the end of this thesis. 
 
Appendix 3: Daily isocentre location data form 
The data forms used for collecting the daily isocentre location are available for 
viewing on the CD-ROM included at the end of this thesis. 
 
 Appendix 4: XIO manual 
The manual used for data collection from the XIO planning computer system is 
available for viewing on the CD-ROM included at the end of this thesis. 
 
Appendix 5: Primatom CT verification manual 
The instruction manual used for CT verification using the Primatom is available for 
viewing on the CD-ROM included at the end of this thesis. 
 
Appendix 6: Blank data sheets 
Blank research data sheets are available for viewing on the CD-ROM included at the 
end of this thesis. 
 
Appendix 7: Patient raw data 
A file containing the raw data for each of the 25 patients enrolled in this study is 
available for viewing on the CD-ROM included at the end of this thesis. 
 
Appendix 8: Contouring uncertainty data 
The file containing the raw data and additional analysis for the contouring 
uncertainty study is available for viewing on the CD-ROM included at the end of 
this thesis. 
 
Appendix 9: Patient set up uncertainty analysis 
The file containing the analysis used for patient set up uncertainty is available for 
viewing on the CD-ROM included at the end of this thesis. 
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Appendix 10: Rectum volume analysis 
The file containing the analysis used for Rectum volumes is available for viewing on 
the CD-ROM included at the end of this thesis. 
 
Appendix 11: Bladder volume analysis 
The file containing the analysis used for Bladder volumes is available for viewing on 
the CD-ROM included at the end of this thesis. 
 
Appendix 12: Prostate volume analysis 
The file containing the analysis used for Prostate volumes is available for viewing 
on the CD-ROM included at the end of this thesis. 
 
Appendix 13: COV analysis 
The file containing the COV analysis is available for viewing on the CD-ROM 
included at the end of this thesis. 
 
Appendix 14: Dose analysis 
The files containing the dose analysis is available for viewing on the CD-ROM 
included at the end of this thesis. 
 
 
 
 
 
 
 
 
